Patent application title: INFLUENZA VIRUS REASSORTMENT
Inventors:
Derek O'Hagan (Winchester, MA, US)
Derek O'Hagan (Winchester, MA, US)
Peter Mason (Sommerville, MA, US)
Pirada Suphaphiphat, I (Brookline, MA, US)
Daniel G. Gibson (Carlsbad, CA, US)
David E. Wentworth (Rockville, MD, US)
Timothy B. Stockwell (Chantilly, VA, US)
John I. Glass (Germantown, MD, US)
Assignees:
SYNTHETIC GENOMICS VACCINES
NOVARTIS AG
IPC8 Class: AC12N700FI
USPC Class:
506 17
Class name: Library containing only organic compounds nucleotides or polynucleotides, or derivatives thereof rna or dna which encodes proteins (e.g., gene library, etc.)
Publication date: 2014-09-18
Patent application number: 20140274806
Abstract:
Improved methods for the production of reassortant influenza viruses are
provided.Claims:
1. A method of preparing an influenza virus, comprising: a) preparing one
or more expression construct(s) which comprise(s) coding sequences for
expressing at least one segment of an influenza virus genome; b)
introducing into a cell which is not 293T one or more expression
construct(s) which encode(s) the viral segments of an influenza virus,
wherein at least one expression construct is the expression construct
prepared in step (a); and c) culturing the cell in order to produce a
reassortant influenza virus from the expression construct(s) introduced
in step (b); wherein steps (a) to (c) are performed in a time period of
124 hours or less.
2. The method of claim 1, wherein the cell is a non-human cell or a human non-kidney cell.
3. A method of preparing an influenza virus comprising the steps of a) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome; b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); and c) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) introduced in step (b); wherein steps (a) to (c) are performed in a time period of 100 hours or less.
4. The method of claim 3, wherein the cell is a non-human cell or a human non-kidney cell.
5. A method of preparing a reassortant influenza virus, comprising: a) providing a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct; b) introducing into a cell which is not 293T one or more expression construct(s) which encode(s) the viral segments required to produce an influenza virus, wherein at least one expression construct is the synthetic expression construct prepared in step (a); and c) culturing the cell in order to produce a reassortant influenza virus from the viral segments introduced in step (b); wherein steps (a) to (c) are performed in a time period of 124 hours or less.
6. The method of claim 5, wherein the cell is a non-human cell or a human non-kidney cell.
7. The method of claim 5, further comprising (d) contacting a cell which is of the same cell type as the cell used in step (c) with the virus produced in step (c) to produce further reassortant influenza virus.
8. A method of preparing an influenza virus, comprising: a) providing a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct; b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the synthetic expression construct prepared in step (a); c) culturing the cell in order to produce a reassortant influenza virus from the viral segments introduced in step (b); and d) contacting a cell which is of the same cell type as the cell used in step (c) with the virus produced in step (c) to produce further reassortant influenza virus; wherein steps (a) to (c) are performed in a time period of 124 hours or less.
9. The method of claim 8, wherein the cell used in steps (c) and (d) is not 293T.
10. The method of claim 8, wherein the cell used in steps (c) and (d) is a non-human cell or a human non-kidney cell.
11. The method of claim 8, wherein the synthetic expression construct comprises coding sequences for the HA and/or NA segment.
12. The method of claim 8, wherein the synthetic expression construct is linear.
13. The method of claim 8, wherein the fragments have a length between 61 and 100 nucleotides.
14. The method of claim 13, wherein the fragments have a length between 61 and 74 nucleotides.
15. The method of claim 8, wherein the fragments have an overlap of about 40 nucleotides.
16. The method of claim 8, wherein at least part of the synthetic expression construct obtained in step (a) is amplified.
17. The method of claim 1, wherein the step of providing the synthetic expression construct comprises: (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, (ii) joining the fragments to provide a DNA molecule; (iii) melting the DNA molecule; (iv) re-annealing the DNA in the presence of an agent which excises mismatched nucleotides from the DNA molecule; and (v) amplifying the DNA to produce the synthetic expression construct.
18. The method of claim 1, wherein the reassortant influenza virus is a reassortant influenza A virus.
19. The method of claim 18, wherein the reassortant influenza A virus comprises one or more backbone segments having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NOs 9 to 14.
20. The method of claim 18, wherein the reassortant influenza A virus comprises one or more backbone segments having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NOs 42 to 47.
21. The method of claim 18, wherein the reassortant influenza A virus comprises backbone segments from two or more influenza A strains.
22. The method of claim 18, wherein the reassortant influenza A virus comprises the PB1 segment of SEQ ID NO: 43; the PB2 segment of SEQ ID NO: 44; the PA segment of SEQ ID NO: 9; the NP segment of SEQ ID NO: 45; the M segment of SEQ ID NO: 13; and the NS segment of SEQ ID NO: 14.
23. The method of claim 18, wherein the reassortant influenza A virus comprises the PB1 segment of SEQ ID NO: 18; the PB2 segment of SEQ ID NO: 11; the PA segment of SEQ ID NO: 9; the NP segment of SEQ ID NO: 12; the M segment of SEQ ID NO: 13; and the NS segment of SEQ ID NO: 14.
24. The method of claim 1, wherein the reassortant influenza virus is a reassortant influenza B virus.
25. The method of claim 24, wherein the reassortant influenza B viruses comprises the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 72, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 76 and the M segment of SEQ ID NO: 75.
26. The method of claim 24, wherein the reassortant influenza B viruses comprises the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 72, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 76 and the M segment of SEQ ID NO: 81.
27. A method of preparing an influenza vaccine, comprising: a) contacting a cell with a reassortant influenza virus prepared by the method of any preceding claim; b) culturing the cell in order to produce an influenza virus; and c) preparing a vaccine from the influenza virus produced in step (b).
28. The method of claim 27, wherein the cell is a human non-kidney cell or a non-human cell.
29. The method of claim 27, wherein the cell used in step (a) is of the same cell type as the cell used to prepare the reassortant influenza virus.
30. The method of claim 27, wherein step (c) involves inactivating the virus.
31. The method of claim 27, wherein the vaccine is a whole virion vaccine.
32. The method of claim 27, wherein the vaccine is a split virion vaccine.
33. The method of claim 27, wherein the vaccine is a surface antigen vaccine.
34. The method of claim 27, wherein the vaccine is a virosomal vaccine.
35. The method of claim 27, wherein the vaccine contains less than 10 ng of residual host cell DNA per dose.
36. A method of preparing a synthetic expression construct which encodes a viral segment from an influenza virus, comprising: a) providing the sequence of at least part of the coding region of the HA or NA segment from an influenza virus; b) identifying the HA and/or NA subtype of the influenza virus from which the coding region is derived; c) providing a UTR sequence from an influenza virus with the same HA or NA subtype as the subtype identified in step (b); and d) preparing a synthetic expression construct which encodes a viral segment comprising the coding sequence and the UTR.
37. The method of claim 1, wherein the cell is a mammalian cell or an avian cell.
38. The method of claim 37, wherein the cell is an MDCK, Vero or PerC6 cell.
39. The method of claim 38, wherein the cell is of the cell line MDCK 33016 (DSM ACC2219).
40. The method of claim 1, wherein the cell grows in suspension.
41. The method of claim 1, wherein the cell grows adherently.
42. A library comprising two or more influenza backbones.
Description:
TECHNICAL FIELD
[0003] This invention is in the field of influenza virus reassortment. Furthermore, it relates to manufacturing vaccines for protecting against influenza viruses.
BACKGROUND ART
[0004] The 2009 H1N1 influenza pandemic response was the fastest global vaccine development effort in history. Within six months of the pandemic declaration, vaccine companies had developed, produced, and distributed hundreds of millions of doses of licensed pandemic vaccines. Unfortunately, the response was not fast enough as substantial vaccine quantities were available only after the second pandemic wave had peaked. This delay was at least partially due to the late availability of a high-yielding influenza strain which could be used for vaccine production.
[0005] One way of obtaining a high-yielding influenza strain is to reassort the circulating vaccine strain with a faster-growing high-yield donor strain. This can be achieved by co-infecting a culture host with the circulating influenza strain and the high-yield donor strain and selecting for reassortant viruses which contain the hemagglutinin (HA) and neuraminidase (NA) segments from the vaccine strain and the other viral segments (i.e. those encoding PB1, PB2, PA, NP, M1, M2, NS1 and NS2) from the donor strain. Another approach is to reassort the influenza viruses by reverse genetics (see, for example references 1 and 2).
[0006] As the 2009 experience has shown, the traditional methods for reassorting influenza viruses may not be fast enough to provide sufficient amounts of influenza vaccine during a pandemic. In particular, valuable time is lost in preparing the high-yielding seed virus. There is therefore still a need in the art to provide methods which allow the rapid generation of high-yielding seed viruses in order to further decrease the time it takes between the emergence of an influenza pandemic and the provision of an influenza vaccine. The prior art had suggested solving this problem by preparing HA segments synthetically (see, for example, references 3, 4 and 5). The fastest reported time frame in which the influenza viruses can be prepared using these methods is nine days. Furthermore, these techniques rely on the use of 293T cells which have a high transfection efficacy but which are not approved for vaccine manufacture. There is therefore a need in the art to provide further and improved methods for preparing reassortant influenza viruses.
SUMMARY OF PREFERRED EMBODIMENTS
[0007] In some aspects, the invention provides methods which allow a faster preparation of influenza viruses. For example, the invention provides a method of preparing an influenza virus, comprising the steps of (a) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome; (b) introducing into a cell which is not 293T one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); and (c) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) introduced in step (b); wherein steps (a) to (c) are performed in a time period of 124 hours or less. The cell is preferably a non-human cell or a human non-kidney cell.
[0008] Also provided is a method of preparing an influenza virus comprising the steps of (a) preparing one or more expression construct(s) which comprise(s) coding sequences for expressing at least one segment of an influenza virus genome; (b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the expression construct prepared in step (a); and (c) culturing the cell in order to produce a reassortant influenza virus from the expression construct(s) introduced in step (b); wherein steps (a) to (c) are performed in a time period of 100 hours or less.
[0009] The invention also provides a method of preparing an influenza virus comprising the steps of (a) providing a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct; (b) introducing into a cell which is not 293T one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the synthetic expression construct prepared in step (a); and (c) culturing the cell in order to produce a reassortant influenza virus from the viral segments introduced in step (b); wherein steps (a) to (c) are performed in a time period of 124 hours or less. The cell is preferably a non-human cell or a human non-kidney cell.
[0010] The methods may further comprise a step (d) contacting a cell which is of the same cell type as the cell used in step (c) with the virus produced in step (b) to produce further reassortant influenza virus.
[0011] The invention also provides a method of preparing an influenza virus, comprising the steps of (a) providing a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct; (b) introducing into a cell one or more expression construct(s) which encode(s) the viral segments of an influenza virus, wherein at least one expression construct is the synthetic expression construct prepared in step (a); (c) culturing the cell in order to produce a reassortant influenza virus from the viral segments introduced in step (b); and (d) contacting a cell which is of the same cell type as the cell used in step (c) with the virus produced in step (c) to produce further reassortant influenza virus; wherein steps (a) to (c) are performed in a time period of 124 hours or less. The cell used is preferably not 293T.
[0012] Further provided is a method of preparing an influenza vaccine, comprising the steps of (a) contacting a cell with the reassortant influenza virus prepared by a method according to the invention; (b) culturing the cell in order to produce an influenza virus; and (c) preparing a vaccine from the influenza virus produced in step (b). The cell used in the method is preferably a human non-kidney cell or a non-human cell. Alternatively, or in addition, the cell used in step (a) is of the same cell type as the cell which was used to rescue the influenza virus in the methods discussed in the preceding paragraphs. This is preferred because it facilitates regulatory approval, avoids conflicting culture conditions and avoids the need to retain two different cell types. The cell used is preferably not 293T as this cell is not approved for human vaccine manufacture.
[0013] The invention also provides a method of preparing a synthetic expression construct which encodes a viral segment from an influenza virus, comprising: (a) providing the sequence of at least part of the coding region of the HA or NA segment from an influenza virus; (b) identifying the HA and/or NA subtype of the influenza virus from which the coding region is derived; (c) providing a UTR sequence from an influenza virus with the same HA or NA subtype as the subtype identified in step (b); and (d) preparing a synthetic expression construct which encodes a viral segment comprising the coding sequence and the UTR.
The Synthetic Expression Construct
[0014] The synthetic expression construct is a DNA molecule which comprises coding sequences for expressing one or more viral RNA segment(s) of an influenza virus genome. The encoded segments can be expressed and then function as viral RNAs which can be packaged into virions to give recombinantly expressed virus. Thus the synthetic expression construct is suitable for producing an influenza virus by reverse genetics, either alone or in combination with other expression constructs.
[0015] The synthetic expression construct can be produced by (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, and (ii) joining the fragments to provide the synthetic expression construct.
[0016] The method can involve notionally splitting the desired DNA sequence into fragments which can be prepared by a chosen DNA synthesis method e.g. by phosphoramidite chemistry. References 6 and 7 report that the entire 16,299 base pair mouse mitochondrial genome could be synthesized from 600 overlapping 60-base oligonucleotides. The method uses Phusion DNA polymerase (New England Biolabs [NEB]), T5 exonuclease (Epicentre) and Taq DNA ligase (NEB) to join multiple DNA fragments during a brief 50° C. reaction (6). The inventors have discovered that this method can be used to generate synthetic DNA copies of the influenza virus genome and that the resulting method is particularly advantageous because it is rapid and readily automated. Joining the fragments in step (ii) of the methods described above can thus comprise contacting the fragments with a DNA polymerase and a DNA ligase. The method can be practised with any DNA polymerase which can amplify DNA, including Phusion® DNA polymerase and Taq DNA® polymerase. Preferably, the methods use a high fidelity DNA polymerase, such as Phusion® DNA polymerase, PFU®, AccuPrime® Taq DNA Polymerase, AMPLITAQ® GOLD DNA pol, T5 DNA polymerase, phi29 DNA polymerase, VENTR® DNA pol, Deep Vent DNA pol. etc. This is preferred because it decreases the error rate of the resulting DNA molecule. Suitable DNA ligases are also known to the skilled person and include Taq® DNA ligase, AMPLIGASE thermostable DNA ligase, and Tfi ligase. Reference 8 also discusses suitable ligases which can be used.
[0017] Suitable buffers and reaction conditions are described in references 6 and 7 and are also known to the skilled person. The methods can be performed at a temperature between 40° C. and 60° C., for example at a temperature between 45° C. and 55° C. or at a temperature of about 50° C. Preferably, the fragments are incubated with the DNA polymerase and the DNA ligase for a time period of between 15 and 60 minutes.
[0018] The synthetic expression constructs may be assembled from fragments with a size of about 30 nucleotides, at least 30 nucleotides, 40-60 nucleotides or at least 61 nucleotides. The fragments may also have a length of less than 40 nucleotides, less than 50 nucleotides, less than 60 nucleotides, less than 100 nucleotides, less than 200 nucleotides, less than 500 nucleotides, less than 1000 nucleotides, less than 5000 nucleotides, or less than 10000 nucleotides. Preferably, the synthetic expression constructs are assembled from fragments with a size of between 61 and 100 nucleotides, for example between 61 and 74 nucleotides. Such fragments are longer than the fragments used in the prior art. For example, references 6 and 7 used fragments with a length of 60 nucleotides. By using longer fragments, the inventors found that the speed for obtaining synthetic expression constructs was increased. This was unexpected as a skilled person would have expected longer fragments to be thermodynamically unfavourable and that it would be harder for overlaps to anneal to each other.
[0019] The fragments are synthesised and joined to give the synthetic expression constructs. This can be achieved by performing more than one joining (e.g. ligation) step. For example, some of the DNA fragments may be joined to give longer fragments, and these longer fragments can then be joined again, etc. until the complete synthetic expression construct is eventually prepared. Where the molecule is assembled step-wise in this fashion, the fragments at each stage may be maintained as inserts in vectors e.g. in plasmids or BAC or YAC vectors.
[0020] The synthetic expression construct may also be assembled using a single joining step (e.g. a single ligation step) and this is preferred because it allows for a faster assembly of the synthetic expression construct. In these embodiments, fragments which span the entire synthetic expression construct are treated with a joining agent (e.g. a DNA ligase) which assembles the whole synthetic expression construct in a single reaction.
[0021] The fragments can be designed to overlap, thereby facilitating the assembly in the correct order and this is preferred when the synthetic expression construct is assembled in a single joining step. It is preferred that the fragments overlap by at least 15 nucleotides, at least 20 nucleotides, at least 40 nucleotides or at least 60 nucleotides. This is preferred because the inventors have found that this increased overlap allowed rapid synthesis of the fragments with high accuracy. Thus the method may involve the synthesis of a plurality of overlapping fragments of the desired synthetic expression construct, such that the overlapping fragments span the complete synthetic expression construct. Both ends of each fragment overlap with a neighbouring 5' or 3' fragment, except for the terminal fragments of a linear molecule where no overlap is required (but if a circular molecule is desired, the two terminal fragments may overlap). Assembly of fragments during the synthetic process can involve in vitro and/or in vivo recombination. For in vitro methods, digestion with a 3' exonuclease can be used to expose overhangs at the terminus of a fragment, and complementary overhangs in overlapping fragments can then be annealed, followed by joint repair ("chewback assembly"). For in vivo methods, overlapping clones can be assembled using e.g. the TAR cloning method disclosed in reference 9. For fragments <100 kbp (e.g. easily enough to encode all segments of an influenza virus genome) it is readily possible to rely solely on in vitro recombination methods.
[0022] Other synthetic methods may be used. For instance, reference 10 discloses a method in which fragments of about 5 kbp are synthesised and then assembled into longer sequences by conventional cloning methods. Unpurified 40 base synthetic oligonucleotides are built into 500-800 bp synthons by automated PCR-based gene synthesis, and these synthons joined into multisynthon ˜5 kbp segments using a small number of endonucleases and "ligation by selection." These large segments can subsequently be assembled into longer sequences by conventional cloning. This method can readily provide a 32 kbp DNA molecule, which is easily enough to encode a complete influenza virus. Similarly, reference 11 discloses a method where a 32 kb molecule was assembled from seven DNA fragments which spanned the complete sequence. The ends of the seven DNAs were engineered with unique junctions, thereby permitting assembly only of adjacent fragments. The interconnecting restriction site junctions at the ends of each DNA are systematically removed after assembly.
[0023] Following the assembly of the synthetic expression construct, it is possible to amplify the whole or part of the synthetic expression construct. Methods for DNA amplification are known in the art and include, for example, polymerase chain reaction (PCR). Where only part of the synthetic expression construct is amplified it is preferred to amplify the part of the expression construct which encodes the one or more viral segments.
[0024] One drawback of the reference 6 method is that only 3% of the synthetic products have the correct sequence. In the prior art this problem was solved by cloning and sequencing subassemblies, and sets of error-free sequences were selected for subsequent rounds of assembly. Whilst this addresses the problem of errors in the resulting DNA molecule, the method is time-consuming and thus not suitable for use in a method which requires high speed and accuracy. The inventors have thus addressed the problem of error correction differently. In particular, they have discovered that the error rate can be decreased significantly by including an alternative error correction step. The invention thus provides a method of preparing a synthetic expression construct, comprising the steps of (i) synthesising a plurality of overlapping fragments of the synthetic expression construct, wherein the overlapping fragments span the complete synthetic expression construct, (ii) joining the fragments to provide a DNA molecule; (iii) melting the DNA molecule; (iv) re-annealing the DNA in the presence of an agent which excises mismatched nucleotides from the DNA molecule; and (v) amplifying the DNA to produce the synthetic expression construct. By including this additional step, the inventors were able to obtain full-length sequences in which 80-100% had the correct sequence. The DNA in step (v) can be amplified using DNA polymerases, preferably high-fidelity DNA polymerases, as known in the art and described above.
[0025] Suitable conditions for melting (i.e. dissociating the DNA double helix into single strands) and re-annealing DNA are known in the art. For example, the DNA can be melted by heating it to a temperature of at least 90° C. Likewise, the DNA can be re-annealed by reducing the temperature. The agent used to excise mismatched nucleotides is usually an enzyme such as, for example, the Res 1 enzyme (which is available in the ErrASE® error correction kit (Novici Biotech)), Cel I, T7 endonuclease I, S1 nuclease, T7 endonuclease, E. coli endo. V, Mung Bean endo., etc.
[0026] A synthetic expression construct may include one or more "watermark" sequences. These are sequences which can be used to identify or encode information in the DNA. It can be in either noncoding or coding sequences. Most commonly, it encodes information within coding sequences without altering the amino acid sequences. For DNAs encoding segmented RNA viral genomes, any watermark sequences are ideally included in intergenic sites because synonymous codon changes may have substantial biological effects for encoded RNA segments.
[0027] The synthetic expression construct may be linear (14) or circular. Circular synthetic expression constructs can be made by circularising linear constructs and vice versa. Methods for such circularisation are described in ref. 14. Linearisation of a circular molecule can be achieved in various easy ways e.g. by utilising one or more restriction enzyme(s), or by amplification from a template (including a circular template) using a nucleic acid amplification technique (e.g. by PCR).
[0028] Where the synthetic expression construct is circular, it is possible to contact the DNA following step (ii) with an agent (for example an enzyme) that degrades linear DNA. This has the advantage that linear synthetic expression constructs are selectively removed, thus selecting for the circular product. Suitable agents are known in the art and include, for example, T5 exonuclease, lambda exonuclease, and exonuclease III.
[0029] The synthetic expression construct may be incorporated into a vector, such as a plasmid or other episomal construct, using conventional techniques known in the art. The 3' and/or 5' terminal fragment of the synthetic expression construct may comprise an overhang which is complementary to an overhang on the vector, which facilitates the cloning of the synthetic expression construct (such that, for example, the synthetic expression construct may be cloned into an overhang created by a restriction enzyme). The vector may provide the regulatory sequences which are necessary to express the viral RNA segments from the DNA construct (e.g. RNA pol I promoter, RNA pol II promoter; RNA polymerase I transcription termination sequence, RNA polymerase II transcription termination sequence etc.). This can be advantageous because these sequences do then not need to be included in the synthetic expression construct. It is also possible to clone a synthetic expression construct without regulatory sequences into a vector that provides these sequences and subsequently amplifying a linear synthetic expression construct which comprises the original synthetic expression construct in conjunction with the regulatory sequences so that the resulting synthetic expression construct can then be used to express the viral segments.
Expression Constructs
[0030] The invention produces influenza viruses through reverse genetics techniques. In these techniques, the viruses may be produced in culture hosts using a synthetic expression construct which comprises coding sequences for expressing at least one segment of an influenza virus genome, as described in the preceding sections. The synthetic expression construct can drive expression in a eukaryotic cell of viral segments encoded therein. The expressed viral segment RNA can be translated into a viral protein that can be incorporated into a virion.
[0031] The term "synthetic expression construct" refers to an expression construct which has been prepared synthetically as described in the preceding sections, or which is derived from an expression construct prepared in this manner (for example by DNA amplification). It also encompasses vectors which comprise such an expression construct. The term "expression construct" encompasses both synthetic expression construct as well as expression constructs which were not prepared synthetically.
[0032] The synthetic expression construct may encode all the viral segments which are necessary to produce an influenza virus. Alternatively, it may encode one, two, three, four, five, six, or seven viral segments. Where the synthetic expression construct does not encode all the viral segments which are necessary to produce an influenza virus, the remaining viral segments are provided by one or more further expression construct(s). These one or more further expression constructs may also be synthetic expression constructs or they may be expression constructs which have been generated using alternative methods such as, for example, the methods described in reference 12.
[0033] Where the synthetic expression construct does not encode all the viral segments which are necessary to produce an influenza virus, the synthetic expression construct may encode the neuraminidase (NA) and/or hemagglutinin (HA) segments and the remaining vRNA encoding segments, excluding the HA and/or NA segment(s), are included on a different expression construct. This has the advantage that only the expression construct comprising the HA and/or NA segments needs to be replaced when a new influenza vaccine strain emerges (e.g. a new pandemic influenza virus or a new seasonal influenza virus).
[0034] The expression constructs may be uni-directional or bi-directional expression constructs. Where a host cell expresses more than one transgene (whether on the same or different expression constructs) it is possible to use uni-directional and/or bi-directional expression.
[0035] Bi-directional expression constructs contain at least two promoters which drive expression in different directions (i.e. both 5' to 3' and 3' to 5') from the same construct. The two promoters can be operably linked to different strands of the same double stranded DNA. Preferably, one of the promoters is a pol I promoter and at least one of the other promoters is a pol II promoter. This is useful as the pol I promoter can be used to express uncapped vRNAs while the pol II promoter can be used to transcribe mRNAs which can subsequently be translated into proteins, thus allowing simultaneous expression of RNA and protein from the same construct.
[0036] The pol I and pol II promoters used in the expression constructs may be endogenous to an organism from the same taxonomic order from which the host cell is derived. Alternatively, the promoters can be derived from an organism in a different taxonomic order than the host cell. The term "order" refers to conventional taxonomic ranking, and examples of orders are primates, rodentia, carnivora, marsupialia, cetacean, etc. Humans and chimpanzees are in the same taxonomic order (primates), but humans and dogs are in different orders (primates vs. carnivora). For example, the human pol I promoter can be used to express viral segments in canine cells (e.g. MDCK cells) [13]. Where more than one expression construct is used within an expression system, the promoters may be a mixture of endogenous and non-endogenous promoters.
[0037] The expression construct will typically include an RNA transcription termination sequence. The termination sequence may be an endogenous termination sequence or a termination sequence which is not endogenous to the host cell. Suitable termination sequences will be evident to those of skill in the art and include, but are not limited to, RNA polymerase I transcription termination sequence, RNA polymerase II transcription termination sequence, and ribozymes. Furthermore, the expression constructs may contain one or more polyadenylation signals for mRNAs, particularly at the end of a gene whose expression is controlled by a pol II promoter.
[0038] An expression construct may be a vector, such as a plasmid or other episomal construct. Such vectors will typically comprise at least one bacterial and/or eukaryotic origin of replication. Furthermore, the vector may comprise a selectable marker which allows for selection in prokaryotic and/or eukaryotic cells. Examples of such selectable markers are genes conferring resistance to antibiotics, such as ampicillin or kanamycin. The vector may further comprise one or more multiple cloning sites to facilitate cloning of a DNA sequence.
[0039] As an alternative, an expression construct may be a linear expression construct. Such linear expression constructs will typically not contain any amplification and/or selection sequences. However, linear constructs comprising such amplification and/or selection sequences are also within the scope of the present invention. An example of a method using such linear expression constructs for the expression of influenza virus is described in reference 14.
[0040] Where the expression construct is a linear expression construct, it is possible to linearise it before introduction into the host cell utilising a single restriction enzyme site. Alternatively, it is possible to excise the expression construct from a vector using at least two restriction enzyme sites. Furthermore, it is also possible to obtain a linear expression construct by amplifying it using a nucleic acid amplification technique (e.g. by PCR).
[0041] Where the expression construct is not a synthetic expression construct, it may be generated using methods known in the art. Such methods were described, for example, in reference 15.
[0042] The expression constructs of the invention can be introduced into host cells using any technique known to those of skill in the art. For example, expression constructs of the invention can be introduced into host cells by employing electroporation, DEAE-dextran, calcium phosphate precipitation, liposomes, microinjection, or microparticle-bombardment. Once transfected, the host cell will recognise genetic elements in the construct and will begin to express the encoded viral RNA segments.
[0043] The expression construct(s) can be introduced into the same cell type which is subsequently used for the propagation of the influenza viruses. Alternatively, the cells into which the expression constructs are introduced and the cells used for propagation of the influenza viruses may be different. In some embodiments, cells may be added following the introduction of the expression construct(s) into the cell, as described in reference 16. This is particularly preferred because it increases the rescue efficiency of the viruses further and can thus help to reduce the time required for viral rescue. The cells which are added may be of the same or a different cell type as the cell into which the expression construct(a) is/are introduced, but it is preferred to use cells of the same cell type as this facilitates regulatory approval and avoids conflicting culture conditions.
[0044] Where the expression host is a canine cell, such as a MDCK cell line, protein-coding regions may be optimised for canine expression e.g. using a promoter from a wild-type canine gene or from a canine virus, and/or having codon usage more suitable for canine cells than for human cells. For instance, whereas human genes slightly favour UUC as the codon for Phe (54%), in canine cells the preference is stronger (59%). Similarly, whereas there is no majority preference for Ile codons in human cells, 53% of canine codons use AUC for Ile. Canine viruses, such as canine parvovirus (a ssDNA virus) can also provide guidance for codon optimisation e.g. 95% of Phe codons in canine parvovirus sequences are UUU (vs. 41% in the canine genome), 68% of Ile codons are AUU (vs. 32%), 46% of Val codons are GUU (vs. 14%), 72% of Pro codons are CCA (vs. 25%), 87% of Tyr codons are UAU (vs. 40%), 87% of His codons are CAU (vs. 39%), 92% of Gln codons are CAA (vs. 25%), 81% of Glu codons are GAA (vs. 40%), 94% of Cys codons are UGU (vs. 42%), only 1% of Ser codons are UCU (vs. 24%), CCC is never used for Phe and UAG is never used as a stop codon. Thus protein-coding genes can be made more like genes which nature has already optimised for expression in canine cells, thereby facilitating expression.
Reverse Genetics
[0045] Reverse genetics for influenza viruses can be practised with 12 expression constructs to express the four proteins required to initiate replication and transcription (PB1, PB2, PA and NP) and all eight viral genome segments. To reduce the number of expression constructs, however, a plurality of RNA polymerase I transcription cassettes (for viral RNA synthesis) can be included on a single expression construct (e.g. sequences encoding 1, 2, 3, 4, 5, 6, 7 or all 8 influenza vRNA segments), and a plurality of protein-coding regions with RNA polymerase II promoters on another expression construct (e.g. sequences encoding 1, 2, 3, 4, 5, 6, 7 or 8 influenza mRNA transcripts) [17]. It is also possible to include one or more influenza vRNA segments under control of a pol I promoter and one or more influenza protein coding regions under control of another promoter, in particular a pol II promoter, on the same expression construct. This is preferably done by using bi-directional expression constructs.
[0046] Known reverse genetics systems involve expressing viral RNA (vRNA) molecules from pol I promoters, bacterial RNA polymerase promoters, bacteriophage polymerase promoters, etc. As influenza viruses require the presence of viral polymerase to initiate the life cycle, systems may also provide these proteins e.g. the system further comprises expression constructs that encode viral polymerase proteins such that expression of both types of DNA leads to assembly of a complete infectious virus. It is also possible to supply the viral polymerase as a protein.
[0047] Where reverse genetics is used for the expression of influenza vRNA, it will be evident to the person skilled in the art that precise spacing of the sequence elements with reference to each other is important for the polymerase to initiate replication. It is therefore important that the sequence encoding the viral RNA is positioned correctly between the pol I promoter and the termination sequence, but this positioning is well within the capabilities of those who work with reverse genetics systems.
[0048] In order to produce a recombinant virus, a cell must express all segments of the viral genome which are necessary to assemble a virion. The expression constructs preferably provide all of the viral RNA and proteins, but it is also possible to use a helper virus to provide some of the RNA and proteins, although systems which do not use a helper virus are preferred.
[0049] In some embodiments an expression construct will also be included which leads to expression of an accessory protein in the host cell. For instance, it can be advantageous to express a non-viral serine protease (e.g. trypsin) as part of a reverse genetics system.
Viral Segments
[0050] The synthetic expression construct encodes one or more viral segments. During the early days of an influenza pandemic it is not unusual to have sequences of the circulating strains available which include only the complete coding region but incomplete untranslated regions (UTRs). Awaiting the complete segment sequence (including the coding region and the UTRs) before commencing production of viruses costs time and delays the provision of the vaccines. The inventors have provided an improved method for preparing a synthetic expression construct encoding a viral segment, which method reduces the time required to obtain the viral segment. The method comprises the steps of: (a) providing the sequence of at least part of the coding region of the HA or NA segment from an influenza virus; (b) identifying the HA and/or NA subtype of the virus from which the coding region is derived; (c) providing a UTR sequence from an influenza virus with the same HA or NA subtype as the subtype identified in step (b); and (d) preparing a synthetic expression construct which encodes a viral segment comprising the coding sequence and the UTR.
[0051] The sequence of the coding region of the viral segment can be provided by sequencing the circulating strain. The sequence may also be obtained from other sources such as, for example, a health care authority. Preferably, the whole coding region is used in the method as this will facilitate the determination of the HA or NA subtype of the virus from which the coding region is derived. It is also possible to use at least part of the coding region provided the coding region is complete enough to allow the determination of the HA or NA subtype. This will generally be the case where a fragment covering at least 90%, at least 95%, or at least 99% of the full-length coding region is available. The viral segment used in the analysis is preferably the HA or NA segment.
[0052] The HA and/or NA subtype of the virus from which the coding sequence is derived can be determined using standard methods in the art. For example, the sequence of the coding region can be aligned to the sequences of coding regions from viruses with known HA and/or NA subtypes. The coding regions which are aligned need, of course, be the coding region of the same viral segment (e.g. the HA or NA segment). Influenza viral segments from viruses with the same HA and/or NA subtype will show the highest sequence identity between the sequences. Suitable programs for performing the analysis are known in the art and include BLAST®.
[0053] In order to provide a suitable UTR for the viral segment, the UTR of the viral strain which showed the highest sequence identity in step (a) can be used. Alternatively, the UTR can be identified by determining the consensus sequences of UTRs from viral strains with the same HA or NA subtype. This can be achieved by aligning two or more influenza strains with the same HA or NA subtype and determining the conserved residues in the UTRs. For example, the consensus sequence may be determined by aligning the UTRs from 2, 5, 10, 15, 20, 30 or more influenza strains with the same HA or NA subtype. The consensus UTR sequence can then be used to prepare the complete DNA molecule. Suitable programs for aligning multiple sequences are known in the art and include ClustalW2®.
[0054] Where the DNA molecules are prepared using a consensus UTR sequence, it is not necessary to determine this consensus sequence every time. Instead, the analysis can be performed for influenza virus strains with various HA and NA subtypes and the resulting UTRs for each HA and NA subtype can be kept in a database. Once the HA or NA subtype of the circulating strain has been determined it is then necessary only to choose the UTR of an influenza strain with the same HA or NA subtype from the database.
[0055] The DNA molecule comprising the coding sequence and the identified UTRs can be prepared by any of the methods described herein.
The Culture Host
[0056] The influenza viruses are typically produced using a cell line, although primary cells may be used as an alternative. The cell will typically be mammalian, although avian or insect cells can also be used. Suitable mammalian cells include, but are not limited to, human, hamster, cattle, primate and dog cells. In some embodiments, the cell is a human non-kidney cell or a non-human cell. Various cells may be used, such as kidney cells, fibroblasts, retinal cells, lung cells, etc. Examples of suitable hamster cells are the cell lines having the names BHK21 or HKCC. Suitable monkey cells are e.g. African green monkey cells, such as kidney cells as in the Vero cell line [18-20]. Suitable dog cells are e.g. kidney cells, as in the CLDK and MDCK cell lines. Suitable avian cells include the EBx cell line derived from chicken embryonic stem cells, EB45, EB14, and EB14-074 [21].
[0057] Further suitable cells include, but are not limited to: CHO; MRC 5; PER.C6 [22]; FRhL2; WI-38; etc. Suitable cells are widely available e.g. from the American Type Cell Culture (ATCC) collection [23], from the Coriell Cell Repositories [24], or from the European Collection of Cell Cultures (ECACC). For example, the ATCC supplies various different Vero cells under catalogue numbers CCL 81, CCL 81.2, CRL 1586 and CRL-1587, and it supplies MDCK cells under catalogue number CCL 34. PER.C6 is available from the ECACC under deposit number 96022940.
[0058] Preferred cells for use in the invention are MDCK cells [25-27], derived from Madin Darby canine kidney. The original MDCK cells are available from the ATCC as CCL 34. It is preferred that derivatives of these or other MDCK cells are used. Such derivatives were described, for instance, in reference 25 which discloses MDCK cells that were adapted for growth in suspension culture (`MDCK 33016` or `33016-PF`, deposited as DSM ACC 2219). Furthermore, reference 28 discloses MDCK-derived cells that grow in suspension in serum free culture (`B-702`, deposited as FERM BP-7449). In some embodiments, the MDCK cell line used may be tumorigenic, but it is also envisioned to use non-tumorigenic MDCK cells. For example, reference 29 discloses non-tumorigenic MDCK cells, including `MDCK-S` (ATCC PTA-6500), `MDCK-SF101` (ATCC PTA-6501), `MDCK-SF102` (ATCC PTA-6502) and `MDCK-SF103` (ATCC PTA-6503). Reference 30 discloses MDCK cells with high susceptibility to infection, including `MDCK.5F1` cells (ATCC CRL 12042).
[0059] It is possible to use a mixture of more than one cell type in the methods of the invention, but it is preferred to use a single cell type e.g. using monoclonal cells.
[0060] The cells used in the methods of the invention are preferably cells which are suitable for producing an influenza vaccine that can be used for administration to humans. Such cells must be derived from a cell bank system which is approved for vaccine manufacture and registered with a national control authority, and must be within the maximum number of passages permitted for vaccine production (see reference 31 for a summary). Examples of suitable cells which have been approved for vaccine manufacture include MDCK cells (like MDCK 33016; see reference 25), CHO cells, Vero cells, and PER.C6 cells. The methods of the invention preferably do not use 293T cells as these cells are not approved for vaccine manufacture.
[0061] Preferably, the cells used for preparing the virus and for preparing the vaccine are of the same cell type. For example, the cells may both be MDCK, Vero or PerC6 cells. This is preferred because it facilitates regulatory approval as approval needs to be obtained only for a single cell line. It also has the further advantage that competing culture selection pressures or different cell culture conditions can be avoided. The methods of the invention may also use the same cell line throughout, for example MDCK 33016.
[0062] The influenza viruses prepared according to the methods of the invention may subsequently be propagated in eggs. The current standard method for influenza virus growth for vaccines uses embryonated SPF hen eggs, with virus being purified from the egg contents (allantoic fluid). It is also possible to passage a virus through eggs and subsequently propagate it in cell culture and vice versa.
[0063] Preferably, the cells are cultured in the absence of serum, to avoid a common source of contaminants. Various serum-free media for eukaryotic cell culture are known to the person skilled in the art e.g. Iscove's medium, ultra CHO medium (BioWhittaker), EX-CELL (JRH Biosciences). Furthermore, protein-free media may be used e.g. PF-CHO (JRH Biosciences). Otherwise, the cells for replication can also be cultured in the customary serum-containing media (e.g. MEM or DMEM medium with 0.5% to 10% of fetal calf serum).
[0064] The cells may be in adherent culture or in suspension.
Reassortant Viruses
[0065] The reassortant influenza strains produced by the methods of the invention contain viral segments from a vaccine strain and one or more donor strain(s). The vaccine strain is the influenza strain which provides the HA segment of the reassortant influenza strain. The vaccine strain can be any strain and can vary from season to season.
[0066] A donor strain is an influenza strain which provides one or more of the backbone segments (i.e. those encoding PB1, PB2, PA, NP, M1, M2, NS1 and NS2) of the influenza strain. The NA segment may also be provided by a donor strain or it may be provided by the vaccine strain. The reassortant influenza strains of the invention may also comprise one or more, but not all, of the backbone segments from the vaccine strain. As the reassortant influenza virus contains a total of eight segments, it will therefore contain x (wherein x is from 1-7) viral segments from the vaccine strain and 8-x viral segments from the one or more donor strain(s).
[0067] The reassortant influenza virus strains may grow to higher or similar viral titres in cell culture and/or in eggs in the same time (for example 12 hours, 24 hours, 48 hours or 72 hours) and under the same growth conditions compared to the wild-type vaccine strain. In particular, they can grow to higher or similar viral titres in MDCK cells (such as MDCK 33016) in the same time and under the same growth conditions compared to the wild-type vaccine strain. The viral titre can be determined by standard methods known to those of skill in the art. Usefully, the reassortant viruses of the invention may achieve a viral titre which is at least 5% higher, at least 10% higher, at least 20% higher, at least 50% higher, at least 100% higher, at least 200% higher, or at least 500% higher than the viral titre of the wild-type vaccine strain in the same time frame and under the same conditions. The reassortant influenza viruses may also grow to similar viral titres in the same time and under the same growth conditions compared to the wild-type vaccine strain. A similar titre in this context means that the reassortant influenza viruses grow to a titre which is within 3% of the viral titre achieved with the wild-type vaccine strain in the same time and under the same growth conditions (i.e. wild-type titre±3%).
[0068] The reassortant viruses of the invention can contain the backbone segments from two or more donor strains, or at least one (i.e. one, two, three, four, five or six) backbone viral segment from a donor strain as described herein. The backbone viral segments are those which do not encode HA or NA. Thus, backbone segments will typically encode the PB1, PB2, PA, NP, M1, M2, NS1 and NS2 polypeptides of the influenza virus.
[0069] When the reassortant viruses of the invention are reassortants comprising the backbone segments from a single donor strain, the reassortant viruses will generally include segments from the donor strain and the vaccine strain in a ratio of 1:7, 2:6, 3:5, 4:4, 5:3, 6:2 or 7:1. Having a majority of segments from the donor strain, in particular a ratio of 6:2, is typical. When the reassortant viruses comprise backbone segments from two donor strains, the reassortant virus will generally include segments from the first donor strain, the seconds donor strain and the vaccine strain in a ratio of 1:1:6, 1:2:5, 1:3:4, 1:4:3, 1:5:2, 1:6:1, 2:1:5, 2:2:4, 2:3:3, 2:4:2, 2:5:1, 3:1:2, 3:2:1, 4:1:3, 4:2:2, 4:3:1, 5:1:2, 5:2:1 or 6:1:1. The reassortant influenza viruses may also comprise viral segments from more than two, for example from three, four, five or six donor strains.
[0070] Where the reassortant influenza virus comprises backbone segments from two or three donor strains, each donor strain may provide more than one of the backbone segments of the reassortant influenza virus, but one or two of the donor strains can also provide only a single backbone segment.
[0071] Where the reassortant influenza virus comprises backbone segments from two, three, four or five donor strains, one or two of the donor strains may provide more than one of the backbone segments of the reassortant influenza virus. In general the reassortant influenza virus cannot comprise more than six backbone segments. Accordingly, for example, if one of the donor strains provides five of the viral segments, the reassortant influenza virus can only comprise backbone segments from a total of two different donor strains.
[0072] In general a reassortant influenza virus will contain only one of each backbone segment. For example, when the influenza virus comprises the NP segment from B/Brisbane/60/08 it will not at the same time comprise the NP segment from another influenza strain.
[0073] Strains which can be used as vaccine strains include strains which are resistant to antiviral therapy (e.g. resistant to oseltamivir [32] and/or zanamivir), including resistant pandemic strains [33].
[0074] The reassortant influenza strains produced by the methods of the invention may comprise segments from a vaccine strain which is an inter-pandemic (seasonal) influenza vaccine strain. It may also comprise segments from a vaccine strain which is a pandemic strain or a potentially pandemic strain. The characteristics of an influenza strain that give it the potential to cause a pandemic outbreak are: (a) it contains a new hemagglutinin compared to the hemagglutinins in currently-circulating human strains, i.e. one that has not been evident in the human population for over a decade (e.g. H2), or has not previously been seen at all in the human population (e.g. H5, H6 or H9, that have generally been found only in bird populations), such that the human population will be immunologically naive to the strain's hemagglutinin; (b) it is capable of being transmitted horizontally in the human population; and (c) it is pathogenic to humans. A vaccine strain with H5 hemagglutinin type is preferred where the reassortant virus is used in vaccines for immunizing against pandemic influenza, such as a H5N1 strain. Other possible strains include H5N3, H9N2, H2N2, H7N1 and H7N7, and any other emerging potentially pandemic strains. The invention is particularly suitable for producing reassortant viruses for use in vaccine for protecting against potential pandemic virus strains that can or have spread from a non-human animal population to humans, for example a swine-origin H1N1 influenza strain.
[0075] The methods of the invention can be used to prepare reassortant influenza A strains and reassortant influenza B strains.
Reassortant Influenza A Viruses
[0076] Where the methods are used to prepare reassortant influenza A strains, the strains may contain the influenza A virus HA subtypes H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H11, H12, H13, H14, H15, H16 or H17. They may contain the influenza A virus NA subtypes N1, N2, N3, N4, N5, N6, N7, N8 or N9. Where the vaccine strain is a seasonal influenza strain, it may have a H1 or H3 subtype. In one aspect of the invention the vaccine strain is a H1N1 or H3N2 strain.
[0077] The reassortant influenza A viruses preferably comprise at least one backbone viral segment from the donor strain PR8-X. Thus, the influenza viruses of the invention may comprise one or more genome segments selected from: a PA segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 9, a PB1 segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 10, a PB2 segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 11, a M segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 13, a NP segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 12, and/or a NS segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 14. The reassortant influenza A virus may comprise all of these backbone segments.
[0078] Alternatively, or in addition, the reassortant influenza A virus may comprise one or more backbone viral segments from the 105p30 strain. Thus, where the reassortant influenza A virus comprises one or more genome segments from the 105p30 strain, the viral segments may have sequences selected from: a PA segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 42, a PB1 segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 43, a PB2 segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 44, a M segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 46, a NP segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 45, and/or a NS segment having at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identity to the sequence of SEQ ID NO: 47. The reassortant influenza A virus may comprise all of these backbone segments.
[0079] The reassortant influenza viruses may comprise backbone segments from two or more influenza donor strains. The inventors have found that such reassortant influenza A viruses grow particularly well in culture hosts. For example, the inventors have found that a reassortant influenza A virus comprising the NP, PB1 and PB2 segments from 105p30 and the M, NS and PA segments from PR8-X provided a higher rescue efficiency and grew faster compared to reassortant influenza A viruses which comprise all backbone segments from PR8-X. Likewise, a reassortant influenza A strain comprising the PB1 segment from A/California/4/09 and the other backbone segments from PR8-X often had greater rescue efficiencies and HA yields than reassortant influenza A viruses which comprise all backbone segments from PR8-X. Such reassortant influenza A viruses are particularly suitable for use in the methods of the invention because the increased rescue efficiency increases the speed further by which seed viruses for vaccine manufacture can be obtained.
[0080] Reassortant influenza A viruses with backbone segments from two or more influenza donor strains may comprise the HA segment and the PB1 segment from different influenza A strains. In these reassortant influenza viruses the PB1 segment may be from donor viruses with the same influenza virus HA subtype as the vaccine strain. For example, the PB1 segment and the HA segment may both be from influenza viruses with a H1 subtype. The reassortant influenza A viruses may also comprise the HA segment and the PB1 segment from different influenza A strains with different influenza virus HA subtypes, wherein the PB1 segment is not from an influenza virus with a H3 HA subtype and/or wherein the HA segment is not from an influenza virus with a H1 or H5 HA subtype. For example, the PB1 segment may be from a H1 virus and/or the HA segment may be from a H3 influenza virus. Where the reassortants contain viral segments from more than one influenza donor strain, the further donor strain(s) can be any donor strain. For example, some of the viral segments may be derived from the A/Puerto Rico/8/34 or A/Ann Arbor/6/60 influenza strains. Reassortants containing viral segments from the A/Ann Arbor/6/60 strain may be advantageous, for example, where the reassortant virus is to be used in a live attenuated influenza vaccine.
[0081] The reassortant influenza A virus may also comprise backbone segments from two or more influenza donor strains, wherein the PB1 segment is from the A/California/07/09 influenza strain. This segment may have at least 95% identity, at least 96% identity, at least 97% identity, at least 98% identity, at least 99% identity or 100% identity with the sequence of SEQ ID NO: 24. The reassortant influenza A virus may have the H1 HA subtype. It will be understood that a reassortant influenza virus according to this aspect of the invention will not comprise the HA and/or NA segments from A/California/07/09.
[0082] The reassortant influenza strains may comprise the HA segment and/or the NA segment from an A/California/4/09 strain. Thus, for instance, the HA gene segment may encode a H1 hemagglutinin which is more closely related to SEQ ID NO: 70 than to SEQ ID NO: 50 (i.e. has a higher degree sequence identity when compared to SEQ ID NO: 70 than to SEQ ID NO: 50 using the same algorithm and parameters). SEQ ID NOs: 70 and 50 are 80% identical. Similarly, the NA gene may encode a N1 neuraminidase which is more closely related to SEQ ID NO: 99 than to SEQ ID NO: 51. SEQ ID NOs: 99 and 51 are 82% identical.
[0083] The reassortant influenza A virus may also comprise at least one backbone viral segment from the A/California/07/09 influenza strain. When the at least one backbone viral segment is the PA segment it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 23. When the at least one backbone viral segment is the PB1 segment, it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 24. When the at least one backbone viral segment is the PB2 segment, it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 25. When the at least one backbone viral segment is the NP segment it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 26. When the at least one backbone viral segment is the M segment it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 27. When the at least one backbone viral segment is the NS segment it may have a sequence having at least 95%, at least 96%, at least 97% or at least 99% identity with the sequence of SEQ ID NO: 28.
[0084] Where a reassortant influenza A virus comprises the PB1 segment from A/Texas/1/77, it preferably does not comprise the PA, NP or M segment from A/Puerto Rico/8/34. Where a reassortant influenza A virus comprises the PA, NP or M segment from A/Puerto Rico/8/34, it preferably does not comprise the PB1 segment from A/Texas/1/77. In some embodiments, the invention does not encompass reassortant influenza A viruses which have the PB1 segment from A/Texas/1/77 and the PA, NP and M segments from A/Puerto Rico/8/34. The PB1 protein from A/Texas/1/77 may have the sequence of SEQ ID NO: 29 and the PA, NP or M proteins from A/Puerto Rico/8/34 may have the sequence of SEQ ID NOs 30, 31 or 32, respectively.
[0085] The backbone viral segments may be optimized for culture in the specific culture host. For example, where the reassortant influenza viruses are cultured in mammalian cells, it is advantageous to adapt at least one of the viral segments for optimal growth in the culture host. For example, where the expression host is a canine cell, such as a MDCK cell line, the viral segments may have a sequence which optimises viral growth in the cell. Thus, the reassortant influenza viruses of the invention may comprise a PB2 genome segment which has lysine in the position corresponding to amino acid 389 of SEQ ID NO: 3 when aligned to SEQ ID NO: 3 using a pairwise alignment algorithm, and/or asparagine in the position corresponding to amino acid 559 of SEQ ID NO: 3 when aligned to SEQ ID NO: 3 using a pairwise alignment algorithm. Also provided are reassortant influenza viruses in accordance with the invention in which the PA genome segment has lysine in the position corresponding to amino acid 327 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1 using a pairwise alignment algorithm, and/or aspartic acid in the position corresponding to amino acid 444 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1, using a pairwise alignment algorithm, and/or aspartic acid in the position corresponding to amino acid 675 of SEQ ID NO: 1 when aligned to SEQ ID NO: 1, using a pairwise alignment algorithm. The reassortant influenza strains of the invention may also have a NP genome segment with threonine in the position corresponding to amino acid 27 of SEQ ID NO: 4 when aligned to SEQ ID NO: 4 using a pairwise alignment algorithm, and/or asparagine in the position corresponding to amino acid 375 of SEQ ID NO: 4 when aligned to SEQ ID NO: 4, using a pairwise alignment algorithm. Variant influenza strains may also comprise two or more of these mutations. It is preferred that the variant influenza virus contains a variant PB2 segment with both of the amino acids changes identified above, and/or a PA which contains all three of the amino acid changes identified above, and/or a NP segment which contains both of the amino acid changes identified above. The influenza A virus may be a H1 strain.
[0086] Alternatively, or in addition, the reassortant influenza A viruses may comprise a PB1 segment which has isoleucine in the position corresponding to amino acid 200 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm, and/or asparagine in the position corresponding to amino acid 338 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm, and/or isoleucine in the position corresponding to amino acid 529 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm, and/or isoleucine in the position corresponding to amino acid 591 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm, and/or histidine in the position corresponding to amino acid 687 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm, and/or lysine in the position corresponding to amino acid 754 of SEQ ID NO: 2 when aligned to SEQ ID NO: 2 using a pairwise alignment algorithm.
[0087] The preferred pairwise alignment algorithm is the Needleman-Wunsch global alignment algorithm [34], using default parameters (e.g. with Gap opening penalty=10.0, and with Gap extension penalty=0.5, using the EBLOSUM62 scoring matrix). This algorithm is conveniently implemented in the needle tool in the EMBOSS package [35].
[0088] The choice of donor strain for use in the methods of the invention can depend on the vaccine strain which is to be reassorted. As reassortants between evolutionary distant strains might not replicate well in cell culture, it is possible that the donor strain and the vaccine strain have the same HA and/or NA subtype. In other embodiments, however, the vaccine strain and the donor strain can have different HA and/or NA subtypes, and this arrangement can facilitate selection for reassortant viruses that contain the HA and/or NA segment from the vaccine strain. Therefore, although the 105p30 and PR8-X strains contain the H1 influenza subtype these donor strains can be used for vaccine strains which do not contain the H1 influenza subtype.
[0089] Reassortants of the donor strains wherein the HA and/or NA segment has been changed to another subtype can also be used. The H1 influenza subtype of the 105p30 or PR8-X strain may be changed, for example, to a H3 or H5 subtype.
[0090] Thus, an influenza A virus may comprises one, two, three, four, five, six or seven viral segments from the 105p30 or PR8-X strains and a HA segment which is not of the H1 subtype. The reassortant donor strains may further comprise an NA segment which is not of the N1 subtype.
[0091] The reassortant donor strains may comprise at least one, at least two, at least three, at least four, at least five, at least six or at least seven viral segments from the 105p30 or PR8-X strains of the invention and a H1 HA segment which is derived from a different influenza strain.
[0092] The `second influenza strain` used in the methods of the invention is different to the donor strain which is used.
Reassortant Influenza B Viruses
[0093] The invention can also be used to prepare reassortant influenza B strains.
[0094] For example, the methods can be used to produce a reassortant influenza B virus which comprises the HA segment from a first influenza B virus and the NP and/or PB2 segment from a second influenza B virus which is a B/Victoria/2/87-like strain. The B/Victoria/2/87-like strain may be B/Brisbane/60/08.
[0095] The methods can also be used to produce reassortant influenza B viruses comprising the HA segment from a first influenza B virus and the NP segment from a second influenza B virus which is not B/Lee/40 or B/Ann Arbor/1/66 or B/Panama/45/90. For example, the reassortant influenza B virus may have a NP segment which does not have the sequence of SEQ ID NOs: 80, 100, 103 or 104. The reassortant influenza B virus may also have a NP segment which does not encode the protein of SEQ ID NOs: 19, 23, 44 or 45. The reassortant influenza B virus may comprise both the NP and PB2 segments from the second influenza B virus. The second influenza B virus is preferably a B/Victoria/2/87-like strain. The B/Victoria/2/87-like strain may be B/Brisbane/60/08.
[0096] The invention can also be used to produce a reassortant influenza B virus comprising the HA segment from a B/Yamagata/16/88-like strain and at least one backbone segment from a B/Victoria/2/87-like strain. The reassortant influenza B virus may comprise two, three, four, five or six backbone segments from the B/Victoria/2/87-like strain. In a preferred embodiment, the reassortant influenza B virus comprises all the backbone segments from the B/Victoria/2/87-like strain. The B/Victoria/2/87-like strain may be B/Brisbane/60/08.
[0097] The methods are also suitable for producing a reassortant influenza B virus comprising viral segments from a B/Victoria/2/87-like strain and a B/Yamagata/16/88-like strain, wherein the ratio of segments from the B/Victoria/2/87-like strain and the B/Yamagata/16/88-like strain is 1:7, 2:6, 4:4, 5:3, 6:2 or 7:1. A ratio of 7:1, 6:2, 4:4, 3:4 or 1:7, in particular a ratio of 4:4, is preferred because such reassortant influenza B viruses grow particularly well in a culture host. The B/Victoria/2/87-like strain may be B/Brisbane/60/08. The B/Yamagata/16/88-like strain may be B/Panama/45/90. In these embodiments, the reassortant influenza B virus usually does not comprise all backbone segments from the same influenza B donor strain.
[0098] The methods can also be used to produce a reassortant influenza B virus which comprises:
a) the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 72, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 76 and the M segment of SEQ ID NO: 75; or b) the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 78, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 82 and the M segment of SEQ ID NO: 81; or c) the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 78, the PB2 segment of SEQ ID NO: 79, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 76 and the M segment of SEQ ID NO: 75; or d) the PA segment of SEQ ID NO: 30, the PB1 segment of SEQ ID NO: 72, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 76 and the M segment of SEQ ID NO: 75, or e) the PA segment of SEQ ID NO: 71, the PB1 segment of SEQ ID NO: 72, the PB2 segment of SEQ ID NO: 73, the NP segment of SEQ ID NO: 74, the NS segment of SEQ ID NO: 82 and the M segment of SEQ ID NO: 81.
[0099] Influenza B viruses currently do not display different HA subtypes, but influenza B virus strains do fall into two distinct lineages. These lineages emerged in the late 1980s and have HAs which can be antigenically and/or genetically distinguished from each other [36]. Current influenza B virus strains are either B/Victoria/2/87-like or B/Yamagata/16/88-like. These strains are usually distinguished antigenically, but differences in amino acid sequences have also been described for distinguishing the two lineages e.g. B/Yamagata/16/88-like strains often (but not always) have HA proteins with deletions at amino acid residue 164, numbered relative to the `Lee40` HA sequence [37]. In some embodiments, the reassortant influenza B viruses of the invention may comprise viral segments from a B/Victoria/2/87-like strain. They may comprise viral segments from a B/Yamagata/16/88-like strain. Alternatively, they may comprise viral segments from a B/Victoria/2/87-like strain and a B/Yamagata/16/88-like strain.
[0100] Where the reassortant influenza B virus comprises viral segments from two or more influenza B virus strains, these viral segments may be derived from influenza strains which have related neuraminidases. For instance, the influenza strains which provide the viral segments may both have a B/Victoria/2/87-like neuraminidase [38] or may both have a B/Yamagata/16/88-like neuraminidase. For example, two B/Victoria/2/87-like neuraminidases may both have one or more of the following sequence characteristics: (1) not a serine at residue 27, but preferably a leucine; (2) not a glutamate at residue 44, but preferably a lysine; (3) not a threonine at residue 46, but preferably an isoleucine; (4) not a proline at residue 51, but preferably a serine; (5) not an arginine at residue 65, but preferably a histidine; (6) not a glycine at residue 70, but preferably a glutamate; (7) not a leucine at residue 73, but preferably a phenylalanine; and/or (8) not a proline at residue 88, but preferably a glutamine. Similarly, in some embodiments the neuraminidase may have a deletion at residue 43, or it may have a threonine; a deletion at residue 43, arising from a trinucleotide deletion in the NA gene, which has been reported as a characteristic of B/Victoria/2/87-like strains, although recent strains have regained Thr-43 [38]. Conversely, of course, the opposite characteristics may be shared by two B/Yamagata/16/88-like neuraminidases e.g. S27, E44, T46, P51, R65, G70, L73, and/or P88. These amino acids are numbered relative to the `Lee40` neuraminidase sequence [39]. The reassortant influenza B virus may comprise a NA segment with the characteristics described above. Alternatively, or in addition, the reassortant influenza B virus may comprise a viral segment (other than NA) from an influenza strain with a NA segment with the characteristics described above.
[0101] The backbone viral segments of an influenza B virus which is a B/Victoria/2/87-like strain can have a higher level of identity to the corresponding viral segment from B/Victoria/2/87 than it does to the corresponding viral segment of B/Yamagata/16/88 and vice versa. For example, the NP segment of B/Panama/45/90 (which is a B/Yamagata/16/88-like strain) has 99% identity to the NP segment of B/Yamagata/16/88 and only 96% identity to the NP segment of B/Victoria/2/87.
[0102] Where the reassortant influenza B virus of the invention comprises a backbone viral segment from a B/Victoria/2/87-like strain, the viral segments may encode proteins with the following sequences. The PA protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 83. The PB1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 84. The PB2 protein may have at least 97%, at least 98%, at least 99% or 100% identity with the sequence of SEQ ID NO: 85. The NP protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 86. The M1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 87. The M2 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 88. The NS1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 89. The NS2 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 90. In some embodiments, the reassortant influenza B virus may also comprise all of these backbone segments.
[0103] Where the reassortant influenza B viruses of the invention comprise a backbone viral segment from a B/Yamagata/16/88-like strain, the viral segment may encode proteins with the following sequences. The PA protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 91. The PB1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 92. The PB2 protein may have at least 97%, at least 98%, at least 99% or 100% identity with the sequence of SEQ ID NO: 93. The NP protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 94. The M1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 95. The M2 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 96. The NS1 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 97. The NS2 protein may have at least 97% identity, at least 98%, at least 99% identity or 100% identity to the sequence of SEQ ID NO: 98.
[0104] The invention can be practised with donor strains having a viral segment that has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95% or at least about 99%, or 100% identity to a sequence of SEQ ID NOs 71-76 or 77-82. Due to the degeneracy of the genetic code, it is possible to have the same polypeptide encoded by several nucleic acids with different sequences. For example, the nucleic acid sequences of SEQ ID NOs: 33 and 34 have only 73% identity even though they encode the same viral protein. Thus, the invention may be practised with viral segments that encode the same polypeptides as the sequences of SEQ ID NOs 71-76 or 77-82.
[0105] Reassortant viruses which contain an NS segment that does not encode a functional NS protein are also within the scope of the present invention. NS1 knockout mutants are described in reference 40. These NS1-mutant virus strains are particularly suitable for preparing live attenuated influenza vaccines.
[0106] The `second influenza strain` used in the methods of the invention is different to the donor strain which is used.
Backbone Libraries
[0107] In order to supply influenza vaccines rapidly during a pandemic it is important that the reassortant influenza viruses can grow to high viral titres in a short time frame. The inventors have discovered that it can be useful to test a number of reassortant influenza viruses comprising the HA and NA segments of the vaccine strain in combination with different backbones in order to identify the fastest growing reassortants. The invention thus provides a library comprising two or more influenza backbones. For example, the library may comprise 5, 10, 15, 20, 30, 40, 50, 100 or 200 different influenza backbones. The backbones may be included on expression constructs in the library. In some embodiments, the library may not comprise expression constructs which encode the HA and/or NA segments of influenza viruses as these segments will come from the circulating influenza strain. The library may comprise at least one influenza backbone as described in the preceding sections.
[0108] Each expression construct in the library may encode all the backbone segments of an influenza virus. It is also possible to include expression constructs which do not encode all the backbone segments. For example, the library may comprise expression constructs which encode one, two, three, four, five, six or seven viral backbone segment(s).
[0109] When a new circulating strain is identified, the HA and NA segments of that strain may be included in an expression construct (which may be a synthetic expression construct). This expression construct and the expression constructs in the library can be co-transfected into host cells (which are preferably all of the same cell line or the same cell type). Cells which receive expression constructs that encode all the viral segments of an influenza virus will produce reassortant influenza viruses from these expression constructs. In this manner, it is possible to produce a number of different reassortant influenza viruses which all comprise the same HA and NA segments but which will have different backbone segments. The growth rate of these reassortant influenza viruses can be determined using standard methods in the art and the fastest growing reassortant can be selected for vaccine production.
Virus Preparation
[0110] In one embodiment, the invention provides a method for producing influenza viruses comprising steps of (a) infecting a culture host with a reassortant virus of the invention; (b) culturing the host from step (a) to produce the virus; and optionally (c) purifying the virus produced in step (b).
[0111] The culture host may be cells or embryonated hen eggs, as described above. Where cells are used as a culture host in this aspect of the invention, it is known that cell culture conditions (e.g. temperature, cell density, pH value, etc.) are variable over a wide range subject to the cell line and the virus employed and can be adapted to the requirements of the application. The following information therefore merely represents guidelines.
[0112] As mentioned above, cells are preferably cultured in serum-free or protein-free media.
[0113] Multiplication of the cells can be conducted in accordance with methods known to those of skill in the art. For example, the cells can be cultivated in a perfusion system using ordinary support methods like centrifugation or filtration. Moreover, the cells can be multiplied according to the invention in a fed-batch system before infection. In the context of the present invention, a culture system is referred to as a fed-batch system in which the cells are initially cultured in a batch system and depletion of nutrients (or part of the nutrients) in the medium is compensated by controlled feeding of concentrated nutrients. It can be advantageous to adjust the pH value of the medium during multiplication of cells before infection to a value between pH 6.6 and pH 7.8 and especially between a value between pH 7.2 and pH 7.3. Culturing of cells preferably occurs at a temperature between 30 and 40° C. When culturing the infected cells (step b), the cells are preferably cultured at a temperature of between 30° C. and 36° C. or between 32° C. and 34° C. or at 33° C. This is particularly preferred, as it has been shown that incubation of infected cells in this temperature range results in production of a virus that results in improved efficacy when formulated into a vaccine [41].
[0114] Oxygen partial pressure can be adjusted during culturing before infection preferably at a value between 25% and 95% and especially at a value between 35% and 60%. The values for the oxygen partial pressure stated in the context of the invention are based on saturation of air. Infection of cells occurs at a cell density of preferably about 8-25×105 cells/mL in the batch system or preferably about 5-20×106 cells/mL in the perfusion system. The cells can be infected with a viral dose (MOI value, "multiplicity of infection"; corresponds to the number of virus units per cell at the time of infection) between 10-8 and 10, preferably between 0.0001 and 0.5.
[0115] Virus may be grown on cells in adherent culture or in suspension. Microcarrier cultures can be used. In some embodiments, the cells may thus be adapted for growth in suspension.
[0116] The methods according to the invention also include harvesting and isolation of viruses or the proteins generated by them. During isolation of viruses or proteins, the cells are separated from the culture medium by standard methods like separation, filtration or ultrafiltration. The viruses or the proteins are then concentrated according to methods sufficiently known to those skilled in the art, like gradient centrifugation, filtration, precipitation, chromatography, etc., and then purified. It is also preferred according to the invention that the viruses are inactivated during or after purification. Virus inactivation can occur, for example, by β-propiolactone or formaldehyde at any point within the purification process.
[0117] The culture host may be eggs. The current standard method for influenza virus growth for vaccines uses embryonated SPF hen eggs, with virus being purified from the egg contents (allantoic fluid). It is also possible to passage a virus through eggs and subsequently propagate it in cell culture and vice versa.
Vaccine
[0118] The invention utilises virus produced according to the method to produce vaccines.
[0119] Vaccines (particularly for influenza virus) are generally based either on live virus or on inactivated virus. Inactivated vaccines may be based on whole virions, split virions, or on purified surface antigens. Antigens can also be presented in the form of virosomes. The invention can be used for manufacturing any of these types of vaccine.
[0120] Where an inactivated virus is used, the vaccine may comprise whole virion, split virion, or purified surface antigens (for influenza, including hemagglutinin and, usually, also including neuraminidase). Chemical means for inactivating a virus include treatment with an effective amount of one or more of the following agents: detergents, formaldehyde, β-propiolactone, methylene blue, psoralen, carboxyfullerene (C60), binary ethylamine, acetyl ethyleneimine, or combinations thereof. Non-chemical methods of viral inactivation are known in the art, such as for example UV light or gamma irradiation.
[0121] Virions can be harvested from virus-containing fluids, e.g. allantoic fluid or cell culture supernatant, by various methods. For example, a purification process may involve zonal centrifugation using a linear sucrose gradient solution that includes detergent to disrupt the virions. Antigens may then be purified, after optional dilution, by diafiltration.
[0122] Split virions are obtained by treating purified virions with detergents (e.g. ethyl ether, polysorbate 80, deoxycholate, tri-N-butyl phosphate, Triton X-100, Triton N101, cetyltrimethylammonium bromide, Tergitol NP9, etc.) to produce subvirion preparations, including the `Tween-ether` splitting process. Methods of splitting influenza viruses, for example are well known in the art e.g. see refs. 42-47, etc. Splitting of the virus is typically carried out by disrupting or fragmenting whole virus, whether infectious or non-infectious with a disrupting concentration of a splitting agent. The disruption results in a full or partial solubilisation of the virus proteins, altering the integrity of the virus. Preferred splitting agents are non-ionic and ionic (e.g. cationic) surfactants e.g. alkylglycosides, alkylthioglycosides, acyl sugars, sulphobetaines, betains, polyoxyethylenealkylethers, N,N-dialkyl-Glucamides, Hecameg, alkylphenoxy-polyethoxyethanols, NP9, quaternary ammonium compounds, sarcosyl, CTABs (cetyl trimethyl ammonium bromides), tri-N-butyl phosphate, Cetavlon, myristyltrimethylammonium salts, lipofectin, lipofectamine, and DOT-MA, the octyl- or nonylphenoxy polyoxyethanols (e.g. the Triton surfactants, such as Triton X-100 or Triton N101), polyoxyethylene sorbitan esters (the Tween surfactants), polyoxyethylene ethers, polyoxyethlene esters, etc. One useful splitting procedure uses the consecutive effects of sodium deoxycholate and formaldehyde, and splitting can take place during initial virion purification (e.g. in a sucrose density gradient solution). Thus a splitting process can involve clarification of the virion-containing material (to remove non-virion material), concentration of the harvested virions (e.g. using an adsorption method, such as CaHPO4 adsorption), separation of whole virions from non-virion material, splitting of virions using a splitting agent in a density gradient centrifugation step (e.g. using a sucrose gradient that contains a splitting agent such as sodium deoxycholate), and then filtration (e.g. ultrafiltration) to remove undesired materials. Split virions can usefully be resuspended in sodium phosphate-buffered isotonic sodium chloride solution. Examples of split influenza vaccines are the BEGRIVAC®, FLUARIX®, FLUZONE® and FLUSHIELD® products.
[0123] Purified influenza virus surface antigen vaccines comprise the surface antigens hemagglutinin and, typically, also neuraminidase. Processes for preparing these proteins in purified form are well known in the art. The FLUVIRIN®, AGRIPPAL® and INFLUVAC® products are influenza subunit vaccines.
[0124] Another form of inactivated antigen is the virosome [48] (nucleic acid free viral-like liposomal particles). Virosomes can be prepared by solubilization of virus with a detergent followed by removal of the nucleocapsid and reconstitution of the membrane containing the viral glycoproteins. An alternative method for preparing virosomes involves adding viral membrane glycoproteins to excess amounts of phospholipids, to give liposomes with viral proteins in their membrane.
[0125] The methods of the invention may also be used to produce live vaccines. Such vaccines are usually prepared by purifying virions from virion-containing fluids. For example, the fluids may be clarified by centrifugation, and stabilized with buffer (e.g. containing sucrose, potassium phosphate, and monosodium glutamate). Various forms of influenza virus vaccine are currently available (e.g. see chapters 17 & 18 of reference 49). Live virus vaccines include MedImmune's FLUMIST® product (trivalent live virus vaccine).
[0126] The virus may be attenuated. The virus may be temperature-sensitive. The virus may be cold-adapted. These three features are particularly useful when using live virus as an antigen.
[0127] HA is the main immunogen in current inactivated influenza vaccines, and vaccine doses are standardised by reference to HA levels, typically measured by SRID. Existing vaccines typically contain about 15 μg of HA per strain, although lower doses can be used e.g. for children, or in pandemic situations, or when using an adjuvant. Fractional doses such as 1/2 (i.e. 7.5 μg HA per strain), 1/4 and 1/8 have been used, as have higher doses (e.g. 3× or 9× doses [50,51]). Thus vaccines may include between 0.1 and 150 μg of HA per influenza strain, preferably between 0.1 and 50 μg e.g. 0.1-10 μg, 0.5-5 μg, etc. Particular doses include e.g. about 45, about 30, about 15, about 10, about 7.5, about 5, about 3.8, about 3.75, about 1.9, about 1.5, etc. per strain.
[0128] For live vaccines, dosing is measured by median tissue culture infectious dose (TCID50) rather than HA content, and a TCID50 of between 106 and 108 (preferably between 1065-1075) per strain is typical.
[0129] Influenza strains used with the invention may have a natural HA as found in a wild-type virus, or a modified HA. For instance, it is known to modify HA to remove determinants (e.g. hyper-basic regions around the HA1/HA2 cleavage site) that cause a virus to be highly pathogenic in avian species. The use of reverse genetics facilitates such modifications.
[0130] As well as being suitable for immunizing against inter-pandemic strains, the compositions of the invention are particularly useful for immunizing against pandemic or potentially-pandemic strains. The invention is suitable for vaccinating humans as well as non-human animals.
[0131] Other strains whose antigens can usefully be included in the compositions are strains which are resistant to antiviral therapy (e.g. resistant to oseltamivir [52] and/or zanamivir), including resistant pandemic strains [53].
[0132] Compositions of the invention may include antigen(s) from one or more (e.g. 1, 2, 3, 4 or more) influenza virus strains, including influenza A virus and/or influenza B virus provided that at least one influenza strain is a reassortant influenza strain of the invention. Compositions wherein at least two, at least three or all of the antigens are from reassortant influenza strains of the invention are also envisioned. Where a vaccine includes more than one strain of influenza, the different strains are typically grown separately and are mixed after the viruses have been harvested and antigens have been prepared. Thus a process of the invention may include the step of mixing antigens from more than one influenza strain. A trivalent vaccine is typical, including antigens from two influenza A virus strains and one influenza B virus strain. A tetravalent vaccine is also useful [54], including antigens from two influenza A virus strains and two influenza B virus strains, or three influenza A virus strains and one influenza B virus strain.
Pharmaceutical Compositions
[0133] Vaccine compositions manufactured according to the invention are pharmaceutically acceptable. They usually include components in addition to the antigens e.g. they typically include one or more pharmaceutical carrier(s) and/or excipient(s). As described below, adjuvants may also be included. A thorough discussion of such components is available in reference 55.
[0134] Vaccine compositions will generally be in aqueous form. However, some vaccines may be in dry form, e.g. in the form of injectable solids or dried or polymerized preparations on a patch.
[0135] Vaccine compositions may include preservatives such as thiomersal or 2-phenoxyethanol. It is preferred, however, that the vaccine should be substantially free from (i.e. less than 5 μg/ml) mercurial material e.g. thiomersal-free [46,56]. Vaccines containing no mercury are more preferred. An α-tocopherol succinate can be included as an alternative to mercurial compounds [46]. Preservative-free vaccines are particularly preferred.
[0136] To control tonicity, it is preferred to include a physiological salt, such as a sodium salt. Sodium chloride (NaCl) is preferred, which may be present at between 1 and 20 mg/ml. Other salts that may be present include potassium chloride, potassium dihydrogen phosphate, disodium phosphate dehydrate, magnesium chloride, calcium chloride, etc.
[0137] Vaccine compositions will generally have an osmolality of between 200 mOsm/kg and 400 mOsm/kg, preferably between 240-360 mOsm/kg, and will more preferably fall within the range of 290-310 mOsm/kg. Osmolality has previously been reported not to have an impact on pain caused by vaccination [57], but keeping osmolality in this range is nevertheless preferred.
[0138] Vaccine compositions may include one or more buffers. Typical buffers include: a phosphate buffer; a Tris buffer; a borate buffer; a succinate buffer; a histidine buffer (particularly with an aluminum hydroxide adjuvant); or a citrate buffer. Buffers will typically be included in the 5-20 mM range.
[0139] The pH of a vaccine composition will generally be between 5.0 and 8.1, and more typically between 6.0 and 8.0 e.g. 6.5 and 7.5, or between 7.0 and 7.8. A process of the invention may therefore include a step of adjusting the pH of the bulk vaccine prior to packaging.
[0140] The vaccine composition is preferably sterile. The vaccine composition is preferably non-pyrogenic e.g. containing <1 EU (endotoxin unit, a standard measure) per dose, and preferably <0.1 EU per dose. The vaccine composition is preferably gluten-free.
[0141] Vaccine compositions of the invention may include detergent e.g. a polyoxyethylene sorbitan ester surfactant (known as `Tweens`), an octoxynol (such as octoxynol-9 (Triton X-100) or t-octylphenoxypolyethoxyethanol), a cetyl trimethyl ammonium bromide (`CTAB`), or sodium deoxycholate, particularly for a split or surface antigen vaccine. The detergent may be present only at trace amounts. Thus the vaccine may include less than 1 mg/ml of each of octoxynol-10 and polysorbate 80. Other residual components in trace amounts could be antibiotics (e.g. neomycin, kanamycin, polymyxin B).
[0142] A vaccine composition may include material for a single immunisation, or may include material for multiple immunisations (i.e. a `multidose` kit). The inclusion of a preservative is preferred in multidose arrangements. As an alternative (or in addition) to including a preservative in multidose compositions, the compositions may be contained in a container having an aseptic adaptor for removal of material.
[0143] Influenza vaccines are typically administered in a dosage volume of about 0.5 ml, although a half dose (i.e. about 0.25 ml) may be administered to children.
[0144] Compositions and kits are preferably stored at between 2° C. and 8° C. They should not be frozen. They should ideally be kept out of direct light.
Host Cell DNA
[0145] Where virus has been isolated and/or grown on a cell line, it is standard practice to minimize the amount of residual cell line DNA in the final vaccine, in order to minimize any potential oncogenic activity of the DNA.
[0146] Thus a vaccine composition prepared according to the invention preferably contains less than 10 ng (preferably less than ing, and more preferably less than 100 pg) of residual host cell DNA per dose, although trace amounts of host cell DNA may be present.
[0147] It is preferred that the average length of any residual host cell DNA is less than 500 bp e.g. less than 400 bp, less than 300 bp, less than 200 bp, less than 100 bp, etc.
[0148] Contaminating DNA can be removed during vaccine preparation using standard purification procedures e.g. chromatography, etc. Removal of residual host cell DNA can be enhanced by nuclease treatment e.g. by using a DNase. A convenient method for reducing host cell DNA contamination is disclosed in references 58 & 59, involving a two-step treatment, first using a DNase (e.g. Benzonase), which may be used during viral growth, and then a cationic detergent (e.g. CTAB), which may be used during virion disruption. Treatment with an alkylating agent, such as β-propiolactone, can also be used to remove host cell DNA, and advantageously may also be used to inactivate virions [60].
Adjuvants
[0149] Compositions of the invention may advantageously include an adjuvant, which can function to enhance the immune responses (humoral and/or cellular) elicited in a subject who receives the composition. Preferred adjuvants comprise oil-in-water emulsions. Various such adjuvants are known, and they typically include at least one oil and at least one surfactant, with the oil(s) and surfactant(s) being biodegradable (metabolisable) and biocompatible. The oil droplets in the emulsion are generally less than 5 μm in diameter, and ideally have a sub-micron diameter, with these small sizes being achieved with a microfluidiser to provide stable emulsions. Droplets with a size less than 220 nm are preferred as they can be subjected to filter sterilization.
[0150] The emulsion can comprise oils such as those from an animal (such as fish) or vegetable source. Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive oil, the most commonly available, exemplify the nut oils. Jojoba oil can be used e.g. obtained from the jojoba bean. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats, rye, rice, teff, triticale and the like may also be used. 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art. Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemically in 5-carbon isoprene units and are generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, which is particularly preferred herein. Squalane, the saturated analog to squalene, is also a preferred oil. Fish oils, including squalene and squalane, are readily available from commercial sources or may be obtained by methods known in the art. Another preferred oil is α-tocopherol (see below).
[0151] Mixtures of oils can be used.
[0152] Surfactants can be classified by their `HLB` (hydrophile/lipophile balance). Preferred surfactants of the invention have a HLB of at least 10, preferably at least 15, and more preferably at least 16. The invention can be used with surfactants including, but not limited to: the polyoxyethylene sorbitan esters surfactants (commonly referred to as the Tweens), especially polysorbate 20 and polysorbate 80; copolymers of ethylene oxide (EO), propylene oxide (PO), and/or butylene oxide (BO), sold under the DOWFAX® tradename, such as linear EO/PO block copolymers; octoxynols, which can vary in the number of repeating ethoxy (oxy-1,2-ethanediyl) groups, with octoxynol-9 (Triton X-100, or t-octylphenoxypolyethoxyethanol) being of particular interest; (octylphenoxy)polyethoxyethanol (IGEPAL CA-630/NP-40); phospholipids such as phosphatidylcholine (lecithin); nonylphenol ethoxylates, such as the Tergitol® NP series; polyoxyethylene fatty ethers derived from lauryl, cetyl, stearyl and oleyl alcohols (known as Brij surfactants), such as triethyleneglycol monolauryl ether (Brij 30); and sorbitan esters (commonly known as the SPANs), such as sorbitan trioleate (Span 85) and sorbitan monolaurate. Non-ionic surfactants are preferred. Preferred surfactants for including in the emulsion are Tween 80 (polyoxyethylene sorbitan monooleate), Span 85 (sorbitan trioleate), lecithin and Triton X-100.
[0153] Mixtures of surfactants can be used e.g. Tween 80/Span 85 mixtures. A combination of a polyoxyethylene sorbitan ester such as polyoxyethylene sorbitan monooleate (Tween 80) and an octoxynol such as t-octylphenoxypolyethoxyethanol (Triton X-100) is also suitable. Another useful combination comprises laureth 9 plus a polyoxyethylene sorbitan ester and/or an octoxynol.
[0154] Preferred amounts of surfactants (% by weight) are: polyoxyethylene sorbitan esters (such as Tween 80) 0.01 to 1%, in particular about 0.1%; octyl- or nonylphenoxy polyoxyethanols (such as Triton X-100, or other detergents in the Triton series) 0.001 to 0.1%, in particular 0.005 to 0.02%; polyoxyethylene ethers (such as laureth 9) 0.1 to 20%, preferably 0.1 to 10% and in particular 0.1 to 1% or about 0.5%.
[0155] Where the vaccine contains a split virus, it is preferred that it contains free surfactant in the aqueous phase. This is advantageous as the free surfactant can exert a `splitting effect` on the antigen, thereby disrupting any unsplit virions and/or virion aggregates that might otherwise be present. This can improve the safety of split virus vaccines [61].
[0156] Preferred emulsions have an average droplets size of <1 μm e.g. ≦750 nm, ≦500 nm, ≦400 nm, ≦300 nm, ≦250 nm, ≦220 nm, ≦200 nm, or smaller. These droplet sizes can conveniently be achieved by techniques such as microfluidisation.
[0157] Specific oil-in-water emulsion adjuvants useful with the invention include, but are not limited to:
[0158] A submicron emulsion of squalene, Tween 80, and Span 85. The composition of the emulsion by volume can be about 5% squalene, about 0.5% polysorbate 80 and about 0.5% Span 85. In weight terms, these ratios become 4.3% squalene, 0.5% polysorbate 80 and 0.48% Span 85. This adjuvant is known as `MF59` [62-64], as described in more detail in Chapter 10 of ref. 65 and chapter 12 of ref. 66. The MF59 emulsion advantageously includes citrate ions e.g. 10 mM sodium citrate buffer.
[0159] An emulsion comprising squalene, a tocopherol, and polysorbate 80. The emulsion may include phosphate buffered saline. These emulsions may have by volume from 2 to 10% squalene, from 2 to 10% tocopherol and from 0.3 to 3% polysorbate 80, and the weight ratio of squalene:tocopherol is preferably <1 (e.g. 0.90) as this can provide a more stable emulsion. Squalene and polysorbate 80 may be present in a volume ratio of about 5:2 or at a weight ratio of about 11:5. Thus the three components (squalene, tocopherol, polysorbate 80) may be present at a weight ratio of 1068:1186:485 or around 55:61:25. One such emulsion (`AS03`) can be made by dissolving Tween 80 in PBS to give a 2% solution, then mixing 90 ml of this solution with a mixture of (5 g of DL a tocopherol and 5 ml squalene), then microfluidising the mixture. The resulting emulsion may have submicron oil droplets e.g. with an average diameter of between 100 and 250 nm, preferably about 180 nm. The emulsion may also include a 3-de-O-acylated monophosphoryl lipid A (3d MPL). Another useful emulsion of this type may comprise, per human dose, 0.5-10 mg squalene, 0.5-11 mg tocopherol, and 0.1-4 mg polysorbate 80 [67] e.g. in the ratios discussed above.
[0160] An emulsion of squalene, a tocopherol, and a Triton detergent (e.g. Triton X-100). The emulsion may also include a 3d-MPL (see below). The emulsion may contain a phosphate buffer.
[0161] An emulsion comprising a polysorbate (e.g. polysorbate 80), a Triton detergent (e.g. Triton X-100) and a tocopherol (e.g. an α-tocopherol succinate). The emulsion may include these three components at a mass ratio of about 75:11:10 (e.g. 750 μg/ml polysorbate 80, 110 μg/ml Triton X-100 and 100 μg/ml α-tocopherol succinate), and these concentrations should include any contribution of these components from antigens. The emulsion may also include squalene. The emulsion may also include a 3d-MPL (see below). The aqueous phase may contain a phosphate buffer.
[0162] An emulsion of squalane, polysorbate 80 and poloxamer 401 ("Pluronic® L121"). The emulsion can be formulated in phosphate buffered saline, pH 7.4. This emulsion is a useful delivery vehicle for muramyl dipeptides, and has been used with threonyl-MDP in the "SAF-1" adjuvant [68] (0.05-1% Thr-MDP, 5% squalane, 2.5% Pluronic L121 and 0.2% polysorbate 80). It can also be used without the Thr-MDP, as in the "AF" adjuvant [69] (5% squalane, 1.25% Pluronic L121 and 0.2% polysorbate 80). Microfluidisation is preferred.
[0163] An emulsion comprising squalene, an aqueous solvent, a polyoxyethylene alkyl ether hydrophilic nonionic surfactant (e.g. polyoxyethylene (12) cetostearyl ether) and a hydrophobic nonionic surfactant (e.g. a sorbitan ester or mannide ester, such as sorbitan monoleate or `Span 80`). The emulsion is preferably thermoreversible and/or has at least 90% of the oil droplets (by volume) with a size less than 200 nm [70]. The emulsion may also include one or more of: alditol; a cryoprotective agent (e.g. a sugar, such as dodecylmaltoside and/or sucrose); and/or an alkylpolyglycoside. The emulsion may include a TLR4 agonist [71]. Such emulsions may be lyophilized.
[0164] An emulsion of squalene, poloxamer 105 and Abil-Care [72]. The final concentration (weight) of these components in adjuvanted vaccines are 5% squalene, 4% poloxamer 105 (pluronic polyol) and 2% Abil-Care 85 (Bis-PEG/PPG-16/16 PEG/PPG-16/16 dimethicone; caprylic/capric triglyceride).
[0165] An emulsion having from 0.5-50% of an oil, 0.1-10% of a phospholipid, and 0.05-5% of a non-ionic surfactant. As described in reference 73, preferred phospholipid components are phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, sphingomyelin and cardiolipin. Submicron droplet sizes are advantageous.
[0166] A submicron oil-in-water emulsion of a non-metabolisable oil (such as light mineral oil) and at least one surfactant (such as lecithin, Tween 80 or Span 80). Additives may be included, such as QuilA saponin, cholesterol, a saponin-lipophile conjugate (such as GPI-0100, described in reference 74, produced by addition of aliphatic amine to desacylsaponin via the carboxyl group of glucuronic acid), dimethyldioctadecylammonium bromide and/or N,N-dioctadecyl-N,N-bis (2-hydroxyethyl)propanediamine.
[0167] An emulsion in which a saponin (e.g. QuilA or QS21) and a sterol (e.g. a cholesterol) are associated as helical micelles [75].
[0168] An emulsion comprising a mineral oil, a non-ionic lipophilic ethoxylated fatty alcohol, and a non-ionic hydrophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) [76].
[0169] An emulsion comprising a mineral oil, a non-ionic hydrophilic ethoxylated fatty alcohol, and a non-ionic lipophilic surfactant (e.g. an ethoxylated fatty alcohol and/or polyoxyethylene-polyoxypropylene block copolymer) [76].
[0170] In some embodiments an emulsion may be mixed with antigen extemporaneously, at the time of delivery, and thus the adjuvant and antigen may be kept separately in a packaged or distributed vaccine, ready for final formulation at the time of use. In other embodiments an emulsion is mixed with antigen during manufacture, and thus the composition is packaged in a liquid adjuvanted form.
[0171] The antigen will generally be in an aqueous form, such that the vaccine is finally prepared by mixing two liquids. The volume ratio of the two liquids for mixing can vary (e.g. between 5:1 and 1:5) but is generally about 1:1 and this is most preferred. Where concentrations of components are given in the above descriptions of specific emulsions, these concentrations are typically for an undiluted composition, and the concentration after mixing with an antigen solution will thus decrease (e.g. it will be half the concentration where the antigen and the adjuvant are mixed at a ratio of 1:1).
Packaging of Vaccine Compositions
[0172] Suitable containers for compositions of the invention (or kit components) include vials, syringes (e.g. disposable syringes), nasal sprays, etc. These containers should be sterile.
[0173] Where a composition/component is located in a vial, the vial is preferably made of a glass or plastic material. The vial is preferably sterilized before the composition is added to it. To avoid problems with latex-sensitive patients, vials are preferably sealed with a latex-free stopper, and the absence of latex in all packaging material is preferred. The vial may include a single dose of vaccine, or it may include more than one dose (a `multidose` vial) e.g. 10 doses. Preferred vials are made of colourless glass.
[0174] A vial can have a cap (e.g. a Luer lock) adapted such that a pre-filled syringe can be inserted into the cap, the contents of the syringe can be expelled into the vial (e.g. to reconstitute lyophilised material therein), and the contents of the vial can be removed back into the syringe. After removal of the syringe from the vial, a needle can then be attached and the composition can be administered to a patient. The cap is preferably located inside a seal or cover, such that the seal or cover has to be removed before the cap can be accessed. A vial may have a cap that permits aseptic removal of its contents, particularly for multidose vials.
[0175] Where a component is packaged into a syringe, the syringe may have a needle attached to it. If a needle is not attached, a separate needle may be supplied with the syringe for assembly and use. Such a needle may be sheathed. Safety needles are preferred. 1-inch 23-gauge, 1-inch 25-gauge and 5/8-inch 25-gauge needles are typical. Syringes may be provided with peel-off labels on which the lot number, influenza season and expiration date of the contents may be printed, to facilitate record keeping. The plunger in the syringe preferably has a stopper to prevent the plunger from being accidentally removed during aspiration. The syringes may have a latex rubber cap and/or plunger. Disposable syringes contain a single dose of vaccine. The syringe will generally have a tip cap to seal the tip prior to attachment of a needle, and the tip cap is preferably made of a butyl rubber. If the syringe and needle are packaged separately then the needle is preferably fitted with a butyl rubber shield. Preferred syringes are those marketed under the trade name "Tip-Lok"®.
[0176] Containers may be marked to show a half-dose volume e.g. to facilitate delivery to children. For instance, a syringe containing a 0.5 ml dose may have a mark showing a 0.25 ml volume.
[0177] Where a glass container (e.g. a syringe or a vial) is used, then it is preferred to use a container made from a borosilicate glass rather than from a soda lime glass.
[0178] A kit or composition may be packaged (e.g. in the same box) with a leaflet including details of the vaccine e.g. instructions for administration, details of the antigens within the vaccine, etc. The instructions may also contain warnings e.g. to keep a solution of adrenaline readily available in case of anaphylactic reaction following vaccination, etc.
Methods of Treatment, and Administration of the Vaccine
[0179] The invention provides a vaccine manufactured according to the invention. These vaccine compositions are suitable for administration to human or non-human animal subjects, such as pigs or birds, and the invention provides a method of raising an immune response in a subject, comprising the step of administering a composition of the invention to the subject. The invention also provides a composition of the invention for use as a medicament, and provides the use of a composition of the invention for the manufacture of a medicament for raising an immune response in a subject.
[0180] The immune response raised by these methods and uses will generally include an antibody response, preferably a protective antibody response. Methods for assessing antibody responses, neutralising capability and protection after influenza virus vaccination are well known in the art. Human studies have shown that antibody titers against hemagglutinin of human influenza virus are correlated with protection (a serum sample hemagglutination-inhibition titer of about 30-40 gives around 50% protection from infection by a homologous virus) [77]. Antibody responses are typically measured by hemagglutination inhibition, by microneutralisation, by single radial immunodiffusion (SRID), and/or by single radial hemolysis (SRH). These assay techniques are well known in the art.
[0181] Compositions of the invention can be administered in various ways. The most preferred immunisation route is by intramuscular injection (e.g. into the arm or leg), but other available routes include subcutaneous injection, intranasal [78-80], oral [81], intradermal [82,83], transcutaneous, transdermal [84], etc.
[0182] Vaccines prepared according to the invention may be used to treat both children and adults. Influenza vaccines are currently recommended for use in pediatric and adult immunisation, from the age of 6 months. Thus a human subject may be less than 1 year old, 1-5 years old, 5-15 years old, 15-55 years old, or at least 55 years old. Preferred subjects for receiving the vaccines are the elderly (e.g. ≧50 years old, ≧60 years old, and preferably ≧65 years), the young (e.g. ≦5 years old), hospitalised subjects, healthcare workers, armed service and military personnel, pregnant women, the chronically ill, immunodeficient subjects, subjects who have taken an antiviral compound (e.g. an oseltamivir or zanamivir compound; see below) in the 7 days prior to receiving the vaccine, people with egg allergies and people travelling abroad. The vaccines are not suitable solely for these groups, however, and may be used more generally in a population. For pandemic strains, administration to all age groups is preferred.
[0183] Preferred compositions of the invention satisfy 1, 2 or 3 of the CPMP criteria for efficacy. In adults (18-60 years), these criteria are: (1) ≧70% seroprotection; (2) ≧40% seroconversion; and/or (3) a GMT increase of ≧2.5-fold. In elderly (>60 years), these criteria are: (1) ≧60% seroprotection; (2) ≧30% seroconversion; and/or (3) a GMT increase of ≧2-fold. These criteria are based on open label studies with at least 50 patients.
[0184] Treatment can be by a single dose schedule or a multiple dose schedule. Multiple doses may be used in a primary immunisation schedule and/or in a booster immunisation schedule. In a multiple dose schedule the various doses may be given by the same or different routes e.g. a parenteral prime and mucosal boost, a mucosal prime and parenteral boost, etc. Administration of more than one dose (typically two doses) is particularly useful in immunologically naive patients e.g. for people who have never received an influenza vaccine before, or for vaccinating against a new HA subtype (as in a pandemic outbreak). Multiple doses will typically be administered at least 1 week apart (e.g. about 2 weeks, about 3 weeks, about 4 weeks, about 6 weeks, about 8 weeks, about 10 weeks, about 12 weeks, about 16 weeks, etc.).
[0185] Vaccines produced by the invention may be administered to patients at substantially the same time as (e.g. during the same medical consultation or visit to a healthcare professional or vaccination centre) other vaccines e.g. at substantially the same time as a measles vaccine, a mumps vaccine, a rubella vaccine, a MMR vaccine, a varicella vaccine, a MMRV vaccine, a diphtheria vaccine, a tetanus vaccine, a pertussis vaccine, a DTP vaccine, a conjugated H. influenzae type b vaccine, an inactivated poliovirus vaccine, a hepatitis B virus vaccine, a meningococcal conjugate vaccine (such as a tetravalent A-C-W135-Y vaccine), a respiratory syncytial virus vaccine, a pneumococcal conjugate vaccine, etc. Administration at substantially the same time as a pneumococcal vaccine and/or a meningococcal vaccine is particularly useful in elderly patients.
[0186] Similarly, vaccines of the invention may be administered to patients at substantially the same time as (e.g. during the same medical consultation or visit to a healthcare professional) an antiviral compound, and in particular an antiviral compound active against influenza virus (e.g. oseltamivir and/or zanamivir). These antivirals include neuraminidase inhibitors, such as a (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carbox- ylic acid or 5-(acetylamino)-4-[(aminoiminomethyl)-amino]-2,6-anhydro-3,4,5-trideoxy-D- -glycero-D-galactonon-2-enonic acid, including esters thereof (e.g. the ethyl esters) and salts thereof (e.g. the phosphate salts). A preferred antiviral is (3R,4R,5S)-4-acetylamino-5-amino-3(1-ethylpropoxy)-1-cyclohexene-1-carbox- ylic acid, ethyl ester, phosphate (1:1), also known as oseltamivir phosphate (TAMIFLU®).
Other Biologicals
[0187] Whilst the invention has been described with reference to influenza viruses and influenza vaccines, the invention can also be used for the production of other viruses which can be produced by reverse genetics, as well as other viral vaccines. For example, the methods of the invention are particularly suitable for producing viruses such as dengue virus, rotaviruses, measles virus, rubella virus, coronaviruses.
[0188] Other biologicals which can be produced recombinantly can also be produced by the methods of the invention. Suitable examples include antibodies, growth factors, cytokines, lymphokines, receptors, hormones, diagnostic antigens, etc.
[0189] The method steps described herein will apply mutatis mutandis to these viruses, vaccines or biologicals.
General
[0190] The term "comprising" encompasses "including" as well as "consisting" e.g. a composition "comprising" X may consist exclusively of X or may include something additional e.g. X+Y.
[0191] The word "substantially" does not exclude "completely" e.g. a composition which is "substantially free" from Y may be completely free from Y. Where necessary, the word "substantially" may be omitted from the definition of the invention.
[0192] The term "about" in relation to a numerical value x is optional and means, for example, x±10%.
[0193] Unless specifically stated, a process comprising a step of mixing two or more components does not require any specific order of mixing. Thus components can be mixed in any order. Where there are three components then two components can be combined with each other, and then the combination may be combined with the third component, etc.
[0194] The various steps of the methods may be carried out at the same or different times, in the same or different geographical locations, e.g. countries, and by the same or different people or entities.
[0195] Where animal (and particularly bovine) materials are used in the culture of cells, they should be obtained from sources that are free from transmissible spongiform encephalopathies (TSEs), and in particular free from bovine spongiform encephalopathy (BSE). Overall, it is preferred to culture cells in the total absence of animal-derived materials.
[0196] Where a compound is administered to the body as part of a composition then that compound may alternatively be replaced by a suitable prodrug.
[0197] References to a percentage sequence identity between two amino acid sequences means that, when aligned, that percentage of amino acids are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of reference 85. A preferred alignment is determined by the Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is taught in reference 86.
[0198] References to a percentage sequence identity between two nucleic acid sequences mean that, when aligned, that percentage of bases are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in section 7.7.18 of reference 85. A preferred alignment program is GCG Gap (Genetics Computer Group, Wisconsin, Suite Version 10.1), preferably using default parameters, which are as follows: open gap=3; extend gap=1.
BRIEF DESCRIPTION OF THE DRAWINGS
[0199] FIG. 1. Method of synthetic gene segment assembly and error correction. (A) Process flow. Time for performance of each step is indicated on the right. (B) Schematic diagram of process. "X" indicates sites of oligonucleotide synthesis errors. In the circular DNA and final assembled gene diagrams (the bottom two), pKS10 sequences are white, and influenza coding sequences are black. (C) Ethidium bromide stained agarose gel of linear synthetic HA and NA genes, including regulatory elements used for virus rescue. MW--molecular weight marker.
[0200] FIG. 2. Timeline of rescue of synthetic H7N9 influenza viruses from transmission of oligonucleotide sequence information to confirmation of recovered viruses.
[0201] FIG. 3. Performance of synthetic H7N9 reassortant viruses from the simulated pandemic response. (A) Titers of influenza viruses in culture fluid harvested from MDCK-supplemented 293T cells 48 hours (dotted columns) and 72 hours (white columns) after co-transfection with the indicated backbone plasmids and synthetic HA and NA gene constructs. Viral titers were determined by a focus formation assay using MDCK cell monolayers. (B) Replication kinetics of synthetic H7N9 reassortant viruses in MDCK 33016 PF suspension cultures. (C) HA yields from synthetic H7N9 viruses in MDCK suspension cultures, determined by RP-HPLC after purification of viruses on sucrose density gradients. The y-axis in FIGS. 3(A) and (B) shows infectious units (log 10 IU/mL). The y-axis in FIG. 3(C) shows HA yield in μg/mL.
[0202] FIG. 4. Effect of MDCK feeder cell addition 24 hours after transfection of MDCK cells on rescue efficiency. Titers of recombinant viruses containing the PR8x backbone with HA and NA segments from either (A) A/WSN/1933 (H1N1) or (B) A/California/04/2009 were measured 72 hours after transfection by a focus formation assay. The dotted column shows the results with additional cells whilst the white column shows the results without additional cells. The y-axis indicates infectious units (log 10 IU/mL).
[0203] FIG. 5. Synthetic influenza virus rescue efficiencies. Representative data showing effect of optimized backbones on virus rescue efficiency from transfected cultures of MDCK cells. Detection of influenza viruses in culture fluid harvested at different time points after transfection with the indicated backbone plasmids and synthetic HA and NA constructs, or 24-48 hours after a blind passage using 500 μl of the culture fluid on fresh MDCK cell monolayers (Passage 1). Viral titers were determined using a focus formation assay for (A) an H1N1 strain, (B) an H3N2 strain, (C) an attenuated H5N1 strain, (D) a swine origin H3N2v strain, (E) a B/Yamagata lineage strain, and (F) a B/Victoria lineage strain. The y-axis indicates infectious units (log 10 IU/mL).
[0204] FIG. 6. Rescue of synthetic H7N9a viruses from either MDCK-supplemented 293T cells or from MDCK cells only. Detection of influenza viruses in culture fluid harvested 48 hours (dotted columns) and 72 hours (white columns) after transfection with the #19 backbone plasmids and synthetic H7 and N9 constructs. Viral titers were determined on MDCK cell monolayers using a focus formation assay. The y-axis indicates infectious units (log 10 IU/mL).
[0205] FIG. 7. Replication kinetics of synthetic H7N9 reassortant viruses with alternative NA UTRs in MDCK 33016 PF suspension cultures. Replication kinetics of synthetic H7N9 viruses with alternative NA UTRs and different backbones, (A) PR8x, (B) #19, and (C) #21, in MDCK suspension cultures. Starting m.o.i. was 0.001. The x-axis indicates the hours post infection. The y-axis indicates infectious units (log 10 IU/mL).
[0206] FIG. 8. HA yield by turkey RBC agglutination by synthetic H7N9 viruses with alternative NA UTRs. The y-axis indicates the HA units.
[0207] FIG. 9 compares the HA content (determined by lectin-capture ELISA) of sucrose gradient-purified viruses harvested at 60 h post-infection from MDCK cell cultures infected with reverse genetics-derived 6:2 reassortants containing either the PR8-X or #21 backbone with the HA and NA segments from (A) a pandemic-like H1 strain (strain 1) or (B) a second pandemic-like strain (strain 2). In FIGS. 9A and 9B, the black bar represents a reference vaccine strain (derived from WHO-Collaborating Centre-supplied strain) as control, the grey bar represents a reassortant virus containing the PR8-X backbone, and the white bar represents a reassortant virus containing the #21 backbone. The y-axis indicates HA yield in μg/ml.
[0208] FIG. 10 compares the HA content (determined by a lectin-capture ELISA) of unpurified viruses harvested at 60 h post-infection from MDCK cell cultures infected with reverse genetics-derived 6:2 reassortants containing either the PR8-X or #21 backbone with the HA and NA segments from (A) a pre-pandemic H1 strain (strain 1) and (B) a second pre-pandemic H1 strain (strain 2). In FIGS. 10A and 10B, the black bar represents a reference vaccine strain (derived from WHO-Collaborating Centre-supplied strain) as control, the grey bar represents a reassortant virus containing the PR8-X backbone, and the white bar represents a reassortant virus containing the #21 backbone. The y-axis indicates HA yield in μg/ml.
[0209] FIG. 11 compares the HA yield (determined by HPLC) of sucrose-purified viruses harvested at 60 h post-infection from MDCK cell cultures infected with reverse genetics-derived 6:2 reassortants containing either the PR8-X or #21 backbone with the HA and NA segments from an H3 strain (strain 1). The black bar represents a reference vaccine strain (derived from WHO-Collaborating Centre-supplied strain) as control, the grey bar represents a reassortant virus containing the PR8-X backbone, and the white bar represents a reassortant virus containing the #21 backbone. The y-axis indicates HA yield in μg/ml.
[0210] FIG. 12 compares virus titers (determined by focus formation assay (FFA); FIG. 12A) and HA titers (determined by lectin-capture ELISA; FIG. 12B) of viruses harvested from embyronated chicken eggs at 60 h post-infection with a reference vaccine strain or reverse genetics-derived 6:2 reassortant viruses made with either the PR8-X or #21 backbone and the HA and NA segments from a pandemic-like H1 strain (strain 2). In FIG. 12A, the individual dots represent data from single eggs. The line represents the average of the individual data points. The y-axis indicates infectious units/ml. In FIG. 12B, the black bar represents the reference vaccine strain (derived from WHO-Collaborating Centre-supplied strain), the grey bar represents a reassortant virus containing the PR8-X backbone, and the white bar represents a reassortant virus containing the #21 backbone. The y-axis indicates HA yield in μg/ml for pooled egg samples.
[0211] FIG. 13 compares the HA yield of different reassortant influenza B strains in MDCK cells relative to the wild-type (WT) or reverse genetics-derived (RG) B/Brisbane/60/08 strain. The viral segments of the tested influenza B viruses are shown in Table 1. The y-axis indicates the HA yield in μg/mL.
[0212] FIG. 14 compares the HA yield of different reassortant influenza B strains in MDCK cells relative to the wild-type (WT) or reverse genetics-derived (RG) B/Panama/45/90 strain. The viral segments of the tested influenza B viruses are shown in Table 1. The y-axis indicates the HA yield in μg/mL.
MODES FOR CARRYING OUT THE INVENTION
Increased Gene Synthesis Speed and Accuracy Through Enzymatic Assembly and In Vitro Error Correction.
[0213] A purely enzymatic one-step, isothermal assembly method of gene assembly, previously used to synthesize the entire 16,299 base pair mouse mitochondrial genome from 600 overlapping 60-base oligonucleotides (6), was adapted for the generation of synthetic DNA copies of influenza virus genome segments. The method uses 5' T5 exonuclease (Epicentre), Phusion DNA polymerase (New England Biolabs [NEB]) and Taq DNA ligase (NEB) to join multiple DNA fragments during a brief 50° C. reaction (7). The method was selected to assemble genes for synthetic vaccine seeds because it is rapid and readily automated. All bases of the resulting synthetic genes have their origin in chemically synthesized oligonucleotides. Using current techniques, DNA oligonucleotide synthesis has an error rate of about 1 per 325 bases, typically due to missing bases from failed chemical coupling, and the error rate increases with the length of the oligonucleotide synthesized (6). When DNA copies of the 1.7 kb HA and 1.5 kb NA viral RNA genome segments are synthesized by this technique using oligonucleotides approximately 60 bases in length with 30 bases of overlap between oligonucleotides on opposite strands, only 3% of the synthetic products have the correct sequence. During the mouse mitochondrial genome synthesis, subassemblies were cloned and sequenced, and sets of error-free sequences were selected for subsequent rounds of assembly (6). For the purpose of rapid influenza vaccine seed virus generation, this method of error correction would introduce unacceptable delays.
[0214] The problem of synthesizing DNA copies of HA and NA genome segments with both accuracy and speed was solved by (i) increasing the overlap between oligonucleotides, (ii) introducing an enzymatic error correction step, and (iii) increasing the number of oligonucleotides assembled at once, eliminating the need for stepwise assembly via sub-assemblies (FIGS. 1a and b). Specifically, the length of oligonucleotides was increased to 60-74 bases, and full length genes (including 5' and 3' un-translated regions) were assembled from staggered sets of oligonucleotides that contained all residues of a double-stranded DNA molecule so that, prior to ligation, the full double-stranded gene can be annealed. In practice, a software algorithm generates a set of sequences for oligonucleotides (a maximum of 96 oligonucleotides per HA, NA pair) that meet these criteria. After chemical synthesis of the oligonucleotides, enzymatic isothermal assembly, and PCR amplification, error-containing DNA is removed enzymatically by treating melted and re-annealed DNA with the commercially available ErrASE error correction kit (Novici Biotech), which excises areas of base mismatch in double-stranded DNA molecules before another round of PCR amplification.
[0215] After agarose gel verification of the products' sizes, the control sequences (including Pol I and Pol II promoters and their terminator and polyadenylation signals) needed to generate RNA genome segments and mRNA for virus rescue are added by isothermally coupling the synthetic DNA with a linearized plasmid (pKS10) that contains these regulatory sequences (87). Nucleotide identity between the ends of the linearized plasmid and the 5' and 3' primers used for gene synthesis guide this assembly. The assembled molecule is the substrate for a round of high fidelity PCR amplification using primers outside the transcription control regions.
[0216] After purification and concentration of the amplicons, approximately 10 μg of assembled linear DNA cassettes that contain the influenza gene flanked by control sequences are obtained, ready for transfection into the MDCK 33016 PF cell line for influenza virus rescue (FIG. 1c). The time from receipt of oligonucleotides to a purified HA or NA-encoding DNA cassette ready for transfection is approximately 10 hours. While virus rescue is underway using the enzymatically assembled, error corrected, and amplified DNA, parallel cloning and sequencing verifies the sequence of the assembled genes. Typically, 80-100% of the full-length sequences obtained are correct.
Optimized Rescue of Influenza Viruses from Synthetic DNA on a Vaccine Manufacturing Cell Line.
[0217] The rescue protocol for synthetic seed virus generation is adapted from a previously described eight-plasmid ambisense system in which each expression plasmid has a cDNA copy of a viral gene segment bounded at the 5' end by a Pol II promoter to drive transcription of messenger RNA and at the 3' end by a human Pol I promoter to drive transcription of negative-stranded influenza RNA genome segments (88). The manufacturing-qualified MDCK 33016 PF cell line is a less efficient substrate for transfection and influenza virus rescue by reverse genetics than 293T cells (which are not qualified for vaccine production). Influenza virus reverse genetic rescue has been described using Vero cells (some banks of which are qualified for vaccine production) (89, 90). However, using one cell line for vaccine virus rescue and a different cell line for antigen production would add adventitious agent risk and regulatory and manufacturing complexity. Therefore, we elected to increase the efficiency of reverse genetic DNA rescue in MDCK 33016 PF cells so that a single cell line can be used for seed generation and vaccine antigen production. Although Pol I promoters are generally species specific, human Pol I efficiently drives transcription in MDCK 33016 PF cells, which are of canine origin.
[0218] One μg of each linear synthetic cassette encoding HA or NA is co-transfected into MDCK 33016 PF cells together with 1 μg of each ambisense plasmid that encodes PA, PB1, PB2, NP, NS, or M and a helper plasmid that encodes the protease TMPRSS2 (91). To increase rescue efficiency, we add cultures of fresh (un-transfected) MDCK 33016 PF cells after transfection, which increases the probability of virus recovery, presumably by providing a healthier population of cells in which rescued viruses can further amplify (FIG. 4). Viruses are detected in cell culture medium within 72 hours after transfection (approximately 24 hours later than after transfection of Vero or 293T cells), using a focus-formation assay in which the medium from the transfected culture is added to a fresh MDCK cell monolayer, and infectious virus is detected by immuno-staining for expressed NP.
Improved Backbones for Synthetic Virus Rescue.
[0219] A significant increase in rescue efficiency was provided by using improved influenza backbones (sets of genome segments encoding influenza virus proteins other than HA and NA). The initial backbone improvement resulted from using genes from a PR8 variant (designated PR8x) that had been adapted over five passages to growth in MDCK 33016 PF cells. Additional improvements resulted from combining backbone genome segments of multiple strains. During pilot manufacturing of influenza vaccines using MDCK 33016 PF cells, several human influenza viruses, such as strain 105p30 (an A/New Calcdonia/20/1999 (H1N1)-like strain that was passaged 30 times in MDCK 33016 PF cells), were adapted to grow efficiently in cultured cells, although not as efficiently as strain PR8x. Synthesized viruses with HA and NA genes from historical H3N2 strains and a backbone (designated #19) composed of NP, PB1, and PB2 genome segments from strain 105p30 and M, NS, and PA genome segments from strain PR8x often outperformed equivalent viruses with entirely PR8x backbones in reverse genetic rescue efficiency and yield of HA (table 1 and FIG. 5). Similarly, synthesized viruses with HA and NA genes from H1N1 strains and a backbone (designated #21) with the PB1 genome segment of A/California/7/2009 and the other genome segments from strain PR8x often had greater rescue efficiencies and HA yields than equivalent viruses with entirely PR8x backbones (table 1 and FIG. 5). This finding is consistent with a report that the A/California PB1 genome segment is preferentially found in the reassortant progeny of co-infections of chicken eggs with A/California/7/2009 and a donor strain that has a PR8 backbone (18).
TABLE-US-00001 TABLE 1 Representative data showing virus titers and HA yields (in mass per volume of cell culture medium before purification) from synthetic influenza viruses relative to conventional vaccine viruses (reference strains obtained from the US CDC or the UK National Institute for Biological Standards and Control) in MDCK 33016PF cells. HA HA yield yield Best Reference FFA by RP- by back- strain titer HPLC ELISA bone Synthetic H1N1 strain A/Christchurch/16/2010a,b NIB74b 4.9 1.6 2.3 #21 A/Brisbane/10/2010a wild-type 19 2.1 7.2 #21 A/Brisbane/59/2007 IVR-148 5.5 1.9 2.9 #21 A/Solomon/3/2006 IVR-145 3.4 1.8 5.9 #21 Synthetic H3N2 strain A/Victoria/361/2011a,b IVR-165b 2.6 2.5 1.4 PR8x A/Victoria/210/2009a X187 2.6 2.3 1.7 PR8x A/Wisconsin/15/2009b X183b 35 below 15 #19 detec- tion A/Uruguay/716/2007b X175Cb 2.0 1.3 1.4 #19 Synthetic H5N1 strain A/turkey/Turkey/1/2005a,b NIBRG23b 1.9 1.6 n/a #19 Synthetic H3N2v strain A/Indiana/8/2011a,b X213b 1.9 2.3 n/a #21 Synthetic B-Yamagata strain B/Wisconsin/1/2010a,b wild-typeb 1.7 1.4 1.7 Brisbane B/Brisbane/3/2007 wild-type 0.88 3.5 5.2 #B34 Synthetic B-Victoria strain B/Brisbane/60/2008a wild-type 0.72 1.8 0.67 Brisbane Data values are normalized and shown as fold-improvement over reference strains, where values of the reference strains are set to 1.0. RP-HPLC or lectin-capture ELISA was used to detect HA antigen directly from the culture medium of virus-infected MDCK cells (m.o.i = 0.001 or 0.0001), unless specified. arecombinant viruses containing synthetic HA and NA segments bviruses from culture medium were purified by sucrose-density gradient prior to characterization n/a = data not available because strain-specific anti-sera were not available for ELISA below detection = data not available because the reference strain had undetectable HA levels by RP-HPLC
[0220] Historically, most influenza type B vaccine seeds have been wild type viruses, not reassortants, because wild type influenza B viruses generally provide adequate yields. To use the synthetic procedures for influenza B viruses more readily, two optimized type B backbones that provide consistent rescue of synthetic influenza B viruses were developed (table 1 and FIG. 5). In the first (designated Brisbane), all backbone genome segments originate from B/Brisbane/60/2008; in the second (designated #B34), the genome segments encoding PA, PB1, PB2, and NP originate from B/Brisbane/60/2008, and those encoding M and NS originate from B/Panama/45/1990.
[0221] Overall, the use of optimized backbones for A strains increased rescue efficiencies up to 1000-fold (as measured by infectious titers obtained after transfection, FIG. 5) and increased HA yields in research scale infections of MDCK 33016 PF cells by 30% to 15-fold, depending on the strain and assay used for HA detection (table 1). In general, yields of HA from these viruses are also increased relative to those from viruses with PR8 backbones when the viruses are propagated in embryonated chicken eggs (table 2). To make use of such strain-specific differences, an optimal synthetic seed generation strategy would combine the HAs and NAs from circulating strains of interest with a panel of alternative backbones to maximize the chances of isolating a high-yielding vaccine virus.
TABLE-US-00002 TABLE 2 Representative data showing virus titers and HA yields (in mass per volume of egg allantoic fluid before purification) from synthetic influenza viruses relative to conventional vaccine viruses (reference strains obtained from the US CDC or the UK National Institute for Biological Standards and Control) in chicken eggs. HA titer by GP- RBC HA yield by RP- HA yield by Synthetic strain Reference strains FFA titer agglutination HPLC ELISA Best backbone A/H1N1/Chirstchruch/16/2010b NIB74 3.0 3.5 18 8.4 #21 A/H3N2/Victoria/210/2009b X187 0.94 1.3 not tested 1.2 PR8x A/H3N2/Victoria/361/2011a IVR-165 6.4 2.6 not tested 3.4 #21 A/H3N2v/Indiana/8/2011a,b X213 not tested 3.0 1.6 n/a PR8x B/Yam/Wisconsin/1/2010a wild-type 4.7 3.4 not tested 3.5 Brisbane B/Vic/Brisbane/60/2008a wild-type 1.1 0.82 not tested 0.79 Brisbane Data values are normalized and shown as fold-improvement over reference strains, where values of the reference strains are set to 1.0. GP-RBC agglutination, RP-HPLC or lectin-capture ELISA was used to detect HA antigen directly from the allantoic fluid of virus-infected chicken eggs, unless specified. a= recombinant viruses containing synthetic HA and NA genome segments b= viruses from egg allantoic fluid were purified by sucrose density gradient before characterization n/a = data not available because strain-specific antisera were not available for ELISA not tested = data not available because assay was not performed
Speed of Synthetic Vaccine Virus Generation in a Simulated Pandemic Response.
[0222] In a timed proof-of-concept test of the synthetic system's first iteration, the virus synthesis group was provided with unidentified HA and NA genome segment sequences by collaborators not directly involved in the synthesis (17). The sequences included complete coding regions but incomplete un-translated regions (UTRs), mimicking the information likely to be available in the early days of a pandemic. Sequence analysis of the HA genome segment showed that it was very closely related (96% nucleotide sequence identity by Blast to GenBank) to a low pathogenicity North American avian H7N3 virus (A/Canada goose/BC/3752/2007), and that the NA genome segment was very closely related (96% nucleotide sequence identity by Blast to GenBank) to a low pathogenicity North American avian H10N9 virus (A/king eider/Alaska/44397-858/2008). Although our software generates the sequences of the oligonucleotides used for rescue, user intervention is needed when there are ambiguities in the available sequence data. In this case, the unknown terminal UTR sequences were generated based on sequence alignments with a limited number of related full-length H7 sequences and by comparison with consensus UTRs for H7 and N9 genomic segments created from high quality sequence data in GenBank. This analysis revealed heterogeneity in the non-coding regions of NA genes of H7N9 strains (U/C at 1434 in the positive-sense orientation). So, alternative sets of 5' NA oligonucleotides were used to construct two variants of the NA cassettes.
[0223] Oligonucleotide synthesis began at 8:00 am EDT on Monday, Aug. 29, 2011 (FIG. 2). By noon on Friday, September 4, immunostaining of a secondary culture confirmed that the virus had been rescued. The 4 days and 4 hours from start of synthesis to detection of rescued virus included time spent shipping DNA from the oligonucleotide synthesis and gene assembly laboratories in California to the virus rescue laboratory in Massachusetts. When all functions are consolidated in one location, the potential for delays and mishaps due to shipping will be reduced. The original proof-of-concept rescues were conducted using 293T cells; rescue of the strains using MDCK cells, as would be done during an actual pandemic response, slows detection of rescued virus by approximately 24 hours (FIG. 6). The sequences of the HA and NA genome segments of the synthetic H7N9 reassortant viruses from the proof-of-concept exercise were determined following two rounds of virus amplification in MDCK 33016 PF cells and were identical to those used to program oligonucleotide synthesis. Two-way hemagglutination inhibition (HI) testing (reciprocal HI assays using antigen from the synthetic and natural strains and ferret sera drawn after synthetic and natural virus infection) (19, 20) demonstrated antigenic identity of the synthetic virus to A/goose/Nebraska/17097-4/2011 (H7N9), which had subsequently been revealed as the wild type virus from which the sequences that were electronically transmitted to the virus synthesis group had been obtained (Table 1).
[0224] The A/goose/Nebraska/17097-4/2011 HA and NA genes were rescued with PR8x, #19, and #21 backbones. Virus rescue was more efficient using the #19 and #21 backbones than the PR8x backbone, based on the titers of viruses harvested 48 and 72 hours after transfection (FIG. 3a). To test growth characteristics, the synthetic viruses were amplified once in MDCK 33016 PF monolayers and then used to infect suspension MDCK 33016 PF cultures at a multiplicity-of-infection (m.o.i.) of 0.001. Despite differences in the efficiency of virus recovery, viruses exhibited similar growth characteristics, regardless of backbone (FIG. 3b). The H7N9a set of viruses (C1434 positive sense NA) achieved infectious titers approximately 10-fold higher than their H7N9b counterparts (U1434 positive sense NA; FIG. 7). The viruses with the highest infectious yields also produced the most HA per volume of infected MDCK suspension culture (FIG. 3c). Thus, the single nucleotide substitution in the 5' NA non-coding region of the genomic RNA strongly influenced both infectious titer and HA yield (FIG. 8). The H7N9a virus with the #19 backbone produced 1.5-fold more HA than a virus with the same HA and NA in the context of the standard PR8x backbone (FIG. 3c). This demonstration confirmed the importance of rescuing multiple HA or NA variants with multiple backbones to increase the probability of identifying high yielding vaccine virus strains early in the vaccine seed generation process. Simultaneous rescue of multiple variants is faster and more easily accomplished using the synthetic approach than standard plasmid mutagenesis approaches. This example also indicates the importance for pandemic response of including as complete genome segment sequences as possible in genetic databases and of clearly delineating terminal sequences originating from viral genome segments from those originating from sequencing primers.
Robustness of the Synthetic Approach to Vaccine Virus Generation.
[0225] By combining gene synthesis, enzymatic error correction, optimized rescue protocols, and optimized backbones, the synthetic approach provides a robust tool to obtain influenza vaccine viruses. To date, the team has not encountered any influenza virus strain that cannot be rescued synthetically. The synthetic process has been used to generate a wide variety of influenza strains, including H1N1 (pre- and post-2009 variants), seasonal H3N2, swine origin H3N2v, B (Yamagata and Victoria lineages), attenuated H5N1, and H7N9 strains (table 3). The robustness of synthetic influenza virus recovery on MDCK cells is in striking contrast to the unreliability of conventional vaccine virus isolation using eggs, particularly for recent H3N2 strains (21).
TABLE-US-00003 TABLE 3 Diversity of synthetic influenza virus strains rescued. SEASONAL SEROTYPE A VIRUSES Backbone Source of synthetic HA NA PR8x #19 #21 A/H1N1/Brisbane/10/2010 + + + A/H1N1/Chirstchruch/16/2010 (NIB74) + + + A/H1N1/Chirstchruch/16/2010 NIB74-K170E n/a n/a + A/H1N1/Chirstchruch/16/2010 NIB74-K171E n/a n/a + A/H1N1/Chirstchruch/16/2010 NIB74-G172E n/a n/a + A/H1N1/Chirstchruch/16/2010 NIB74-G173D n/a n/a + A/H3N2/Uruguay/716/2007 + + + A/H3N2/Victoria/210/2009 (X187) + + + A/H3N2/Victoria/361/2011 (CDC E3) + + + A/H3N2/Victoria/361/2011 (WHO E3) + + + A/H3N2/Victoria/361/2011 (MDCK) + + + A/H3N2/Berlin/93/2011 (egg-derived) + + + A/H3N2/Berlin/93/2011 (cell-derived) + + + A/H3N2/Brisbane/402/2011 + + + A/H3N2/Victoria/304/2011 NVD p2/E3 - - + A/H3N2/Brisbane/256/2011 MDCK P2 + + + A/H3N2/Brisbane/256/2011 P2/E3 - + + A/H3N2/South Australia/34/2011 - + + A/H3N2/Brisbane/299/2011 (IVR164) + + + A/H3N2/Brisbane/299/2011 (E5) + + + A/H3N2/South Australia/3/2011 + + + A/H3N2/Wisconsin/1/2011 + + + SEASONAL SEROTYPE B VIRUSES Backbone Source of synthetic HA NA Bris #B34 B/Yam/Hubel-Wujiangang/158/2009 + + B/Yam/Wisconsin/1/2010 + + B/Yam/Brisbane/3/2007 + + B/Yam/Jiangsu/10/2003 + + B/Yam/Johannesburg/05/1999 + + B/Yam/Yamanashi/166/1998 + + B/Yam/Yamagata/16/1998 + + B/Yam/Texas/6/2011 + - B/Vic/New Hampshire/1/2012 + + B/Vic/Malaysia/2506/2004 + + B/Vic/Brisbane/32/2002 + + B/Vic/Brisbane/60/2008 (cell) + + B/Vic/Brisbane/60/2008 (egg) + n/a B/Vic/Nevada/3/2011 + + PANDEMIC VIRUSES Backbone Source of synthetic HA NA PR8x #19 #21 A/H5N1/Hubel/1/2010 + + + A/H5N1/Egypt/N03072/2010 + + + A/H5N1/Turkey/Turkey/1/2005 + + + A/H7N9/goose/Nebraska/11-017097-4/2011 + + + A/H3N2v/Indiana/8/2011 + + + n/a = not attempted; + = virus recovered in ≦6 days post-transfection; - = virus not recovered by 6 days post-transfection.
Implications for the Global Strain Change and Pandemic Response Systems.
[0226] The speed, ease, and accuracy with which higher yielding influenza vaccine seeds can be produced using synthetic techniques promises more rapid future pandemic responses and a more reliable supply of better matched seasonal and pandemic influenza vaccines. The potential for propagation of adventitious agents from the human nasal secretions used for original influenza virus isolation will be eliminated when such materials are used only to generate sequence information, not for propagation into viruses used to seed vaccine production bioreactors or eggs. The speed of the technical steps of synthesis and virus rescue is actually a relatively minor component of the potential acceleration of seed generation based on synthetic technology. If the performance of synthetic vaccine viruses is sufficient, much greater time savings will result from the ability of synthetic technology to alleviate the need to ship viruses and clinical specimens between laboratories and use a classic reassortment approach to generate high-yielding vaccine strains.
[0227] Today, the more than 120 National Influenza Centers (NICs) that conduct influenza surveillance periodically ship clinical specimens to WHO Collaborating Centers, where attempts are made to propagate the wild type viruses in MDCK cells. With synthetic vaccine viruses, the system could realize increased efficiency. Sequence data obtained by directly sequencing HA and NA genomic RNAs in clinical specimens at the NICs could be posted on publically accessible websites, where they can be downloaded immediately by manufacturers, public health agencies, and other researchers worldwide. Continuous comparison of the stream of sequence data to databases of sequence and HI data by algorithms now under development could identify those emerging viruses that are most likely to have significant antigenic differences from current vaccine strains. Efficient primary synthetic rescue with a panel of high growth backbones will simultaneously generate the viruses needed for antigenic testing and the best vaccine seed candidates to be used if a virus is found to be antigenically distinct and epidemiologically important.
[0228] Today, vaccine viruses are only shipped from WHO Collaborating Centers or reassortant generating laboratories to manufacturers after they are fully tested, and testing often takes longer than the generation of the vaccine strains. The decentralization of seed generation permitted by these synthetic techniques could allow manufacturers to undertake scale up and process development at risk for strains that they could generate immediately after the NICs post sequences. Carrying out these manufacturing activities simultaneously with seed testing would cut additional weeks from pandemic response times. Libraries of synthetic influenza genes could further accelerate pandemic responses, if the pre-synthesized genes in the libraries match future pandemic strains.
Growth Characteristics of Reassortant Viruses Containing PR8-X or Canine Adapted PR8-X Backbones
[0229] In order to provide high-growth donor strains, the inventors found that a reassortant influenza virus comprising the PB1 segment of A/California/07/09 and all other backbone segments from PR8-X shows improved growth characteristics compared with reassortant influenza viruses which contain all backbone segments from PR8-X. This influenza backbone is referred to as #21.
[0230] In order to test the suitability of the #21 strain as a donor strain for virus reassortment, reassortant influenza viruses are produced by reverse genetics which contain the HA and NA proteins from various influenza strains (including zoonotic, seasonal, and pandemic-like strains) and the other viral segments from either PR8-X or the #21 backbone. The HA content, HA yield and the viral titres of these reassortant viruses are determined. As a control a reference vaccine strain which does not contain any backbone segments from PR8-X or A/California/07/09 is used. These viruses are cultured either in embyronated chicken eggs or in MDCK cells.
[0231] The results indicate that reassortant viruses which contain the #21 backbone consistently give higher viral titres and HA yields compared with the control virus and the virus which contains all backbone segments from PR8-X in both eggs and cell culture. This difference is due to the PB1 segment because this is the only difference between #21 reassortants and PR8-X reassortants (see FIGS. 8 to 11).
[0232] In order to test the effect of canine-adapted mutations on the growth characteristics of PR8-X, the inventors introduce mutations into the PA segment (E327K, N444D, and N675D), or the NP segment (A27T, E375N) of PR8-X. These backbones are referred to as PR8-X(cPA) and PR8-X(cNP), respectively. Reassortant influenza viruses are produced containing the PR8-X(cPA) and PR8-X(cNP) backbones and the HA and NA segments of a pandemic-like H1 influenza strain (strain 1) or a H3 influenza strain (strain 2). As a control a reference vaccine strain which does not contain any backbone segments from PR8-X is used. The reassortant influenza viruses are cultured in MDCK cells.
[0233] The results show that reassortant influenza viruses which contain canine-adapted backbone segments consistently grow to higher viral titres compared with reassortant influenza viruses which contain unmodified PR8-X backbone segments (see FIGS. 8 and 9).
Growth Characteristics of Reassortant Viruses Containing PR8-X, #21 or #21C Backbones
[0234] In order to test whether canine-adapted mutations in the backbone segments improve the growth characteristics of the #21 backbone, the inventors modify the #21 backbone by introducing mutations into the PR8-X PB2 segment (R389K, T559N). This backbone is referred to as #21C. Reassortant influenza viruses are produced by reverse genetics which contain the HA and NA proteins from two different pandemic-like H1 strains (strains 1 and 2) and the other viral segments from either PR8-X, the #21 backbone or the #21C backbone. As a control a reference vaccine strain which does not contain any backbone segments from PR8-X or A/California/07/09 is used. These viruses are cultured in MDCK cells. The virus yield of these reassortant viruses is determined. For reassortant influenza viruses containing the HA and NA segments from the pandemic-like H1 strain (strain 1) and the PR8-X or #21C backbones the HA titres are also determined.
[0235] The results show that reassortant influenza viruses which contain the #21C backbone consistently grow to higher viral titres compared with reassortant influenza viruses which contain only PR8-X backbone segments or the #21 backbone (see FIGS. 5, 6 and 7). Reassortant influenza viruses comprising the #21C backbone also show higher HA titres compared with PR8-X reassortants.
Growth Characteristics of Reassortant Influenza B Viruses
[0236] Reassortant influenza B viruses are produced by reverse genetics which contain the HA and NA proteins from various influenza strains and the other viral segments from B/Brisbane/60/08 and/or B/Panama/45/90. As a control the corresponding wild-type influenza B strain is used. These viruses 30 are cultured either in embyronated chicken eggs or in MDCK cells. The following influenza B strains are used:
TABLE-US-00004 TABLE 4 Antigenic Backbone segments determinants combo # PA PB1 PB2 NP NS M HA NA 1 (WT) Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane 2 Panama Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane 3 Brisbane Panama Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane 4 Brisbane Brisbane Panama Brisbane Brisbane Brisbane Brisbane Brisbane 5 Brisbane Brisbane Brisbane Panama Brisbane Brisbane Brisbane Brisbane 6 Panama Panama Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane 7 Panama Brisbane Panama Brisbane Brisbane Brisbane Brisbane Brisbane 8 Panama Brisbane Brisbane Panama Brisbane Brisbane Brisbane Brisbane 9 Brisbane Panama Panama Brisbane Brisbane Brisbane Brisbane Brisbane 10 Brisbane Panama Brisbane Panama Brisbane Brisbane Brisbane Brisbane 11 Brisbane Brisbane Panama Panama Brisbane Brisbane Brisbane Brisbane 12 Panama Panama Panama Brisbane Brisbane Brisbane Brisbane Brisbane 13 Panama Panama Brisbane Panama Brisbane Brisbane Brisbane Brisbane 14 Panama Brisbane Panama Panama Brisbane Brisbane Brisbane Brisbane 15 Brisbane Panama Panama Panama Brisbane Brisbane Brisbane Brisbane 16 Panama Panama Panama Panama Brisbane Brisbane Brisbane Brisbane 17 Panama Panama Panama Panama Panama Panama Brisbane Brisbane 20 Brisbane Panama Panama Panama Panama Panama Panama Panama 21 Panama Brisbane Panama Panama Panama Panama Panama Panama 22 Panama Panama Brisbane Panama Panama Panama Panama Panama 23 Panama Panama Panama Brisbane Panama Panama Panama Panama 24 Brisbane Brisbane Panama Panama Panama Panama Panama Panama 25 Brisbane Panama Brisbane Panama Panama Panama Panama Panama 26 Brisbane Panama Panama Brisbane Panama Panama Panama Panama 27 Panama Brisbane Brisbane Panama Panama Panama Panama Panama 28 Panama Brisbane Panama Brisbane Panama Panama Panama Panama 29 Panama Panama Brisbane Brisbane Panama Panama Panama Panama 30 Brisbane Brisbane Brisbane Panama Panama Panama Panama Panama 31 Brisbane Brisbane Panama Brisbane Panama Panama Panama Panama 32 Brisbane Panama Brisbane Brisbane Panama Panama Panama Panama 33 Panama Brisbane Brisbane Brisbane Panama Panama Panama Panama 34 Brisbane Brisbane Brisbane Brisbane Panama Panama Panama Panama 35 Brisbane Brisbane Brisbane Brisbane Brisbane Brisbane Panama Panama
[0237] The results indicate that reassortant viruses #2, #9, #30, #31, #32, #33, #34 and #35 grow equally well or even better in the culture host (see FIGS. 13 and 14) than the corresponding wild-type strain. Most of these strains comprise the NP segment from B/Brisbane/60/08 and some (in particular those which grew best) further contain the PB2 segment from B/Brisbane/60/08. All of these viruses also contain viral segments from the B/Victoria/2/87-like strain and the B/Yamagata/16/88-like strain at a ratio 7:1, 6:2, 4:4, 3:4 or 1:7.
[0238] It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
REFERENCES
[0239] [1] WO2007/002008
[0240] [2] WO2007/124327
[0241] [3] WO2011/012999
[0242] [4] Verity et al. (2012); Influenza Other Respi Viruses; 6(2):101-9.
[0243] [5] Zhou et al. (2009) J. Virol.; 83(19):10309-13
[0244] [6] Gibson et al. (2010); Nature Methods 7, 901-903.
[0245] [7] Gibson et al. (2009) Nature Methods 6, 343-345.
[0246] [8] U.S. Pat. No. 6,576,453
[0247] [9] Yount et al. (2002) J Virol 76:11065-78.
[0248] [10] Kodumal et al. (2004) Proc Natl Acad Sci USA. 101(44):15573-8.
[0249] [11] Yount et al. (2002) J Virol 76:11065-78.
[0250] [12] Sambrook et al, Molecular Cloning: A Laboratory Manual, 2 ed., 1989, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
[0251] [13] WO2010/133964
[0252] [14] WO2009/000891
[0253] [15] Sambrook et al, Molecular Cloning: A Laboratory Manual, 2 ed., 1989, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.
[0254] [16] WO2011048560
[0255] [17] Neumann et al. (2005) Proc Natl Acad Sci USA 102: 16825-9
[0256] [18] Kistner et al. (1998) Vaccine 16:960-8.
[0257] [19] Kistner et al., (1999) Dev Biol Stand 98:101-110.
[0258] [20] Bruhl et al. (2000) Vaccine 19:1149-58.
[0259] [21] WO2006/108846.
[0260] [22] Pau et al. (2001) Vaccine 19:2716-21.
[0261] [23] http://www.atcc.org/
[0262] [24] http://locus.umdnj.edu/
[0263] [25] WO97/37000.
[0264] [26] Brands et al. (1999) Dev Biol Stand 98:93-100.
[0265] [27] Halperin et al. (2002) Vaccine 20:1240-7.
[0266] [28] EP-A-1260581 (WO01/64846).
[0267] [29] WO2006/071563.
[0268] [30] WO2005/113758.
[0269] [31] Grachev et al. (1998) Biologicals; 26(3):175-93.
[0270] [32] Herlocher et al. (2004) J Infect Dis 190(9):1627-30.
[0271] [33] Le et al. (2005) Nature 437(7062):1108.
[0272] [34] Needleman & Wunsch (1970) J. Mol. Biol. 48, 443-453.
[0273] [35] Rice et al. (2000) Trends Genet. 16:276-277.
[0274] [36] Rota et al. (1992) J Gen Virol 73:2737-42.
[0275] [37] GenBank sequence GI:325176.
[0276] [38] McCullers et al. (1999) J Virol 73:7343-8.
[0277] [39] GenBank sequence GI:325237.
[0278] [40] U.S. Pat. No. 6,468,544.
[0279] [41] WO97/37001
[0280] [42] WO02/28422.
[0281] [43] WO02/067983.
[0282] [44] WO02/074336.
[0283] [45] WO01/21151.
[0284] [46] WO02/097072.
[0285] [47] WO2005/113756.
[0286] [48] Huckriede et al. (2003) Methods Enzymol 373:74-91.
[0287] [49] Vaccines. (eds. Plotkins & Orenstein). 4th edition, 2004, ISBN: 0-7216-9688-0
[0288] [50] Treanor et al. (1996) J Infect Dis 173:1467-70.
[0289] [51] Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10.
[0290] [52] Herlocher et al. (2004) J Infect Dis 190(9):1627-30.
[0291] [53] Le et al. (2005) Nature 437(7062):1108.
[0292] [54] WO2008/068631.
[0293] [55] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th edition, ISBN: 0683306472.
[0294] [56] Banzhoff (2000) Immunology Letters 71:91-96.
[0295] [57] Nony et al. (2001) Vaccine 27:3645-51.
[0296] [58] EP-B-0870508.
[0297] [59] U.S. Pat. No. 5,948,410.
[0298] [60] WO2007/052163.
[0299] [61] WO2007/052061
[0300] [62] WO90/14837.
[0301] [63] Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203.
[0302] [64] Podda (2001) Vaccine 19: 2673-2680.
[0303] [65] Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X).
[0304] [66] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.
[0305] [67] WO2008/043774.
[0306] [68] Allison & Byars (1992) Res Immunol 143:519-25.
[0307] [69] Hariharan et al. (1995) Cancer Res 55:3486-9.
[0308] [70] US-2007/014805.
[0309] [71] US-2007/0191314.
[0310] [72] Suli et al. (2004) Vaccine 22(25-26):3464-9.
[0311] [73] WO95/11700.
[0312] [74] U.S. Pat. No. 6,080,725.
[0313] [75] WO2005/097181.
[0314] [76] WO2006/113373.
[0315] [77] Potter & Oxford (1979) Br Med Bull 35: 69-75.
[0316] [78] Greenbaum et al. (2004) Vaccine 22:2566-77.
[0317] [79] Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304.
[0318] [80] Piascik (2003) J Am Pharm Assoc (Wash DC). 43:728-30.
[0319] [81] Mann et al. (2004) Vaccine 22:2425-9.
[0320] [82] Halperin et al. (1979) Am J Public Health 69:1247-50.
[0321] [83] Herbert et al. (1979) J Infect Dis 140:234-8.
[0322] [84] Chen et al. (2003) Vaccine 21:2830-6.
[0323] [85] Current Protocols in Molecular Biology (F. M. Ausubel et al., eds., 1987) Supplement 30.
[0324] [86] Smith & Waterman (1981) Adv. Appl. Math. 2: 482-489.
[0325] [87] Suphaphiphat et al. (2010), Virology J. 7, 157.
[0326] [88] Hoffmann et al. (2000) PNAS 97, 6108-6113.
[0327] [89] Nicolson et al. (2005) Vaccine 23, 2943-2952.
[0328] [90] Ozaki et al (2004) J. Virol. 78, 1851-1857.
[0329] [91] Boettcher et al. (2006) J. Virol. 80, 9896-9898.
Sequence CWU
1
1
1041716PRTInfluenza 1Met Glu Asp Phe Val Arg Gln Cys Phe Asn Pro Met Ile
Val Glu Leu 1 5 10 15
Ala Glu Lys Thr Met Lys Glu Tyr Gly Glu Asp Leu Lys Ile Glu Thr
20 25 30 Asn Lys Phe Ala
Ala Ile Cys Thr His Leu Glu Val Cys Phe Met Tyr 35
40 45 Ser Asp Phe His Phe Ile Asn Glu Gln
Gly Glu Ser Ile Ile Val Glu 50 55
60 Leu Gly Asp Pro Asn Ala Leu Leu Lys His Arg Phe Glu
Ile Ile Glu 65 70 75
80 Gly Arg Asp Arg Thr Met Ala Trp Thr Val Val Asn Ser Ile Cys Asn
85 90 95 Thr Thr Gly Ala
Glu Lys Pro Lys Phe Leu Pro Asp Leu Tyr Asp Tyr 100
105 110 Lys Glu Asn Arg Phe Ile Glu Ile Gly
Val Thr Arg Arg Glu Val His 115 120
125 Ile Tyr Tyr Leu Glu Lys Ala Asn Lys Ile Lys Ser Glu Lys
Thr His 130 135 140
Ile His Ile Phe Ser Phe Thr Gly Glu Glu Met Ala Thr Lys Ala Asp 145
150 155 160 Tyr Thr Leu Asp Glu
Glu Ser Arg Ala Arg Ile Lys Thr Arg Leu Phe 165
170 175 Thr Ile Arg Gln Glu Met Ala Ser Arg Gly
Leu Trp Asp Ser Phe Arg 180 185
190 Gln Ser Glu Arg Gly Glu Glu Thr Ile Glu Glu Arg Phe Glu Ile
Thr 195 200 205 Gly
Thr Met Arg Lys Leu Ala Asp Gln Ser Leu Pro Pro Asn Phe Ser 210
215 220 Ser Leu Glu Asn Phe Arg
Ala Tyr Val Asp Gly Phe Glu Pro Asn Gly 225 230
235 240 Tyr Ile Glu Gly Lys Leu Ser Gln Met Ser Lys
Glu Val Asn Ala Arg 245 250
255 Ile Glu Pro Phe Leu Lys Thr Thr Pro Arg Pro Leu Arg Leu Pro Asn
260 265 270 Gly Pro
Pro Cys Ser Gln Arg Ser Lys Phe Leu Leu Met Asp Ala Leu 275
280 285 Lys Leu Ser Ile Glu Asp Pro
Ser His Glu Gly Glu Gly Ile Pro Leu 290 295
300 Tyr Asp Ala Ile Lys Cys Met Arg Thr Phe Phe Gly
Trp Lys Glu Pro 305 310 315
320 Asn Val Val Lys Pro His Glu Lys Gly Ile Asn Pro Asn Tyr Leu Leu
325 330 335 Ser Trp Lys
Gln Val Leu Ala Glu Leu Gln Asp Ile Glu Asn Glu Glu 340
345 350 Lys Ile Pro Lys Thr Lys Asn Met
Lys Lys Thr Ser Gln Leu Lys Trp 355 360
365 Ala Leu Gly Glu Asn Met Ala Pro Glu Lys Val Asp Phe
Asp Asp Cys 370 375 380
Lys Asp Val Gly Asp Leu Lys Gln Tyr Asp Ser Asp Glu Pro Glu Leu 385
390 395 400 Arg Ser Leu Ala
Ser Trp Ile Gln Asn Glu Phe Asn Lys Ala Cys Glu 405
410 415 Leu Thr Asp Ser Ser Trp Ile Glu Leu
Asp Glu Ile Gly Glu Asp Val 420 425
430 Ala Pro Ile Glu His Ile Ala Ser Met Arg Arg Asn Tyr Phe
Thr Ser 435 440 445
Glu Val Ser His Cys Arg Ala Thr Glu Tyr Ile Met Lys Gly Val Tyr 450
455 460 Ile Asn Thr Ala Leu
Leu Asn Ala Ser Cys Ala Ala Met Asp Asp Phe 465 470
475 480 Gln Leu Ile Pro Met Ile Ser Lys Cys Arg
Thr Lys Glu Gly Arg Arg 485 490
495 Lys Thr Asn Leu Tyr Gly Phe Ile Ile Lys Gly Arg Ser His Leu
Arg 500 505 510 Asn
Asp Thr Asp Val Val Asn Phe Val Ser Met Glu Phe Ser Leu Thr 515
520 525 Asp Pro Arg Leu Glu Pro
His Lys Trp Glu Lys Tyr Cys Val Leu Glu 530 535
540 Ile Gly Asp Met Leu Ile Arg Ser Ala Ile Gly
Gln Val Ser Arg Pro 545 550 555
560 Met Phe Leu Tyr Val Arg Thr Asn Gly Thr Ser Lys Ile Lys Met Lys
565 570 575 Trp Gly
Met Glu Met Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln Ile 580
585 590 Glu Ser Met Ile Glu Ala Glu
Ser Ser Val Lys Glu Lys Asp Met Thr 595 600
605 Lys Glu Phe Phe Glu Asn Lys Ser Glu Thr Trp Pro
Ile Gly Glu Ser 610 615 620
Pro Lys Gly Val Glu Glu Ser Ser Ile Gly Lys Val Cys Arg Thr Leu 625
630 635 640 Leu Ala Lys
Ser Val Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu 645
650 655 Gly Phe Ser Ala Glu Ser Arg Lys
Leu Leu Leu Ile Val Gln Ala Leu 660 665
670 Arg Asp Asn Leu Glu Pro Gly Thr Phe Asp Leu Gly Gly
Leu Tyr Glu 675 680 685
Ala Ile Glu Glu Cys Leu Ile Asn Asp Pro Trp Val Leu Leu Asn Ala 690
695 700 Ser Trp Phe Asn
Ser Phe Leu Thr His Ala Leu Ser 705 710
715 2757PRTInfluenza 2Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Val
Pro Thr Gln Asn 1 5 10
15 Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser His
20 25 30 Gly Thr Gly
Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His Gln 35
40 45 Tyr Ser Glu Lys Gly Arg Trp Thr
Thr Asn Thr Glu Thr Gly Ala Pro 50 55
60 Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp Asn
Glu Pro Ser 65 70 75
80 Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala Met Ala Phe Leu Glu
85 90 95 Glu Ser His Pro
Gly Ile Phe Glu Asn Ser Cys Ile Glu Thr Met Glu 100
105 110 Val Val Gln Gln Thr Arg Val Asp Lys
Leu Thr Gln Gly Arg Gln Thr 115 120
125 Tyr Asp Trp Thr Leu Asn Arg Asn Gln Pro Ala Ala Thr Ala
Leu Ala 130 135 140
Asn Thr Ile Glu Val Phe Arg Ser Asn Gly Leu Thr Ala Asn Glu Ser 145
150 155 160 Gly Arg Leu Ile Asp
Phe Leu Lys Asp Val Met Glu Ser Met Asn Lys 165
170 175 Glu Glu Met Gly Ile Thr Thr His Phe Gln
Arg Lys Arg Arg Val Arg 180 185
190 Asp Asn Met Thr Lys Lys Met Ile Thr Gln Arg Thr Met Gly Lys
Lys 195 200 205 Lys
Gln Arg Leu Asn Lys Arg Ser Tyr Leu Ile Arg Ala Leu Thr Leu 210
215 220 Asn Thr Met Thr Lys Asp
Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225 230
235 240 Ile Ala Thr Pro Gly Met Gln Ile Arg Gly Phe
Val Tyr Phe Val Glu 245 250
255 Thr Leu Ala Arg Ser Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu Pro
260 265 270 Val Gly
Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val Arg Lys 275
280 285 Met Met Thr Asn Ser Gln Asp
Thr Glu Leu Ser Phe Thr Ile Thr Gly 290 295
300 Asp Asn Thr Lys Trp Asn Glu Asn Gln Asn Pro Arg
Met Phe Leu Ala 305 310 315
320 Met Ile Thr Tyr Met Thr Arg Asn Gln Pro Glu Trp Phe Arg Asn Val
325 330 335 Leu Ser Ile
Ala Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu Gly 340
345 350 Lys Gly Tyr Met Phe Glu Ser Lys
Ser Met Lys Leu Arg Thr Gln Ile 355 360
365 Pro Ala Glu Met Leu Ala Ser Ile Asp Leu Lys Tyr Phe
Asn Asp Ser 370 375 380
Thr Arg Lys Lys Ile Glu Lys Ile Arg Pro Leu Leu Ile Glu Gly Thr 385
390 395 400 Ala Ser Leu Ser
Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser 405
410 415 Thr Val Leu Gly Val Ser Ile Leu Asn
Leu Gly Gln Lys Arg Tyr Thr 420 425
430 Lys Thr Thr Tyr Trp Trp Asp Gly Leu Gln Ser Ser Asp Asp
Phe Ala 435 440 445
Leu Ile Val Asn Ala Pro Asn His Glu Gly Ile Gln Ala Gly Val Asp 450
455 460 Arg Phe Tyr Arg Thr
Cys Lys Leu Leu Gly Ile Asn Met Ser Lys Lys 465 470
475 480 Lys Ser Tyr Ile Asn Arg Thr Gly Thr Phe
Glu Phe Thr Ser Phe Phe 485 490
495 Tyr Arg Tyr Gly Phe Val Ala Asn Phe Ser Met Glu Leu Pro Ser
Phe 500 505 510 Gly
Val Ser Gly Ile Asn Glu Ser Ala Asp Met Ser Ile Gly Val Thr 515
520 525 Val Ile Lys Asn Asn Met
Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala 530 535
540 Gln Met Ala Leu Gln Leu Phe Ile Lys Asp Tyr
Arg Tyr Thr Tyr Arg 545 550 555
560 Cys His Arg Gly Asp Thr Gln Ile Gln Thr Arg Arg Ser Phe Glu Ile
565 570 575 Lys Lys
Leu Trp Glu Gln Thr Arg Ser Lys Ala Gly Leu Leu Val Ser 580
585 590 Asp Gly Gly Pro Asn Leu Tyr
Asn Ile Arg Asn Leu His Ile Pro Glu 595 600
605 Val Cys Leu Lys Trp Glu Leu Met Asp Glu Asp Tyr
Gln Gly Arg Leu 610 615 620
Cys Asn Pro Leu Asn Pro Phe Val Ser His Lys Glu Ile Glu Ser Met 625
630 635 640 Asn Asn Ala
Val Met Met Pro Ala His Gly Pro Ala Lys Asn Met Glu 645
650 655 Tyr Asp Ala Val Ala Thr Thr His
Ser Trp Ile Pro Lys Arg Asn Arg 660 665
670 Ser Ile Leu Asn Thr Ser Gln Arg Gly Val Leu Glu Asp
Glu Gln Met 675 680 685
Tyr Gln Arg Cys Cys Asn Leu Phe Glu Lys Phe Phe Pro Ser Ser Ser 690
695 700 Tyr Arg Arg Pro
Val Gly Ile Ser Ser Met Val Glu Ala Met Val Ser 705 710
715 720 Arg Ala Arg Ile Asp Ala Arg Ile Asp
Phe Glu Ser Gly Arg Ile Lys 725 730
735 Lys Glu Glu Phe Thr Glu Ile Met Lys Ile Cys Ser Thr Ile
Glu Glu 740 745 750
Leu Arg Arg Gln Lys 755 3759PRTInfluenza 3Met Glu Arg Ile
Lys Glu Leu Arg Asn Leu Met Ser Gln Ser Arg Thr 1 5
10 15 Arg Glu Ile Leu Thr Lys Thr Thr Val
Asp His Met Ala Ile Ile Lys 20 25
30 Lys Tyr Thr Ser Gly Arg Gln Glu Lys Asn Pro Ala Leu Arg
Met Lys 35 40 45
Trp Met Met Ala Met Lys Tyr Pro Ile Thr Ala Asp Lys Arg Ile Thr 50
55 60 Glu Met Ile Pro Glu
Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys 65 70
75 80 Met Asn Asp Ala Gly Ser Asp Arg Val Met
Val Ser Pro Leu Ala Val 85 90
95 Thr Trp Trp Asn Arg Asn Gly Pro Ile Thr Asn Thr Val His Tyr
Pro 100 105 110 Lys
Ile Tyr Lys Thr Tyr Phe Glu Arg Val Glu Arg Leu Lys His Gly 115
120 125 Thr Phe Gly Pro Val His
Phe Arg Asn Gln Val Lys Ile Arg Arg Arg 130 135
140 Val Asp Ile Asn Pro Gly His Ala Asp Leu Ser
Ala Lys Glu Ala Gln 145 150 155
160 Asp Val Ile Met Glu Val Val Phe Pro Asn Glu Val Gly Ala Arg Ile
165 170 175 Leu Thr
Ser Glu Ser Gln Leu Thr Ile Thr Lys Glu Lys Lys Glu Glu 180
185 190 Leu Gln Asp Cys Lys Ile Ser
Pro Leu Met Val Ala Tyr Met Leu Glu 195 200
205 Arg Glu Leu Val Arg Lys Thr Arg Phe Leu Pro Val
Ala Gly Gly Thr 210 215 220
Ser Ser Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly Thr Cys Trp 225
230 235 240 Glu Gln Met
Tyr Thr Pro Gly Gly Glu Val Arg Asn Asp Asp Val Asp 245
250 255 Gln Ser Leu Ile Ile Ala Ala Arg
Asn Ile Val Arg Arg Ala Ala Val 260 265
270 Ser Ala Asp Pro Leu Ala Ser Leu Leu Glu Met Cys His
Ser Thr Gln 275 280 285
Ile Gly Gly Ile Arg Met Val Asp Ile Leu Arg Gln Asn Pro Thr Glu 290
295 300 Glu Gln Ala Val
Asp Ile Cys Lys Ala Ala Met Gly Leu Arg Ile Ser 305 310
315 320 Ser Ser Phe Ser Phe Gly Gly Phe Thr
Phe Lys Arg Thr Ser Gly Ser 325 330
335 Ser Val Lys Arg Glu Glu Glu Val Leu Thr Gly Asn Leu Gln
Thr Leu 340 345 350
Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe Thr Met Val Gly Arg
355 360 365 Arg Ala Thr Ala
Ile Leu Arg Lys Ala Thr Arg Arg Leu Ile Gln Leu 370
375 380 Ile Val Ser Gly Arg Asp Glu Gln
Ser Ile Ala Glu Ala Ile Ile Val 385 390
395 400 Ala Met Val Phe Ser Gln Glu Asp Cys Met Ile Lys
Ala Val Arg Gly 405 410
415 Asp Leu Asn Phe Val Asn Arg Ala Asn Gln Arg Leu Asn Pro Met His
420 425 430 Gln Leu Leu
Arg His Phe Gln Lys Asp Ala Arg Val Leu Phe Gln Asn 435
440 445 Trp Gly Val Glu Pro Ile Asp Asn
Val Met Gly Met Ile Gly Ile Leu 450 455
460 Pro Asp Met Thr Pro Ser Ile Glu Met Ser Met Arg Gly
Val Arg Ile 465 470 475
480 Ser Lys Met Gly Val Asp Glu Tyr Ser Ser Thr Glu Arg Val Val Val
485 490 495 Ser Ile Asp Arg
Phe Leu Arg Ile Arg Asp Gln Arg Gly Asn Val Leu 500
505 510 Leu Ser Pro Glu Glu Val Ser Glu Thr
Gln Gly Thr Glu Lys Leu Thr 515 520
525 Ile Thr Tyr Ser Ser Ser Met Met Trp Glu Ile Asn Gly Pro
Glu Ser 530 535 540
Val Leu Val Asn Thr Tyr Gln Trp Ile Ile Arg Asn Trp Glu Thr Val 545
550 555 560 Lys Ile Gln Trp Ser
Gln Asn Pro Thr Met Leu Tyr Asn Lys Met Glu 565
570 575 Phe Glu Pro Phe Gln Ser Leu Val Pro Lys
Ala Ile Arg Gly Gln Tyr 580 585
590 Ser Gly Phe Val Arg Thr Leu Phe Gln Gln Met Arg Asp Val Leu
Gly 595 600 605 Thr
Phe Asp Thr Ala Gln Ile Ile Lys Leu Leu Pro Phe Ala Ala Ala 610
615 620 Pro Pro Lys Gln Ser Arg
Met Gln Phe Ser Ser Phe Thr Val Asn Val 625 630
635 640 Arg Gly Ser Gly Met Arg Ile Leu Val Arg Gly
Asn Ser Pro Val Phe 645 650
655 Asn Tyr Asn Lys Ala Thr Lys Arg Leu Thr Val Leu Gly Lys Asp Ala
660 665 670 Gly Thr
Leu Thr Glu Asp Pro Asp Glu Gly Thr Ala Gly Val Glu Ser 675
680 685 Ala Val Leu Arg Gly Phe Leu
Ile Leu Gly Lys Glu Asp Lys Arg Tyr 690 695
700 Gly Pro Ala Leu Ser Ile Asn Glu Leu Ser Asn Leu
Ala Lys Gly Glu 705 710 715
720 Lys Ala Asn Val Leu Ile Gly Gln Gly Asp Val Val Leu Val Met Lys
725 730 735 Arg Lys Arg
Asp Ser Ser Ile Leu Thr Asp Ser Gln Thr Ala Thr Lys 740
745 750 Arg Ile Arg Met Ala Ile Asn
755 4498PRTInfluenza 4Met Ala Ser Gln Gly Thr Lys Arg
Ser Tyr Glu Gln Met Glu Thr Asp 1 5 10
15 Gly Glu Arg Gln Asn Ala Thr Glu Ile Arg Ala Ser Val
Gly Lys Met 20 25 30
Ile Gly Gly Ile Gly Arg Phe Tyr Ile Gln Met Cys Thr Glu Leu Lys
35 40 45 Leu Ser Asp Tyr
Glu Gly Arg Leu Ile Gln Asn Ser Leu Thr Ile Glu 50
55 60 Arg Met Val Leu Ser Ala Phe Asp
Glu Arg Arg Asn Lys Tyr Leu Glu 65 70
75 80 Glu His Pro Ser Ala Gly Lys Asp Pro Lys Lys Thr
Gly Gly Pro Ile 85 90
95 Tyr Arg Arg Val Asn Gly Lys Trp Met Arg Glu Leu Ile Leu Tyr Asp
100 105 110 Lys Glu Glu
Ile Arg Arg Ile Trp Arg Gln Ala Asn Asn Gly Asp Asp 115
120 125 Ala Thr Ala Gly Leu Thr His Met
Met Ile Trp His Ser Asn Leu Asn 130 135
140 Asp Ala Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg Thr
Gly Met Asp 145 150 155
160 Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr Leu Pro Arg Arg Ser
165 170 175 Gly Ala Ala Gly
Ala Ala Val Lys Gly Val Gly Thr Met Val Met Glu 180
185 190 Leu Val Arg Met Ile Lys Arg Gly Ile
Asn Asp Arg Asn Phe Trp Arg 195 200
205 Gly Glu Asn Gly Arg Lys Thr Arg Ile Ala Tyr Glu Arg Met
Cys Asn 210 215 220
Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Lys Ala Met Met Asp 225
230 235 240 Gln Val Arg Glu Ser
Arg Asn Pro Gly Asn Ala Glu Phe Glu Asp Leu 245
250 255 Thr Phe Leu Ala Arg Ser Ala Leu Ile Leu
Arg Gly Ser Val Ala His 260 265
270 Lys Ser Cys Leu Pro Ala Cys Val Tyr Gly Pro Ala Val Ala Ser
Gly 275 280 285 Tyr
Asp Phe Glu Arg Glu Gly Tyr Ser Leu Val Gly Ile Asp Pro Phe 290
295 300 Arg Leu Leu Gln Asn Ser
Gln Val Tyr Ser Leu Ile Arg Pro Asn Glu 305 310
315 320 Asn Pro Ala His Lys Ser Gln Leu Val Trp Met
Ala Cys His Ser Ala 325 330
335 Ala Phe Glu Asp Leu Arg Val Leu Ser Phe Ile Lys Gly Thr Lys Val
340 345 350 Leu Pro
Arg Gly Lys Leu Ser Thr Arg Gly Val Gln Ile Ala Ser Asn 355
360 365 Glu Asn Met Glu Thr Met Glu
Ser Ser Thr Leu Glu Leu Arg Ser Arg 370 375
380 Tyr Trp Ala Ile Arg Thr Arg Ser Gly Gly Asn Thr
Asn Gln Gln Arg 385 390 395
400 Ala Ser Ala Gly Gln Ile Ser Ile Gln Pro Thr Phe Ser Val Gln Arg
405 410 415 Asn Leu Pro
Phe Asp Arg Thr Thr Ile Met Ala Ala Phe Asn Gly Asn 420
425 430 Thr Glu Gly Arg Thr Ser Asp Met
Arg Thr Glu Ile Ile Arg Met Met 435 440
445 Glu Ser Ala Arg Pro Glu Asp Val Ser Phe Gln Gly Arg
Gly Val Phe 450 455 460
Glu Leu Ser Asp Glu Lys Ala Ala Ser Pro Ile Val Pro Ser Phe Asp 465
470 475 480 Met Ser Asn Glu
Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu Glu Tyr 485
490 495 Asp Asn 5252PRTInfluenza 5Met Ser
Leu Leu Thr Glu Val Glu Thr Tyr Val Leu Ser Ile Ile Pro 1 5
10 15 Ser Gly Pro Leu Lys Ala Glu
Ile Ala Gln Arg Leu Glu Asp Val Phe 20 25
30 Ala Gly Lys Asn Thr Asp Leu Glu Val Leu Met Glu
Trp Leu Lys Thr 35 40 45
Arg Pro Ile Leu Ser Pro Leu Thr Lys Gly Ile Leu Gly Phe Val Phe
50 55 60 Thr Leu Thr
Val Pro Ser Glu Arg Gly Leu Gln Arg Arg Arg Phe Val 65
70 75 80 Gln Asn Ala Leu Asn Gly Asn
Gly Asp Pro Asn Asn Met Asp Lys Ala 85
90 95 Val Lys Leu Tyr Arg Lys Leu Lys Arg Glu Ile
Thr Phe His Gly Ala 100 105
110 Lys Glu Ile Ser Leu Ser Tyr Ser Ala Gly Ala Leu Ala Ser Cys
Met 115 120 125 Gly
Leu Ile Tyr Asn Arg Met Gly Ala Val Thr Thr Glu Val Ala Phe 130
135 140 Gly Leu Val Cys Ala Thr
Cys Glu Gln Ile Ala Asp Ser Gln His Arg 145 150
155 160 Ser His Arg Gln Met Val Thr Thr Thr Asn Pro
Leu Ile Arg His Glu 165 170
175 Asn Arg Met Val Leu Ala Ser Thr Thr Ala Lys Ala Met Glu Gln Met
180 185 190 Ala Gly
Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Val Ala Ser Gln 195
200 205 Ala Arg Gln Met Val Gln Ala
Met Arg Thr Ile Gly Thr His Pro Ser 210 215
220 Ser Ser Ala Gly Leu Lys Asn Asp Leu Leu Glu Asn
Leu Gln Ala Tyr 225 230 235
240 Gln Lys Arg Met Gly Val Gln Met Gln Arg Phe Lys 245
250 6230PRTInfluenza 6Met Asp Pro Asn Thr Val Ser
Ser Phe Gln Val Asp Cys Phe Leu Trp 1 5
10 15 His Val Arg Lys Arg Val Ala Asp Gln Glu Leu
Gly Asp Ala Pro Phe 20 25
30 Leu Asp Arg Leu Arg Arg Asp Gln Lys Ser Leu Arg Gly Arg Gly
Ser 35 40 45 Thr
Leu Gly Leu Asp Ile Lys Thr Ala Thr Arg Ala Gly Lys Gln Ile 50
55 60 Val Glu Arg Ile Leu Lys
Glu Glu Ser Asp Glu Ala Leu Lys Met Thr 65 70
75 80 Met Ala Ser Val Pro Ala Ser Arg Tyr Leu Thr
Asp Met Thr Leu Glu 85 90
95 Glu Met Ser Arg Asp Trp Ser Met Leu Ile Pro Lys Gln Lys Val Ala
100 105 110 Gly Pro
Leu Cys Ile Arg Met Asp Gln Ala Ile Met Asp Lys Asn Ile 115
120 125 Ile Leu Lys Ala Asn Phe Ser
Val Ile Phe Asp Arg Leu Glu Thr Leu 130 135
140 Ile Leu Leu Arg Ala Phe Thr Glu Glu Gly Ala Ile
Val Gly Glu Ile 145 150 155
160 Ser Pro Leu Pro Ser Leu Pro Gly His Thr Ala Glu Asp Val Lys Asn
165 170 175 Ala Val Gly
Val Leu Ile Gly Gly Leu Glu Trp Asn Asp Asn Thr Val 180
185 190 Arg Val Ser Glu Thr Leu Gln Arg
Phe Ala Trp Arg Ser Ser Asn Glu 195 200
205 Asn Gly Arg Pro Pro Leu Thr Pro Lys Gln Lys Arg Glu
Met Ala Gly 210 215 220
Thr Ile Arg Ser Glu Val 225 230 7565PRTInfluenza 7Met
Lys Ala Asn Leu Leu Val Leu Leu Cys Ala Leu Ala Ala Ala Asp 1
5 10 15 Ala Asp Thr Ile Cys Ile
Gly Tyr His Thr Asn Asn Ser Thr Asp Thr 20
25 30 Val Asp Thr Val Leu Glu Lys Asn Val Thr
Val Thr His Ser Val Asn 35 40
45 Leu Leu Glu Asp Ser His Asn Gly Lys Leu Cys Arg Leu Lys
Gly Ile 50 55 60
Ala Pro Leu Gln Leu Gly Lys Cys Asn Ile Ala Gly Trp Leu Leu Gly 65
70 75 80 Asn Pro Glu Cys Asp
Pro Leu Leu Pro Val Arg Ser Trp Ser Tyr Ile 85
90 95 Val Glu Thr Pro Asn Ser Glu Asn Gly Ile
Cys Tyr Pro Gly Asp Phe 100 105
110 Ile Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser
Phe 115 120 125 Glu
Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Asn His Asn 130
135 140 Thr Asn Gly Val Thr Ala
Ala Cys Ser His Glu Gly Lys Ser Ser Phe 145 150
155 160 Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys Glu
Gly Ser Tyr Pro Lys 165 170
175 Leu Lys Asn Ser Tyr Val Asn Lys Lys Gly Lys Glu Val Leu Val Leu
180 185 190 Trp Gly
Ile His His Pro Pro Asn Ser Lys Glu Gln Gln Asn Leu Tyr 195
200 205 Gln Asn Glu Asn Ala Tyr Val
Ser Val Val Thr Ser Asn Tyr Asn Arg 210 215
220 Arg Phe Thr Pro Glu Ile Ala Glu Arg Pro Lys Val
Arg Asp Gln Ala 225 230 235
240 Gly Arg Met Asn Tyr Tyr Trp Thr Leu Leu Lys Pro Gly Asp Thr Ile
245 250 255 Ile Phe Glu
Ala Asn Gly Asn Leu Ile Ala Pro Met Tyr Ala Phe Ala 260
265 270 Leu Ser Arg Gly Phe Gly Ser Gly
Ile Ile Thr Ser Asn Ala Ser Met 275 280
285 His Glu Cys Asn Thr Lys Cys Gln Thr Pro Leu Gly Ala
Ile Asn Ser 290 295 300
Ser Leu Pro Tyr Gln Asn Ile His Pro Val Thr Ile Gly Glu Cys Pro 305
310 315 320 Lys Tyr Val Arg
Ser Ala Lys Leu Arg Met Val Thr Gly Leu Arg Asn 325
330 335 Ile Pro Ser Ile Gln Ser Arg Gly Leu
Phe Gly Ala Ile Ala Gly Phe 340 345
350 Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr Gly
Tyr His 355 360 365
His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser Thr 370
375 380 Gln Asn Ala Ile Asn
Gly Ile Thr Asn Lys Val Asn Thr Val Ile Glu 385 390
395 400 Lys Met Asn Ile Gln Phe Thr Ala Val Gly
Lys Glu Phe Asn Lys Leu 405 410
415 Glu Lys Arg Met Glu Asn Leu Asn Lys Lys Val Asp Asp Gly Phe
Leu 420 425 430 Asp
Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn Glu 435
440 445 Arg Thr Leu Glu Phe His
Asp Ser Asn Val Lys Asn Leu Tyr Glu Lys 450 455
460 Val Lys Ser Gln Leu Lys Asn Asn Ala Lys Glu
Ile Gly Asn Gly Cys 465 470 475
480 Phe Glu Phe Tyr His Lys Cys Asp Asn Glu Cys Met Glu Ser Val Arg
485 490 495 Asn Gly
Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu Asn 500
505 510 Arg Glu Lys Val Asp Gly Val
Lys Leu Glu Ser Met Gly Ile Tyr Gln 515 520
525 Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser Leu
Val Leu Leu Val 530 535 540
Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu Gln 545
550 555 560 Cys Arg Ile
Cys Ile 565 8454PRTInfluenza 8Met Asn Pro Asn Gln Lys Ile
Ile Thr Ile Gly Ser Ile Cys Leu Val 1 5
10 15 Val Gly Leu Ile Ser Leu Ile Leu Gln Ile Gly
Asn Ile Ile Ser Ile 20 25
30 Trp Ile Ser His Ser Ile Gln Thr Gly Ser Gln Asn His Thr Gly
Ile 35 40 45 Cys
Asn Gln Asn Ile Ile Thr Tyr Lys Asn Ser Thr Trp Val Lys Asp 50
55 60 Thr Thr Ser Val Ile Leu
Thr Gly Asn Ser Ser Leu Cys Pro Ile Arg 65 70
75 80 Gly Trp Ala Ile Tyr Ser Lys Asp Asn Ser Ile
Arg Ile Gly Ser Lys 85 90
95 Gly Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu
100 105 110 Glu Cys
Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys 115
120 125 His Ser Ser Gly Thr Val Lys
Asp Arg Ser Pro Tyr Arg Ala Leu Met 130 135
140 Ser Cys Pro Val Gly Glu Ala Pro Ser Pro Tyr Asn
Ser Arg Phe Glu 145 150 155
160 Ser Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Met Gly Trp Leu
165 170 175 Thr Ile Gly
Ile Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys 180
185 190 Tyr Asn Gly Ile Ile Thr Glu Thr
Ile Lys Ser Trp Arg Lys Lys Ile 195 200
205 Leu Arg Thr Gln Glu Ser Glu Cys Ala Cys Val Asn Gly
Ser Cys Phe 210 215 220
Thr Ile Met Thr Asp Gly Pro Ser Asp Gly Leu Ala Ser Tyr Lys Ile 225
230 235 240 Phe Lys Ile Glu
Lys Gly Lys Val Thr Lys Ser Ile Glu Leu Asn Ala 245
250 255 Pro Asn Ser His Tyr Glu Glu Cys Ser
Cys Tyr Pro Asp Thr Asp Lys 260 265
270 Val Met Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg
Pro Trp 275 280 285
Val Ser Phe Asp Gln Asn Leu Asp Tyr Gln Ile Gly Tyr Ile Cys Ser 290
295 300 Gly Val Phe Gly Asp
Asn Pro Arg Pro Glu Asp Gly Thr Gly Ser Cys 305 310
315 320 Gly Pro Val Tyr Val Asp Gly Ala Asn Gly
Val Lys Gly Phe Ser Tyr 325 330
335 Arg Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser His Ser
Ser 340 345 350 Arg
His Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Glu Thr 355
360 365 Asp Ser Lys Phe Ser Val
Arg Gln Asp Val Val Ala Met Thr Asp Trp 370 375
380 Ser Gly Tyr Ser Gly Ser Phe Val Gln His Pro
Glu Leu Thr Gly Leu 385 390 395
400 Asp Cys Met Arg Pro Cys Phe Trp Val Glu Leu Ile Arg Gly Arg Pro
405 410 415 Lys Glu
Lys Thr Ile Trp Thr Ser Ala Ser Ser Ile Ser Phe Cys Gly 420
425 430 Val Asn Ser Asp Thr Val Asp
Trp Ser Trp Pro Asp Gly Ala Glu Leu 435 440
445 Pro Phe Ser Ile Asp Lys 450
92233DNAInfluenza 9agcgaaagca ggtactgatc caaaatggaa gattttgtgc gacaatgctt
caatccgatg 60attgtcgagc ttgcggaaaa aacaatgaaa gagtatgggg aggacctgaa
aatcgaaaca 120aacaaatttg cagcaatatg cactcacttg gaagtatgct tcatgtattc
agattttcac 180ttcatcaatg agcaaggcga gtcaataatc gtagaacttg gtgatccaaa
tgcacttttg 240aagcacagat ttgaaataat cgagggaaga gatcgcacaa tggcctggac
agtagtaaac 300agtatttgca acactacagg ggctgagaaa ccaaagtttc taccagattt
gtatgattac 360aaggagaata gatttatcga aattggagta acaaggagag aagttcacat
atactatctg 420gaaaaggcca ataaaattaa atctgagaaa acacacatcc acattttctc
gttcactggg 480gaagaaatgg ccacaaaggc agactacact ctcgatgaag aaagcagggc
taggatcaaa 540accagactat tcaccataag acaagaaatg gccagcagag gcctctggga
ttcctttcgt 600cagtccgaga gaggagaaga gacaattgaa gaaaggtttg aaatcacagg
aacaatgcgc 660aagcttgccg accaaagtct cccgccgaac ttctccagcc ttgaaaattt
tagagcctat 720gtggatggat tcgaaccgaa cggctacatt gagggcaagc tgtctcaaat
gtccaaagaa 780gtaaatgcta gaattgaacc ttttttgaaa acaacaccac gaccacttag
acttccgaat 840gggcctccct gttctcagcg gtccaaattc ctgctgatgg atgccttaaa
attaagcatt 900gaggacccaa gtcatgaagg agagggaata ccgctatatg atgcaatcaa
atgcatgaga 960acattctttg gatggaagga acccaatgtt gttaaaccac acgaaaaggg
aataaatcca 1020aattatcttc tgtcatggaa gcaagtactg gcagaactgc aggacattga
gaatgaggag 1080aaaattccaa agactaaaaa tatgaagaaa acaagtcagc taaagtgggc
acttggtgag 1140aacatggcac cagaaaaggt agactttgac gactgtaaag atgtaggtga
tttgaagcaa 1200tatgatagtg atgaaccaga attgaggtcg cttgcaagtt ggattcagaa
tgagtttaac 1260aaggcatgcg aactgacaga ttcaagctgg atagagctcg atgagattgg
agaagatgtg 1320gctccaattg aacacattgc aagcatgaga aggaattatt tcacatcaga
ggtgtctcac 1380tgcagagcca cagaatacat aatgaagggg gtgtacatca atactgcctt
gcttaatgca 1440tcttgtgcag caatggatga tttccaatta attccaatga taagcaagtg
tagaactaag 1500gagggaaggc gaaagaccaa cttgtatggt ttcatcataa aaggaagatc
ccacttaagg 1560aatgacaccg acgtggtaaa ctttgtgagc atggagtttt ctctcactga
cccaagactt 1620gaaccacata aatgggagaa gtactgtgtt cttgagatag gagatatgct
tataagaagt 1680gccataggcc aggtttcaag gcccatgttc ttgtatgtga gaacaaatgg
aacctcaaaa 1740attaaaatga aatggggaat ggagatgagg cgttgcctcc tccagtcact
tcaacaaatt 1800gagagtatga ttgaagctga gtcctctgtc aaagagaaag acatgaccaa
agagttcttt 1860gagaacaaat cagaaacatg gcccattgga gagtccccca aaggagtgga
ggaaagttcc 1920attgggaagg tctgcaggac tttattagca aagtcggtat tcaacagctt
gtatgcatct 1980ccacaactag aaggattttc agctgaatca agaaaactgc ttcttatcgt
tcaggctctt 2040agggacaacc ttgaacctgg gacctttgat cttggggggc tatatgaagc
aattgaggag 2100tgcctgatta atgatccctg ggttttgctt aatgcttctt ggttcaactc
cttccttaca 2160catgcattga gttagttgtg gcagtgctac tatttgctat ccatactgtc
caaaaaagta 2220ccttgtttct act
2233102341DNAInfluenza 10agcgaaagca ggcaaaccat ttgaatggat
gtcaatccga ccttactttt cttaaaagtg 60ccaacacaaa atgctataag cacaactttc
ccttatactg gagaccctcc ttacagccat 120gggacaggaa caggatacac catggatact
gtcaacagga cacatcagta ctcagaaaag 180ggaagatgga caacaaacac cgaaactgga
gcaccgcaac tcaacccgat tgatgggcca 240ctgccagaag acaatgaacc aagtggttat
gcccaaacag attgtgtatt ggaggcgatg 300gctttccttg aggaatccca tcctggtatt
tttgaaaact cgtgtattga aacgatggag 360gttgttcagc aaacacgagt agacaagctg
acacaaggcc gacagaccta tgactggact 420ctaaatagaa accaacctgc tgcaacagca
ttggccaaca caatagaagt gttcagatca 480aatggcctca cggccaatga gtctggaagg
ctcatagact tccttaagga tgtaatggag 540tcaatgaaca aagaagaaat ggggatcaca
actcattttc agagaaagag acgggtgaga 600gacaatatga ctaagaaaat gataacacag
agaacaatgg gtaaaaagaa gcagagattg 660aacaaaagga gttatctaat tagagcattg
accctgaaca caatgaccaa agatgctgag 720agagggaagc taaaacggag agcaattgca
accccaggga tgcaaataag ggggtttgta 780tactttgttg agacactggc aaggagtata
tgtgagaaac ttgaacaatc agggttgcca 840gttggaggca atgagaagaa agcaaagttg
gcaaatgttg taaggaagat gatgaccaat 900tctcaggaca ccgaactttc tttcaccatc
actggagata acaccaaatg gaacgaaaat 960cagaatcctc ggatgttttt ggccatgatc
acatatatga ccagaaatca gcccgaatgg 1020ttcagaaatg ttctaagtat tgctccaata
atgttctcaa acaaaatggc gagactggga 1080aaagggtata tgtttgagag caagagtatg
aaacttagaa ctcaaatacc tgcagaaatg 1140ctagcaagca tcgatttgaa atatttcaat
gattcaacaa gaaagaagat tgaaaaaatc 1200cgaccgctct taatagaggg gactgcatca
ttgagccctg gaatgatgat gggcatgttc 1260aatatgttaa gcactgtatt aggcgtctcc
atcctgaatc ttggacaaaa gagatacacc 1320aagactactt actggtggga tggtcttcaa
tcctctgacg attttgctct gattgtgaat 1380gcacccaatc atgaagggat tcaagccgga
gtcgacaggt tttatcgaac ctgtaagcta 1440cttggaatca atatgagcaa gaaaaagtct
tacataaaca gaacaggtac atttgaattc 1500acaagttttt tctatcgtta tgggtttgtt
gccaatttca gcatggagct tcccagtttt 1560ggggtgtctg ggatcaacga gtcagcggac
atgagtattg gagttactgt catcaaaaac 1620aatatgataa acaatgatct tggtccagca
acagctcaaa tggcccttca gttgttcatc 1680aaagattaca ggtacacgta ccgatgccat
agaggtgaca cacaaataca aacccgaaga 1740tcatttgaaa taaagaaact gtgggagcaa
acccgttcca aagctggact gctggtctcc 1800gacggaggcc caaatttata caacattaga
aatctccaca ttcctgaagt ctgcctaaaa 1860tgggaattga tggatgagga ttaccagggg
cgtttatgca acccactgaa cccatttgtc 1920agccataaag aaattgaatc aatgaacaat
gcagtgatga tgccagcaca tggtccagcc 1980aaaaacatgg agtatgatgc tgttgcaaca
acacactcct ggatccccaa aagaaatcga 2040tccatcttga atacaagtca aagaggagta
cttgaggatg aacaaatgta ccaaaggtgc 2100tgcaatttat ttgaaaaatt cttccccagc
agttcataca gaagaccagt cgggatatcc 2160agtatggtgg aggctatggt ttccagagcc
cgaattgatg cacggattga tttcgaatct 2220ggaaggataa agaaagaaga gttcactgag
atcatgaaga tctgttccac cattgaagag 2280ctcagacggc aaaaatagtg aatttagctt
gtccttcatg aaaaaatgcc ttgtttctac 2340t
2341112341DNAInfluenza 11agcgaaagca
ggtcaattat attcaatatg gaaagaataa aagaactaag aaatctaatg 60tcgcagtctc
gcacccgcga gatactcaca aaaaccaccg tggaccatat ggccataatc 120aagaagtaca
catcaggaag acaggagaag aacccagcac ttaggatgaa atggatgatg 180gcaatgaaat
atccaattac agcagacaag aggataacgg aaatgattcc tgagagaaat 240gagcaaggac
aaactttatg gagtaaaatg aatgatgccg gatcagaccg agtgatggta 300tcacctctgg
ctgtgacatg gtggaatagg aatggaccaa taacaaatac agttcattat 360ccaaaaatct
acaaaactta ttttgaaaga gtagaaaggc taaagcatgg aacctttggc 420cctgtccatt
ttagaaacca agtcaaaata cgtcggagag ttgacataaa tcctggtcat 480gcagatctca
gtgccaagga ggcacaggat gtaatcatgg aagttgtttt ccctaacgaa 540gtgggagcca
ggatactaac atcggaatcg caactaacga taaccaaaga gaagaaagaa 600gaactccagg
attgcaaaat ttctcctttg atggttgcat acatgttgga gagagaactg 660gtccgcaaaa
cgagattcct cccagtggct ggtggaacaa gcagtgtgta cattgaagtg 720ttgcatttga
ctcaaggaac atgctgggaa cagatgtata ctccaggagg ggaagtgagg 780aatgatgatg
ttgatcaaag cttgattatt gctgctagga acatagtgag aagagctgca 840gtatcagcag
atccactagc atctttattg gagatgtgcc acagcacaca gattggtgga 900attaggatgg
tagacatcct taggcagaac ccaacagaag agcaagccgt ggatatatgc 960aaggctgcaa
tgggactgag aattagctca tccttcagtt ttggtggatt cacatttaag 1020agaacaagcg
gatcatcagt caagagagag gaagaggtgc ttacgggaaa tcttcaaaca 1080ttgaagataa
gagtgcatga gggatatgaa gagttcacaa tggttgggag aagagcaaca 1140gccatactca
gaaaagcaac caggagattg attcagctga tagtgagtgg gagagacgaa 1200cagtcgattg
ccgaagcaat aattgtggcc atggtatttt cacaagagga ttgtatgata 1260aaagcagtca
gaggtgatct gaatttcgtc aatagggcga atcagcgatt gaatcctatg 1320catcaacttt
taagacattt tcagaaggat gcgagagtgc tttttcaaaa ttggggagtt 1380gaacctatcg
acaatgtgat gggaatgatt gggatattgc ccgacatgac tccaagcatc 1440gagatgtcaa
tgagaggagt gagaatcagc aaaatgggtg tagatgagta ctccagcacg 1500gagagggtag
tggtgagcat tgaccgtttt ttgagaatcc gggaccaacg aggaaatgta 1560ctactgtctc
ccgaggaggt cagtgaaaca cagggaacag agaaactgac aataacttac 1620tcatcgtcaa
tgatgtggga gattaatggt cctgaatcag tattggtcaa tacctatcaa 1680tggatcatca
gaaactggga aactgttaaa attcagtggt cccagaaccc tacaatgcta 1740tacaataaaa
tggaatttga accatttcag tctttagtac ctaaggccat tagaggccaa 1800tacagtgggt
ttgtaagaac tctgttccaa caaatgaggg atgtgcttgg gacatttgat 1860accgcacaga
taataaaact tcttcccttc gcagccgctc caccaaagca aagtagaatg 1920cagttctcct
catttactgt gaatgtgagg ggatcaggaa tgagaatact tgtaaggggc 1980aattctcctg
tattcaacta taacaaggcc acgaagagac tcacagttct cggaaaggat 2040gctggcactt
taactgaaga cccagatgaa ggcacagctg gagtggagtc cgctgttctg 2100aggggattcc
tcattctggg caaagaagac aagagatatg ggccagcact aagcatcaat 2160gaactgagca
accttgcgaa aggagagaag gctaatgtgc taattgggca aggagacgtg 2220gtgttggtaa
tgaaacggaa acgggactct agcatactta ctgacagcca gacagcgacc 2280aaaagaattc
ggatggccat caattagtgt cgaatagttt aaaaacgacc ttgtttctac 2340t
2341121565DNAInfluenza 12agcaaaagca gggtagataa tcactcactg agtgacatca
aaatcatggc gtctcaaggc 60accaaacgat cttacgaaca gatggagact gatggagaac
gccagaatgc cactgaaatc 120agagcatccg tcggaaaaat gattggtgga attggacgat
tctacatcca aatgtgcacc 180gaactcaaac tcagtgatta tgagggacgg ttgatccaaa
acagcttaac aatagagaga 240atggtgctct ctgcttttga cgaaaggaga aataaatacc
ttgaagaaca tcccagtgcg 300ggaaaagatc ctaagaaaac tggaggacct atatacagga
gagtaaacgg aaagtggatg 360agagaactca tcctttatga caaagaagaa ataaggcgaa
tctggcgcca agctaataat 420ggtgacgatg caacggctgg tctgactcac atgatgatct
ggcattccaa tttgaatgat 480gcaacttatc agaggacaag agctcttgtt cgcaccggaa
tggatcccag gatgtgctct 540ctgatgcaag gttcaactct ccctaggagg tctggagccg
caggtgctgc agtcaaagga 600gttggaacaa tggtgatgga attggtcaga atgatcaaac
gtgggatcaa tgatcggaac 660ttctggaggg gtgagaatgg acgaaaaaca agaattgctt
atgaaagaat gtgcaacatt 720ctcaaaggga aatttcaaac tgctgcacaa aaagcaatga
tggatcaagt gagagagagc 780cggaacccag ggaatgctga gttcgaagat ctcacttttc
tagcacggtc tgcactcata 840ttgagagggt cggttgctca caagtcctgc ctgcctgcct
gtgtgtatgg acctgccgta 900gccagtgggt acgactttga aagggaggga tactctctag
tcggaataga ccctttcaga 960ctgcttcaaa acagccaagt gtacagccta atcagaccaa
atgagaatcc agcacacaag 1020agtcaactgg tgtggatggc atgccattct gccgcatttg
aagatctaag agtattaagc 1080ttcatcaaag ggacgaaggt gctcccaaga gggaagcttt
ccactagagg agttcaaatt 1140gcttccaatg aaaatatgga gactatggaa tcaagtacac
ttgaactgag aagcaggtac 1200tgggccataa ggaccagaag tggaggaaac accaatcaac
agagggcatc tgcgggccaa 1260atcagcatac aacctacgtt ctcagtacag agaaatctcc
cttttgacag aacaaccatt 1320atggcagcat tcaatgggaa tacagagggg agaacatctg
acatgaggac cgaaatcata 1380aggatgatgg aaagtgcaag accagaagat gtgtctttcc
aggggcgggg agtcttcgag 1440ctctcggacg aaaaggcagc gagcccgatc gtgccttcct
ttgacatgag taatgaagga 1500tcttatttct tcggagacaa tgcagaggag tacgacaatt
aaagaaaaat acccttgttt 1560ctact
1565131027DNAInfluenza 13agcaaaagca ggtagatatt
gaaagatgag tcttctaacc gaggtcgaaa cgtacgtact 60ctctatcatc ccgtcaggcc
ccctcaaagc cgagatcgca cagagacttg aagatgtctt 120tgcagggaag aacaccgatc
ttgaggttct catggaatgg ctaaagacaa gaccaatcct 180gtcacctctg actaagggga
ttttaggatt tgtgttcacg ctcaccgtgc ccagtgagcg 240aggactgcag cgtagacgct
ttgtccaaaa tgcccttaat gggaacgggg atccaaataa 300catggacaaa gcagttaaac
tgtataggaa gctcaagagg gagataacat tccatggggc 360caaagaaatc tcactcagtt
attctgctgg tgcacttgcc agttgtatgg gcctcatata 420caacaggatg ggggctgtga
ccactgaagt ggcatttggc ctggtatgtg caacctgtga 480acagattgct gactcccagc
atcggtctca taggcaaatg gtgacaacaa ccaatccact 540aatcagacat gagaacagaa
tggttttagc cagcactaca gctaaggcta tggagcaaat 600ggctggatcg agtgagcaag
cagcagaggc catggaggtt gctagtcagg ctagacaaat 660ggtgcaagcg atgagaacca
ttgggactca tcctagctcc agtgctggtc tgaaaaatga 720tcttcttgaa aatttgcagg
cctatcagaa acgaatgggg gtgcagatgc aacggttcaa 780gtgatcctct cactattgcc
gcaaatatca ttgggatctt gcacttgaca ttgtggattc 840ttgatcgtct ttttttcaaa
tgcatttacc gtcgctttaa atacggactg aaaggagggc 900cttctacgga aggagtgcca
aagtctatga gggaagaata tcgaaaggaa cagcagagtg 960ctgtggatgc tgacgatggt
cattttgtca gcatagagct ggagtaaaaa actaccttgt 1020ttctact
102714890DNAInfluenza
14agcaaaagca gggtgacaaa aacataatgg atccaaacac tgtgtcaagc tttcaggtag
60attgctttct ttggcatgtc cgcaaacgag ttgcagacca agaactaggt gatgccccat
120tccttgatcg gcttcgccga gatcagaaat ccctaagagg aaggggcagt actctcggtc
180tggacatcaa gacagccaca cgtgctggaa agcagatagt ggagcggatt ctgaaagaag
240aatccgatga ggcacttaaa atgaccatgg cctctgtacc tgcgtcgcgt tacctaactg
300acatgactct tgaggaaatg tcaagggact ggtccatgct catacccaag cagaaagtgg
360caggccctct ttgtatcaga atggaccagg cgatcatgga taagaacatc atactgaaag
420cgaacttcag tgtgattttt gaccggctgg agactctaat attgctaagg gctttcaccg
480aagagggagc aattgttggc gaaatttcac cattgccttc tcttccagga catactgctg
540aggatgtcaa aaatgcagtt ggagtcctca tcggaggact tgaatggaat gataacacag
600ttcgagtctc tgaaactcta cagagattcg cttggagaag cagtaatgag aatgggagac
660ctccactcac tccaaaacag aaacgagaaa tggcgggaac aattaggtca gaagtttgaa
720gaaataagat ggttgattga agaagtgaga cacaaactga agataacaga gaatagtttt
780gagcaaataa catttatgca agccttacat ctattgcttg aagtggagca agagataaga
840actttctcgt ttcagcttat ttagtactaa aaaacaccct tgtttctact
890151775DNAInfluenza 15agcaaaagca ggggaaaata aaaacaacca aaatgaaggc
aaacctactg gtcctgttat 60gtgcacttgc agctgcagat gcagacacaa tatgtatagg
ctaccatacg aacaattcaa 120ccgacactgt tgacacagta ctcgagaaga atgtgacagt
gacacactct gttaacctgc 180tcgaagacag ccacaacgga aaactatgta gattaaaagg
aatagcccca ctacaattgg 240ggaaatgtaa catcgccgga tggctcttgg gaaacccaga
atgcgaccca ctgcttccag 300tgagatcatg gtcctacatt gtagaaacac caaactctga
gaatggaata tgttatccag 360gagatttcat cgactatgag gagctgaggg agcaattgag
ctcagtgtca tcattcgaaa 420gattcgaaat atttcccaaa gaaagctcat ggcccaacca
caacacaaac ggagtaacgg 480cagcatgctc ccatgagggg aaaagcagtt tttacagaaa
tttgctatgg ctgacggaga 540aggagggctc atacccaaag ctgaaaaatt cttatgtgaa
caaaaaaggg aaagaagtcc 600ttgtactgtg gggtattcat cacccgccta acagtaagga
acaacagaat ctctatcaga 660atgaaaatgc ttatgtctct gtagtgactt caaattataa
caggagattt accccggaaa 720tagcagaaag acccaaagta agagatcaag ctgggaggat
gaactattac tggaccttgc 780taaaacccgg agacacaata atatttgagg caaatggaaa
tctaatagca ccaatgtatg 840ctttcgcact gagtagaggc tttgggtccg gcatcatcac
ctcaaacgca tcaatgcatg 900agtgtaacac gaagtgtcaa acacccctgg gagctataaa
cagcagtctc ccttaccaga 960atatacaccc agtcacaata ggagagtgcc caaaatacgt
caggagtgcc aaattgagga 1020tggttacagg actaaggaac attccgtcca ttcaatccag
aggtctattt ggagccattg 1080ccggttttat tgaaggggga tggactggaa tgatagatgg
atggtatggt tatcatcatc 1140agaatgaaca gggatcaggc tatgcagcgg atcaaaaaag
cacacaaaat gccattaacg 1200ggattacaaa caaggtgaac actgttatcg agaaaatgaa
cattcaattc acagctgtgg 1260gtaaagaatt caacaaatta gaaaaaagga tggaaaattt
aaataaaaaa gttgatgatg 1320gatttctgga catttggaca tataatgcag aattgttagt
tctactggaa aatgaaagga 1380ctctggaatt ccatgactca aatgtgaaga atctgtatga
gaaagtaaaa agccaattaa 1440agaataatgc caaagaaatc ggaaatggat gttttgagtt
ctaccacaag tgtgacaatg 1500aatgcatgga aagtgtaaga aatgggactt atgattatcc
caaatattca gaagagtcaa 1560agttgaacag ggaaaaggta gatggagtga aattggaatc
aatggggatc tatcagattc 1620tggcgatcta ctcaactgtc gccagttcac tggtgctttt
ggtctccctg ggggcaatca 1680gtttctggat gtgttctaat ggatctttgc agtgcagaat
atgcatctga gattagaatt 1740tcagagatat gaggaaaaac acccttgttt ctact
1775161413DNAInfluenza 16agcaaaagca ggggtttaaa
atgaatccaa atcagaaaat aataaccatt ggatcaatct 60gtctggtagt cggactaatt
agcctaatat tgcaaatagg gaatataatc tcaatatgga 120ttagccattc aattcaaact
ggaagtcaaa accatactgg aatatgcaac caaaacatca 180ttacctataa aaatagcacc
tgggtaaagg acacaacttc agtgatatta accggcaatt 240catctctttg tcccatccgt
gggtgggcta tatacagcaa agacaatagc ataagaattg 300gttccaaagg agacgttttt
gtcataagag agccctttat ttcatgttct cacttggaat 360gcaggacctt ttttctgacc
caaggtgcct tactgaatga caagcattca agtgggactg 420ttaaggacag aagcccttat
agggccttaa tgagctgccc tgtcggtgaa gctccgtccc 480cgtacaattc aagatttgaa
tcggttgctt ggtcagcaag tgcatgtcat gatggcatgg 540gctggctaac aatcggaatt
tcaggtccag ataatggagc agtggctgta ttaaaataca 600acggcataat aactgaaacc
ataaaaagtt ggaggaagaa aatattgagg acacaagagt 660ctgaatgtgc ctgtgtaaat
ggttcatgtt ttactataat gactgatggc ccgagtgatg 720ggctggcctc gtacaaaatt
ttcaagatcg aaaaggggaa ggttactaaa tcaatagagt 780tgaatgcacc taattctcac
tatgaggaat gttcctgtta ccctgatacc gacaaagtga 840tgtgtgtgtg cagagacaat
tggcatggtt cgaaccggcc atgggtgtct ttcgatcaaa 900acctggatta tcaaatagga
tacatctgca gtggggtttt cggtgacaac ccgcgtcccg 960aagatggaac aggcagctgt
ggtccagtgt atgttgatgg agcaaacgga gtaaagggat 1020tttcatatag gtatggtaat
ggtgtttgga taggaaggac caaaagtcac agttccagac 1080atgggtttga gatgatttgg
gatcctaatg gatggacaga gactgatagt aagttctctg 1140tgaggcaaga tgttgtggca
atgactgatt ggtcagggta tagcggaagt ttcgttcaac 1200atcctgagct gacagggcta
gactgtatga ggccgtgctt ctgggttgaa ttaatcaggg 1260gacgacctaa agaaaaaaca
atctggacta gtgcgagcag catttctttt tgtggcgtga 1320atagtgatac tgtagattgg
tcttggccag acggtgctga gttgccattc agcattgaca 1380agtagtctgt tcaaaaaact
ccttgtttct act 141317716PRTInfluenza 17Met
Glu Asp Phe Val Arg Gln Cys Phe Asn Pro Met Ile Val Glu Leu 1
5 10 15 Ala Glu Lys Ala Met Lys
Glu Tyr Gly Glu Asp Pro Lys Ile Glu Thr 20
25 30 Asn Lys Phe Ala Ala Ile Cys Thr His Leu
Glu Val Cys Phe Met Tyr 35 40
45 Ser Asp Phe His Phe Ile Asp Glu Arg Gly Glu Ser Ile Ile
Val Glu 50 55 60
Ser Gly Asp Pro Asn Ala Leu Leu Lys His Arg Phe Glu Ile Ile Glu 65
70 75 80 Gly Arg Asp Arg Ile
Met Ala Trp Thr Val Val Asn Ser Ile Cys Asn 85
90 95 Thr Thr Gly Val Glu Lys Pro Lys Phe Leu
Pro Asp Leu Tyr Asp Tyr 100 105
110 Lys Glu Asn Arg Phe Ile Glu Ile Gly Val Thr Arg Arg Glu Val
His 115 120 125 Ile
Tyr Tyr Leu Glu Lys Ala Asn Lys Ile Lys Ser Glu Lys Thr His 130
135 140 Ile His Ile Phe Ser Phe
Thr Gly Glu Glu Met Ala Thr Lys Ala Asp 145 150
155 160 Tyr Thr Leu Asp Glu Glu Ser Arg Ala Arg Ile
Lys Thr Arg Leu Phe 165 170
175 Thr Ile Arg Gln Glu Met Ala Ser Arg Ser Leu Trp Asp Ser Phe Arg
180 185 190 Gln Ser
Glu Arg Gly Glu Glu Thr Ile Glu Glu Lys Phe Glu Ile Thr 195
200 205 Gly Thr Met Arg Lys Leu Ala
Asp Gln Ser Leu Pro Pro Asn Phe Pro 210 215
220 Ser Leu Glu Asn Phe Arg Ala Tyr Val Asp Gly Phe
Glu Pro Asn Gly 225 230 235
240 Cys Ile Glu Gly Lys Leu Ser Gln Met Ser Lys Glu Val Asn Ala Lys
245 250 255 Ile Glu Pro
Phe Leu Arg Thr Thr Pro Arg Pro Leu Arg Leu Pro Asp 260
265 270 Gly Pro Leu Cys His Gln Arg Ser
Lys Phe Leu Leu Met Asp Ala Leu 275 280
285 Lys Leu Ser Ile Glu Asp Pro Ser His Glu Gly Glu Gly
Ile Pro Leu 290 295 300
Tyr Asp Ala Ile Lys Cys Met Lys Thr Phe Phe Gly Trp Lys Glu Pro 305
310 315 320 Asn Ile Val Lys
Pro His Glu Lys Gly Ile Asn Pro Asn Tyr Leu Met 325
330 335 Ala Trp Lys Gln Val Leu Ala Glu Leu
Gln Asp Ile Glu Asn Glu Glu 340 345
350 Lys Ile Pro Arg Thr Lys Asn Met Lys Arg Thr Ser Gln Leu
Lys Trp 355 360 365
Ala Leu Gly Glu Asn Met Ala Pro Glu Lys Val Asp Phe Asp Asp Cys 370
375 380 Lys Asp Val Gly Asp
Leu Lys Gln Tyr Asp Ser Asp Glu Pro Glu Pro 385 390
395 400 Arg Ser Leu Ala Ser Trp Val Gln Asn Glu
Phe Asn Lys Ala Cys Glu 405 410
415 Leu Thr Asp Ser Ser Trp Ile Glu Leu Asp Glu Ile Gly Glu Asp
Val 420 425 430 Ala
Pro Ile Glu His Ile Ala Ser Met Arg Arg Asn Tyr Phe Thr Ala 435
440 445 Glu Val Ser His Cys Arg
Ala Thr Glu Tyr Ile Met Lys Gly Val Tyr 450 455
460 Ile Asn Thr Ala Leu Leu Asn Ala Ser Cys Ala
Ala Met Asp Asp Phe 465 470 475
480 Gln Leu Ile Pro Met Ile Ser Lys Cys Arg Thr Lys Glu Gly Arg Arg
485 490 495 Lys Thr
Asn Leu Tyr Gly Phe Ile Ile Lys Gly Arg Ser His Leu Arg 500
505 510 Asn Asp Thr Asp Val Val Asn
Phe Val Ser Met Glu Phe Ser Leu Thr 515 520
525 Asp Pro Arg Leu Glu Pro His Lys Trp Glu Lys Tyr
Cys Val Leu Glu 530 535 540
Ile Gly Asp Met Leu Leu Arg Thr Ala Ile Gly Gln Val Ser Arg Pro 545
550 555 560 Met Phe Leu
Tyr Val Arg Thr Asn Gly Thr Ser Lys Ile Lys Met Lys 565
570 575 Trp Gly Met Glu Met Arg Arg Cys
Leu Leu Gln Ser Leu Gln Gln Ile 580 585
590 Glu Ser Met Ile Glu Ala Glu Ser Ser Val Lys Glu Lys
Asp Met Thr 595 600 605
Lys Glu Phe Phe Glu Asn Lys Ser Glu Thr Trp Pro Ile Gly Glu Ser 610
615 620 Pro Arg Gly Val
Glu Glu Gly Ser Ile Gly Lys Val Cys Arg Thr Leu 625 630
635 640 Leu Ala Lys Ser Val Phe Asn Ser Leu
Tyr Ala Ser Pro Gln Leu Glu 645 650
655 Gly Phe Ser Ala Glu Ser Arg Lys Leu Leu Leu Ile Val Gln
Ala Leu 660 665 670
Arg Asp Asn Leu Glu Pro Gly Thr Phe Asp Leu Gly Gly Leu Tyr Glu
675 680 685 Ala Ile Glu Glu
Cys Leu Ile Asn Asp Pro Trp Val Leu Leu Asn Ala 690
695 700 Ser Trp Phe Asn Ser Phe Leu Thr
His Ala Leu Lys 705 710 715
18757PRTInfluenza 18Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys Ile Pro
Ala Gln Asn 1 5 10 15
Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser His
20 25 30 Gly Thr Gly Thr
Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His Gln 35
40 45 Tyr Ser Glu Lys Gly Lys Trp Thr Thr
Asn Thr Glu Thr Gly Ala Pro 50 55
60 Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp Asn
Glu Pro Ser 65 70 75
80 Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala Met Ala Phe Leu Glu
85 90 95 Glu Ser His Pro
Gly Ile Phe Glu Asn Ser Cys Leu Glu Thr Met Glu 100
105 110 Val Val Gln Gln Thr Arg Val Asp Lys
Leu Thr Gln Gly Arg Gln Thr 115 120
125 Tyr Asp Trp Thr Leu Asn Arg Asn Gln Pro Ala Ala Thr Ala
Leu Ala 130 135 140
Asn Thr Ile Glu Val Phe Arg Ser Asn Gly Leu Thr Ala Asn Glu Ser 145
150 155 160 Gly Arg Leu Ile Asp
Phe Leu Lys Asp Val Met Glu Ser Met Asn Lys 165
170 175 Glu Glu Ile Glu Ile Thr Thr His Phe Gln
Arg Lys Arg Arg Val Arg 180 185
190 Asp Asn Met Thr Lys Lys Met Val Thr Gln Arg Thr Ile Gly Lys
Lys 195 200 205 Lys
Gln Arg Leu Asn Lys Arg Gly Tyr Leu Ile Arg Ala Leu Thr Leu 210
215 220 Asn Thr Met Thr Lys Asp
Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225 230
235 240 Ile Ala Thr Pro Gly Met Gln Ile Arg Gly Phe
Val Tyr Phe Val Glu 245 250
255 Thr Leu Ala Arg Ser Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu Pro
260 265 270 Val Gly
Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val Arg Lys 275
280 285 Met Met Thr Asn Ser Gln Asp
Thr Glu Ile Ser Phe Thr Ile Thr Gly 290 295
300 Asp Asn Thr Lys Trp Asn Glu Asn Gln Asn Pro Arg
Met Phe Leu Ala 305 310 315
320 Met Ile Thr Tyr Ile Thr Arg Asn Gln Pro Glu Trp Phe Arg Asn Ile
325 330 335 Leu Ser Met
Ala Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu Gly 340
345 350 Lys Gly Tyr Met Phe Glu Ser Lys
Arg Met Lys Ile Arg Thr Gln Ile 355 360
365 Pro Ala Glu Met Leu Ala Ser Ile Asp Leu Lys Tyr Phe
Asn Glu Ser 370 375 380
Thr Lys Lys Lys Ile Glu Lys Ile Arg Pro Leu Leu Ile Asp Gly Thr 385
390 395 400 Ala Ser Leu Ser
Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser 405
410 415 Thr Val Leu Gly Val Ser Ile Leu Asn
Leu Gly Gln Lys Lys Tyr Thr 420 425
430 Lys Thr Ile Tyr Trp Trp Asp Gly Leu Gln Ser Ser Asp Asp
Phe Ala 435 440 445
Leu Ile Val Asn Ala Pro Asn His Glu Gly Ile Gln Ala Gly Val Asp 450
455 460 Arg Phe Tyr Arg Thr
Cys Lys Leu Val Gly Ile Asn Met Ser Lys Lys 465 470
475 480 Lys Ser Tyr Ile Asn Lys Thr Gly Thr Phe
Glu Phe Thr Ser Phe Phe 485 490
495 Tyr Arg Tyr Gly Phe Val Ala Asn Phe Ser Met Glu Leu Pro Ser
Phe 500 505 510 Gly
Val Ser Gly Val Asn Glu Ser Ala Asp Met Ser Ile Gly Val Thr 515
520 525 Val Ile Lys Asn Asn Met
Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala 530 535
540 Gln Met Ala Leu Gln Leu Phe Ile Lys Asp Tyr
Arg Tyr Thr Tyr Arg 545 550 555
560 Cys His Arg Gly Asp Thr Gln Ile Gln Thr Arg Arg Ser Phe Glu Leu
565 570 575 Lys Lys
Leu Trp Asp Gln Thr Gln Ser Lys Val Gly Leu Leu Val Ser 580
585 590 Asp Gly Gly Pro Asn Leu Tyr
Asn Ile Arg Asn Leu His Ile Pro Glu 595 600
605 Val Cys Leu Lys Trp Glu Leu Met Asp Asp Asp Tyr
Arg Gly Arg Leu 610 615 620
Cys Asn Pro Leu Asn Pro Phe Val Ser His Lys Glu Ile Asp Ser Val 625
630 635 640 Asn Asn Ala
Val Val Met Pro Ala His Gly Pro Ala Lys Ser Met Glu 645
650 655 Tyr Asp Ala Val Ala Thr Thr His
Ser Trp Ile Pro Lys Arg Asn Arg 660 665
670 Ser Ile Leu Asn Thr Ser Gln Arg Gly Ile Leu Glu Asp
Glu Gln Met 675 680 685
Tyr Gln Lys Cys Cys Asn Leu Phe Glu Lys Phe Phe Pro Ser Ser Ser 690
695 700 Tyr Arg Arg Pro
Val Gly Ile Ser Ser Met Val Glu Ala Met Val Ser 705 710
715 720 Arg Ala Arg Ile Asp Ala Arg Val Asp
Phe Glu Ser Gly Arg Ile Lys 725 730
735 Lys Glu Glu Phe Ser Glu Ile Met Lys Ile Cys Ser Thr Ile
Glu Glu 740 745 750
Leu Arg Arg Gln Lys 755 19759PRTInfluenza 19Met Glu Arg
Ile Lys Glu Leu Arg Asp Leu Met Ser Gln Ser Arg Thr 1 5
10 15 Arg Glu Ile Leu Thr Lys Thr Thr
Val Asp His Met Ala Ile Ile Lys 20 25
30 Lys Tyr Thr Ser Gly Arg Gln Glu Lys Asn Pro Ala Leu
Arg Met Lys 35 40 45
Trp Met Met Ala Met Arg Tyr Pro Ile Thr Ala Asp Lys Arg Ile Met 50
55 60 Asp Met Ile Pro
Glu Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys 65 70
75 80 Thr Asn Asp Ala Gly Ser Asp Arg Val
Met Val Ser Pro Leu Ala Val 85 90
95 Thr Trp Trp Asn Arg Asn Gly Pro Thr Thr Ser Thr Val His
Tyr Pro 100 105 110
Lys Val Tyr Lys Thr Tyr Phe Glu Lys Val Glu Arg Leu Lys His Gly
115 120 125 Thr Phe Gly Pro
Val His Phe Arg Asn Gln Val Lys Ile Arg Arg Arg 130
135 140 Val Asp Thr Asn Pro Gly His Ala
Asp Leu Ser Ala Lys Glu Ala Gln 145 150
155 160 Asp Val Ile Met Glu Val Val Phe Pro Asn Glu Val
Gly Ala Arg Ile 165 170
175 Leu Thr Ser Glu Ser Gln Leu Ala Ile Thr Lys Glu Lys Lys Glu Glu
180 185 190 Leu Gln Asp
Cys Lys Ile Ala Pro Leu Met Val Ala Tyr Met Leu Glu 195
200 205 Arg Glu Leu Val Arg Lys Thr Arg
Phe Leu Pro Val Ala Gly Gly Thr 210 215
220 Gly Ser Val Tyr Ile Glu Val Leu His Leu Thr Gln Gly
Thr Cys Trp 225 230 235
240 Glu Gln Met Tyr Thr Pro Gly Gly Glu Val Arg Asn Asp Asp Val Asp
245 250 255 Gln Ser Leu Ile
Ile Ala Ala Arg Asn Ile Val Arg Arg Ala Ala Val 260
265 270 Ser Ala Asp Pro Leu Ala Ser Leu Leu
Glu Met Cys His Ser Thr Gln 275 280
285 Ile Gly Gly Val Arg Met Val Asp Ile Leu Arg Gln Asn Pro
Thr Glu 290 295 300
Glu Gln Ala Val Asp Ile Cys Lys Ala Ala Ile Gly Leu Arg Ile Ser 305
310 315 320 Ser Ser Phe Ser Phe
Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly Ser 325
330 335 Ser Val Lys Lys Glu Glu Glu Val Leu Thr
Gly Asn Leu Gln Thr Leu 340 345
350 Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe Thr Met Val Gly
Arg 355 360 365 Arg
Ala Thr Ala Ile Leu Arg Lys Ala Thr Arg Arg Leu Ile Gln Leu 370
375 380 Ile Val Ser Gly Arg Asp
Glu Gln Ser Ile Ala Glu Ala Ile Ile Val 385 390
395 400 Ala Met Val Phe Ser Gln Glu Asp Cys Met Ile
Lys Ala Val Arg Gly 405 410
415 Asp Leu Asn Phe Val Asn Arg Ala Asn Gln Arg Leu Asn Pro Met His
420 425 430 Gln Leu
Leu Arg His Phe Gln Lys Asp Ala Lys Val Leu Phe Gln Asn 435
440 445 Trp Gly Ile Glu Ser Ile Asp
Asn Val Met Gly Met Ile Gly Ile Leu 450 455
460 Pro Asp Met Thr Pro Ser Thr Glu Met Ser Leu Arg
Gly Ile Arg Val 465 470 475
480 Ser Lys Met Gly Val Asp Glu Tyr Ser Ser Thr Glu Arg Val Val Val
485 490 495 Ser Ile Asp
Arg Phe Leu Arg Val Arg Asp Gln Arg Gly Asn Val Leu 500
505 510 Leu Ser Pro Glu Glu Val Ser Glu
Thr Gln Gly Thr Glu Lys Leu Thr 515 520
525 Ile Thr Tyr Ser Ser Ser Met Met Trp Glu Ile Asn Gly
Pro Glu Ser 530 535 540
Val Leu Val Asn Thr Tyr Gln Trp Ile Ile Arg Asn Trp Glu Ile Val 545
550 555 560 Lys Ile Gln Trp
Ser Gln Asp Pro Thr Met Leu Tyr Asn Lys Met Glu 565
570 575 Phe Glu Pro Phe Gln Ser Leu Val Pro
Lys Ala Thr Arg Ser Arg Tyr 580 585
590 Ser Gly Phe Val Arg Thr Leu Phe Gln Gln Met Arg Asp Val
Leu Gly 595 600 605
Thr Phe Asp Thr Val Gln Ile Ile Lys Leu Leu Pro Phe Ala Ala Ala 610
615 620 Pro Pro Glu Gln Ser
Arg Met Gln Phe Ser Ser Leu Thr Val Asn Val 625 630
635 640 Arg Gly Ser Gly Leu Arg Ile Leu Val Arg
Gly Asn Ser Pro Val Phe 645 650
655 Asn Tyr Asn Lys Ala Thr Lys Arg Leu Thr Val Leu Gly Lys Asp
Ala 660 665 670 Gly
Ala Leu Thr Glu Asp Pro Asp Glu Gly Thr Ser Gly Val Glu Ser 675
680 685 Ala Val Leu Arg Gly Phe
Leu Ile Leu Gly Lys Glu Asp Lys Arg Tyr 690 695
700 Gly Pro Ala Leu Ser Ile Asn Glu Leu Ser Asn
Leu Ala Lys Gly Glu 705 710 715
720 Lys Ala Asn Val Leu Ile Gly Gln Gly Asp Val Val Leu Val Met Lys
725 730 735 Arg Lys
Arg Asp Ser Ser Ile Leu Thr Asp Ser Gln Thr Ala Thr Lys 740
745 750 Arg Ile Arg Met Ala Ile Asn
755 20319PRTInfluenza 20Met Ala Ser Gln Gly Thr
Lys Arg Ser Tyr Glu Gln Met Glu Thr Gly 1 5
10 15 Gly Glu Arg Gln Asp Ala Thr Glu Ile Arg Ala
Ser Val Gly Arg Met 20 25
30 Ile Gly Gly Ile Gly Arg Phe Tyr Ile Gln Met Cys Thr Glu Leu
Lys 35 40 45 Leu
Ser Asp Tyr Asp Gly Arg Leu Ile Gln Asn Ser Ile Thr Ile Glu 50
55 60 Arg Met Val Leu Ser Ala
Phe Asp Glu Arg Arg Asn Lys Tyr Leu Glu 65 70
75 80 Glu His Pro Ser Ala Gly Lys Asp Pro Lys Lys
Thr Gly Gly Pro Ile 85 90
95 Tyr Arg Arg Val Asp Gly Lys Trp Met Arg Glu Leu Ile Leu Tyr Asp
100 105 110 Lys Glu
Glu Ile Arg Arg Val Trp Arg Gln Ala Asn Asn Gly Glu Asp 115
120 125 Ala Thr Ala Gly Leu Thr His
Ile Met Ile Trp His Ser Asn Leu Asn 130 135
140 Asp Ala Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg
Thr Gly Met Asp 145 150 155
160 Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr Leu Pro Arg Arg Ser
165 170 175 Gly Ala Ala
Gly Ala Ala Val Lys Gly Val Gly Thr Ile Ala Met Glu 180
185 190 Leu Ile Arg Met Ile Lys Arg Gly
Ile Asn Asp Arg Asn Phe Trp Arg 195 200
205 Gly Glu Asn Gly Arg Arg Thr Arg Val Ala Tyr Glu Arg
Met Cys Asn 210 215 220
Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Arg Ala Met Met Asp 225
230 235 240 Gln Val Arg Glu
Ser Arg Asn Pro Gly Asn Ala Glu Ile Glu Asp Leu 245
250 255 Ile Phe Leu Ala Arg Ser Ala Leu Ile
Leu Arg Gly Ser Val Ala His 260 265
270 Lys Ser Cys Leu Pro Ala Cys Val Tyr Gly Leu Ala Val Ala
Ser Gly 275 280 285
His Asp Phe Glu Arg Glu Gly Tyr Ser Leu Val Gly Ile Asp Pro Phe 290
295 300 Lys Leu Leu Gln Asn
Ser Gln Val Val Ser Leu Met Arg Pro Asn 305 310
315 21252PRTInfluenza 21Met Ser Leu Leu Thr Glu Val
Glu Thr Tyr Val Leu Ser Ile Ile Pro 1 5
10 15 Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg
Leu Glu Ser Val Phe 20 25
30 Ala Gly Lys Asn Thr Asp Leu Glu Ala Leu Met Glu Trp Leu Lys
Thr 35 40 45 Arg
Pro Ile Leu Ser Pro Leu Thr Lys Gly Ile Leu Gly Phe Val Phe 50
55 60 Thr Leu Thr Val Pro Ser
Glu Arg Gly Leu Gln Arg Arg Arg Phe Val 65 70
75 80 Gln Asn Ala Leu Asn Gly Asn Gly Asp Pro Asn
Asn Met Asp Arg Ala 85 90
95 Val Lys Leu Tyr Lys Lys Leu Lys Arg Glu Ile Thr Phe His Gly Ala
100 105 110 Lys Glu
Val Ser Leu Ser Tyr Ser Thr Gly Ala Leu Ala Ser Cys Met 115
120 125 Gly Leu Ile Tyr Asn Arg Met
Gly Thr Val Thr Thr Glu Ala Ala Phe 130 135
140 Gly Leu Val Cys Ala Thr Cys Glu Gln Ile Ala Asp
Ser Gln His Arg 145 150 155
160 Ser His Arg Gln Met Ala Thr Thr Thr Asn Pro Leu Ile Arg His Glu
165 170 175 Asn Arg Met
Val Leu Ala Ser Thr Thr Ala Lys Ala Met Glu Gln Met 180
185 190 Ala Gly Ser Ser Glu Gln Ala Ala
Glu Ala Met Glu Val Ala Asn Gln 195 200
205 Thr Arg Gln Met Val His Ala Met Arg Thr Ile Gly Thr
His Pro Ser 210 215 220
Ser Ser Ala Gly Leu Lys Asp Asp Leu Leu Glu Asn Leu Gln Ala Tyr 225
230 235 240 Gln Lys Arg Met
Gly Val Gln Met Gln Arg Phe Lys 245 250
22219PRTInfluenza 22Met Asp Ser Asn Thr Met Ser Ser Phe Gln Val Asp
Cys Phe Leu Trp 1 5 10
15 His Ile Arg Lys Arg Phe Ala Asp Asn Gly Leu Gly Asp Ala Pro Phe
20 25 30 Leu Asp Arg
Leu Arg Arg Asp Gln Lys Ser Leu Lys Gly Arg Gly Asn 35
40 45 Thr Leu Gly Leu Asp Ile Glu Thr
Ala Thr Leu Val Gly Lys Gln Ile 50 55
60 Val Glu Trp Ile Leu Lys Glu Glu Ser Ser Glu Thr Leu
Arg Met Thr 65 70 75
80 Ile Ala Ser Val Pro Thr Ser Arg Tyr Leu Ser Asp Met Thr Leu Glu
85 90 95 Glu Met Ser Arg
Asp Trp Phe Met Leu Met Pro Arg Gln Lys Ile Ile 100
105 110 Gly Pro Leu Cys Val Arg Leu Asp Gln
Ala Ile Met Glu Lys Asn Ile 115 120
125 Val Leu Lys Ala Asn Phe Ser Val Ile Phe Asn Arg Leu Glu
Thr Leu 130 135 140
Ile Leu Leu Arg Ala Phe Thr Glu Glu Gly Ala Ile Val Gly Glu Ile 145
150 155 160 Ser Pro Leu Pro Ser
Leu Pro Gly His Thr Tyr Glu Asp Val Lys Asn 165
170 175 Ala Val Gly Val Leu Ile Gly Gly Leu Glu
Trp Asn Gly Asn Thr Val 180 185
190 Arg Val Ser Glu Asn Ile Gln Arg Phe Ala Trp Arg Asn Cys Asp
Glu 195 200 205 Asn
Gly Arg Pro Ser Leu Pro Pro Glu Gln Lys 210 215
232151DNAInfluenza 23atggaagact ttgtgcgaca atgcttcaat
ccaatgatcg tcgagcttgc ggaaaaggca 60atgaaagaat atggggaaga tccgaaaatc
gaaactaaca agtttgctgc aatatgcaca 120catttggaag tttgtttcat gtattcggat
ttccatttca tcgacgaacg gggtgaatca 180ataattgtag aatctggtga cccgaatgca
ctattgaagc accgatttga gataattgaa 240ggaagagacc gaatcatggc ctggacagtg
gtgaacagta tatgtaacac aacaggggta 300gagaagccta aatttcttcc tgatttgtat
gattacaaag agaaccggtt cattgaaatt 360ggagtaacac ggagggaagt ccacatatat
tacctagaga aagccaacaa aataaaatct 420gagaagacac acattcacat cttttcattc
actggagagg agatggccac caaagcggac 480tacacccttg acgaagagag cagggcaaga
atcaaaacta ggcttttcac tataagacaa 540gaaatggcca gtaggagtct atgggattcc
tttcgtcagt ccgaaagagg cgaagagaca 600attgaagaaa aatttgagat tacaggaact
atgcgcaagc ttgccgacca aagtctccca 660ccgaacttcc ccagccttga aaactttaga
gcctatgtag atggattcga gccgaacggc 720tgcattgagg gcaagctttc ccaaatgtca
aaagaagtga acgccaaaat tgaaccattc 780ttgaggacga caccacgccc cctcagattg
cctgatgggc ctctttgcca tcagcggtca 840aagttcctgc tgatggatgc tctgaaatta
agtattgaag acccgagtca cgagggggag 900ggaataccac tatatgatgc aatcaaatgc
atgaagacat tctttggctg gaaagagcct 960aacatagtca aaccacatga gaaaggcata
aatcccaatt acctcatggc ttggaagcag 1020gtgctagcag agctacagga cattgaaaat
gaagagaaga tcccaaggac aaagaacatg 1080aagagaacaa gccaattgaa gtgggcactc
ggtgaaaata tggcaccaga aaaagtagac 1140tttgatgact gcaaagatgt tggagacctt
aaacagtatg acagtgatga gccagagccc 1200agatctctag caagctgggt ccaaaatgaa
ttcaataagg catgtgaatt gactgattca 1260agctggatag aacttgatga aataggagaa
gatgttgccc cgattgaaca tatcgcaagc 1320atgaggagga actattttac agcagaagtg
tcccactgca gggctactga atacataatg 1380aagggagtgt acataaatac ggccttgctc
aatgcatcct gtgcagccat ggatgacttt 1440cagctgatcc caatgataag caaatgtagg
accaaagaag gaagacggaa aacaaacctg 1500tatgggttca ttataaaagg aaggtctcat
ttgagaaatg atactgatgt ggtgaacttt 1560gtaagtatgg agttctcact cactgacccg
agactggagc cacacaaatg ggaaaaatac 1620tgtgttcttg aaataggaga catgctcttg
aggactgcga taggccaagt gtcgaggccc 1680atgttcctat atgtgagaac caatggaacc
tccaagatca agatgaaatg gggcatggaa 1740atgaggcgct gccttcttca gtctcttcag
cagattgaga gcatgattga ggccgagtct 1800tctgtcaaag agaaagacat gaccaaggaa
ttctttgaaa acaaatcgga aacatggcca 1860atcggagagt cacccagggg agtggaggaa
ggctctattg ggaaagtgtg caggacctta 1920ctggcaaaat ctgtattcaa cagtctatat
gcgtctccac aacttgaggg gttttcggct 1980gaatctagaa aattgcttct cattgttcag
gcacttaggg acaacctgga acctggaacc 2040ttcgatcttg gggggctata tgaagcaatc
gaggagtgcc tgattaatga tccctgggtt 2100ttgcttaatg catcttggtt caactccttc
ctcacacatg cactgaagta g 2151242341DNAInfluenza 24agcgaaagca
ggcaaaccat ttgaatggat gtcaatccga ctctactttt cctaaaaatt 60ccagcgcaaa
atgccataag caccacattc ccttatactg gagatcctcc atacagccat 120ggaacaggaa
caggatacac catggacaca gtaaacagaa cacaccaata ctcagaaaag 180ggaaagtgga
cgacaaacac agagactggt gcaccccagc tcaacccgat tgatggacca 240ctacctgagg
ataatgaacc aagtgggtat gcacaaacag actgtgttct agaggctatg 300gctttccttg
aagaatccca cccaggaata tttgagaatt catgccttga aacaatggaa 360gttgttcaac
aaacaagggt agataaacta actcaaggtc gccagactta tgattggaca 420ttaaacagaa
atcaaccggc agcaactgca ttggccaaca ccatagaagt ctttagatcg 480aatggcctaa
cagctaatga gtcaggaagg ctaatagatt tcttaaagga tgtaatggaa 540tcaatgaaca
aagaggaaat agagataaca acccactttc aaagaaaaag gagagtaaga 600gacaacatga
ccaagaagat ggtcacgcaa agaacaatag ggaagaaaaa acaaagactg 660aataagagag
gctatctaat aagagcactg acattaaata cgatgaccaa agatgcagag 720agaggcaagt
taaaaagaag ggctatcgca acacctggga tgcagattag aggtttcgta 780tactttgttg
aaactttagc taggagcatt tgcgaaaagc ttgaacagtc tgggctccca 840gtagggggca
atgaaaagaa ggccaaactg gcaaatgttg tgagaaagat gatgactaat 900tcacaagaca
cagagatttc tttcacaatc actggggaca acactaagtg gaatgaaaat 960caaaatcctc
gaatgttcct ggcgatgatt acatatatca ccagaaatca acccgagtgg 1020ttcagaaaca
tcctgagcat ggcacccata atgttctcaa acaaaatggc aagactaggg 1080aaagggtaca
tgttcgagag taaaagaatg aagattcgaa cacaaatacc agcagaaatg 1140ctagcaagca
ttgacctgaa gtacttcaat gaatcaacaa agaagaaaat tgagaaaata 1200aggcctcttc
taatagatgg cacagcatca ctgagtcctg ggatgatgat gggcatgttc 1260aacatgctaa
gtacggtctt gggagtctcg atactgaatc ttggacaaaa gaaatacacc 1320aagacaatat
actggtggga tgggctccaa tcatccgacg attttgctct catagtgaat 1380gcaccaaacc
atgagggaat acaagcagga gtggacagat tctacaggac ctgcaagtta 1440gtgggaatca
acatgagcaa aaagaagtcc tatataaata agacagggac atttgaattc 1500acaagctttt
tttatcgcta tggatttgtg gctaatttta gcatggagct acccagcttt 1560ggagtgtctg
gagtaaatga atcagctgac atgagtattg gagtaacagt gataaagaac 1620aacatgataa
acaatgacct tggacctgca acggcccaga tggctcttca attgttcatc 1680aaagactaca
gatacacata taggtgccat aggggagaca cacaaattca gacaagaaga 1740tcatttgagt
taaagaagct gtgggatcaa acccaatcaa aggtagggct attagtatca 1800gatggaggac
caaacttata caatatacgg aatcttcaca ttcctgaagt ctgcttaaaa 1860tgggagctaa
tggatgatga ttatcgggga agactttgta atcccctgaa tccctttgtc 1920agtcataaag
agattgattc tgtaaacaat gctgtggtaa tgccagccca tggtccagcc 1980aaaagcatgg
aatatgatgc cgttgcaact acacattcct ggattcccaa gaggaatcgt 2040tctattctca
acacaagcca aaggggaatt cttgaggatg aacagatgta ccagaagtgc 2100tgcaatctat
tcgagaaatt tttccctagc agttcatata ggagaccggt tggaatttct 2160agcatggtgg
aggccatggt gtctagggcc cggattgatg ccagggtcga cttcgagtct 2220ggacggatca
agaaagaaga gttctctgag atcatgaaga tctgttccac cattgaagaa 2280ctcagacggc
aaaaataatg aatttaactt gtccttcatg aaaaaatgcc ttgtttctac 2340t
2341252280DNAInfluenza 25atggagagaa taaaagaact gagagatcta atgtcgcagt
cccgcactcg cgagatactc 60actaagacca ctgtggacca tatggccata atcaaaaagt
acacatcagg aaggcaagag 120aagaaccccg cactcagaat gaagtggatg atggcaatga
gatacccaat tacagcagac 180aagagaataa tggacatgat tccagagagg aatgaacaag
gacaaaccct ctggagcaaa 240acaaacgatg ctggatcaga ccgagtgatg gtatcacctc
tggccgtaac atggtggaat 300aggaatggcc caacaacaag tacagttcat taccctaagg
tatataaaac ttatttcgaa 360aaggtcgaaa ggttgaaaca tggtaccttc ggccctgtcc
acttcagaaa tcaagttaaa 420ataaggagga gagttgatac aaaccctggc catgcagatc
tcagtgccaa ggaggcacag 480gatgtgatta tggaagttgt tttcccaaat gaagtggggg
caagaatact gacatcagag 540tcacagctgg caataacaaa agagaagaaa gaagagctcc
aggattgtaa aattgctccc 600ttgatggtgg cgtacatgct agaaagagaa ttggtccgta
aaacaaggtt tctcccagta 660gccggcggaa caggcagtgt ttatattgaa gtgttgcact
taacccaagg gacgtgctgg 720gagcagatgt acactccagg aggagaagtg agaaatgatg
atgttgacca aagtttgatt 780atcgctgcta gaaacatagt aagaagagca gcagtgtcag
cagacccatt agcatctctc 840ttggaaatgt gccacagcac acagattgga ggagtaagga
tggtggacat ccttagacag 900aatccaactg aggaacaagc cgtagacata tgcaaggcag
caatagggtt gaggattagc 960tcatctttca gttttggtgg gttcactttc aaaaggacaa
gcggatcatc agtcaagaaa 1020gaagaagaag tgctaacggg caacctccaa acactgaaaa
taagagtaca tgaagggtat 1080gaagaattca caatggttgg gagaagagca acagctattc
tcagaaaggc aaccaggaga 1140ttgatccagt tgatagtaag cgggagagac gagcagtcaa
ttgctgaggc aataattgtg 1200gccatggtat tctcacagga ggattgcatg atcaaggcag
ttaggggcga tctgaacttt 1260gtcaataggg caaaccagcg actgaacccc atgcaccaac
tcttgaggca tttccaaaaa 1320gatgcaaaag tgcttttcca gaactgggga attgaatcca
tcgacaatgt gatgggaatg 1380atcggaatac tgcccgacat gaccccaagc acggagatgt
cgctgagagg gataagagtc 1440agcaaaatgg gagtagatga atactccagc acggagagag
tggtagtgag tattgaccga 1500tttttaaggg ttagagatca aagagggaac gtactattgt
ctcccgaaga agtcagtgaa 1560acgcaaggaa ctgagaagtt gacaataact tattcgtcat
caatgatgtg ggagatcaat 1620ggccctgagt cagtgctagt caacacttat caatggataa
tcaggaactg ggaaattgtg 1680aaaattcaat ggtcacaaga tcccacaatg ttatacaaca
aaatggaatt tgaaccattt 1740cagtctcttg tccctaaggc aaccagaagc cggtacagtg
gattcgtaag gacactgttc 1800cagcaaatgc gggatgtgct tgggacattt gacactgtcc
aaataataaa acttctcccc 1860tttgctgctg ccccaccaga acagagtagg atgcaatttt
cctcattgac tgtgaatgtg 1920agaggatcag ggttgaggat actggtaaga ggcaattctc
cagtattcaa ttacaacaag 1980gcaaccaaac gacttacagt tcttggaaag gatgcaggtg
cattgactga agatccagat 2040gaaggcacat ctggggtgga gtctgctgtc ctgagaggat
ttctcatttt gggcaaagaa 2100gacaagagat atggcccagc attaagcatc aatgaactga
gcaatcttgc aaaaggagag 2160aaggctaatg tgctaattgg gcaaggggac gtagtgttgg
taatgaaacg aaaacgggac 2220tctagcatac ttactgacag ccagacagcg accaaaagaa
ttcggatggc catcaattag 228026958DNAInfluenza 26atggcgtctc aaggcaccaa
acgatcatat gaacaaatgg agactggtgg ggagcgccag 60gatgccacag aaatcagagc
atctgtcgga agaatgattg gtggaatcgg gagattctac 120atccaaatgt gcactgaact
caaactcagt gattatgatg gacgactaat ccagaatagc 180ataacaatag agaggatggt
gctttctgct tttgatgaga gaagaaataa atacctagaa 240gagcatccca gtgctgggaa
ggaccctaag aaaacaggag gacccatata tagaagagta 300gacggaaagt ggatgagaga
actcatcctt tatgacaaag aagaaataag gagagtttgg 360cgccaagcaa acaatggcga
agatgcaaca gcaggtctta ctcatatcat gatttggcat 420tccaacctga atgatgccac
atatcagaga acaagagcgc ttgttcgcac cggaatggat 480cccagaatgt gctctctaat
gcaaggttca acacttccca gaaggtctgg tgccgcaggt 540gctgcggtga aaggagttgg
aacaatagca atggagttaa tcagaatgat caaacgtgga 600atcaatgacc gaaatttctg
gaggggtgaa aatggacgaa ggacaagggt tgcttatgaa 660agaatgtgca atatcctcaa
aggaaaattt caaacagctg cccagagggc aatgatggat 720caagtaagag aaagtcgaaa
cccaggaaac gctgagattg aagacctcat tttcctggca 780cggtcagcac tcattctgag
gggatcagtt gcacataaat cctgcctgcc tgcttgtgtg 840tatgggcttg cagtagcaag
tgggcatgac tttgaaaggg aagggtactc actggtcggg 900atagacccat tcaaattact
ccaaaacagc caagtggtca gcctgatgag accaaatg 95827982DNAInfluenza
27atgagtcttc taaccgaggt cgaaacgtac gttctttcta tcatcccgtc aggccccctc
60aaagccgaga tcgcgcagag actggaaagt gtctttgcag gaaagaacac agatcttgag
120gctctcatgg aatggctaaa gacaagacca atcttgtcac ctctgactaa gggaatttta
180ggatttgtgt tcacgctcac cgtgcccagt gagcgaggac tgcagcgtag acgctttgtc
240caaaatgccc taaatgggaa tggggacccg aacaacatgg atagagcagt taaactatac
300aagaagctca aaagagaaat aacgttccat ggggccaagg aggtgtcact aagctattca
360actggtgcac ttgccagttg catgggcctc atatacaaca ggatgggaac agtgaccaca
420gaagctgctt ttggtctagt gtgtgccact tgtgaacaga ttgctgattc acagcatcgg
480tctcacagac agatggctac taccaccaat ccactaatca ggcatgaaaa cagaatggtg
540ctggctagca ctacggcaaa ggctatggaa cagatggctg gatcgagtga acaggcagcg
600gaggccatgg aggttgctaa tcagactagg cagatggtac atgcaatgag aactattggg
660actcatccta gctccagtgc tggtctgaaa gatgaccttc ttgaaaattt gcaggcctac
720cagaagcgaa tgggagtgca gatgcagcga ttcaagtgat cctctcgtca ttgcagcaaa
780tatcattggg atcttgcacc tgatattgtg gattactgat cgtctttttt tcaaatgtat
840ttatcgtcgc tttaaatacg gtttgaaaag agggccttct acggaaggag tgcctgagtc
900catgagggaa gaatatcaac aggaacagca gagtgctgtg gatgttgacg atggtcattt
960tgtcaacata gagctagagt aa
98228865DNAInfluenza 28atggactcca acaccatgtc aagctttcag gtagactgtt
tcctttggca tatccgcaag 60cgatttgcag acaatggatt gggtgatgcc ccattccttg
atcggctccg ccgagatcaa 120aagtccttaa aaggaagagg caacaccctt ggcctcgata
tcgaaacagc cactcttgtt 180gggaaacaaa tcgtggaatg gatcttgaaa gaggaatcca
gcgagacact tagaatgaca 240attgcatctg tacctacttc gcgctacctt tctgacatga
ccctcgagga aatgtcacga 300gactggttca tgctcatgcc taggcaaaag ataataggcc
ctctttgcgt gcgattggac 360caggcgatca tggaaaagaa catagtactg aaagcgaact
tcagtgtaat ctttaaccga 420ttagagacct tgatactact aagggctttc actgaggagg
gagcaatagt tggagaaatt 480tcaccattac cttctcttcc aggacatact tatgaggatg
tcaaaaatgc agttggggtc 540ctcatcggag gacttgaatg gaatggtaac acggttcgag
tctctgaaaa tatacagaga 600ttcgcttgga gaaactgtga tgagaatggg agaccttcac
tacctccaga gcagaaatga 660aaagtggcga gagcaattgg gacagaaatt tgaggaaata
aggtggttaa ttgaagaaat 720gcggcacaga ttgaaagcga cagagaatag tttcgaacaa
ataacattta tgcaagcctt 780acaactactg cttgaagtag aacaagagat aagagctttc
tcgtttcagc ttatttaatg 840ataaaaaaca cccttgtttc tactg
86529758PRTInfluenza 29Met Asp Val Asn Pro Thr Leu
Leu Phe Leu Lys Ile Pro Ala Gln Asn 1 5
10 15 Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp
Pro Pro Tyr Ser His 20 25
30 Gly Thr Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His
Gln 35 40 45 Tyr
Ser Glu Lys Gly Lys Trp Thr Thr Asn Thr Glu Thr Gly Ala Pro 50
55 60 Gln Leu Asn Pro Ile Asp
Gly Pro Leu Pro Glu Asp Asn Glu Pro Ser 65 70
75 80 Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala
Met Ala Phe Leu Glu 85 90
95 Glu Ser His Pro Gly Ile Phe Glu Asn Ser Cys Leu Glu Thr Met Glu
100 105 110 Val Val
Gln Gln Thr Arg Val Asp Arg Leu Thr Gln Gly Arg Gln Thr 115
120 125 Tyr Asp Trp Thr Leu Asn Arg
Asn Gln Pro Ala Ala Thr Ala Leu Ala 130 135
140 Asn Thr Ile Glu Val Phe Arg Ser Asn Gly Leu Thr
Ala Asn Glu Ser 145 150 155
160 Gly Arg Leu Ile Asp Phe Leu Lys Asp Val Met Glu Ser Met Asp Lys
165 170 175 Glu Glu Ile
Glu Ile Thr Thr His Phe Gln Arg Lys Arg Arg Val Arg 180
185 190 Asp Asn Met Thr Lys Lys Met Val
Thr Gln Arg Thr Ile Gly Lys Lys 195 200
205 Lys Gln Arg Val Asn Lys Arg Ser Tyr Leu Ile Arg Ala
Leu Thr Leu 210 215 220
Asn Thr Met Thr Lys Asp Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225
230 235 240 Ile Ala Thr Pro
Gly Met Gln Ile Arg Gly Phe Val Tyr Phe Val Glu 245
250 255 Thr Leu Ala Arg Ser Ile Cys Glu Lys
Leu Glu Gln Ser Gly Leu Pro 260 265
270 Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val
Arg Lys 275 280 285
Met Met Thr Asn Ser Gln Asp Thr Glu Leu Ser Phe Thr Ile Thr Gly 290
295 300 Asp Asn Thr Lys Trp
Asn Glu Asn Gln Asn Pro Arg Met Phe Leu Ala 305 310
315 320 Met Ile Thr Tyr Ile Thr Lys Asn Gln Pro
Glu Trp Phe Arg Asn Ile 325 330
335 Leu Ser Ile Ala Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu
Gly 340 345 350 Lys
Gly Tyr Met Phe Glu Ser Lys Arg Met Lys Leu Arg Thr Gln Ile 355
360 365 Pro Ala Glu Met Leu Ala
Ser Ile Asp Leu Lys Tyr Phe Asn Glu Ser 370 375
380 Thr Arg Lys Lys Ile Glu Lys Ile Arg Pro Leu
Leu Ile Asp Gly Thr 385 390 395
400 Ala Ser Leu Ser Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser
405 410 415 Thr Val
Leu Gly Val Ser Ile Leu Asn Leu Gly Gln Lys Lys Tyr Thr 420
425 430 Lys Thr Thr Tyr Trp Trp Asp
Gly Leu Gln Ser Ser Asp Asp Phe Ala 435 440
445 Leu Ile Val Asn Ala Pro Asn His Glu Gly Ile Gln
Ala Gly Val Asp 450 455 460
Arg Phe Tyr Arg Thr Cys Lys Leu Val Gly Ile Asn Met Ser Lys Lys 465
470 475 480 Lys Ser Tyr
Ile Asn Arg Thr Gly Thr Phe Glu Phe Thr Ser Phe Phe 485
490 495 Tyr Arg Tyr Gly Phe Val Ala Asn
Phe Ser Met Glu Leu Pro Ser Phe 500 505
510 Gly Val Ser Gly Ile Asn Glu Ser Ala Asp Met Ser Ile
Gly Val Thr 515 520 525
Val Ile Lys Asn Asn Met Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala 530
535 540 Gln Met Ala Leu
Gln Leu Phe Ile Lys Asp Tyr Arg Tyr Thr Tyr Arg 545 550
555 560 Cys His Arg Gly Asp Thr Gln Ile Gln
Thr Arg Arg Ser Phe Glu Leu 565 570
575 Lys Lys Leu Trp Glu Gln Thr Arg Ser Lys Ala Gly Leu Leu
Val Ser 580 585 590
Asp Gly Gly Pro Asn Leu Tyr Asn Ile Arg Asn Leu His Ile Pro Glu
595 600 605 Val Cys Leu Lys
Trp Glu Leu Met Asp Glu Asp Tyr Gln Gly Arg Leu 610
615 620 Cys Asn Pro Leu Asn Pro Phe Val
Ser His Lys Glu Ile Glu Ser Val 625 630
635 640 Asn Asn Ala Val Val Met Pro Ala His Gly Pro Ala
Lys Ser Met Glu 645 650
655 Tyr Asp Ala Val Ala Thr Thr His Ser Trp Ile Pro Lys Arg Asn Arg
660 665 670 Ser Ile Leu
Asn Thr Ser Gln Arg Gly Ile Leu Glu Asp Glu Gln Met 675
680 685 Tyr Gln Lys Cys Cys Asn Leu Phe
Glu Lys Phe Phe Pro Ser Ser Ser 690 695
700 Tyr Arg Arg Pro Val Gly Ile Ser Ser Met Val Glu Ala
Met Val Ser 705 710 715
720 Arg Ala Arg Ile Asp Ala Arg Ile Asp Phe Glu Ser Gly Arg Ile Lys
725 730 735 Lys Glu Glu Phe
Ser Glu Ile Met Lys Ile Cys Ser Thr Ile Glu Glu 740
745 750 Leu Arg Arg Gln Lys Gln 755
30716PRTInfluenza 30Met Glu Asp Phe Val Arg Gln Cys Phe Asn
Pro Met Ile Val Glu Leu 1 5 10
15 Ala Glu Lys Thr Met Lys Glu Tyr Gly Glu Asp Leu Lys Ile Glu
Thr 20 25 30 Asn
Lys Phe Ala Ala Ile Cys Thr His Leu Glu Val Cys Phe Met Tyr 35
40 45 Ser Asp Phe His Phe Ile
Asn Glu Gln Gly Glu Ser Ile Ile Val Glu 50 55
60 Leu Gly Asp Pro Asn Ala Leu Leu Lys His Arg
Phe Glu Ile Ile Glu 65 70 75
80 Gly Arg Asp Arg Thr Met Ala Trp Thr Val Val Asn Ser Ile Cys Asn
85 90 95 Thr Thr
Gly Ala Glu Lys Pro Lys Phe Leu Pro Asp Leu Tyr Asp Tyr 100
105 110 Lys Glu Asn Arg Phe Ile Glu
Ile Gly Val Thr Arg Arg Glu Val His 115 120
125 Ile Tyr Tyr Leu Glu Lys Ala Asn Lys Ile Lys Ser
Glu Lys Thr His 130 135 140
Ile His Ile Phe Ser Phe Thr Gly Glu Glu Met Ala Thr Lys Ala Asp 145
150 155 160 Tyr Thr Leu
Asp Glu Glu Ser Arg Ala Arg Ile Lys Thr Arg Leu Phe 165
170 175 Thr Ile Arg Gln Glu Met Ala Ser
Arg Gly Leu Trp Asp Ser Phe Arg 180 185
190 Gln Ser Glu Arg Gly Glu Glu Thr Ile Glu Glu Arg Phe
Glu Ile Thr 195 200 205
Gly Thr Met Arg Lys Leu Ala Asp Gln Ser Leu Pro Pro Asn Phe Ser 210
215 220 Ser Leu Glu Asn
Phe Arg Ala Tyr Val Asp Gly Phe Glu Pro Asn Gly 225 230
235 240 Tyr Ile Glu Gly Lys Leu Ser Gln Met
Ser Lys Glu Val Asn Ala Arg 245 250
255 Ile Glu Pro Phe Leu Lys Thr Thr Pro Arg Pro Leu Arg Leu
Pro Asn 260 265 270
Gly Pro Pro Cys Ser Gln Arg Ser Lys Phe Leu Leu Met Asp Ala Leu
275 280 285 Lys Leu Ser Ile
Glu Asp Pro Ser His Glu Gly Glu Gly Ile Pro Leu 290
295 300 Tyr Asp Ala Ile Lys Cys Met Arg
Thr Phe Phe Gly Trp Lys Glu Pro 305 310
315 320 Asn Val Val Lys Pro His Glu Lys Gly Ile Asn Pro
Asn Tyr Leu Leu 325 330
335 Ser Trp Lys Gln Val Leu Ala Glu Leu Gln Asp Ile Glu Asn Glu Glu
340 345 350 Lys Ile Pro
Lys Thr Lys Asn Met Lys Lys Thr Ser Gln Leu Lys Trp 355
360 365 Ala Leu Gly Glu Asn Met Ala Pro
Glu Lys Val Asp Phe Asp Asp Cys 370 375
380 Lys Asp Val Gly Asp Leu Lys Gln Tyr Asp Ser Asp Glu
Pro Glu Leu 385 390 395
400 Arg Ser Leu Ala Ser Trp Ile Gln Asn Glu Phe Asn Lys Ala Cys Glu
405 410 415 Leu Thr Asp Ser
Ser Trp Ile Glu Leu Asp Glu Ile Gly Glu Asp Val 420
425 430 Ala Pro Ile Glu His Ile Ala Ser Met
Arg Arg Asn Tyr Phe Thr Ser 435 440
445 Glu Val Ser His Cys Arg Ala Thr Glu Tyr Ile Met Lys Gly
Val Tyr 450 455 460
Ile Asn Thr Ala Leu Leu Asn Ala Ser Cys Ala Ala Met Asp Asp Phe 465
470 475 480 Gln Leu Ile Pro Met
Ile Ser Lys Cys Arg Thr Lys Glu Gly Arg Arg 485
490 495 Lys Thr Asn Leu Tyr Gly Phe Ile Ile Lys
Gly Arg Ser His Leu Arg 500 505
510 Asn Asp Thr Asp Val Val Asn Phe Val Ser Met Glu Phe Ser Leu
Thr 515 520 525 Asp
Pro Arg Leu Glu Pro His Lys Trp Glu Lys Tyr Cys Val Leu Glu 530
535 540 Ile Gly Asp Met Leu Ile
Arg Ser Ala Ile Gly Gln Val Ser Arg Pro 545 550
555 560 Met Phe Leu Tyr Val Arg Thr Asn Gly Thr Ser
Lys Ile Lys Met Lys 565 570
575 Trp Gly Met Glu Met Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln Ile
580 585 590 Glu Ser
Met Ile Glu Ala Glu Ser Ser Val Lys Glu Lys Asp Met Thr 595
600 605 Lys Glu Phe Phe Glu Asn Lys
Ser Glu Thr Trp Pro Ile Gly Glu Ser 610 615
620 Pro Lys Gly Val Glu Glu Ser Ser Ile Gly Lys Val
Cys Arg Thr Leu 625 630 635
640 Leu Ala Lys Ser Val Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu
645 650 655 Gly Phe Ser
Ala Glu Ser Arg Lys Leu Leu Leu Ile Val Gln Ala Leu 660
665 670 Arg Asp Asn Leu Glu Pro Gly Thr
Phe Asp Leu Gly Gly Leu Tyr Glu 675 680
685 Ala Ile Glu Glu Cys Leu Ile Asn Asp Pro Trp Val Leu
Leu Asn Ala 690 695 700
Ser Trp Phe Asn Ser Phe Leu Thr His Ala Leu Ser 705 710
715 31326PRTInfluenza 31Met Ala Ser Gln Gly Thr Lys
Arg Ser Tyr Glu Gln Met Glu Thr Asp 1 5
10 15 Gly Glu Arg Gln Asn Ala Thr Glu Ile Arg Ala
Ser Val Gly Lys Met 20 25
30 Ile Gly Gly Ile Gly Arg Phe Tyr Ile Gln Met Cys Thr Glu Leu
Lys 35 40 45 Leu
Ser Asp Tyr Glu Gly Arg Leu Ile Gln Asn Ser Leu Thr Ile Glu 50
55 60 Arg Met Val Leu Ser Ala
Phe Asp Glu Arg Arg Asn Lys Tyr Leu Glu 65 70
75 80 Glu His Pro Ser Ala Gly Lys Asp Pro Lys Lys
Thr Gly Gly Pro Ile 85 90
95 Tyr Arg Arg Val Asn Gly Lys Trp Met Arg Glu Leu Ile Leu Tyr Asp
100 105 110 Lys Glu
Glu Ile Arg Arg Ile Trp Arg Gln Ala Asn Asn Gly Asp Asp 115
120 125 Ala Thr Ala Gly Leu Thr His
Met Met Ile Trp His Ser Asn Leu Asn 130 135
140 Asp Ala Thr Tyr Gln Arg Thr Arg Ala Leu Val Arg
Thr Gly Met Asp 145 150 155
160 Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr Leu Pro Arg Arg Ser
165 170 175 Gly Ala Ala
Gly Ala Ala Val Lys Gly Val Gly Thr Met Val Met Glu 180
185 190 Leu Val Arg Met Ile Lys Arg Gly
Ile Asn Asp Arg Asn Phe Trp Arg 195 200
205 Gly Glu Asn Gly Arg Lys Thr Arg Ile Ala Tyr Glu Arg
Met Cys Asn 210 215 220
Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Lys Ala Met Met Asp 225
230 235 240 Gln Val Arg Glu
Ser Arg Asp Pro Gly Asn Ala Glu Phe Glu Asp Leu 245
250 255 Thr Phe Leu Ala Arg Ser Ala Leu Ile
Leu Arg Gly Ser Val Ala His 260 265
270 Lys Ser Cys Leu Pro Ala Cys Val Tyr Gly Pro Ala Val Ala
Ser Gly 275 280 285
Tyr Asp Phe Glu Arg Glu Gly Tyr Ser Leu Val Gly Ile Asp Pro Phe 290
295 300 Arg Leu Leu Gln Asn
Ser Gln Val Tyr Ser Leu Ile Arg Pro Asn Glu 305 310
315 320 Asn Pro Ala His Lys Ser
325 32252PRTInfluenza 32Met Ser Leu Leu Thr Glu Val Glu Thr Tyr Val
Leu Ser Ile Ile Pro 1 5 10
15 Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg Leu Glu Asp Val Phe
20 25 30 Ala Gly
Lys Asn Thr Asp Leu Glu Val Leu Met Glu Trp Leu Lys Thr 35
40 45 Arg Pro Ile Leu Ser Pro Leu
Thr Lys Gly Ile Leu Gly Phe Val Phe 50 55
60 Thr Leu Thr Val Pro Ser Glu Arg Gly Leu Gln Arg
Arg Arg Phe Val 65 70 75
80 Gln Asn Ala Leu Asn Gly Asn Gly Asp Pro Asn Asn Met Asp Lys Ala
85 90 95 Val Lys Leu
Tyr Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly Ala 100
105 110 Lys Glu Ile Ser Leu Ser Tyr Ser
Ala Gly Ala Leu Ala Ser Cys Met 115 120
125 Gly Leu Ile Tyr Asn Arg Met Gly Ala Val Thr Thr Glu
Val Ala Phe 130 135 140
Gly Leu Val Cys Ala Thr Cys Glu Gln Ile Ala Asp Ser Gln His Arg 145
150 155 160 Ser His Arg Gln
Met Val Thr Thr Thr Asn Pro Leu Ile Arg His Glu 165
170 175 Asn Arg Met Val Leu Ala Ser Thr Thr
Ala Lys Ala Met Glu Gln Met 180 185
190 Ala Gly Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Val Ala
Ser Gln 195 200 205
Ala Arg Gln Met Val Gln Ala Met Arg Thr Ile Gly Thr His Pro Ser 210
215 220 Ser Ser Ala Gly Leu
Lys Asn Asp Leu Leu Glu Asn Leu Gln Ala Tyr 225 230
235 240 Gln Lys Arg Met Gly Val Gln Met Gln Arg
Phe Lys 245 250
332299DNAInfluenza 33aatatggaaa gaataaaaga gctaaggaat ctgatgtcac
aatctcgcac tcgcgagata 60cttacaaaaa ctactgtaga ccacatggcc ataatcaaga
aatacacatc aggaagacag 120gagaaaaacc catcacttag aatgaaatgg atgatggcaa
tgaaataccc aattacagca 180gataaaagga taacggaaat gattcctgaa agaaatgagc
aaggacagac attatggagt 240aaagtgaatg atgccggatc agaccgagtg atgatatcac
ccctggctgt gacatggtgg 300aacagaaatg gaccagtggc aagtactatt cactatccaa
aaatctacaa aacttacttt 360gaaaaggttg aaaggttaaa acatggaacc tttggccctg
tacactttag aaaccaagtc 420aaaatacgcc gaagagtcga cataaatcct ggtcatgcag
acctcagcgc caaggaggca 480caggatgtaa ttatggaagt tgttttccct aatgaagtgg
gagccagaat actaacatca 540gaatcgcaat taacgataac caaggagaaa aaagaagaac
tccagaattg caaaatttcc 600cctttgatgg ttgcatacat gttagagagg gaacttgtcc
gcaaaacgag atttctcccg 660gttgctggtg gaacaagcag tgtgtacatt gaagttttgc
atttaacaca ggggacatgc 720tgggagcaga tgtacactcc aggtggggag gtgaggaatg
atgatgttga tcaaagccta 780attattgctg ctaggaacat agtgagaaga gctgcagtat
cagcagatcc actagcatct 840ttattagaaa tgtgccatag cacacagatt ggtgggacaa
ggatggtgga tattctcagg 900caaaatccaa cagaagaaca agctgtggat atatgcaaag
cagcaatggg gctgagaatc 960agttcatcct tcagttttgg cggattcaca tttaagagaa
caagtggatc atcagtcaaa 1020agggaggaag aagtgctcac gggcaatctg caaacattga
agctaactgt gcatgaggga 1080tatgaagagt tcacaatggt tgggaaaagg gcaacagcta
tactcagaaa agcaaccagg 1140agattgattc aactaatagt gagtggaaga gacgaacagt
caatagtcga agcaatagtt 1200gtagcaatgg tattctcaca agaagattgc atggtaaaag
cagttagagg tgatctgaat 1260ttcgttaata gagcgaatca gcggttgaat cccatgcatc
aacttttgag acattttcag 1320aaggatgcta aagtactttt cttaaattgg ggaattgaac
ctatcgacaa tgtgatggga 1380atgattggga tattacctga tatgactcca agtaccgaga
tgtcaatgag aggagtgaga 1440gtcagcaaaa tgggtgtaga tgaatactcc aatgctgaaa
gggtagtggt gagcattgac 1500cgttttttga gagtccggga ccaaagagga aatgtactac
tgtctccaga ggaagtcagt 1560gaaacacagg gaacagagaa actgacaata acttactctt
catcaatgat gtgggagatt 1620aatggccctg agtcagtgtt gatcaatacc tatcagtgga
tcatcagaaa ctgggagact 1680gttaaaattc agtggtctca gaaccctaca atgctataca
ataaaatgga attcgagcca 1740tttcagtctc tagtccctaa ggccattaga ggccaataca
gtgggtttgt tagaactcta 1800tttcaacaaa tgagggatgt gcttgggacc tttgacacaa
ctcagataat aaaacttctt 1860ccctttgcag ccgctccacc aaagcaaagt agaatgcaat
tctcatcatt gactgtgaat 1920gtgaggggat caggaatgag aatacttgta aggggtaatt
ctccagtatt caactacaac 1980aagaccacta agagactcac agtcctcgga aaggatgctg
gcactttaac tgaagaccca 2040gatgaaggca cagctggagt ggaatctgct gttctaaggg
gattcctcat tctaggcaaa 2100gaagatagaa gatatgggcc agcattaagc atcaatgaat
tgagcaacct tgcgaaaggg 2160gaaaaagcta atgtgctaat tgggcaaggg gacgtagtgt
tggtaatgaa acgaaaacgg 2220gactctagca tacttactga cagccagaca gcgaccaaaa
gaattcggat ggccatcaat 2280taatttcgaa taatttaaa
2299342277DNAInfluenza 34atggaacgca ttaaagaact
gcgcaacctg atgagccaga gccgcacccg cgaaattctg 60accaaaacca ccgtggatca
tatggcgatt attaaaaaat ataccagcgg ccgccaggaa 120aaaaacccga gcctgcgcat
gaaatggatg atggcgatga aatatccgat taccgcggat 180aaacgcatta ccgaaatgat
tccggaacgc aacgaacagg gccagaccct gtggagcaaa 240gtgaacgatg cgggcagcga
tcgcgtgatg attagcccgc tggcggtgac ctggtggaac 300cgcaacggcc cggtggcgag
caccattcat tatccgaaaa tttataaaac ctattttgaa 360aaagtggaac gcctgaaaca
tggcaccttt ggcccggtgc attttcgcaa ccaggtgaaa 420attcgccgcc gcgtggatat
taacccgggc catgcggatc tgagcgcgaa agaagcgcag 480gatgtgatta tggaagtggt
gtttccgaac gaagtgggcg cgcgcattct gaccagcgaa 540agccagctga ccattaccaa
agaaaaaaaa gaagaactgc agaactgcaa aattagcccg 600ctgatggtgg cgtatatgct
ggaacgcgaa ctggtgcgca aaacccgctt tctgccggtg 660gcgggcggca ccagcagcgt
gtatattgaa gtgctgcatc tgacccaggg cacctgctgg 720gaacagatgt ataccccggg
cggcgaagtg cgcaacgatg atgtggatca gagcctgatt 780attgcggcgc gcaacattgt
gcgccgcgcg gcggtgagcg cggatccgct ggcgagcctg 840ctggaaatgt gccatagcac
ccagattggc ggcacccgca tggtggatat tctgcgccag 900aacccgaccg aagaacaggc
ggtggatatt tgcaaagcgg cgatgggcct gcgcattagc 960agcagcttta gctttggcgg
ctttaccttt aaacgcacca gcggcagcag cgtgaaacgc 1020gaagaagaag tgctgaccgg
caacctgcag accctgaaac tgaccgtgca tgaaggctat 1080gaagaattta ccatggtggg
caaacgcgcg accgcgattc tgcgcaaagc gacccgccgc 1140ctgattcagc tgattgtgag
cggccgcgat gaacagagca ttgtggaagc gattgtggtg 1200gcgatggtgt ttagccagga
agattgcatg gtgaaagcgg tgcgcggcga tctgaacttt 1260gtgaaccgcg cgaaccagcg
cctgaacccg atgcatcagc tgctgcgcca ttttcagaaa 1320gatgcgaaag tgctgtttct
gaactggggc attgaaccga ttgataacgt gatgggcatg 1380attggcattc tgccggatat
gaccccgagc accgaaatga gcatgcgcgg cgtgcgcgtg 1440agcaaaatgg gcgtggatga
atatagcaac gcggaacgcg tggtggtgag cattgatcgc 1500tttctgcgcg tgcgcgatca
gcgcggcaac gtgctgctga gcccggaaga agtgagcgaa 1560acccagggca ccgaaaaact
gaccattacc tatagcagca gcatgatgtg ggaaattaac 1620ggcccggaaa gcgtgctgat
taacacctat cagtggatta ttcgcaactg ggaaaccgtg 1680aaaattcagt ggagccagaa
cccgaccatg ctgtataaca aaatggaatt tgaaccgttt 1740cagagcctgg tgccgaaagc
gattcgcggc cagtatagcg gctttgtgcg caccctgttt 1800cagcagatgc gcgatgtgct
gggcaccttt gataccaccc agattattaa actgctgccg 1860tttgcggcgg cgccgccgaa
acagagccgc atgcagttta gcagcctgac cgtgaacgtg 1920cgcggcagcg gcatgcgcat
tctggtgcgc ggcaacagcc cggtgtttaa ctataacaaa 1980accaccaaac gcctgaccgt
gctgggcaaa gatgcgggca ccctgaccga agatccggat 2040gaaggcaccg cgggcgtgga
aagcgcggtg ctgcgcggct ttctgattct gggcaaagaa 2100gatcgccgct atggcccggc
gctgagcatt aacgaactga gcaacctggc gaaaggcgaa 2160aaagcgaacg tgctgattgg
ccagggcgat gtggtgctgg tgatgaaacg caaacgcgat 2220agcagcattc tgaccgatag
ccagaccgcg accaaacgca ttcgcatggc gattaac 2277352201DNAInfluenza
35gattcgaaat ggaagatttt gtgcgacaat gcttcaatcc gatgattgtc gagcttgcgg
60aaaaggcaat gaaagagtat ggagaggacc tgaaaatcga aacaaacaaa tttgcagcaa
120tatgcactca cttggaagta tgcttcatgt attcagattt tcatttcatc aatgagcaag
180gcgaatcaat aatagtagag cctgaggacc caaatgcact tttaaagcac agatttgaga
240taatagaggg acgagatcgt acaatggcat ggacagttgt aaacagtatt tgcaacacca
300caggagctga gaaaccaaag tttctgccag atctgtatga ttacaaagag aatagattca
360tcgagattgg agtgacaagg agggaagttc acatatacta tctggaaaag gccaacaaaa
420ttaaatctga gaagacacac attcacattt tctcattcac tggcgaagaa atggccacaa
480aggccgatta cactctcgat gaagaaagca gggctaggat taaaaccaga ctattcacca
540taagacaaga aatggcaagc agaggtcttt gggactcctt tcgtcagtcc gaaagaggcg
600aagaaacaat tgaagaaaga tttgaaatca cagggacaat gcgcaggctc gctgaccaaa
660gccttccgcc gaacttctcc tgcattgaga attttagagc ctatgtggat ggatttgaac
720cgaacggcta cattgagggc aagctttctc aaatgtccaa agaagtaaat gctagaattg
780agcctttttt gaaaacaaca ccacgaccaa ttagacttcc ggatgggcct ccttgttttc
840agcggtcaaa attcctgctg atggattctt taaaattaag cattgaggat ccaaatcatg
900aaggagaggg aataccacta tatgatgcaa tcaagtgtat gagaacattc tttggatgga
960aagaaccctc tgttgtcaag ccacacggga agggaataaa tccgaattat ctgctgtcat
1020ggaagcaggt attggaagag ctgcaggaca ttgagagtga ggagaagatt ccaagaacaa
1080aaaacatgaa aaaaacgagt cagctaaagt gggcacttgg tgagaacatg gcaccagaga
1140aggtggattt tgatgactgt aaagatataa gcgatttgaa gcaatatgat agtgacgaac
1200ctgaattaag gtcattttca agttggatcc agaatgagtt caacaaggca tgcgagctga
1260ccgattcaat ctggatagag ctcgatgaga ttggagaaga tgtggccccg attgaacaca
1320ttgcaagcat gagaagaaat tacttcacag ctgaggtgtc ccattgcaga gccacagaat
1380atataatgaa gggggtatac attaatactg ctttgcttaa tgcatcctgt gcagcaatgg
1440atgatttcca actaattccc atgataagca aatgtagaac taaagaggga aggagaaaga
1500ccaatttgta cggcttcatc gtaaaaggaa gatctcactt aaggaatgac accgatgtgg
1560taaactttgt gagcatggag ttttccctca ctgacccaag acttgagcca cacaaatggg
1620agaagtactg tgttcttgag ataggagata tgcttctaag gagtgcaata ggccaagtgt
1680caaggcccat gttcttgtat gtaaggacaa atggaacctc aaaaattaaa atgaaatggg
1740gaatggagat gaggcgttgc ctcctccaat cccttcaaca aatagagagc atgattgaag
1800ctgagtcctc cgtcaaggag aaagacatga caaaagagtt ttttgagaat agatcagaaa
1860catggcccat tggagagtca ccaaaaggag tggaagaagg ttccattggg aaagtatgca
1920ggacactatt ggctaagtca gtattcaata gtctgtatgc atctccacaa ttagaaggat
1980tttcagctga gtcaagaaag ttgctcctca ttgttcaggc tcttagggac aatctggaac
2040ctgggacctt tgatcttggg gggctatatg aagcaattga ggagtgcctg attaatgatc
2100cctgggtttt gcttaatgct tcttggttca actccttcct aacacatgca ttgagatagc
2160tggggcaatg ctactattta ctatccatac tgtccaaaaa a
2201362301DNAInfluenza 36aatggatgtc aatccgacat tacttttctt aaaagtgcca
gcacaaaatg ctataagcac 60aacttttcct tatactggtg accctcctta cagccatggg
acaggaacag ggtacaccat 120ggatacagtc aacaggacac atcagtactc agaaagagga
agatggacaa aaaataccga 180aactggagca ccgcaactca acccaattga tgggccacta
ccaaaagaca atgaaccaag 240tggctatgcc caaacagatt gtgtattaga agcaatggct
ttccttgagg aatcccatcc 300tggtattttt gaaaactctt gtattgaaac aatggaggtt
gttcagcaaa caagggtgga 360caaactgaca caaggcagac agacctatga ctggactcta
aataggaacc agcctgctgc 420cacagcattg gccaacacta tagaagtgtt cagatcaaac
ggcctcatag caaatgaatc 480tgggaggcta atagacttcc ttaaagatgt aatggagtcg
atggacagag acgaagtaga 540gatcacaact cattttcaaa gaaagaggag agtgagagac
aatgtaacta aaaaaatggt 600gacccaaaga acaataggca aaaagaaaca taaattagac
aaaagaagtt acctaattag 660ggcattaacc ctgaacacaa tgaccaaaga tgctgagagg
gggaaactaa aacgcagagc 720aattgcaacc ccaggaatgc aaataagggg gtttgtatac
tttgttgaga cactggcaag 780aagcatatgt gaaaagcttg aacaatcagg gttgccagtt
ggaggaaatg aaaagaaagc 840aaagttagca aatgttgtaa ggaagatgat gaccaactcc
caggacactg aaatttcttt 900caccatcact ggagataaca caaaatggaa cgaaaatcaa
aaccctagaa tgttcttggc 960catgatcaca tatataacca aaaatcagcc tgaatggttc
agaaatattc taagtattgc 1020tccaataatg ttttcaaaca aaatggcgag actaggtaag
gggtacatgt ttgaaagcaa 1080gagtatgaaa ctgagaactc aaatacctgc agagatgcta
gccaacatag atttgaaata 1140tttcaatgat tcaactaaaa agaaaattga aaaaatccgg
ccattattaa tagatggaac 1200tgcatcattg agtcctggaa tgatgatggg catgttcaat
atgttaagca ccgtcttggg 1260cgtctccatt ctgaatcttg ggcaaaagag atacaccaag
actacttact ggtgggatgg 1320tcttcaatcg tctgatgatt ttgctctgat tgtgaatgca
cccaactatg caggaattca 1380agctggagtt gacaggtttt atcgaacctg taagctgctc
ggaattaata tgagcaaaaa 1440gaagtcttac ataaacagaa caggtacctt tgagttcacg
agctttttct atcgttatgg 1500gtttgttgcc aatttcagca tggagcttcc tagttttggg
gtgtctgggg tcaatgaatc 1560tgcagacatg agtattggag tcactgtcat caaaaacaat
atgataaaca atgaccttgg 1620cccagcaact gctcaaatgg cccttcagtt atttataaaa
gattacaggt acacgtatcg 1680atgccacaga ggtgacacac aaatacaaac ccggagatca
tttgagataa agaaactatg 1740ggaccaaacc cgctccaaag ctgggctgtt ggtctctgat
ggaggcccca atttatataa 1800cattagaaat ctccatattc ctgaagtctg cttgaaatgg
gagttgatgg atgaggatta 1860ccaggggcgt ttatgcaacc cattgaaccc gtttgtcagt
cataaagaga ttgaatcagt 1920gaacaatgca gtgatgatgc cggcacatgg tccagccaaa
aatatggagt atgacgctgt 1980tgcaacaaca cactcctggg ttcccaaaag gaatcgatcc
attttgaata cgagccaaag 2040ggggatactt gaggatgagc aaatgtatca gaggtgctgc
aatttatttg aaaaattctt 2100cccaagtagc tcatacagaa gaccagttgg aatatccagt
atggtagagg ctatggtttc 2160cagagcccga attgatgcac ggattgattt cgaatctgga
aggataaaaa aagaggaatt 2220cgctgagatc atgaagacct gttccaccat tgaagacctc
agacggcaaa aatagggaat 2280ttggcttgtc cttcatgaaa a
2301371527DNAInfluenza 37atcactcact gagtgacatc
aaagtcatgg cgtcccaagg caccaaacgg tcttacgaac 60agatggagac tgatggggaa
cgccagaatg caactgaaat cagagcatcc gtcggaagaa 120tgattggtgg aattgggcga
ttctacatcc aaatgtgcac cgagcttaaa ctcaatgatt 180atgagggacg actgatccag
aacagcttga caatagagag aatggtgctc tctgcttttg 240atgagaggag gaataaatat
ctggaagaac atcccagcgc ggggaaagat cctaagaaaa 300ctggaggacc catatacaag
agagtagatg gaaagtgggt gagggaactc gtcctttatg 360acaaagaaga aataaggcgg
atttggcgcc aagccaacaa tggtgatgat gcaacggctg 420gtttgactca cattatgatc
tggcattcta atttgaatga tacaacttac cagaggacaa 480gagctcttgt ccgcaccgga
atggatccca ggatgtgctc tttgatgcaa ggttcaactc 540tccctagaag atctggagca
gcaggcgctg cagtcaaagg agttgggaca atggtgttgg 600agttaatcag gatgatcaaa
cgtgggatca atgaccgaaa cttctggagg ggtgagaatg 660gaagaaaaac aaggattgct
tatgagagaa tgtgcaacat tctcaaagga aaatttcaaa 720cagctgcaca aaaagcaatg
atggatcaag tgagagaaag ccggaaccca ggaaatgctg 780agatcgaaga tctcactttt
ctggcacggt ctgcactcat attaagaggg tcagttgctc 840acaagtcttg cctgcctgcc
tgtgtgtatg gaccagccgt agccagtggg tacgacttcg 900aaaaagaggg atactctttg
gtaggggtag acccttttaa actgcttcaa accagtcagg 960tatacagcct aatcagacca
aacgagaatc ccgcacacaa gagtcagttg gtgtggatgg 1020catgcaattc tgctgcattt
gaagatctaa gagtgtcaag cttcatcaga gggacaagag 1080tacttccaag ggggaagctc
tccactagag gagtacaaat tgcttcaaat gaaaacatgg 1140atgctattgt atcaagtact
cttgaactga gaagcagata ctgggccata agaaccagaa 1200gtggagggaa cactaatcaa
caaagggcct ctgcgggcca aatcagcaca caacctacgt 1260tttctgtgca gagaaacctc
ccatttgaca aaacaaccat catggcagca ttcactggga 1320atacggaggg aagaacatca
gacatgaggg cagaaatcat aaagatgatg gaaagtgcaa 1380gaccagaaga agtgtccttc
caggggcggg gagtctttga gctctcggac gaaagggcaa 1440cgaacccgat cgtgccctcc
tttgacatga gtaatgaagg atcttatttc ttcggagaca 1500atgcagagga gtacgacaat
taatgaa 152738984DNAInfluenza
38gatgagtctt ctaaccgagg tcgaaacgta cgttctctct atcgtcccgt caggccccct
60caaagccgag atcgcacaga gacttgaaaa tgtctttgct ggaaagaata ccgatcttga
120ggctctcatg gaatggctaa agacaagacc aatcctgtca cctctgacta aggggatttt
180aggatttgtg ttcacgctca ccgtgcccag tgagcgagga ctgcagcgta gacgctttgt
240ccaaaatgcc cttaatggga atggggatcc aaataatatg gacagagcag ttaaactgta
300tcgaaagctt aagagggaga taacattcca tggggccaaa gaaatagcac tcagttattc
360tgctggtgca cttgccagtt gtatgggact catatacaac aggatggggg ctgtgaccac
420cgaatcagca tttggcctta tatgcgcaac ctgtgaacag attgccgact cccagcataa
480gtctcatagg caaatggtaa caacaaccaa cccattaata agacatgaga acagaatggt
540tctggccagc actacagcta aggctatgga gcaaatggct ggatcgagtg aacaagcagc
600tgaggccatg gaggttgcta gtcaggccag gcagatggtg caggcaatga gagccattgg
660gactcatcct agctctagca ctggtctgaa aaatgatctc cttgaaaatt tgcaggccta
720tcagaaacga atgggggtgc agatgcaacg attcaagtga tcctcttgtt gttgccgcaa
780gtataattgg gattgtgcac ctgatattgt ggattattga tcgccttttt tccaaaagca
840tttatcgtat ctttaaacac ggtttaaaaa gagggccttc tacggaagga gtaccagagt
900ctatgaggga agaatatcga gaggaacagc agaatgctgt ggatgctgac gatggtcatt
960ttgtcagcat agagctagag taaa
98439844DNAInfluenza 39atggattccc acactgtgtc aagctttcag gtagattgct
tcctttggca tgtccgcaaa 60caagttgcag accaagatct aggcgatgcc ccattccttg
atcggcttcg ccgagatcag 120aagtctctaa agggaagagg cagcactctc ggtctgaaca
tcgaaacagc cacttgtgtt 180ggaaagcaaa tagtagagag gattctgaaa gaagaatccg
atgaggcatt taaaatgacc 240atggcctccg cacttgcttc gcggtaccta actgacatga
ctattgaaga aatgtcaagg 300gactggttca tgctcatgcc caagcagaaa gtggctggcc
ctctttgtgt cagaatggac 360caggcgataa tggataagaa catcatactg aaagcgaatt
tcagtgtgat ttttgaccgg 420ttggagaatc tgacattact aagggctttc accgaagagg
gagcaattgt tggcgaaatt 480tcaccattgc cttctcttcc aggacatact aatgaggatg
tcaaaaatgc aattggggtc 540ctcatcgggg gacttgaatg gaatgataac acagttcgag
tctctgaaac tctacagaga 600ttcgcttgga gaagcagtaa tgagactggg ggacctccat
tcactccaac acagaaacgg 660aaaatggcgg gaacaattag gtcagaagtt tgaagaaata
agatggctga ttgaagaagt 720gaggcataaa ttgaagacga cagagaatag ttttgagcaa
ataacattta tgcaagcatt 780acagctattg tttgaagtgg aacaagagat tagaacgttt
tcgtttcagc ttatttaatg 840ataa
844401728DNAInfluenza 40ccaaaatgaa agcaaaacta
ctggtcctgt tatgtacatt tacagctaca tatgcagaca 60caatatgtat aggctaccat
gccaacaact caaccgacac tgttgacaca gtacttgaga 120agaatgtgac agtgacacac
tctgtcaacc tacttgagga cagtcacaat ggaaaactat 180gtctactaaa aggaatagcc
ccactacaat tgggtaattg cagcgttgcc ggatggatct 240taggaaaccc agaatgcgaa
ttactgattt ccaaggaatc atggtcctac attgtagaaa 300caccaaatcc tgagaatgga
acatgttacc cagggtattt cgccgactat gaggaactga 360gggagcaatt gagttcagta
tcttcatttg agagattcga aatattcccc aaagaaagct 420catggcccaa ccacaccgta
accggagtat cagcatcatg ctcccataat gggaaaagca 480gtttttacag aaatttgcta
tggctgacgg ggaagaatgg tttgtaccca aacctgagca 540agtcctatgt aaacaacaaa
gagaaagaag tccttgtact atggggtgtt catcacccgc 600ctaacatagg gaaccaaagg
gccctctatc atacagaaaa tgcttatgtc tctgtagtgt 660cttcacatta tagcagaaga
ttcaccccag aaatagccaa aagacccaaa gtaagagatc 720aggaaggaag aatcaactac
tactggactc tgctggaacc tggggataca ataatatttg 780aggcaaatgg aaatctaata
gcgccatggt atgcttttgc actgagtaga ggctttggat 840caggaatcat cacctcaaat
gcaccaatgg atgaatgtga tgcgaagtgt caaacacctc 900agggagctat aaacagcagt
cttcctttcc agaatgtaca cccagtcaca ataggagagt 960gtccaaagta tgtcaggagt
gcaaaattaa ggatggttac aggactaagg aacatcccat 1020ccattcaatc cagaggtttg
tttggagcca ttgccggttt cattgaaggg gggtggactg 1080gaatggtaga tgggtggtat
ggttatcatc atcagaatga gcaaggatct ggctatgctg 1140cagatcaaaa aagtacacaa
aatgccatta acgggattac aaacaaggtg aattctgtaa 1200ttgagaaaat gaacactcaa
ttcacagctg tgggcaaaga attcaacaaa ttggaaagaa 1260ggatggaaaa cttaaataaa
aaagttgatg atgggtttct agacatttgg acatataatg 1320cagaattgtt ggttctactg
gaaaatgaaa ggactttgga tttccatgac tccaatgtga 1380agaatctgta tgagaaagta
aaaagccaat taaagaataa tgccaaagaa ataggaaacg 1440ggtgttttga attctatcac
aagtgtaaca atgaatgcat ggagagtgtg aaaaatggaa 1500cttatgacta tccaaaatat
tccgaagaat caaagttaaa cagggagaaa attgatggag 1560tgaaattgga atcaatggga
gtctatcaga ttctggcgat ctactcaact gtcgccagtt 1620ccctggttct tttggtctcc
ctgggggcaa tcagcttctg gatgtgttcc aatgggtctt 1680tgcagtgtag aatatgcatc
tgagaccaga atttcagaaa tataagaa 1728411414DNAInfluenza
41aatgaatcca aatcaaaaaa taataaccat tggatcaatc agtatagcaa tcggaataat
60tagtctaatg ttgcaaatag gaaatattat ttcaatatgg gctagtcact caatccaaac
120tggaagtcaa aaccacactg gagtatgcaa ccaaagaatc atcacatatg aaaacagcac
180ctgggtgaat cacacatatg ttaatattaa caacactaat gttgttgctg gaaaggacaa
240aacttcagtg acattggccg gcaattcatc tctttgttct atcagtggat gggctatata
300cacaaaagac aacagcataa gaattggctc caaaggagat gtttttgtca taagagaacc
360tttcatatca tgttctcact tggaatgcag aacctttttt ctgacccaag gtgctctatt
420aaatgacaaa cattcaaatg ggaccgttaa ggacagaagt ccttataggg ccttaatgag
480ctgtcctcta ggtgaagctc cgtccccata caattcaaag tttgaatcag ttgcatggtc
540agcaagcgca tgccatgatg gcatgggctg gttaacaatc ggaatttctg gtccagacaa
600tggagctgtg gctgtactaa aatacaacgg cataataact gaaaccataa aaagttggaa
660aaagcgaata ttaagaacac aagagtctga atgtgtctgt gtgaacgggt catgtttcac
720cataatgacc gatggcccga gtaatggggc cgcctcgtac aaaatcttca agatcgaaaa
780ggggaaggtt actaaatcaa tagagttgaa tgcacccaat tttcattatg aggaatgttc
840ctgttaccca gacactggca cagtgatgtg tgtatgcagg gacaactggc atggttcaaa
900tcgaccttgg gtgtctttta atcaaaacct ggattatcaa ataggataca tctgcagtgg
960ggtgttcggt gacaatccgc gtcccaaaga tggagagggc agctgtaatc cagtgactgt
1020tgatggagca gacggagtaa aggggttttc atacaaatat ggtaatggtg tttggatagg
1080aaggactaaa agtaacagac ttagaaaggg gtttgagatg atttgggatc ctaatggatg
1140gacagatacc gacagtgatt tctcagtgaa acaggatgtt gtggcaataa ctgattggtc
1200agggtacagc ggaagtttcg ttcaacatcc tgagttaaca ggattggact gtataagacc
1260ttgcttctgg gttgagttag tcagaggact gcctagagaa aatacaacaa tctggactag
1320tgggagcagc atttcttttt gtggcgtaaa tagtgatact gcaaactggt cttggccaga
1380cggtgctgag ttgccgttca ccattgacaa gtag
1414422220DNAInfluenza 42agcgaaagca ggtactgatt cgaaatggaa gattttgtgc
gacaatgctt caatccgatg 60attgtcgagc ttgcggaaaa ggcaatgaaa gagtatggag
aggacctgaa aatcgaaaca 120aacaaatttg cagcaatatg cacccacttg gaagtatgct
tcatgtattc agattttcat 180ttcatcaatg agcaaggcga atcaataata gtagagcctg
aggacccaaa tgcactttta 240aaacacagat ttgagataat agaggggcga gatcgtacaa
tggcatggac agttgtaaac 300agtatttgca acaccacagg agctgagaaa ccaaagtttc
tgccagatct gtatgattac 360aaagagaata ggttcatcga aattggagtg acaaggagag
aagttcacat atactatctg 420gaaaaggcca acaaaattaa atctgagaag acacatattc
acattttctc atttactggc 480gaagaaatgg ccacaaaggc cgattacact ctcgatgaag
aaagcagggc tagaattaaa 540accagactat tcaccataag gcaagaaatg gcaagcagag
gtctttggga ctcctttcgt 600cagtccgaaa gaggcgaaga gacaattgaa gaaaggtttg
aaatcacagg gacaatgcgc 660aggctcgctg atcaaagcct tccgccgaac ttctcctgca
ttgagaattt tagagcctat 720gtggatggat ttgaaccgaa cggctacatt gagggcaagc
tttctcaaat gtccaaagaa 780gtaaatgcta aaattgagcc ttttttgaaa acaacacctc
gaccaattag acttccgaat 840gggcctcctt gttttcagcg gtcaaaattc ctgctgatgg
attctttaaa attaagcatt 900gaggatccaa atcatgaagg ggagggaata ccactatatg
atgcaatcaa gtgtatgaga 960acattctttg gatggaaaga acccactgtt gtcaagccac
acgagaaggg aataaatccg 1020aattatctgc tgtcgtggaa gcaggtgttg gaagagctgc
aggacattga gagtgaggag 1080aagattccaa gaacaaaaaa catgaaaaaa acgagtcagt
taaagtgggc acttggtgag 1140aacatggcac cagagaaggt ggattttgat gactgtaaag
atataagcga tttgaagcaa 1200tatgatagtg acgaacctga attaaggtca ttttcaagtt
ggatccagaa tgagttcaac 1260aaggcatgcg agctgaccga ttcaatctgg atagagctcg
atgagattgg agaagatgtg 1320gccccgattg aacacattgc aagcatgaga agaaattact
tcacagctga ggtgtcccat 1380tgcagagcca ctgaatatat aatgaaaggg gtatacatta
atactgcttt gcttaatgca 1440tcctgtgcag caatggatga tttccaacta attcctatga
taagcaaatg tagaactaaa 1500gagggaagga gaaagaccaa tttgtacggc ttcatcataa
aaggaagatc tcacttaagg 1560aatgataccg atgtggtaaa ctttgtgagc atggagtttt
ccctcactga cccaagactt 1620gagccacaca aatgggagaa gtactgtgtt cttgagatag
gagatatgct tctaaggagt 1680gcaataggcc aagtgtcaag gcccatgttc ttgtatgtaa
gaacaaatgg aacctcaaaa 1740attaaaatga aatggggaat ggagatgagg cgttgcctcc
tccaatccct ccaacaaata 1800gagagcatga ttgaagctga gtcctctgtc aaggagaaag
acatgacaaa agagtttttt 1860gagaatagat cagaaacatg gcccattgga gagtcaccaa
aaggagtgga agaaggttcc 1920attgggaaag tatgcaggac actattggct aaatcagtat
tcaatagtct gtatgcatct 1980ccacaattag aaggattttc agctgagtca agaaagttgc
tccttattgt tcaggctctt 2040agggacaatc tggaacctgg gacctttgat cttgggggac
tatatgaagc aattgaggag 2100tgcctgatta atgatccctg ggttttgctt aatgcttctt
ggttcaactc cttcctaaaa 2160catgcattga gatagctgag gcaatgctac tatttgttat
ccatactgtc caaaaaagta 2220432341DNAInfluenza 43agcgaaagca ggcaaaccat
ttgaatggat gtcaatccga cattactttt cttaaaagtg 60ccagcacaaa atgctataag
cacaactttt ccttatactg gtgaccctcc ttacagccat 120ggaacaggaa caggatacac
catggataca gtcaacagga cacatcagta ctcagaaaga 180ggaagatgga cgaaaaatac
cgaaactgga gcaccgcaac tcaacccaat tgatgggcca 240ctaccagaag acaatgaacc
aagtggctat gcccaaacag attgtgtatt agaggcaatg 300gctttccttg aagaatccca
tcctggtatt tttgaaaact cttgtattga aacaatggag 360gttgttcagc aaacaagggt
ggacaaactg acacaaggca gacaaaccta tgactggact 420ctaaatagga accagcctgc
tgccacagca ttggcaaaca ccatagaagt attcagatca 480aatggcctca tagcaaatga
atctggaagg ctaatagact tccttaaaga tgtaatggag 540tcgatggaca gagacgaagt
agaggtcaca actcattttc aaagaaagag gagagtgaga 600gacaatgtaa ctaaaaaaat
ggtgacccaa agaacaatag gaaaaaagaa acataaatta 660gacaaaagaa gttacctaat
tagggcatta accctgaaca caatgaccaa agatgctgag 720agggggaaac taaaacgcag
agcaattgca accccaggaa tgcaaataag ggggtttgta 780tactttgttg agacactggc
aagaagcata tgtgaaaagc ttgaacaatc agggttgcca 840gttggaggaa atgagaagaa
agcaaagtta gcaaatgttg taaggaagat gatgaccaac 900tcccaggaca ctgaaatttc
ttttaccatc actggagata acacaaaatg gaacgaaaat 960caaaacccta gaatgttctt
ggccatgatc acatatataa ccaaagatca gcctgaatgg 1020ttcagaaata ttctaagtat
tgctccaata atgttttcaa acaaaatggc gagactaggt 1080agggggtata tgtttgaaag
caagagtatg aaactgagaa cccaaatacc tgcagagatg 1140ctagccaaca tagatttgaa
atatttcaat gattcaacta aaaagaaaat tgaaaaaatt 1200cgaccattat taatagatgg
aactgcatca ttgagtcctg gaatgatgat gggcatgttc 1260aatatgttaa gcaccgtctt
gggcgtttcc attctgaatc ttgggcaaaa aagatacacc 1320aagactactt actggtggga
tggtcttcaa tcgtctgatg attttgcttt gattgtgaat 1380gcacccaatt atgcaggaat
tcaagctgga gttgacaggt tttatcgaac ctgtaagctg 1440ctcggaatta atatgagcaa
aaagaagtct tacataaaca gaacaggtac ctttgaattc 1500acgagctttt tctatcgtta
tgggtttgtt gccaatttca gcatggagct tcctagtttt 1560ggggtgtctg gggtcaatga
atctgcagac atgagtattg gagtcactgt catcaaaaac 1620aatatgataa acaatgacct
tggcccagca actgctcaaa tggcccttca gttatttata 1680aaagattaca ggtacactta
tcgatgccac agaggtgaca cacaaataca aacccggaga 1740tcatttgaaa taaagaaact
atgggaccaa acccgctcca aagctgggct gttggtctct 1800gatggaggcc ccaatttata
taacattagg aatctacata ttcctgaagt ctgcttgaaa 1860tgggagttga tggatgagga
ttaccagggg cgtttatgca acccattgaa cccgtttgtc 1920agccataaag agattgaatc
agtgaacaat gcagtgataa tgccggcaca tggtccagcc 1980aaaaatatgg agtatgacgc
tgttgcaaca acacactctt gggtccccaa aagaaatcga 2040tccattttaa acacgagcca
aagagggata cttgaagatg agcaaatgta ccaaaggtgc 2100tgcaatttat ttgaaaaatt
cttcccaagt agctcataca gaagaccagt tggaatatcc 2160agtatggtag aggctatggt
ttcaagagcc cgaattgatg cacggattga tttcgaatct 2220ggaaggataa agaaagagga
attcgctgag atcatgaaga cctgttccac cattgaagac 2280ctcagacggc aaaaataggg
aatttggctt gtccttcatg aaaaaatgcc ttgtttctac 2340t
2341442341DNAInfluenza
44agcgaaagca ggtcaattat attcaatatg gaaagaataa aagagctaag gaatctgatg
60tcacaatctc gcactcgcga gatacttacc aaaactactg tagaccacat ggccataata
120aagaaataca catcaggaag acaggagaaa aacccatcac ttaggatgaa atggatgatg
180gcaatgaaat acccaattac agctgataaa aggataacgg aaatgattcc tgaaagaaat
240gagcaaggac agacactatg gagtaaagtg aatgatgccg gatcagaccg agtgatgata
300tcacccctag ctgtgacatg gtggaacaga aatggaccag tggcaaacac tatccactat
360ccaaaaatct acaaaactta ctttgaaaag gttgaaaggt taaaacatgg aacctttggc
420cctgtacact ttagaaacca agtcaaaata cgccgaagag tcgacataaa tcctggtcat
480gcagacctca gcgccaagga ggcacaggat gtaattatgg aagttgtttt ccctaatgaa
540gtgggagcca gaatactaac atcagaatcg caattaacga taactaagga gaaaaaagag
600gaactccaga attgcaaaat ttcccctttg atggttgcat acatgttaga gagggaactt
660gtccgcaaaa caagatttct cccggttgca ggtggaacaa gcagtgtgta cattgaagtt
720ttgcatttaa cacaggggac atgctgggag cagatgtaca ctccaggtgg ggaggtgagg
780aatgatgatg ttgatcaaag cctaattatt gctgctagga acatagtgag aagagctgca
840gtatcagcag atccactagc atctttatta gaaatgtgcc atagcacaca gattggtgga
900acaaggatgg tggatattct caggcaaaat ccaacagaag aacaagctgt ggacatatgc
960aaagcagcaa tggggctgag aatcagttca tccttcagtt ttggcggatt cacatttaag
1020agaacaagtg gatcgtcagt caaaagggag gaagaagtgc taacgggcaa tctgcaaaca
1080ttgaagctaa ctgtgcatga gggatatgaa gaattcacaa tagttgggaa aaaggcaaca
1140gctatactca gaaaagcaac caggagattg attcaactaa tagtgagtgg aagagacgaa
1200cagtcaatag tcgaagcaat agttgtagca atggtattct cacaagaaga ttgcatggta
1260aaagcggtta gaggtgatct gaatttcgtt aatagagcga atcagcggtt gaatcccatg
1320catcaacttt tgagacattt tcagaaggat gctaaagtac ttttcctaaa ttggggaatt
1380gaacatattg acaatgtgat gggaatgatt gggatattac ctgatatgac tccaagtacc
1440gagatgtcaa tgagaggagt gagagtcagc aaaatgggtg tagatgaata ctccaatgct
1500gaaagggtag tggtaagcat tgaccgtttt ttgagggtcc gggaccaaag aggaaatgta
1560ttactgtctc cagaggaagt cagtgaaaca caaggaacag agaaactgac aataacttac
1620tcttcatcat tgatgtggga gattaatggc cctgagtcag tgttgatcaa tacctaccaa
1680tggatcatca gaaactggga gactgttaaa attcagtggt ctcagaaccc tacaatgcta
1740tacaataaaa tggaatttga gccatttcaa tctctagtcc ccaaggccat tagaggccaa
1800tacagtgggt ttgttagaac tctatttcaa caaatgaggg atgtgctcgg gacctttgac
1860acaactcaga taataaaact tcttcccttt gcagccgctc caccaaagca aagtagaatg
1920caattctcgt cattaactgt gaatgtgagg ggatcaggaa tgagaatact tgtaaggggt
1980aattctccag tattcaacta caacaagacc actaagagac tcacaatcct cggaaaggat
2040gctggcactt taactgaaga cccagatgaa ggcacagctg gagtggaatc tgctgtttta
2100aggggattcc tcattctagg caaagaagat agaagatatg ggccagcatt aagcatcagt
2160gaattgagca accttgcgaa aggggagaaa gctaatgtgc taattgggca aggggatgta
2220gtgttggtaa tgaaacgaaa acgggactct agcatactta ctgacagcca gacagcgacc
2280aaaagaattc ggatggccat caattaattt cgaataattt aaaaacgacc ttgtttctac
2340t
2341451565DNAInfluenza 45agcaaaagca gggtagataa tcactcactg agtgacatca
aagtcatggc gtcccaaggc 60accaaacggt cttacgaaca gatggagact gatggggaac
gccagaatgc aactgaaatc 120agagcatccg tcggaagaat gattggggga attgggcgat
tctacatcca aatgtgcacc 180gagcttaagc tcaatgatta tgagggacga ctgatccaga
acagcttaac aatagagaga 240atggtgcttt ctgcttttga tgagaggaga aataaatatc
tggaagaaca tcccagcgca 300gggaaagatc ctaagaaaac tggaggaccc atatacaaga
gagtagatgg aaagtgggtg 360agggaactcg tcctttatga caaagaagaa ataaggcgga
tttggcgcca agccaacaat 420ggtgatgatg caacagctgg tttgactcac attatgatct
ggcattctaa tttgaatgat 480acaacttacc agaggacaag agctcttgtc cgcaccggaa
tggatcccag gatgtgctct 540ttgatgcaag gttcaactct ccctagaaga tctggagcag
caggcgctgc agtcaaagga 600gttgggacaa tggtattgga gttaatcagg atgatcaaac
gtgggatcaa cgaccgaaac 660ttctggaggg gtgagaatgg gagaaaaaca aggattgctt
atgagagaat gtgcaacatt 720ctcaaaggaa aatttcaaac agctgcacaa aaagcaatga
tggatcaagt gagagaaagc 780cggaacccag gaaatgctga gatcgaagat ctcacttttc
tggcacggtc tgcactcata 840ttgagaggat cagttgctca caagtcttgc ctgcctgctt
gtgtgtatgg accagccgta 900gccagtgggt atgacttcga aaaagaggga tactctttgg
tgggagtaga ccctttcaaa 960ctgcttcaaa ccagtcaggt atacagccta attagaccaa
acgagaatcc cgcacacaag 1020agccagttgg tgtggatggc atgcaattct gctgcatttg
aagatctaag agtgtcaagc 1080ttcatcagag ggacaagagt acttccaagg gggaagctct
ccactagagg agtacaaatt 1140gcttcaaatg aaaacatgga tgctattgtc tcaagtactc
ttgaactgag aagcagatac 1200tgggccataa gaaccagaag tggagggaac accaatcaac
aaagggcctc tgcgggccaa 1260atcagcacac aacctacgtt ttctgtgcag agaaacctcc
catttgacaa aacaaccatc 1320atggcagcat tcactgggaa tacagaggga agaacatcag
acatgcgggc agaaatcata 1380aagatgatgg aaagtgcaag accagaagaa gtgtccttcc
agggacgggg agtctttgag 1440ctctcggacg aaagggcaac gaacccgatc gtgccctcct
ttgacatgag taatgaagga 1500tcttatttct tcggagacaa tgcagaggag tacgacaatt
aatgaaaaat acccttgttt 1560ctact
1565461027DNAInfluenza 46agcaaaagca ggtagatatt
gaaagatgag tcttctaacc gaggtcgaaa cgtacgttct 60ctctatcgtc ccatcaggcc
ccctcaaagc cgagatcgca cagagacttg aagatgtatt 120tgctggaaag aataccgatc
ttgaggctct catggaatgg ctaaagacaa gaccaatcct 180gtcacctctg actaagggga
ttttaggatt tgtgttcacg ctcaccgtgc ccagtgagcg 240aggactgcag cgtagacgct
ttgtccaaaa tgcccttaat gggaatgggg atccaaataa 300tatggacaag gctgtcaaac
tgtatcgaaa gcttaagagg gagataacat tccatggggc 360caaagaaata gcactcagtt
attctgctgg agcacttgcc agttgtatgg gactcatata 420caacaggatg ggggctgtga
ccaccgaatc agcatttggc cttatatgtg caacctgtga 480acagattgcc gactcccagc
ataagtctca taggcaaatg gtaacaacaa ccaatccatt 540aataagacat gagaacagaa
tggttctggc cagcactaca gctaaggcta tggagcaaat 600ggctggatcg agtgaacaag
cagctgaggc catggaggtt gctagtcagg ccaggcagat 660ggtgcaggca atgagagcca
ttgggactca tcctagctct agcactggtc tgaaaaatga 720tctccttgaa aatttgcagg
cctatcagaa acgaatgggg gtgcagatgc aacgattcaa 780gtgatcctct tgttgttgcc
gcaagtataa ttgggattgt gcacctgata ttgtggatta 840ttgatcgcct tttttccaaa
agcatttatc gtatttttaa acacggttta aaaagagggc 900cttctacgga aggagtaccg
gagtctatga gggaagaata tcgagaggaa cagcagaatg 960ctgtggatgc tgacgatggt
cattttgtca gcatagagct agagtaaaaa actaccttgt 1020ttctact
102747889DNAInfluenza
47agcaaaagca gggtggcaaa gacataatgg attcccacac tgtgtcaagc tttcaggtag
60attgtttcct ttggcatgtc cgcaaacaag ttgcagacca agatctaggc gatgccccct
120tccttgatcg gcttcgccga gatcagaagt ctctaaaggg acgaggcaac actctcggtc
180tgaacatcga aacagccact tgtgttggaa agcaaatagt agagaggatt ctgaaagaag
240aatccgatga gacatttaga atgaccatgg cctccgcact tgcttcgcgg tacctaactg
300acatgactgt tgaagaaatg tcaagggact ggttcatgct catgcccaag cagaaagtgg
360ctggccctct ttgtgtcaga atggaccagg cgataatgga taagaacatc atactgaaag
420cgaacttcag tgtgattttt gaccggttgg agaatctgac attactaagg gctttcaccg
480aagagggagc aattgttggc gaaatttcac cattgccttc ttttccagga catactaatg
540aggatgtcaa aaatgcaatt ggggtcctca tcgggggact tgaatggaat gataacacag
600ttcgagtctc tgaagctcta cagagattcg cttggagaag cagtaatgag actgggggac
660ctccattcac tacaacacag aaacggaaaa tggcgggaac aattaggtca gaagtttgaa
720gaaataagat ggctgattga agaagtgagg cataaattga agacgacaga gagtagtttt
780gaacaaataa catttatgca agcattacag ctattgtttg aagtggaaca agagattaga
840acgttctcgt ttcagcttat ttaatgataa aaacaccctt gtttctact
889481775DNAInfluenza 48agcgaaagca ggggaaaata aaagcaacca aaatgaaagt
aaaactactg gttctgttat 60gtacatttac agctacatat gcagacacaa tatgtatagg
ctaccatgcc aacaactcaa 120ccgacactgt tgacacagta cttgagaaga atgtaacagt
gacacactct gtcaacctac 180ttgaggacag tcacaatgga aaactatgtc tactaaaagg
aatagcccca ctacaattgg 240gtaattgcag cgttgccgga tggatcttag gaaacccaga
atgcgaatta ctgatttcca 300aggaatcatg gtcctacatt gtagaaacac caaatcctga
gaatggaaca tgttacccag 360ggtatttcgc cgactatgag gaactgaggg agcaattgag
ttcagtatct tcatttgaaa 420ggttcgaaat attccccaaa gagagctcat ggcccaacca
caccgtaacc ggagtatcag 480catcatgctc ccataacggg aaaagcagtt tttacagaaa
tttgctatgg ctgacgggga 540agaatggttt gtacccaaac ctgagcaagt cctatgcaaa
caacaaagag aaagaagtcc 600ttgtactatg gggtgttcat cacccgccta acatagggga
ccaaagggcc ctctatcata 660cagaaaatgc ttatgtctct gtagtgtctt cacattatag
cagaagattc accccagaaa 720tagccaaaag acccaaggtg agagaccagg aaggaagaat
caactactac tggactctgc 780tggaacccgg ggatacaata atatttgagg caaatggaaa
tctaatagcg ccaaggtatg 840ctttcgcact gagtagaggc ttgggatcag gaatcatcac
ctcaaatgca ccaatggatg 900aatgtgatgc aaagtgtcaa acacctcagg gagctataaa
cagcagtctt cctttccaga 960atgtacaccc agtcacaata ggagagtgtc caaagtatgt
caggagtgca aaattaagga 1020tggttacagg actaaggaac atcccatcca ttcaatccag
aggtttgttt ggagcaattg 1080ccggtttcat tgaagggggg tggactggaa tggtagatgg
ttggtatggt tatcatcatc 1140agaatgagca aggatctggg tatgctgcag atcaaaaaag
cacacaaaat gccattaacg 1200ggattacaaa caaggtgaat tctgtaattg agaaaatgaa
cactcaattc acagctgtgg 1260gcaaagaatt caacaaattg gaaagaagga tggaaaactt
aaataaaaaa gttgatgatg 1320ggtttctaga catttggacc tataatgcag aattgttggt
tctactggaa aatgaaagga 1380ctttggattt ccatgactcc aacgtgaaga atctgtatga
gaaagtaaaa agccaattaa 1440agaataatgc caaagaaata ggaaacgggt gttttgaatt
ctatcacaag tgtaacgatg 1500aatgcatgga gagtgtgaaa aatggaactt atgactatcc
aaaatattcc gaagaatcaa 1560agttaaacag agagaaaatt gatggagtga aattggaatc
aatgggagtc tatcagattc 1620tggcgatcta ctcaacagtc gccagttccc tggttctttt
ggtctccctg ggggcaatca 1680gcttctggat gtgttccaat gggtctttgc agtgtagaat
atgcatctaa gaccagaatt 1740tcagaaatat aaggaaaaac acccttgttt ctact
1775491462DNAInfluenza 49agcaaaagca ggagtttaaa
atgaatccaa atcaaaaaat aataaccatt ggatcaatca 60gtatagcaat cggaataatt
agtctaatgt tgcaaatagg aaatattatt tcaatatggg 120ctagtcactc aatccaaact
ggaagtcaaa accacactgg aatatgcaac caaaaaatca 180tcacatatga aaacagcacc
tgggtgaatc acacatatgt taatattaac aacactaatg 240ttgttgctgg aaaggacaaa
acttcagtga cactggccgg caattcatct ctttgtccta 300tcagtggatg ggctatatac
acaaaagaca acagcataag aattggctcc aaaggagatg 360tttttgtcat aagagaacct
ttcatatcat gttctcactt ggaatgcaga accttttttc 420tgacccaagg tgctctatta
aatgacaaac attcaaatgg aaccgttaag gacagaagtc 480cttatagggc cttaatgagc
tgtcctctag gtgaagcccc gtcaccatac aattcaaagt 540ttgaatcagt tgcatggtca
gcaagcgcat gccatgatgg caagggctgg ttaacaatcg 600gaatttctgg tccagacaat
ggagctgtgg ctgtactaaa atacaacgga ataataactg 660aaaccataaa aagttgggaa
aagcgaatat tgagaacaca agagtctgaa tgtgtttgtg 720tgaacgggtc atgtttcacc
ataatgaccg atggcccgag taatggggcc gcctcgtaca 780aaatcttcaa gatcgaaaag
gggaaggtta ctaaatcaac agagttgaat gcacccaatt 840ttcattatga ggaatgttcc
tgttacccag acactggcac agtgatgtgt gtatgcaggg 900acaactggca tggttcaaat
cgaccttggg tatcttttaa tcaaaacttg gattatcaaa 960taggatacat ctgcagtgga
gtgttcggtg acaatccgcg tcccaaagat gggaagggca 1020gctgtaatcc agtgactgtt
gatggagcag acggagttaa ggggttttca tacaaatatg 1080gtaatggtgt ttggatagga
aggactaaaa gtaacagact tagaaagggg tttgagatga 1140tttgggatcc taatggatgg
acagataccg acagtgattt ctcagtgaaa caggatgttg 1200tggcaataac tgattggtca
gggtacagcg gaagtttcgt ccaacatcct gagttaacag 1260gattggactg tataagacct
tgcttctggg ttgagttagt cagaggactg cctagagaaa 1320atacaacaat ctggactagt
gggagcagca tttctttttg tggcgttgat agtgatactg 1380caaattggtc ttggccagac
ggtgctgagt tgccgttcac cattgacaag tagctcgttg 1440aaaaaaactc cttgtttcta
ct 146250566PRTInfluenza 50Met
Lys Ala Lys Leu Leu Val Leu Leu Cys Ala Leu Ser Ala Thr Asp 1
5 10 15 Ala Asp Thr Ile Cys Ile
Gly Tyr His Ala Asn Asn Ser Thr Asp Thr 20
25 30 Val Asp Thr Val Leu Glu Lys Asn Val Thr
Val Thr His Ser Val Asn 35 40
45 Leu Leu Glu Asp Asn His Asn Gly Lys Leu Cys Lys Leu Lys
Gly Ile 50 55 60
Ala Pro Leu Gln Leu Gly Lys Cys Ser Ile Ala Gly Trp Ile Leu Gly 65
70 75 80 Asn Pro Glu Cys Glu
Ser Leu Phe Ser Lys Lys Ser Trp Ser Tyr Ile 85
90 95 Ala Glu Thr Pro Asn Ser Glu Asn Gly Thr
Cys Tyr Pro Gly Tyr Phe 100 105
110 Ala Asp Tyr Glu Glu Leu Arg Glu Gln Leu Ser Ser Val Ser Ser
Phe 115 120 125 Glu
Arg Phe Glu Ile Phe Pro Lys Glu Ser Ser Trp Pro Lys His Asn 130
135 140 Val Thr Lys Gly Val Thr
Ala Ala Cys Ser His Lys Gly Lys Ser Ser 145 150
155 160 Phe Tyr Arg Asn Leu Leu Trp Leu Thr Glu Lys
Asn Gly Ser Tyr Pro 165 170
175 Asn Leu Ser Lys Ser Tyr Val Asn Asn Lys Glu Lys Glu Val Leu Val
180 185 190 Leu Trp
Gly Val His His Pro Ser Asn Ile Glu Asp Gln Lys Thr Ile 195
200 205 Tyr Arg Lys Glu Asn Ala Tyr
Val Ser Val Val Ser Ser His Tyr Asn 210 215
220 Arg Arg Phe Thr Pro Glu Ile Ala Lys Arg Pro Lys
Val Arg Asn Gln 225 230 235
240 Glu Gly Arg Ile Asn Tyr Tyr Trp Thr Leu Leu Glu Pro Gly Asp Thr
245 250 255 Ile Ile Phe
Glu Ala Asn Gly Asn Leu Ile Ala Pro Trp Tyr Ala Phe 260
265 270 Ala Leu Ser Arg Gly Phe Gly Ser
Gly Ile Ile Thr Ser Asn Ala Ser 275 280
285 Met Asp Glu Cys Asp Ala Lys Cys Gln Thr Pro Gln Gly
Ala Ile Asn 290 295 300
Ser Ser Leu Pro Phe Gln Asn Val His Pro Val Thr Ile Gly Glu Cys 305
310 315 320 Pro Lys Tyr Val
Arg Ser Thr Lys Leu Arg Met Val Thr Gly Leu Arg 325
330 335 Asn Ile Pro Ser Ile Gln Ser Arg Gly
Leu Phe Gly Ala Ile Ala Gly 340 345
350 Phe Ile Glu Gly Gly Trp Thr Gly Met Ile Asp Gly Trp Tyr
Gly Tyr 355 360 365
His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp Gln Lys Ser 370
375 380 Thr Gln Asn Ala Ile
Asn Gly Ile Thr Asn Lys Val Asn Ser Ile Ile 385 390
395 400 Glu Lys Met Asn Thr Gln Phe Thr Ala Val
Gly Lys Glu Phe Asn Lys 405 410
415 Leu Glu Lys Arg Met Glu Asn Leu Asn Lys Lys Val Asp Asp Gly
Phe 420 425 430 Leu
Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu Glu Asn 435
440 445 Glu Arg Thr Leu Asp Phe
His Asp Ser Asn Val Lys Asn Leu Tyr Glu 450 455
460 Lys Val Lys Ser Gln Leu Lys Asn Asn Ala Lys
Glu Ile Gly Asn Gly 465 470 475
480 Cys Phe Glu Phe Tyr His Lys Cys Asn Asn Glu Cys Met Glu Ser Val
485 490 495 Lys Asn
Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ser Lys Leu 500
505 510 Asn Arg Glu Lys Ile Asp Gly
Val Lys Leu Glu Ser Met Gly Val Tyr 515 520
525 Gln Ile Leu Ala Ile Tyr Ser Thr Val Ala Ser Ser
Leu Val Leu Leu 530 535 540
Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys Ser Asn Gly Ser Leu 545
550 555 560 Gln Cys Arg
Ile Cys Ile 565 51470PRTInfluenza 51Met Asn Pro Asn
Gln Lys Ile Ile Thr Ile Gly Ser Ile Cys Met Thr 1 5
10 15 Ile Gly Ile Ile Ser Leu Ile Leu Gln
Ile Gly Asn Ile Ile Ser Ile 20 25
30 Trp Val Ser His Ser Ile Gln Thr Gly Ser Gln Asn His Thr
Gly Ile 35 40 45
Cys Asn Gln Arg Ile Ile Thr Tyr Glu Asn Ser Thr Trp Val Asn Gln 50
55 60 Thr Tyr Val Asn Ile
Asn Asn Thr Asn Val Val Ala Gly Lys Asp Thr 65 70
75 80 Thr Ser Val Thr Leu Ala Gly Asn Ser Ser
Leu Cys Pro Ile Arg Gly 85 90
95 Trp Ala Ile Tyr Ser Lys Asp Asn Ser Ile Arg Ile Gly Ser Lys
Gly 100 105 110 Asp
Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu Glu 115
120 125 Cys Arg Thr Phe Phe Leu
Thr Gln Gly Ala Leu Leu Asn Asp Lys His 130 135
140 Ser Asn Gly Thr Val Lys Asp Arg Ser Pro Tyr
Arg Ala Leu Met Ser 145 150 155
160 Cys Pro Ile Gly Glu Ala Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser
165 170 175 Val Ala
Trp Ser Ala Ser Ala Cys His Asp Gly Met Gly Trp Leu Thr 180
185 190 Ile Gly Ile Ser Gly Pro Asp
Asp Gly Ala Val Ala Val Leu Lys Tyr 195 200
205 Asn Gly Ile Ile Thr Glu Thr Ile Lys Ser Trp Arg
Lys Arg Ile Leu 210 215 220
Arg Thr Gln Glu Ser Glu Cys Val Cys Val Asn Gly Ser Cys Phe Thr 225
230 235 240 Ile Met Thr
Asp Gly Pro Ser Asn Gly Pro Ala Ser Tyr Arg Ile Phe 245
250 255 Lys Ile Glu Lys Gly Lys Ile Thr
Lys Ser Ile Glu Leu Asp Ala Pro 260 265
270 Asn Ser His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Thr
Gly Thr Val 275 280 285
Met Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg Pro Trp Val 290
295 300 Ser Phe Asn Gln
Asn Leu Asp Tyr Gln Ile Gly Tyr Ile Cys Ser Gly 305 310
315 320 Val Phe Gly Asp Asn Pro Arg Pro Lys
Asp Gly Lys Gly Ser Cys Asp 325 330
335 Pro Val Thr Val Asp Gly Ala Asp Gly Val Lys Gly Phe Ser
Tyr Arg 340 345 350
Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Asn Ser Ser Arg
355 360 365 Lys Gly Phe Glu
Met Ile Trp Asp Pro Asn Gly Trp Thr Asp Thr Asp 370
375 380 Ser Asn Phe Leu Val Lys Gln Asp
Val Val Ala Met Thr Asp Trp Ser 385 390
395 400 Gly Tyr Ser Gly Ser Phe Val Gln His Pro Glu Leu
Thr Gly Leu Asp 405 410
415 Cys Met Arg Pro Cys Phe Trp Val Glu Leu Val Arg Gly Arg Pro Arg
420 425 430 Glu Gly Thr
Thr Val Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly 435
440 445 Val Asn Ser Asp Thr Ala Asn Trp
Ser Trp Pro Asp Gly Ala Glu Leu 450 455
460 Pro Phe Thr Ile Asp Lys 465 470
52469PRTInfluenza 52Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val
Cys Met Thr 1 5 10 15
Ile Gly Met Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile
20 25 30 Trp Ile Ser His
Ser Ile Gln Leu Gly Asn Gln Asn Gln Ile Glu Thr 35
40 45 Cys Asn Gln Ser Val Ile Thr Tyr Glu
Asn Asn Thr Trp Val Asn Gln 50 55
60 Thr Tyr Val Asn Ile Ser Asn Thr Asn Phe Ala Ala Gly
Gln Ser Val 65 70 75
80 Val Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly
85 90 95 Trp Ala Ile Tyr
Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly 100
105 110 Asp Val Phe Val Ile Arg Glu Pro Phe
Ile Ser Cys Ser Pro Leu Glu 115 120
125 Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp
Lys His 130 135 140
Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser 145
150 155 160 Cys Pro Ile Gly Glu
Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser 165
170 175 Val Ala Trp Ser Ala Ser Ala Cys His Asp
Gly Ile Asn Trp Leu Thr 180 185
190 Ile Gly Ile Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys
Tyr 195 200 205 Asn
Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu 210
215 220 Arg Thr Gln Glu Ser Glu
Cys Ala Cys Val Asn Gly Ser Cys Phe Thr 225 230
235 240 Val Met Thr Asp Gly Pro Ser Asn Gly Gln Ala
Ser Tyr Lys Ile Phe 245 250
255 Arg Ile Glu Lys Gly Lys Ile Val Lys Ser Val Glu Met Asn Ala Pro
260 265 270 Asn Tyr
His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile 275
280 285 Thr Cys Val Cys Arg Asp Asn
Trp His Gly Ser Asn Arg Pro Trp Val 290 295
300 Ser Phe Asn Gln Asn Leu Glu Tyr Gln Ile Gly Tyr
Ile Cys Ser Gly 305 310 315
320 Ile Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly
325 330 335 Pro Val Ser
Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys 340
345 350 Tyr Gly Asn Gly Val Trp Ile Gly
Arg Thr Lys Ser Ile Ser Ser Arg 355 360
365 Asn Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr
Gly Thr Asp 370 375 380
Asn Asn Phe Ser Ile Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser 385
390 395 400 Gly Tyr Ser Gly
Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asp 405
410 415 Cys Ile Arg Pro Cys Phe Trp Val Glu
Leu Ile Arg Gly Arg Pro Lys 420 425
430 Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys
Gly Val 435 440 445
Asn Ser Asp Thr Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro 450
455 460 Phe Thr Ile Asp Lys
465 53716PRTInfluenza 53Met Glu Asp Phe Val Arg Gln Cys
Phe Asn Pro Met Ile Val Glu Leu 1 5 10
15 Ala Glu Lys Ala Met Lys Glu Tyr Gly Glu Asp Pro Lys
Ile Glu Thr 20 25 30
Asn Lys Phe Ala Ala Ile Cys Thr His Leu Glu Val Cys Phe Met Tyr
35 40 45 Ser Asp Phe His
Phe Ile Asp Glu Arg Gly Glu Ser Ile Ile Val Glu 50
55 60 Ser Gly Asp Pro Asn Ala Leu Leu
Lys His Arg Phe Glu Ile Ile Glu 65 70
75 80 Gly Arg Asp Arg Ile Met Ala Trp Thr Val Val Asn
Ser Ile Cys Asn 85 90
95 Thr Thr Gly Val Glu Lys Pro Lys Phe Leu Pro Asp Leu Tyr Asp Tyr
100 105 110 Lys Glu Asn
Arg Phe Ile Glu Ile Gly Val Thr Arg Arg Glu Val His 115
120 125 Ile Tyr Tyr Leu Glu Lys Ala Asn
Lys Ile Lys Ser Glu Lys Thr His 130 135
140 Ile His Ile Phe Ser Phe Thr Gly Glu Glu Met Ala Thr
Lys Ala Asp 145 150 155
160 Tyr Thr Leu Asp Glu Glu Ser Arg Ala Arg Ile Lys Thr Arg Leu Phe
165 170 175 Thr Ile Arg Gln
Glu Met Ala Ser Arg Ser Leu Trp Asp Ser Phe Arg 180
185 190 Gln Ser Glu Arg Gly Glu Glu Thr Ile
Glu Glu Lys Phe Glu Ile Thr 195 200
205 Gly Thr Met Arg Lys Leu Ala Asp Gln Ser Leu Pro Pro Asn
Phe Pro 210 215 220
Ser Leu Glu Asn Phe Arg Ala Tyr Val Asp Gly Phe Glu Pro Asn Gly 225
230 235 240 Cys Ile Glu Gly Lys
Leu Ser Gln Met Ser Lys Glu Val Asn Ala Lys 245
250 255 Ile Glu Pro Phe Leu Arg Thr Thr Pro Arg
Pro Leu Arg Leu Pro Asp 260 265
270 Gly Pro Leu Cys His Gln Arg Ser Lys Phe Leu Leu Met Asp Ala
Leu 275 280 285 Lys
Leu Ser Ile Glu Asp Pro Ser His Glu Gly Glu Gly Ile Pro Leu 290
295 300 Tyr Asp Ala Ile Lys Cys
Met Lys Thr Phe Phe Gly Trp Lys Glu Pro 305 310
315 320 Asn Ile Val Lys Pro His Glu Lys Gly Ile Asn
Pro Asn Tyr Leu Met 325 330
335 Ala Trp Lys Gln Val Leu Ala Glu Leu Gln Asp Ile Glu Asn Glu Glu
340 345 350 Lys Ile
Pro Arg Thr Lys Asn Met Lys Arg Thr Ser Gln Leu Lys Trp 355
360 365 Ala Leu Gly Glu Asn Met Ala
Pro Glu Lys Val Asp Phe Asp Asp Cys 370 375
380 Lys Asp Val Gly Asp Leu Lys Gln Tyr Asp Ser Asp
Glu Pro Glu Pro 385 390 395
400 Arg Ser Leu Ala Ser Trp Val Gln Asn Glu Phe Asn Lys Ala Cys Glu
405 410 415 Leu Thr Asp
Ser Ser Trp Ile Glu Leu Asp Glu Ile Gly Glu Asp Val 420
425 430 Ala Pro Ile Glu His Ile Ala Ser
Met Arg Arg Asn Tyr Phe Thr Ala 435 440
445 Glu Val Ser His Cys Arg Ala Thr Glu Tyr Ile Met Lys
Gly Val Tyr 450 455 460
Ile Asn Thr Ala Leu Leu Asn Ala Ser Cys Ala Ala Met Asp Asp Phe 465
470 475 480 Gln Leu Ile Pro
Met Ile Ser Lys Cys Arg Thr Lys Glu Gly Arg Arg 485
490 495 Lys Thr Asn Leu Tyr Gly Phe Ile Ile
Lys Gly Arg Ser His Leu Arg 500 505
510 Asn Asp Thr Asp Val Val Asn Phe Val Ser Met Glu Phe Ser
Leu Thr 515 520 525
Asp Pro Arg Leu Glu Pro His Lys Trp Glu Lys Tyr Cys Val Leu Glu 530
535 540 Ile Gly Asp Met Leu
Leu Arg Thr Ala Ile Gly Gln Val Ser Arg Pro 545 550
555 560 Met Phe Leu Tyr Val Arg Thr Asn Gly Thr
Ser Lys Ile Lys Met Lys 565 570
575 Trp Gly Met Glu Met Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln
Ile 580 585 590 Glu
Ser Met Ile Glu Ala Glu Ser Ser Val Lys Glu Lys Asp Met Thr 595
600 605 Lys Glu Phe Phe Glu Asn
Lys Ser Glu Thr Trp Pro Ile Gly Glu Ser 610 615
620 Pro Arg Gly Val Glu Glu Gly Ser Ile Gly Lys
Val Cys Arg Thr Leu 625 630 635
640 Leu Ala Lys Ser Val Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu
645 650 655 Gly Phe
Ser Ala Glu Ser Arg Lys Leu Leu Leu Ile Val Gln Ala Leu 660
665 670 Arg Asp Asn Leu Glu Pro Gly
Thr Phe Asp Leu Gly Gly Leu Tyr Glu 675 680
685 Ala Ile Glu Glu Cys Leu Ile Asn Asp Pro Trp Val
Leu Leu Asn Ala 690 695 700
Ser Trp Phe Asn Ser Phe Leu Thr His Ala Leu Lys 705
710 715 54757PRTInfluenza 54Met Asp Val Asn Pro Thr
Leu Leu Phe Leu Lys Val Pro Ala Gln Asn 1 5
10 15 Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp
Pro Pro Tyr Ser His 20 25
30 Gly Thr Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His
Gln 35 40 45 Tyr
Ser Glu Arg Gly Arg Trp Thr Lys Asn Thr Glu Thr Gly Ala Pro 50
55 60 Gln Leu Asn Pro Ile Asp
Gly Pro Leu Pro Lys Asp Asn Glu Pro Ser 65 70
75 80 Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala
Met Ala Phe Leu Glu 85 90
95 Glu Ser His Pro Gly Ile Phe Glu Asn Ser Cys Ile Glu Thr Met Glu
100 105 110 Val Val
Gln Gln Thr Arg Val Asp Lys Leu Thr Gln Gly Arg Gln Thr 115
120 125 Tyr Asp Trp Thr Leu Asn Arg
Asn Gln Pro Ala Ala Thr Ala Leu Ala 130 135
140 Asn Thr Ile Glu Val Phe Arg Ser Asn Gly Leu Ile
Ala Asn Glu Ser 145 150 155
160 Gly Arg Leu Ile Asp Phe Leu Lys Asp Val Met Glu Ser Met Asp Arg
165 170 175 Asp Glu Val
Glu Val Thr Thr His Phe Gln Arg Lys Arg Arg Val Arg 180
185 190 Asp Asn Val Thr Lys Lys Met Val
Thr Gln Arg Thr Ile Gly Lys Lys 195 200
205 Lys His Lys Leu Asp Lys Arg Ser Tyr Leu Ile Arg Ala
Leu Thr Leu 210 215 220
Asn Thr Met Thr Lys Asp Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225
230 235 240 Ile Ala Thr Pro
Gly Met Gln Ile Arg Gly Phe Val Tyr Phe Val Glu 245
250 255 Thr Leu Ala Arg Ser Ile Cys Glu Lys
Leu Glu Gln Ser Gly Leu Pro 260 265
270 Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val
Arg Lys 275 280 285
Met Met Thr Asn Ser Gln Asp Thr Glu Ile Ser Phe Thr Ile Thr Gly 290
295 300 Asp Asn Thr Lys Trp
Asn Glu Asn Gln Asn Pro Arg Met Phe Leu Ala 305 310
315 320 Met Ile Thr Tyr Ile Thr Lys Asn Gln Pro
Glu Trp Phe Arg Asn Ile 325 330
335 Leu Ser Ile Ala Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu
Gly 340 345 350 Lys
Gly Tyr Met Phe Glu Ser Lys Ser Met Lys Leu Arg Thr Gln Ile 355
360 365 Pro Ala Glu Met Leu Ala
Asn Ile Asp Leu Lys Tyr Phe Asn Asp Ser 370 375
380 Thr Lys Arg Lys Ile Glu Lys Ile Arg Pro Leu
Leu Ile Asp Gly Thr 385 390 395
400 Ala Ser Leu Ser Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser
405 410 415 Thr Val
Leu Gly Val Ser Ile Leu Asn Leu Gly Gln Lys Arg Tyr Thr 420
425 430 Lys Thr Thr Tyr Trp Trp Asp
Gly Leu Gln Ser Ser Asp Asp Phe Ala 435 440
445 Leu Ile Val Asn Ala Pro Asn Tyr Ala Gly Ile Gln
Ala Gly Val Asp 450 455 460
Arg Phe Tyr Arg Thr Cys Lys Leu Leu Gly Ile Asn Met Ser Lys Lys 465
470 475 480 Lys Ser Tyr
Ile Asn Arg Thr Gly Thr Phe Glu Phe Thr Ser Phe Phe 485
490 495 Tyr Arg Tyr Gly Phe Val Ala Asn
Phe Ser Met Glu Leu Pro Ser Phe 500 505
510 Gly Val Ser Gly Val Asn Glu Ser Ala Asp Met Ser Ile
Gly Val Thr 515 520 525
Val Ile Lys Asn Asn Met Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala 530
535 540 Gln Met Ala Leu
Gln Leu Phe Ile Lys Asp Tyr Arg Tyr Thr Tyr Arg 545 550
555 560 Cys His Arg Gly Asp Thr Gln Ile Gln
Thr Arg Arg Ser Phe Glu Ile 565 570
575 Lys Lys Leu Trp Asp Gln Thr Arg Ser Lys Ala Gly Leu Leu
Val Ser 580 585 590
Asp Gly Gly Pro Asn Leu Tyr Asn Ile Arg Asn Leu His Ile Pro Glu
595 600 605 Val Cys Leu Lys
Trp Glu Leu Met Asp Glu Asp Tyr Gln Gly Arg Leu 610
615 620 Cys Asn Pro Ser Asn Pro Phe Val
Ser His Lys Glu Ile Glu Ser Val 625 630
635 640 Asn Asn Ala Val Met Met Pro Ala His Gly Pro Ala
Lys Asn Met Glu 645 650
655 Tyr Asp Ala Val Ala Thr Thr His Ser Trp Val Pro Lys Arg Asn Arg
660 665 670 Ser Ile Leu
Asn Thr Ser Gln Arg Gly Ile Leu Glu Asp Glu Gln Met 675
680 685 Tyr Gln Arg Cys Cys Asn Leu Phe
Glu Lys Phe Phe Pro Ser Ser Ser 690 695
700 Tyr Arg Arg Pro Val Gly Ile Ser Ser Met Val Glu Ala
Met Val Ser 705 710 715
720 Arg Ala Arg Ile Asp Ala Arg Ile Asp Phe Glu Ser Gly Arg Ile Lys
725 730 735 Lys Glu Glu Phe
Ala Glu Ile Met Lys Thr Cys Ser Thr Ile Glu Asp 740
745 750 Leu Arg Arg Gln Lys 755
55759PRTInfluenza 55Met Glu Arg Ile Lys Glu Leu Arg Asn Leu Met Ser
Gln Ser Arg Thr 1 5 10
15 Arg Glu Ile Leu Thr Lys Thr Thr Val Asp His Met Ala Ile Ile Lys
20 25 30 Lys Tyr Thr
Ser Gly Arg Gln Glu Lys Asn Pro Ser Leu Arg Met Lys 35
40 45 Trp Met Met Ala Met Lys Tyr Pro
Ile Thr Ala Asp Lys Arg Ile Thr 50 55
60 Glu Met Ile Pro Glu Arg Asn Glu Gln Gly Gln Thr Leu
Trp Ser Lys 65 70 75
80 Val Asn Asp Ala Gly Ser Asp Arg Val Met Ile Ser Pro Leu Ala Val
85 90 95 Thr Trp Trp Asn
Arg Asn Gly Pro Val Ala Ser Thr Ile His Tyr Pro 100
105 110 Lys Ile Tyr Lys Thr Tyr Phe Glu Lys
Val Glu Arg Leu Lys His Gly 115 120
125 Thr Phe Gly Pro Val His Phe Arg Asn Gln Val Lys Ile Arg
Arg Arg 130 135 140
Val Asp Ile Asn Pro Gly His Ala Asp Leu Ser Ala Lys Glu Ala Gln 145
150 155 160 Asp Val Ile Met Glu
Val Val Phe Pro Asn Glu Val Gly Ala Arg Ile 165
170 175 Leu Thr Ser Glu Ser Gln Leu Thr Ile Thr
Lys Glu Lys Lys Glu Glu 180 185
190 Leu Gln Asn Cys Lys Ile Ser Pro Leu Met Val Ala Tyr Met Leu
Glu 195 200 205 Arg
Glu Leu Val Arg Lys Thr Arg Phe Leu Pro Val Ala Gly Gly Thr 210
215 220 Ser Ser Val Tyr Ile Glu
Val Leu His Leu Thr Gln Gly Thr Cys Trp 225 230
235 240 Glu Gln Met Tyr Thr Pro Gly Gly Glu Val Arg
Asn Asp Asp Val Asp 245 250
255 Gln Ser Leu Ile Ile Ala Ala Arg Asn Ile Val Arg Arg Ala Ala Val
260 265 270 Ser Ala
Asp Pro Leu Ala Ser Leu Leu Glu Met Cys His Ser Thr Gln 275
280 285 Ile Gly Gly Thr Arg Met Val
Asp Ile Leu Arg Gln Asn Pro Thr Glu 290 295
300 Glu Gln Ala Val Asp Ile Cys Lys Ala Ala Met Gly
Leu Arg Ile Ser 305 310 315
320 Ser Ser Phe Ser Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly Ser
325 330 335 Ser Val Lys
Arg Glu Glu Glu Val Leu Thr Gly Asn Leu Gln Thr Leu 340
345 350 Lys Leu Thr Val His Glu Gly Tyr
Glu Glu Phe Thr Met Val Gly Lys 355 360
365 Arg Ala Thr Ala Ile Leu Arg Lys Ala Thr Arg Arg Leu
Ile Gln Leu 370 375 380
Ile Val Ser Gly Arg Asp Glu Gln Ser Ile Val Glu Ala Ile Val Val 385
390 395 400 Ala Met Val Phe
Ser Gln Glu Asp Cys Met Val Lys Ala Val Arg Gly 405
410 415 Asp Leu Asn Phe Val Asn Arg Ala Asn
Gln Arg Leu Asn Pro Met His 420 425
430 Gln Leu Leu Arg His Phe Gln Lys Asp Ala Lys Val Leu Phe
Leu Asn 435 440 445
Trp Gly Ile Glu Pro Ile Asp Asn Val Met Gly Met Ile Gly Ile Leu 450
455 460 Pro Asp Met Thr Pro
Ser Thr Glu Met Ser Met Arg Gly Val Arg Val 465 470
475 480 Ser Lys Met Gly Val Asp Glu Tyr Ser Asn
Ala Glu Arg Val Val Val 485 490
495 Ser Ile Asp Arg Phe Leu Arg Val Arg Asp Gln Arg Gly Asn Val
Leu 500 505 510 Leu
Ser Pro Glu Glu Val Ser Glu Thr Gln Gly Thr Glu Lys Leu Thr 515
520 525 Ile Thr Tyr Ser Ser Ser
Met Met Trp Glu Ile Asn Gly Pro Glu Ser 530 535
540 Val Leu Ile Asn Thr Tyr Gln Trp Ile Ile Arg
Asn Trp Glu Thr Val 545 550 555
560 Lys Ile Gln Trp Ser Gln Asn Pro Thr Met Leu Tyr Asn Lys Met Glu
565 570 575 Phe Glu
Pro Phe Gln Ser Leu Val Pro Lys Ala Ile Arg Gly Gln Tyr 580
585 590 Ser Gly Phe Val Arg Thr Leu
Phe Gln Gln Met Arg Asp Val Leu Gly 595 600
605 Thr Phe Asp Thr Thr Gln Ile Ile Lys Leu Leu Pro
Phe Ala Ala Ala 610 615 620
Pro Pro Lys Gln Ser Arg Met Gln Phe Ser Ser Leu Thr Val Asn Val 625
630 635 640 Arg Gly Ser
Gly Met Arg Ile Leu Val Arg Gly Asn Ser Pro Val Phe 645
650 655 Asn Tyr Asn Lys Thr Thr Lys Arg
Leu Thr Val Leu Gly Lys Asp Ala 660 665
670 Gly Thr Leu Thr Glu Asp Pro Asp Glu Gly Thr Ala Gly
Val Glu Ser 675 680 685
Ala Val Leu Arg Gly Phe Leu Ile Leu Gly Lys Glu Asp Arg Arg Tyr 690
695 700 Gly Pro Ala Leu
Ser Ile Asn Glu Leu Ser Asn Leu Ala Lys Gly Glu 705 710
715 720 Lys Ala Asn Val Leu Ile Gly Gln Gly
Asp Val Val Leu Val Met Lys 725 730
735 Arg Lys Arg Asp Ser Ser Ile Leu Thr Asp Ser Gln Thr Ala
Thr Lys 740 745 750
Arg Ile Arg Met Ala Ile Asn 755 56498PRTInfluenza
56Met Ala Ser Gln Gly Thr Lys Arg Ser Tyr Glu Gln Met Glu Thr Asp 1
5 10 15 Gly Glu Arg Gln
Asn Ala Thr Glu Ile Arg Ala Ser Val Gly Arg Met 20
25 30 Ile Gly Gly Ile Gly Arg Phe Tyr Ile
Gln Met Cys Thr Glu Leu Lys 35 40
45 Leu Asn Asp Tyr Glu Gly Arg Leu Ile Gln Asn Ser Leu Thr
Ile Glu 50 55 60
Arg Met Val Leu Ser Ala Phe Asp Glu Arg Arg Asn Lys Tyr Leu Glu 65
70 75 80 Glu His Pro Ser Ala
Gly Lys Asp Pro Lys Lys Thr Gly Gly Pro Ile 85
90 95 Tyr Lys Arg Val Asp Gly Lys Trp Val Arg
Glu Leu Val Leu Tyr Asp 100 105
110 Lys Glu Glu Ile Arg Arg Ile Trp Arg Gln Ala Asn Asn Gly Asp
Asp 115 120 125 Ala
Thr Ala Gly Leu Thr His Ile Met Ile Trp His Ser Asn Leu Asn 130
135 140 Asp Thr Thr Tyr Gln Arg
Thr Arg Ala Leu Val Arg Thr Gly Met Asp 145 150
155 160 Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr
Leu Pro Arg Arg Ser 165 170
175 Gly Ala Ala Gly Ala Ala Val Lys Gly Val Gly Thr Met Val Leu Glu
180 185 190 Leu Ile
Arg Met Ile Lys Arg Gly Ile Asn Asp Arg Asn Phe Trp Arg 195
200 205 Gly Glu Asn Gly Arg Lys Thr
Arg Ile Ala Tyr Glu Arg Met Cys Asn 210 215
220 Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Lys
Ala Met Met Asp 225 230 235
240 Gln Val Arg Glu Ser Arg Asn Pro Gly Asn Ala Glu Ile Glu Asp Leu
245 250 255 Thr Phe Leu
Ala Arg Ser Ala Leu Ile Leu Arg Gly Ser Val Ala His 260
265 270 Lys Ser Cys Leu Pro Ala Cys Val
Tyr Gly Pro Ala Val Ala Ser Gly 275 280
285 Tyr Asp Phe Glu Lys Glu Gly Tyr Ser Leu Val Gly Val
Asp Pro Phe 290 295 300
Lys Leu Leu Gln Thr Ser Gln Val Tyr Ser Leu Ile Arg Pro Asn Glu 305
310 315 320 Asn Pro Ala His
Lys Ser Gln Leu Val Trp Met Ala Cys Asn Ser Ala 325
330 335 Ala Phe Glu Asp Leu Arg Val Ser Ser
Phe Ile Arg Gly Thr Arg Val 340 345
350 Leu Pro Arg Gly Lys Leu Ser Thr Arg Gly Val Gln Ile Ala
Ser Asn 355 360 365
Glu Asn Met Asp Ala Ile Val Ser Ser Thr Leu Glu Leu Arg Ser Arg 370
375 380 Tyr Trp Ala Ile Arg
Thr Arg Ser Gly Gly Asn Thr Asn Gln Gln Arg 385 390
395 400 Ala Ser Ala Gly Gln Ile Ser Thr Gln Pro
Thr Phe Ser Val Gln Arg 405 410
415 Asn Leu Pro Phe Asp Lys Thr Thr Ile Met Ala Ala Phe Thr Gly
Asn 420 425 430 Thr
Glu Gly Arg Thr Ser Asp Met Arg Ala Glu Ile Ile Lys Met Met 435
440 445 Glu Ser Ala Arg Pro Glu
Glu Val Ser Phe Gln Gly Arg Gly Val Phe 450 455
460 Glu Leu Ser Asp Glu Arg Ala Thr Asn Pro Ile
Val Pro Ser Phe Asp 465 470 475
480 Met Ser Asn Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu Glu Tyr
485 490 495 Asp Asn
57252PRTInfluenza 57Met Ser Leu Leu Thr Glu Val Glu Thr Tyr Val Leu Ser
Ile Val Pro 1 5 10 15
Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg Leu Glu Asn Val Phe
20 25 30 Ala Gly Lys Asn
Thr Asp Leu Glu Ala Leu Met Glu Trp Leu Lys Thr 35
40 45 Arg Pro Ile Leu Ser Pro Leu Thr Lys
Gly Ile Leu Gly Phe Val Phe 50 55
60 Thr Leu Thr Val Pro Ser Glu Arg Gly Leu Gln Arg Arg
Arg Phe Val 65 70 75
80 Gln Asn Ala Leu Asn Gly Asn Gly Asp Pro Asn Asn Met Asp Arg Ala
85 90 95 Val Lys Leu Tyr
Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly Ala 100
105 110 Lys Glu Ile Ala Leu Ser Tyr Ser Ala
Gly Ala Leu Ala Ser Cys Met 115 120
125 Gly Leu Ile Tyr Asn Arg Met Gly Ala Val Thr Thr Glu Ser
Ala Phe 130 135 140
Gly Leu Ile Cys Ala Thr Cys Glu Gln Ile Ala Asp Ser Gln His Lys 145
150 155 160 Ser His Arg Gln Met
Val Thr Thr Thr Asn Pro Leu Ile Arg His Glu 165
170 175 Asn Arg Met Val Leu Ala Ser Thr Thr Ala
Lys Ala Met Glu Gln Met 180 185
190 Ala Gly Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Val Ala Ser
Gln 195 200 205 Ala
Arg Gln Met Val Gln Ala Met Arg Ala Ile Gly Thr His Pro Ser 210
215 220 Ser Ser Thr Gly Leu Lys
Asn Asp Leu Leu Glu Asn Leu Gln Ala Tyr 225 230
235 240 Gln Lys Arg Met Gly Val Gln Met Gln Arg Phe
Lys 245 250 58470PRTInfluenza
58Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Ile Ser Ile Ala 1
5 10 15 Ile Gly Ile Ile
Ser Leu Met Leu Gln Ile Gly Asn Ile Ile Ser Ile 20
25 30 Trp Ala Ser His Ser Ile Gln Thr Gly
Ser Gln Asn His Thr Gly Val 35 40
45 Cys Asn Gln Arg Ile Ile Thr Tyr Glu Asn Ser Thr Trp Val
Asn His 50 55 60
Thr Tyr Val Asn Ile Asn Asn Thr Asn Val Val Ala Gly Lys Asp Lys 65
70 75 80 Thr Ser Val Thr Leu
Ala Gly Asn Ser Ser Leu Cys Ser Ile Ser Gly 85
90 95 Trp Ala Ile Tyr Thr Lys Asp Asn Ser Ile
Arg Ile Gly Ser Lys Gly 100 105
110 Asp Val Phe Val Ile Arg Glu Pro Phe Ile Ser Cys Ser His Leu
Glu 115 120 125 Cys
Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp Lys His 130
135 140 Ser Asn Gly Thr Val Lys
Asp Arg Ser Pro Tyr Arg Ala Leu Met Ser 145 150
155 160 Cys Pro Leu Gly Glu Ala Pro Ser Pro Tyr Asn
Ser Lys Phe Glu Ser 165 170
175 Val Ala Trp Ser Ala Ser Ala Cys His Asp Gly Met Gly Trp Leu Thr
180 185 190 Ile Gly
Ile Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys Tyr 195
200 205 Asn Gly Ile Ile Thr Glu Thr
Ile Lys Ser Trp Lys Lys Arg Ile Leu 210 215
220 Arg Thr Gln Glu Ser Glu Cys Val Cys Val Asn Gly
Ser Cys Phe Thr 225 230 235
240 Ile Met Thr Asp Gly Pro Ser Asn Gly Ala Ala Ser Tyr Lys Ile Phe
245 250 255 Lys Ile Glu
Lys Gly Lys Val Thr Lys Ser Ile Glu Leu Asn Ala Pro 260
265 270 Asn Phe His Tyr Glu Glu Cys Ser
Cys Tyr Pro Asp Thr Gly Thr Val 275 280
285 Met Cys Val Cys Arg Asp Asn Trp His Gly Ser Asn Arg
Pro Trp Val 290 295 300
Ser Phe Asn Gln Asn Leu Asp Tyr Gln Ile Gly Tyr Ile Cys Ser Gly 305
310 315 320 Val Phe Gly Asp
Asn Pro Arg Pro Lys Asp Gly Glu Gly Ser Cys Asn 325
330 335 Pro Val Thr Val Asp Gly Ala Asp Gly
Val Lys Gly Phe Ser Tyr Lys 340 345
350 Tyr Gly Asn Gly Val Trp Ile Gly Arg Thr Lys Ser Asn Arg
Leu Arg 355 360 365
Lys Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr Asp Thr Asp 370
375 380 Ser Asp Phe Ser Val
Lys Gln Asp Val Val Ala Ile Thr Asp Trp Ser 385 390
395 400 Gly Tyr Ser Gly Ser Phe Val Gln His Pro
Glu Leu Thr Gly Leu Asp 405 410
415 Cys Ile Arg Pro Cys Phe Trp Val Glu Leu Val Arg Gly Leu Pro
Arg 420 425 430 Glu
Asn Thr Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys Gly 435
440 445 Val Asn Ser Asp Thr Ala
Asn Trp Ser Trp Pro Asp Gly Ala Glu Leu 450 455
460 Pro Phe Thr Ile Asp Lys 465
470 59716PRTInfluenza 59Met Glu Asp Phe Val Arg Gln Cys Phe Asn Pro Met
Ile Val Glu Leu 1 5 10
15 Ala Glu Lys Ala Met Lys Glu Tyr Gly Glu Asp Leu Lys Ile Glu Thr
20 25 30 Asn Lys Phe
Ala Ala Ile Cys Thr His Leu Glu Val Cys Phe Met Tyr 35
40 45 Ser Asp Phe His Phe Ile Asn Glu
Gln Gly Glu Ser Ile Val Val Glu 50 55
60 Leu Asp Asp Pro Asn Ala Leu Leu Lys His Arg Phe Glu
Ile Ile Glu 65 70 75
80 Gly Arg Asp Arg Thr Met Ala Trp Thr Val Val Asn Ser Ile Cys Asn
85 90 95 Thr Thr Gly Ala
Gly Lys Pro Lys Phe Leu Pro Asp Leu Tyr Asp Tyr 100
105 110 Lys Glu Asn Arg Phe Ile Glu Ile Gly
Val Thr Arg Arg Glu Val His 115 120
125 Ile Tyr Tyr Leu Glu Lys Ala Asn Lys Ile Lys Ser Glu Asn
Thr His 130 135 140
Ile His Ile Phe Ser Phe Thr Gly Glu Glu Met Ala Thr Lys Ala Asp 145
150 155 160 Tyr Thr Leu Asp Glu
Glu Ser Arg Ala Arg Ile Lys Thr Arg Leu Phe 165
170 175 Thr Ile Arg Gln Glu Met Ala Asn Arg Gly
Leu Trp Asp Ser Phe Arg 180 185
190 Gln Ser Glu Arg Gly Glu Glu Thr Ile Glu Glu Lys Phe Glu Ile
Thr 195 200 205 Gly
Thr Met Arg Arg Leu Ala Asp Gln Ser Leu Pro Pro Asn Phe Ser 210
215 220 Cys Leu Glu Asn Phe Arg
Ala Tyr Val Asp Gly Phe Glu Pro Asn Gly 225 230
235 240 Cys Ile Glu Gly Lys Leu Ser Gln Met Ser Lys
Glu Val Asn Ala Gln 245 250
255 Ile Glu Pro Phe Leu Lys Thr Thr Pro Arg Pro Ile Lys Leu Pro Asn
260 265 270 Gly Pro
Pro Cys Tyr Gln Arg Ser Lys Phe Leu Leu Met Asp Ala Leu 275
280 285 Lys Leu Ser Ile Glu Asp Pro
Ser His Glu Gly Glu Gly Ile Pro Leu 290 295
300 Tyr Asp Ala Ile Lys Cys Met Lys Thr Phe Phe Gly
Trp Lys Glu Pro 305 310 315
320 Tyr Ile Val Lys Pro His Glu Lys Gly Ile Asn Ser Asn Tyr Leu Leu
325 330 335 Ser Trp Lys
Gln Val Leu Ser Glu Leu Gln Asp Ile Glu Asn Glu Glu 340
345 350 Lys Ile Pro Arg Thr Lys Asn Met
Lys Lys Thr Ser Gln Leu Lys Trp 355 360
365 Ala Leu Gly Glu Asn Met Ala Pro Glu Lys Val Asp Phe
Glu Asn Cys 370 375 380
Arg Asp Ile Ser Asp Leu Lys Gln Tyr Asp Ser Asp Glu Pro Glu Leu 385
390 395 400 Arg Ser Leu Ser
Ser Trp Ile Gln Asn Glu Phe Asn Lys Ala Cys Glu 405
410 415 Leu Thr Asp Ser Val Trp Ile Glu Leu
Asp Glu Ile Gly Glu Asp Val 420 425
430 Ala Pro Ile Glu His Ile Ala Ser Met Arg Arg Asn Tyr Phe
Thr Ala 435 440 445
Glu Val Ser His Cys Arg Ala Thr Glu Tyr Ile Met Lys Gly Val Tyr 450
455 460 Ile Asn Thr Ala Leu
Leu Asn Ala Ser Cys Ala Ala Met Asp Asp Phe 465 470
475 480 Gln Leu Ile Pro Met Ile Ser Lys Cys Arg
Thr Lys Glu Gly Arg Arg 485 490
495 Lys Thr Asn Leu Tyr Gly Phe Ile Ile Lys Gly Arg Ser His Leu
Arg 500 505 510 Asn
Asp Thr Asp Val Val Asn Phe Val Ser Met Glu Phe Ser Leu Thr 515
520 525 Asp Pro Arg Leu Glu Pro
His Lys Trp Glu Lys Tyr Cys Val Leu Glu 530 535
540 Ile Gly Asp Met Leu Leu Arg Ser Ala Ile Gly
Gln Ile Ser Arg Pro 545 550 555
560 Met Phe Leu Tyr Val Arg Thr Asn Gly Thr Ser Lys Val Lys Met Lys
565 570 575 Trp Gly
Met Glu Met Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln Ile 580
585 590 Glu Ser Met Ile Glu Ala Glu
Ser Ser Val Lys Glu Lys Asp Met Thr 595 600
605 Lys Glu Phe Phe Glu Asn Lys Ser Glu Ala Trp Pro
Ile Gly Glu Ser 610 615 620
Pro Lys Gly Val Glu Glu Gly Ser Ile Gly Lys Val Cys Arg Thr Leu 625
630 635 640 Leu Ala Lys
Ser Val Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu 645
650 655 Gly Phe Ser Ala Glu Ser Arg Lys
Leu Leu Leu Val Val Gln Ala Leu 660 665
670 Arg Asp Asn Leu Glu Pro Gly Thr Phe Asp Leu Gly Gly
Leu Tyr Glu 675 680 685
Ala Ile Glu Glu Cys Leu Ile Asn Asp Pro Trp Val Leu Leu Asn Ala 690
695 700 Ser Trp Phe Asn
Ser Phe Leu Thr His Ala Leu Lys 705 710
715 60757PRTInfluenza 60Met Asp Val Asn Pro Thr Leu Leu Phe Leu Lys
Val Pro Ala Gln Asn 1 5 10
15 Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Asp Pro Pro Tyr Ser His
20 25 30 Gly Thr
Gly Thr Gly Tyr Thr Met Asp Thr Val Asn Arg Thr His Gln 35
40 45 Tyr Ser Glu Lys Gly Lys Trp
Thr Thr Asn Thr Glu Thr Gly Ala Pro 50 55
60 Gln Leu Asn Pro Ile Asp Gly Pro Leu Pro Glu Asp
Asn Glu Pro Ser 65 70 75
80 Gly Tyr Ala Gln Thr Asp Cys Val Leu Glu Ala Met Ala Phe Leu Glu
85 90 95 Glu Ser His
Pro Gly Ile Phe Glu Asn Ser Cys Leu Glu Thr Met Glu 100
105 110 Ala Val Gln Gln Thr Arg Val Asp
Arg Leu Thr Gln Gly Arg Gln Thr 115 120
125 Tyr Asp Trp Thr Leu Asn Arg Asn Gln Pro Ala Ala Thr
Ala Leu Ala 130 135 140
Asn Thr Ile Glu Val Phe Arg Ser Asn Gly Leu Thr Ala Asn Glu Ser 145
150 155 160 Gly Arg Leu Ile
Asp Phe Leu Lys Asp Val Met Glu Ser Met Asp Lys 165
170 175 Glu Glu Met Glu Ile Thr Thr His Phe
Gln Arg Lys Arg Arg Val Arg 180 185
190 Asp Asn Met Thr Lys Lys Met Val Thr Gln Arg Thr Ile Gly
Lys Lys 195 200 205
Lys Gln Arg Val Asn Lys Arg Gly Tyr Leu Ile Arg Ala Leu Thr Leu 210
215 220 Asn Thr Met Thr Lys
Asp Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225 230
235 240 Ile Ala Thr Pro Gly Met Gln Ile Arg Gly
Phe Val Tyr Phe Val Glu 245 250
255 Thr Leu Ala Arg Ser Ile Cys Glu Lys Leu Glu Gln Ser Gly Leu
Pro 260 265 270 Val
Gly Gly Asn Glu Lys Lys Ala Lys Leu Ala Asn Val Val Arg Lys 275
280 285 Met Met Thr Asn Ser Gln
Asp Thr Glu Leu Ser Phe Thr Ile Thr Gly 290 295
300 Asp Asn Thr Lys Trp Asn Glu Asn Gln Asn Pro
Arg Met Phe Leu Ala 305 310 315
320 Met Ile Thr Tyr Ile Thr Lys Asn Gln Pro Glu Trp Phe Arg Asn Ile
325 330 335 Leu Ser
Ile Ala Pro Ile Met Phe Ser Asn Lys Met Ala Arg Leu Gly 340
345 350 Lys Gly Tyr Met Phe Glu Ser
Lys Arg Met Lys Leu Arg Thr Gln Ile 355 360
365 Pro Ala Glu Met Leu Ala Ser Ile Asp Leu Lys Tyr
Phe Asn Glu Ser 370 375 380
Thr Arg Lys Lys Ile Glu Lys Ile Arg Pro Leu Leu Ile Asp Gly Thr 385
390 395 400 Ala Ser Leu
Ser Pro Gly Met Met Met Gly Met Phe Asn Met Leu Ser 405
410 415 Thr Val Leu Gly Val Ser Ile Leu
Asn Leu Gly Gln Lys Lys Tyr Thr 420 425
430 Lys Thr Thr Tyr Trp Trp Asp Gly Leu Gln Ser Ser Asp
Asp Phe Ala 435 440 445
Leu Ile Val Asn Ala Pro Asn His Glu Gly Ile Gln Ala Gly Val Asn 450
455 460 Arg Phe Tyr Arg
Thr Cys Lys Leu Val Gly Ile Asn Met Ser Lys Lys 465 470
475 480 Lys Ser Tyr Ile Asn Lys Thr Gly Thr
Phe Glu Phe Thr Ser Phe Phe 485 490
495 Tyr Arg Tyr Gly Phe Val Ala Asn Phe Ser Met Glu Leu Pro
Ser Phe 500 505 510
Gly Val Ser Gly Ile Asn Glu Ser Ala Asp Met Ser Ile Gly Val Thr
515 520 525 Val Ile Lys Asn
Asn Met Ile Asn Asn Asp Leu Gly Pro Ala Thr Ala 530
535 540 Gln Met Ala Leu Gln Leu Phe Ile
Lys Asp Tyr Arg Tyr Thr Tyr Arg 545 550
555 560 Cys His Arg Gly Asp Thr Gln Ile Gln Thr Arg Arg
Ser Phe Glu Leu 565 570
575 Lys Lys Leu Trp Asp Gln Thr Gln Ser Arg Ala Gly Leu Leu Val Ser
580 585 590 Asp Gly Gly
Pro Asn Leu Tyr Asn Ile Arg Asn Leu His Ile Pro Glu 595
600 605 Val Cys Leu Lys Trp Glu Leu Met
Asp Glu Asn Tyr Arg Gly Arg Leu 610 615
620 Cys Asn Pro Leu Asn Pro Phe Val Ser His Lys Glu Ile
Glu Ser Val 625 630 635
640 Asn Asn Ala Val Val Met Pro Ala His Gly Pro Ala Lys Ser Met Glu
645 650 655 Tyr Asp Ala Val
Ala Thr Thr His Ser Trp Ile Pro Lys Arg Asn Arg 660
665 670 Ser Ile Leu Asn Thr Ser Gln Arg Gly
Ile Leu Glu Asp Glu Gln Met 675 680
685 Tyr Gln Lys Cys Cys Asn Leu Phe Glu Lys Phe Phe Pro Ser
Ser Ser 690 695 700
Tyr Arg Arg Pro Ile Gly Ile Ser Ser Met Val Glu Ala Met Val Ser 705
710 715 720 Arg Ala Arg Ile Asp
Ala Arg Ile Asp Phe Glu Ser Gly Arg Ile Lys 725
730 735 Lys Glu Glu Phe Ser Glu Ile Met Lys Ile
Cys Ser Thr Ile Glu Glu 740 745
750 Leu Arg Arg Gln Arg 755 61759PRTInfluenza
61Met Glu Arg Ile Lys Glu Leu Arg Asn Leu Met Ser Gln Ser Arg Thr 1
5 10 15 Arg Glu Ile Leu
Thr Lys Thr Thr Val Asp His Met Ala Ile Ile Lys 20
25 30 Lys Tyr Thr Ser Gly Arg Gln Glu Lys
Asn Pro Ser Leu Arg Met Lys 35 40
45 Trp Met Met Ala Met Lys Tyr Pro Ile Thr Ala Asp Lys Arg
Ile Thr 50 55 60
Glu Met Val Pro Glu Arg Asn Glu Gln Gly Gln Thr Leu Trp Ser Lys 65
70 75 80 Met Ser Asp Ala Gly
Ser Asp Arg Val Met Val Ser Pro Leu Ala Val 85
90 95 Thr Trp Trp Asn Arg Asn Gly Pro Val Thr
Ser Thr Val His Tyr Pro 100 105
110 Lys Val Tyr Lys Thr Tyr Phe Asp Lys Val Glu Arg Leu Lys His
Gly 115 120 125 Thr
Phe Gly Pro Val His Phe Arg Asn Gln Val Lys Ile Arg Arg Arg 130
135 140 Val Asp Ile Asn Pro Gly
His Ala Asp Leu Ser Ala Lys Glu Ala Gln 145 150
155 160 Asp Val Ile Met Glu Val Val Phe Pro Asn Glu
Val Gly Ala Arg Ile 165 170
175 Leu Thr Ser Glu Ser Gln Leu Thr Ile Thr Lys Glu Lys Lys Glu Glu
180 185 190 Leu Arg
Asp Cys Lys Ile Ser Pro Leu Met Val Ala Tyr Met Leu Glu 195
200 205 Arg Glu Leu Val Arg Lys Thr
Arg Phe Leu Pro Val Ala Gly Gly Thr 210 215
220 Ser Ser Ile Tyr Ile Glu Val Leu His Leu Thr Gln
Gly Thr Cys Trp 225 230 235
240 Glu Gln Met Tyr Thr Pro Gly Gly Glu Val Arg Asn Asp Asp Val Asp
245 250 255 Gln Ser Leu
Ile Ile Ala Ala Arg Asn Ile Val Arg Arg Ala Ala Val 260
265 270 Ser Ala Asp Pro Leu Ala Ser Leu
Leu Glu Met Cys His Ser Thr Gln 275 280
285 Ile Gly Gly Thr Arg Met Val Asp Ile Leu Arg Gln Asn
Pro Thr Glu 290 295 300
Glu Gln Ala Val Asp Ile Cys Lys Ala Ala Met Gly Leu Arg Ile Ser 305
310 315 320 Ser Ser Phe Ser
Phe Gly Gly Phe Thr Phe Lys Arg Thr Ser Gly Ser 325
330 335 Ser Val Lys Lys Glu Glu Glu Val Leu
Thr Gly Asn Leu Gln Thr Leu 340 345
350 Lys Ile Arg Val His Glu Gly Tyr Glu Glu Phe Thr Met Val
Gly Lys 355 360 365
Arg Ala Thr Ala Ile Leu Arg Lys Ala Thr Arg Arg Leu Val Gln Leu 370
375 380 Ile Val Ser Gly Arg
Asp Glu Gln Ser Ile Ala Glu Ala Ile Ile Val 385 390
395 400 Ala Met Val Phe Ser Gln Glu Asp Cys Met
Ile Lys Ala Val Arg Gly 405 410
415 Asp Leu Asn Phe Val Asn Arg Ala Asn Gln Arg Leu Asn Pro Met
His 420 425 430 Gln
Leu Leu Arg His Phe Gln Lys Asp Ala Lys Val Leu Phe Gln Asn 435
440 445 Trp Gly Ile Glu His Ile
Asp Ser Val Met Gly Met Val Gly Val Leu 450 455
460 Pro Asp Met Thr Pro Ser Thr Glu Met Ser Met
Arg Gly Ile Arg Val 465 470 475
480 Ser Lys Met Gly Val Asp Glu Tyr Ser Ser Thr Glu Arg Val Val Val
485 490 495 Ser Ile
Asp Arg Phe Leu Arg Val Arg Asp Gln Arg Gly Asn Val Leu 500
505 510 Leu Ser Pro Glu Glu Val Ser
Glu Thr Gln Gly Thr Glu Arg Leu Thr 515 520
525 Ile Thr Tyr Ser Ser Ser Met Met Trp Glu Ile Asn
Gly Pro Glu Ser 530 535 540
Val Leu Val Asn Thr Tyr Gln Trp Ile Ile Arg Asn Trp Glu Ala Val 545
550 555 560 Lys Ile Gln
Trp Ser Gln Asn Pro Ala Met Leu Tyr Asn Lys Met Glu 565
570 575 Phe Glu Pro Phe Gln Ser Leu Val
Pro Lys Ala Ile Arg Ser Gln Tyr 580 585
590 Ser Gly Phe Val Arg Thr Leu Phe Gln Gln Met Arg Asp
Val Leu Gly 595 600 605
Thr Phe Asp Thr Thr Gln Ile Ile Lys Leu Leu Pro Phe Ala Ala Ala 610
615 620 Pro Pro Lys Gln
Ser Arg Met Gln Phe Ser Ser Leu Thr Val Asn Val 625 630
635 640 Arg Gly Ser Gly Met Arg Ile Leu Val
Arg Gly Asn Ser Pro Val Phe 645 650
655 Asn Tyr Asn Lys Thr Thr Lys Arg Leu Thr Ile Leu Gly Lys
Asp Ala 660 665 670
Gly Thr Leu Ile Glu Asp Pro Asp Glu Ser Thr Ser Gly Val Glu Ser
675 680 685 Ala Val Leu Arg
Gly Phe Leu Ile Ile Gly Lys Glu Asp Arg Arg Tyr 690
695 700 Gly Pro Ala Leu Ser Ile Asn Glu
Leu Ser Asn Leu Ala Lys Gly Glu 705 710
715 720 Lys Ala Asn Val Leu Ile Gly Gln Gly Asp Val Val
Leu Val Met Lys 725 730
735 Arg Lys Arg Asp Ser Ser Ile Leu Thr Asp Ser Gln Thr Ala Thr Lys
740 745 750 Arg Ile Arg
Met Ala Ile Asn 755 62498PRTInfluenza 62Met Ala
Ser Gln Gly Thr Lys Arg Ser Tyr Glu Gln Met Glu Thr Asp 1 5
10 15 Gly Asp Arg Gln Asn Ala Thr
Glu Ile Arg Ala Ser Val Gly Lys Met 20 25
30 Ile Asp Gly Ile Gly Arg Phe Tyr Ile Gln Met Cys
Thr Glu Leu Lys 35 40 45
Leu Ser Asp Tyr Glu Gly Arg Leu Ile Gln Asn Ser Leu Thr Ile Glu
50 55 60 Lys Met Val
Leu Ser Ala Phe Asp Glu Arg Arg Asn Lys Tyr Leu Glu 65
70 75 80 Glu His Pro Ser Ala Gly Lys
Asp Pro Lys Lys Thr Gly Gly Pro Ile 85
90 95 Tyr Arg Arg Val Asp Gly Lys Trp Met Arg Glu
Leu Val Leu Tyr Asp 100 105
110 Lys Glu Glu Ile Arg Arg Ile Trp Arg Gln Ala Asn Asn Gly Glu
Asp 115 120 125 Ala
Thr Ala Gly Leu Thr His Ile Met Ile Trp His Ser Asn Leu Asn 130
135 140 Asp Ala Thr Tyr Gln Arg
Thr Arg Ala Leu Val Arg Thr Gly Met Asp 145 150
155 160 Pro Arg Met Cys Ser Leu Met Gln Gly Ser Thr
Leu Pro Arg Arg Ser 165 170
175 Gly Ala Ala Gly Ala Ala Val Lys Gly Ile Gly Thr Met Val Met Glu
180 185 190 Leu Ile
Arg Met Val Lys Arg Gly Ile Asn Asp Arg Asn Phe Trp Arg 195
200 205 Gly Glu Asn Gly Arg Lys Thr
Arg Ser Ala Tyr Glu Arg Met Cys Asn 210 215
220 Ile Leu Lys Gly Lys Phe Gln Thr Ala Ala Gln Arg
Ala Met Val Asp 225 230 235
240 Gln Val Arg Glu Ser Arg Asn Pro Gly Asn Ala Glu Ile Glu Asp Leu
245 250 255 Ile Phe Leu
Ala Arg Ser Ala Leu Ile Leu Arg Gly Ser Val Ala His 260
265 270 Lys Ser Cys Leu Pro Ala Cys Val
Tyr Gly Pro Ala Val Ser Ser Gly 275 280
285 Tyr Asn Phe Glu Lys Glu Gly Tyr Ser Leu Val Gly Ile
Asp Pro Phe 290 295 300
Lys Leu Leu Gln Asn Ser Gln Val Tyr Ser Leu Ile Arg Pro Asn Glu 305
310 315 320 Asn Pro Ala His
Lys Ser Gln Leu Val Trp Met Ala Cys His Ser Ala 325
330 335 Ala Phe Glu Asp Leu Arg Leu Leu Ser
Phe Ile Arg Gly Thr Lys Val 340 345
350 Ser Pro Arg Gly Lys Leu Ser Thr Arg Gly Val Gln Ile Ala
Ser Asn 355 360 365
Glu Asn Met Asp Asn Met Gly Ser Gly Thr Leu Glu Leu Arg Ser Gly 370
375 380 Tyr Trp Ala Ile Arg
Thr Arg Ser Gly Gly Asn Thr Asn Gln Gln Arg 385 390
395 400 Ala Ser Ala Gly Gln Thr Ser Val Gln Pro
Thr Phe Ser Val Gln Arg 405 410
415 Asn Leu Pro Phe Glu Lys Ser Thr Ile Met Ala Ala Phe Thr Gly
Asn 420 425 430 Thr
Glu Gly Arg Thr Ser Asp Met Arg Ala Glu Ile Ile Arg Met Met 435
440 445 Glu Gly Ala Lys Pro Glu
Glu Val Ser Phe Arg Gly Arg Gly Val Phe 450 455
460 Glu Leu Ser Asp Glu Lys Ala Thr Asn Pro Ile
Val Pro Ser Phe Asp 465 470 475
480 Met Ser Asn Glu Gly Ser Tyr Phe Phe Gly Asp Asn Ala Glu Glu Tyr
485 490 495 Asp Asn
63252PRTInfluenza 63Met Ser Leu Leu Thr Glu Val Glu Thr Tyr Val Leu Ser
Ile Val Pro 1 5 10 15
Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg Leu Glu Asp Val Phe
20 25 30 Ala Gly Lys Asn
Thr Asp Leu Glu Ala Leu Met Glu Trp Leu Lys Thr 35
40 45 Arg Pro Ile Leu Ser Pro Leu Thr Lys
Gly Ile Leu Gly Phe Val Phe 50 55
60 Thr Leu Thr Val Pro Ser Glu Arg Gly Leu Gln Arg Arg
Arg Phe Val 65 70 75
80 Gln Asn Ala Leu Asn Gly Asn Gly Asp Pro Asn Asn Met Asp Lys Ala
85 90 95 Val Lys Leu Tyr
Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly Ala 100
105 110 Lys Glu Ile Ala Leu Ser Tyr Ser Ala
Gly Ala Leu Ala Ser Cys Met 115 120
125 Gly Leu Ile Tyr Asn Arg Met Gly Ala Val Thr Thr Glu Val
Ala Phe 130 135 140
Gly Leu Val Cys Ala Thr Cys Glu Gln Ile Ala Asp Ser Gln His Arg 145
150 155 160 Ser His Arg Gln Met
Val Ala Thr Thr Asn Pro Leu Ile Arg His Glu 165
170 175 Asn Arg Met Val Leu Ala Ser Thr Thr Ala
Lys Ala Met Glu Gln Met 180 185
190 Ala Gly Ser Ser Glu Gln Ala Ala Glu Ala Met Glu Ile Ala Ser
Gln 195 200 205 Ala
Arg Gln Met Val Gln Ala Met Arg Ala Ile Gly Thr His Pro Ser 210
215 220 Ser Ser Thr Gly Leu Arg
Asp Asp Leu Leu Glu Asn Leu Gln Thr Tyr 225 230
235 240 Gln Lys Arg Met Gly Val Gln Met Gln Arg Phe
Lys 245 250 6497PRTInfluenza
64Met Ser Leu Leu Thr Glu Val Glu Thr Pro Ile Arg Asn Glu Trp Gly 1
5 10 15 Cys Arg Cys Asn
Asp Ser Ser Asp Pro Leu Val Val Ala Ala Asn Ile 20
25 30 Ile Gly Ile Leu His Leu Ile Leu Trp
Ile Leu Asp Arg Leu Phe Phe 35 40
45 Lys Cys Val Tyr Arg Leu Phe Lys His Gly Leu Lys Arg Gly
Pro Ser 50 55 60
Thr Glu Gly Val Pro Glu Ser Met Arg Glu Glu Tyr Arg Lys Glu Gln 65
70 75 80 Gln Asn Ala Val Asp
Ala Asp Asp Ser His Phe Val Ser Ile Glu Leu 85
90 95 Glu 65846DNAInfluenza 65aatggattcc
aacactgtgt caagtttcca ggtagattgc tttctttggc atatccggaa 60acaagttgta
gaccaagaac tgagtgatgc cccattcctt gatcggcttc gccgagatca 120gaggtcccta
aggggaagag gcaatactct cggtctagac atcaaagcag ccacccatgt 180tggaaagcaa
attgtagaaa agattctgaa agaagaatct gatgaggcac ttaaaatgac 240catggtctcc
acacctgctt cgcgatacat aactgacatg actattgagg aattgtcaag 300aaactggttc
atgctaatgc ccaagcagaa agtggaagga cctctttgca tcagaatgga 360ccaggcaatc
atggagaaaa acatcatgtt gaaagcgaat ttcagtgtga tttctgaccg 420actagagacc
atagtattac taagggcttt caccgaagag ggagcaattg ttggcgaaat 480ctcaccattg
ccttcttttc caggacatac tattgaggat gtcaaaaatg caattggggt 540cctcatcgga
ggacttgaat ggaatgataa cacagttcga gtctctaaaa atctacagag 600attcgcttgg
agaagcagta atgagaatgg gggacctcca cttactccaa aacagaaacg 660gaaaatggcg
agaacagcta ggtcaaaagt ttgaagagat aagatggctg attgaagaag 720tgagacacag
actaaaaaca actgaaaata gctttgaaca aataacattc atgcaagcat 780tacaactgct
gtttgaagtg gaacaggaga taagaacttt ctcatttcag cttatttaat 840gataaa
84666566PRTInfluenza 66Met Lys Thr Ile Ile Ala Leu Ser Tyr Ile Leu Cys
Leu Val Phe Ala 1 5 10
15 Gln Lys Leu Pro Gly Asn Asp Asn Ser Thr Ala Thr Leu Cys Leu Gly
20 25 30 His His Ala
Val Pro Asn Gly Thr Ile Val Lys Thr Ile Thr Asn Asp 35
40 45 Gln Ile Glu Val Thr Asn Ala Thr
Glu Leu Val Gln Ser Ser Ser Thr 50 55
60 Gly Gly Ile Cys Asp Ser Pro His Gln Ile Leu Asp Gly
Glu Asn Cys 65 70 75
80 Thr Leu Ile Asp Ala Leu Leu Gly Asp Pro Gln Cys Asp Gly Phe Gln
85 90 95 Asn Lys Lys Trp
Asp Leu Phe Val Glu Arg Ser Lys Ala Tyr Ser Asn 100
105 110 Cys Tyr Pro Tyr Asp Val Pro Asp Tyr
Ala Ser Leu Arg Ser Leu Val 115 120
125 Ala Ser Ser Gly Thr Leu Glu Phe Asn Asp Glu Ser Phe Asn
Trp Thr 130 135 140
Gly Val Thr Gln Asn Gly Thr Ser Ser Ser Cys Lys Arg Arg Ser Asn 145
150 155 160 Asn Ser Phe Phe Ser
Arg Leu Asn Trp Leu Thr His Leu Lys Phe Lys 165
170 175 Tyr Pro Ala Leu Asn Val Thr Met Pro Asn
Asn Glu Lys Phe Asp Lys 180 185
190 Leu Tyr Ile Trp Gly Val His His Pro Val Thr Asp Asn Asp Gln
Ile 195 200 205 Phe
Leu Tyr Ala Gln Ala Ser Gly Arg Ile Thr Val Ser Thr Lys Arg 210
215 220 Ser Gln Gln Thr Val Ile
Pro Asn Ile Gly Ser Arg Pro Arg Ile Arg 225 230
235 240 Asn Ile Pro Ser Arg Ile Ser Ile Tyr Trp Thr
Ile Val Lys Pro Gly 245 250
255 Asp Ile Leu Leu Ile Asn Ser Thr Gly Asn Leu Ile Ala Pro Arg Gly
260 265 270 Tyr Phe
Lys Ile Arg Ser Gly Lys Ser Ser Ile Met Arg Ser Asp Ala 275
280 285 Pro Ile Gly Lys Cys Asn Ser
Glu Cys Ile Thr Pro Asn Gly Ser Ile 290 295
300 Pro Asn Asp Lys Pro Phe Gln Asn Val Asn Arg Ile
Thr Tyr Gly Ala 305 310 315
320 Cys Pro Arg Tyr Val Lys Gln Asn Thr Leu Lys Leu Ala Thr Gly Met
325 330 335 Arg Asn Val
Pro Glu Lys Gln Thr Arg Gly Ile Phe Gly Ala Ile Ala 340
345 350 Gly Phe Ile Glu Asn Gly Trp Glu
Gly Met Val Asp Gly Trp Tyr Gly 355 360
365 Phe Arg His Gln Asn Ser Glu Gly Ile Gly Gln Ala Ala
Asp Leu Lys 370 375 380
Ser Thr Gln Ala Ala Ile Asn Gln Ile Asn Gly Lys Leu Asn Arg Leu 385
390 395 400 Ile Gly Lys Thr
Asn Glu Lys Phe His Gln Ile Glu Lys Glu Phe Ser 405
410 415 Glu Val Glu Gly Arg Ile Gln Asp Leu
Glu Lys Tyr Val Glu Asp Thr 420 425
430 Lys Ile Asp Leu Trp Ser Tyr Asn Ala Glu Leu Leu Val Ala
Leu Glu 435 440 445
Asn Gln His Thr Ile Asp Leu Thr Asp Ser Glu Met Asn Lys Leu Phe 450
455 460 Glu Arg Thr Lys Lys
Gln Leu Arg Glu Asn Ala Glu Asp Met Gly Asn 465 470
475 480 Gly Cys Phe Lys Ile Tyr His Lys Cys Asp
Asn Ala Cys Ile Gly Ser 485 490
495 Ile Arg Asn Gly Thr Tyr Asp His Asp Val Tyr Arg Asp Glu Ala
Leu 500 505 510 Asn
Asn Arg Phe Gln Ile Lys Gly Val Glu Leu Lys Ser Gly Tyr Lys 515
520 525 Asp Trp Ile Leu Trp Ile
Ser Phe Ala Ile Ser Cys Phe Leu Leu Cys 530 535
540 Val Ala Leu Leu Gly Phe Ile Met Trp Ala Cys
Gln Lys Gly Asn Ile 545 550 555
560 Arg Cys Asn Ile Cys Ile 565
67469PRTInfluenza 67Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val
Ser Leu Thr 1 5 10 15
Ile Ser Thr Ile Cys Phe Phe Met Gln Ile Ala Ile Leu Ile Thr Thr
20 25 30 Val Thr Leu His
Phe Lys Gln Tyr Glu Phe Asn Ser Pro Pro Asn Asn 35
40 45 Gln Val Met Leu Cys Glu Pro Thr Ile
Ile Glu Arg Asn Ile Thr Glu 50 55
60 Ile Val Tyr Leu Thr Asn Thr Thr Ile Glu Lys Glu Ile
Cys Pro Lys 65 70 75
80 Leu Ala Glu Tyr Arg Asn Trp Ser Lys Pro Gln Cys Asn Ile Thr Gly
85 90 95 Phe Ala Pro Phe
Ser Lys Asp Asn Ser Ile Arg Leu Ser Ala Gly Gly 100
105 110 Asp Ile Trp Val Thr Arg Glu Pro Tyr
Val Ser Cys Asp Pro Asp Lys 115 120
125 Cys Tyr Gln Phe Ala Leu Gly Gln Gly Thr Thr Leu Asn Asn
Val His 130 135 140
Ser Asn Asp Thr Val His Asp Arg Thr Pro Tyr Arg Thr Leu Leu Met 145
150 155 160 Asn Glu Leu Gly Val
Pro Phe His Leu Gly Thr Lys Gln Val Cys Ile 165
170 175 Ala Trp Ser Ser Ser Ser Cys His Asp Gly
Lys Ala Trp Leu His Val 180 185
190 Cys Val Thr Gly Asp Asp Lys Asn Ala Thr Ala Ser Phe Ile Tyr
Asn 195 200 205 Gly
Arg Leu Val Asp Ser Ile Val Ser Trp Ser Lys Glu Ile Leu Arg 210
215 220 Thr Gln Glu Ser Glu Cys
Val Cys Ile Asn Gly Thr Cys Thr Val Val 225 230
235 240 Met Thr Asp Gly Ser Ala Ser Gly Lys Ala Asp
Thr Lys Ile Leu Phe 245 250
255 Ile Glu Glu Gly Lys Ile Val His Thr Ser Thr Leu Ser Gly Ser Ala
260 265 270 Gln His
Val Glu Glu Cys Ser Cys Tyr Pro Arg Tyr Leu Gly Val Arg 275
280 285 Cys Val Cys Arg Asp Asn Trp
Lys Gly Ser Asn Arg Pro Ile Val Asp 290 295
300 Ile Asn Ile Lys Asp Tyr Ser Ile Val Ser Ser Tyr
Val Cys Ser Gly 305 310 315
320 Leu Val Gly Asp Thr Pro Arg Lys Asn Asp Ser Ser Ser Ser Ser His
325 330 335 Cys Leu Asp
Pro Asn Asn Glu Glu Gly Gly His Gly Val Lys Gly Trp 340
345 350 Ala Phe Asp Asp Gly Asn Asp Val
Trp Met Gly Arg Thr Ile Ser Glu 355 360
365 Lys Leu Arg Ser Gly Tyr Glu Thr Phe Lys Val Ile Glu
Gly Trp Ser 370 375 380
Asn Pro Asn Ser Lys Leu Gln Ile Asn Arg Gln Val Ile Val Asp Arg 385
390 395 400 Gly Asn Arg Ser
Gly Tyr Ser Gly Ile Phe Ser Val Glu Gly Lys Ser 405
410 415 Cys Ile Asn Arg Cys Phe Tyr Val Glu
Leu Ile Arg Gly Arg Lys Glu 420 425
430 Glu Thr Glu Val Leu Trp Thr Ser Asn Ser Ile Val Val Phe
Cys Gly 435 440 445
Thr Ser Gly Thr Tyr Gly Thr Gly Ser Trp Pro Asp Gly Ala Asp Ile 450
455 460 Asn Leu Met Pro Ile
465 68716PRTInfluenza 68Met Glu Asp Phe Val Arg Gln Cys
Phe Asn Pro Met Ile Val Glu Leu 1 5 10
15 Ala Glu Lys Ala Met Lys Glu Tyr Gly Glu Asp Pro Lys
Ile Glu Thr 20 25 30
Asn Lys Phe Ala Ala Ile Cys Thr His Leu Glu Val Cys Phe Met Tyr
35 40 45 Ser Asp Phe His
Phe Ile Asp Glu Arg Gly Glu Ser Ile Ile Val Glu 50
55 60 Ser Gly Asp Pro Asn Ala Leu Leu
Lys His Arg Phe Glu Ile Ile Glu 65 70
75 80 Gly Arg Asp Arg Ile Met Ala Trp Thr Val Ile Asn
Ser Ile Cys Asn 85 90
95 Thr Thr Gly Val Glu Lys Pro Lys Phe Leu Pro Asp Leu Tyr Asp Tyr
100 105 110 Lys Glu Asn
Arg Phe Ile Glu Ile Gly Val Thr Arg Arg Glu Val His 115
120 125 Ile Tyr Tyr Leu Glu Lys Ala Asn
Lys Ile Lys Ser Glu Lys Thr His 130 135
140 Ile His Ile Phe Ser Phe Thr Gly Glu Glu Met Ala Thr
Lys Ala Asp 145 150 155
160 Tyr Thr Leu Asp Glu Glu Ser Arg Ala Arg Ile Lys Thr Arg Leu Phe
165 170 175 Thr Ile Arg Gln
Glu Met Ala Ser Lys Ser Leu Trp Asp Ser Phe Arg 180
185 190 Gln Ser Glu Arg Gly Glu Glu Thr Ile
Glu Glu Lys Phe Glu Ile Thr 195 200
205 Gly Thr Met Arg Lys Leu Ala Asp Gln Ser Leu Pro Pro Asn
Phe Pro 210 215 220
Ser Leu Glu Asn Phe Arg Ala Tyr Val Asp Gly Phe Glu Pro Asn Gly 225
230 235 240 Cys Ile Glu Gly Lys
Leu Ser Gln Met Ser Lys Glu Val Asn Ala Lys 245
250 255 Ile Glu Pro Phe Leu Arg Thr Thr Pro Arg
Pro Leu Arg Leu Pro Asp 260 265
270 Gly Pro Leu Cys His Gln Arg Ser Lys Phe Leu Leu Met Asp Ala
Leu 275 280 285 Lys
Leu Ser Ile Glu Asp Pro Ser His Glu Gly Glu Gly Ile Pro Leu 290
295 300 Tyr Asp Ala Ile Lys Cys
Met Lys Thr Phe Phe Gly Trp Lys Glu Pro 305 310
315 320 Asn Ile Val Lys Pro His Glu Lys Gly Ile Asn
Pro Asn Tyr Leu Met 325 330
335 Ala Trp Lys Gln Val Leu Ala Glu Leu Gln Asp Ile Glu Asn Glu Glu
340 345 350 Lys Ile
Pro Arg Thr Lys Asn Met Lys Arg Thr Ser Gln Leu Lys Trp 355
360 365 Ala Leu Gly Glu Asn Met Ala
Pro Glu Lys Val Asp Phe Asp Asp Cys 370 375
380 Lys Asp Val Gly Asp Leu Lys Gln Tyr Asp Ser Asp
Glu Pro Glu Pro 385 390 395
400 Arg Ser Leu Ala Ser Trp Val Gln Asn Glu Phe Asn Lys Ala Cys Glu
405 410 415 Leu Thr Asp
Ser Ser Trp Ile Glu Leu Asp Glu Ile Gly Glu Asp Val 420
425 430 Ala Pro Ile Glu His Ile Ala Ser
Met Arg Arg Asn Tyr Phe Thr Ala 435 440
445 Glu Val Ser His Cys Arg Ala Thr Glu Tyr Ile Met Lys
Gly Val Tyr 450 455 460
Ile Asn Thr Ala Leu Leu Asn Ala Ser Cys Ala Ala Met Asp Asp Phe 465
470 475 480 Gln Leu Ile Pro
Met Ile Ser Lys Cys Arg Thr Lys Glu Gly Arg Arg 485
490 495 Lys Thr Asn Leu Tyr Gly Phe Ile Ile
Lys Gly Arg Ser His Leu Arg 500 505
510 Asn Asp Thr Asp Val Val Asn Phe Val Ser Met Glu Phe Ser
Leu Thr 515 520 525
Asp Pro Arg Leu Glu Pro His Lys Trp Glu Lys Tyr Cys Val Leu Glu 530
535 540 Ile Gly Asp Met Leu
Leu Arg Thr Ala Ile Gly Gln Val Ser Arg Pro 545 550
555 560 Met Phe Leu Tyr Val Arg Thr Asn Gly Thr
Ser Lys Ile Lys Met Lys 565 570
575 Trp Gly Met Glu Met Arg Arg Cys Leu Leu Gln Ser Leu Gln Gln
Ile 580 585 590 Glu
Ser Met Ile Glu Ala Glu Ser Ser Val Lys Glu Lys Asp Met Thr 595
600 605 Lys Glu Phe Phe Glu Asn
Lys Ser Glu Thr Trp Pro Ile Gly Glu Ser 610 615
620 Pro Arg Gly Val Glu Glu Gly Ser Ile Gly Lys
Val Cys Arg Thr Leu 625 630 635
640 Leu Ala Lys Ser Val Phe Asn Ser Leu Tyr Ala Ser Pro Gln Leu Glu
645 650 655 Gly Phe
Ser Ala Glu Ser Arg Lys Leu Leu Leu Ile Val Gln Ala Leu 660
665 670 Arg Asp Asn Leu Glu Pro Gly
Thr Phe Asp Leu Gly Gly Leu Tyr Glu 675 680
685 Ala Ile Glu Glu Cys Leu Ile Asn Asp Pro Trp Val
Leu Leu Asn Ala 690 695 700
Ser Trp Phe Asn Ser Phe Leu Thr His Ala Leu Lys 705
710 715 69252PRTInfluenza 69Met Ser Leu Leu Thr Glu
Val Glu Thr Tyr Val Leu Ser Ile Val Pro 1 5
10 15 Ser Gly Pro Leu Lys Ala Glu Ile Ala Gln Arg
Leu Glu Asn Val Phe 20 25
30 Ala Gly Lys Asn Thr Asp Leu Glu Ala Leu Met Glu Trp Leu Lys
Thr 35 40 45 Arg
Pro Ile Leu Ser Pro Leu Thr Lys Gly Ile Leu Gly Phe Val Phe 50
55 60 Thr Leu Thr Val Pro Ser
Glu Arg Gly Leu Gln Arg Arg Arg Phe Val 65 70
75 80 Gln Asn Ala Leu Asn Gly Asn Gly Asp Pro Asn
Asn Met Asp Lys Ala 85 90
95 Val Lys Leu Tyr Arg Lys Leu Lys Arg Glu Ile Thr Phe His Gly Ala
100 105 110 Lys Glu
Ile Ala Leu Ser Tyr Ser Ala Gly Ala Leu Ala Ser Cys Met 115
120 125 Gly Leu Ile Tyr Asn Arg Met
Gly Ala Val Thr Thr Glu Ser Ala Phe 130 135
140 Gly Leu Ile Cys Ala Thr Cys Glu Gln Ile Ala Asp
Ser Gln His Lys 145 150 155
160 Ser His Arg Gln Met Val Thr Thr Thr Asn Pro Leu Ile Arg His Glu
165 170 175 Asn Arg Met
Val Leu Ala Ser Thr Thr Ala Lys Ala Met Glu Gln Met 180
185 190 Ala Gly Ser Ser Glu Gln Ala Ala
Glu Ala Met Glu Val Ala Ser Gln 195 200
205 Ala Arg Gln Met Val Gln Ala Met Arg Ala Ile Gly Thr
His Pro Ser 210 215 220
Ser Ser Thr Gly Leu Lys Asn Asp Leu Leu Glu Asn Leu Gln Ala Tyr 225
230 235 240 Gln Lys Arg Met
Gly Val Gln Met Gln Arg Phe Lys 245 250
70566PRTInfluenza 70Met Lys Ala Ile Leu Val Val Leu Leu Tyr Thr Phe
Ala Thr Ala Asn 1 5 10
15 Ala Asp Thr Leu Cys Ile Gly Tyr His Ala Asn Asn Ser Thr Asp Thr
20 25 30 Val Asp Thr
Val Leu Glu Lys Asn Val Thr Val Thr His Ser Val Asn 35
40 45 Leu Leu Glu Asp Lys His Asn Gly
Lys Leu Cys Lys Leu Arg Gly Val 50 55
60 Ala Pro Leu His Leu Gly Lys Cys Asn Ile Ala Gly Trp
Ile Leu Gly 65 70 75
80 Asn Pro Glu Cys Glu Ser Leu Ser Thr Ala Ser Ser Trp Ser Tyr Ile
85 90 95 Val Glu Thr Pro
Ser Ser Asp Asn Gly Thr Cys Tyr Pro Gly Asp Phe 100
105 110 Ile Asp Tyr Glu Glu Leu Arg Glu Gln
Leu Ser Ser Val Ser Ser Phe 115 120
125 Glu Arg Phe Glu Ile Phe Pro Lys Thr Ser Ser Trp Pro Asn
His Asp 130 135 140
Ser Asn Lys Gly Val Thr Ala Ala Cys Pro His Ala Gly Ala Lys Ser 145
150 155 160 Phe Tyr Lys Asn Leu
Ile Trp Leu Val Lys Lys Gly Asn Ser Tyr Pro 165
170 175 Lys Leu Ser Lys Ser Tyr Ile Asn Asp Lys
Gly Lys Glu Val Leu Val 180 185
190 Leu Trp Gly Ile His His Pro Ser Thr Ser Ala Asp Gln Gln Ser
Leu 195 200 205 Tyr
Gln Asn Ala Asp Thr Tyr Val Phe Val Gly Ser Ser Arg Tyr Ser 210
215 220 Lys Lys Phe Lys Pro Glu
Ile Ala Ile Arg Pro Lys Val Arg Asp Gln 225 230
235 240 Glu Gly Arg Met Asn Tyr Tyr Trp Thr Leu Val
Glu Pro Gly Asp Lys 245 250
255 Ile Thr Phe Glu Ala Thr Gly Asn Leu Val Val Pro Arg Tyr Ala Phe
260 265 270 Ala Met
Glu Arg Asn Ala Gly Ser Gly Ile Ile Ile Ser Asp Thr Pro 275
280 285 Val His Asp Cys Asn Thr Thr
Cys Gln Thr Pro Lys Gly Ala Ile Asn 290 295
300 Thr Ser Leu Pro Phe Gln Asn Ile His Pro Ile Thr
Ile Gly Lys Cys 305 310 315
320 Pro Lys Tyr Val Lys Ser Thr Lys Leu Arg Leu Ala Thr Gly Leu Arg
325 330 335 Asn Ile Pro
Ser Ile Gln Ser Arg Gly Leu Phe Gly Ala Ile Ala Gly 340
345 350 Phe Ile Glu Gly Gly Trp Thr Gly
Met Val Asp Gly Trp Tyr Gly Tyr 355 360
365 His His Gln Asn Glu Gln Gly Ser Gly Tyr Ala Ala Asp
Leu Lys Ser 370 375 380
Thr Gln Asn Ala Ile Asp Glu Ile Thr Asn Lys Val Asn Ser Val Ile 385
390 395 400 Glu Lys Met Asn
Thr Gln Phe Thr Ala Val Gly Lys Glu Phe Asn His 405
410 415 Leu Glu Lys Arg Ile Glu Asn Leu Asn
Lys Lys Val Asp Asp Gly Phe 420 425
430 Leu Asp Ile Trp Thr Tyr Asn Ala Glu Leu Leu Val Leu Leu
Glu Asn 435 440 445
Glu Arg Thr Leu Asp Tyr His Asp Ser Asn Val Lys Asn Leu Tyr Glu 450
455 460 Lys Val Arg Ser Gln
Leu Lys Asn Asn Ala Lys Glu Ile Gly Asn Gly 465 470
475 480 Cys Phe Glu Phe Tyr His Lys Cys Asp Asn
Thr Cys Met Glu Ser Val 485 490
495 Lys Asn Gly Thr Tyr Asp Tyr Pro Lys Tyr Ser Glu Glu Ala Lys
Leu 500 505 510 Asn
Arg Glu Glu Ile Asp Gly Val Lys Leu Glu Ser Thr Arg Ile Tyr 515
520 525 Gln Ile Leu Ala Ile Tyr
Ser Thr Val Ala Ser Ser Leu Val Leu Val 530 535
540 Val Ser Leu Gly Ala Ile Ser Phe Trp Met Cys
Ser Asn Gly Ser Leu 545 550 555
560 Gln Cys Arg Ile Cys Ile 565
712305DNAInfluenza 71agcagaagcg gtgcgtttga tttgtcataa tggatacttt
tattacaaga aacttccaga 60ctacaataat acaaaaggcc aaaaacacaa tggcagaatt
tagtgaagat cctgaattgc 120aaccagcaat gctattcaat atctgcgtcc atctagaggt
ttgctatgta ataagtgaca 180tgaattttct tgacgaagaa ggaaaagcat atacagcatt
agaaggacaa gggaaagaac 240aaaacttgag accacaatat gaagtaattg agggaatgcc
aagaaccata gcatggatgg 300tccagagatc cttagctcaa gagcatggaa tagagactcc
caagtatctg gctgatttgt 360ttgattataa aaccaaaaga tttatagaag ttggaataac
aaagggattg gctgatgatt 420acttttggaa aaagaaagaa aagttgggaa atagcatgga
actgatgata ttcagctaca 480atcaagacta ctcgttaagt aatgaatcct cattggatga
ggaagggaaa gggagagtgc 540taagcagact cacagaactt caggctgaat taagtctgaa
aaatttatgg caagttctca 600taggagaaga agatgttgaa aagggaattg attttaaact
tggacaaaca atatctagac 660taagggatat atctgttcca gctggtttct ccaattttga
aggaatgagg agctacatag 720acaatataga cccaaaagga gcaatagaga gaaatctagc
aaggatgtct cccttagtat 780cagtcacacc taaaaagtta acatgggagg acctaagacc
aatagggcct cacatttacg 840accatgagct accagaagtt ccatataatg cctttcttct
aatgtctgat gaactgggat 900tggccaatat gactgaggga aagtccaaaa aaccgaagac
attagccaaa gaatgtctag 960aaaagtactc aacactacgg gatcaaactg acccaatatt
aataatgaaa agcgaaaaag 1020ctaacgaaaa tttcctatgg aagctttgga gagactgtgt
aaatacaata agtaatgagg 1080aaacgagtaa cgagttacag aaaaccaatt atgccaaatg
ggccacaggg gatggattaa 1140cataccagaa aataatgaaa gaagtagcaa tagatgacga
aacaatgtgc caagaagagc 1200ctaaaatccc taacaaatgt agagtggctg cttgggttca
aacagagatg aatctattga 1260gcactctgac aagtaaaaga gctctggacc taccagaaat
agggccagac atagcacccg 1320tggagcatgt aggaagtgaa agaaggaaat actttgttaa
tgaaatcaac tactgtaagg 1380cctctacagt tatgatgaag tatgtgcttt ttcacacttc
attgttgaat gaaagcaatg 1440ccagcatggg aaaatacaaa gtaataccaa taaccaatag
agtagtaaat gaaaaaggag 1500aaagtttcga catgctttac ggtctggcgg ttaaaggaca
atctcatctg aggggagata 1560ctgatgttgt aacagttgta actttcgaat ttagtagtac
agatccaaga gtggactcag 1620gaaagtggcc aaaatatact gtgtttagga ttggctccct
atttgtgagt gggagggaaa 1680aatctgtgta cttgtattgc cgagtgaatg gcacaaataa
gatccaaatg aaatggggaa 1740tggaagctag aagatgtttg cttcaatcaa tgcaacaaat
ggaggcaatt gttgaacagg 1800aatcatcaat acaaggatat gacatgacca aagcctgttt
caagggagac agagtaaata 1860gccccaaaac tttcagtatt ggaactcaag aaggaaaact
agtaaaagga tcctttggaa 1920aagcactaag agtaatattt actaaatgct tgatgcacta
tgtatttgga aatgcccaat 1980tggaggggtt tagtgccgag tctaggagac ttctactgtt
gattcaagca ttaaaggaca 2040gaaagggccc ttgggtgttc gacttagagg gaatgtattc
tggaatagaa gaatgtatta 2100gcaacaaccc ttgggtaata cagagtgtat actggttcaa
tgaatggttg ggctttgaaa 2160aggaggggaa taaagtgttg gaatcagtgg atgaaataat
ggatgaataa aaggaaatgg 2220tactcaattt ggtactattt tgttcattat gtatctaaac
atccaataaa aagaaccaag 2280aatcaaaaat gcacgtgttt ctact
2305722369DNAInfluenza 72agcagaagcg gagcctttaa
gatgaatata aatccttatt ttctcttcat agatgtgccc 60gtacaggcag caatttcaac
aacattccca tacactggtg ttccccctta ttcccatgga 120acaggaacag gctacacaat
agacaccgtg atcagaacgc atgagtactc aaacaagggg 180aaacagtaca tttctgatgt
tacaggatgc acaatggtag atccaacaaa tggaccatta 240cccgaagata atgagccgag
tgcctatgcg caattagatt gcgttttaga ggctttggat 300agaatggatg aagaacaccc
aggtcttttt caagcagcct cacagaatgc tatggaggcc 360ctaatggtca caactgtaga
caaattaacc caggggagac agacttttga ttggacagta 420tgcagaaacc aacctgctgc
aacggcactg aacacaacaa taacctcttt taggttgaat 480gatttaaatg gagccgacaa
aggtggatta ataccttttt gccaggatat cattgattca 540ttagaccgac ctgaaatgac
tttcttctca gtaaagaata taaagaaaaa attgcctgcc 600aaaaacagaa agggtttcct
cataaagagg ataccaatga aggtaaaaga caaaataacc 660aaagtggaat acatcaaaag
agcattatca ttaaacacaa tgacaaaaga cgctgaaaga 720ggcaaactga aaagaagagc
gattgccact gctggaatac aaatcagagg gtttgtatta 780gtagttgaaa acttggctaa
aaatatatgt gaaaatctag aacaaagtgg tttaccagta 840ggtggaaacg agaagaaagc
caaactgtca aacgcagtgg ccaaaatgct cagtaactgc 900ccaccaggag ggattagcat
gacagtaaca ggagacaata caaaatggaa tgaatgttta 960aacccaagaa tctttttggc
tatgactgaa agaataacca gagacagccc agtttggttc 1020agggattttt gtagtatagc
accggtcctg ttctccaata agatagcaag attggggaaa 1080gggtttatga taacaagcaa
aacaaaaaga ctgaaggctc aaataccttg tcctgatctg 1140tttagtatac cgttagaaag
atataatgaa gaaacaaggg caaaattgaa aaagctaaaa 1200ccattcttca atgaagaagg
aactgcatct ttgtcgcctg ggatgatgat gggaatgttt 1260aatatgctat ctaccgtgtt
gggagtagct gcactaggta tcaagaacat tggaaacaaa 1320gaatacttat gggatggact
gcaatcttct gatgattttg ctctgtttgt taatgcaaag 1380gatgaagaaa catgtatgga
aggaataaac gacttttacc gaacatgtaa attattggga 1440gtaaacatga gcaaaaagaa
aagttactgt aatgagactg gaatgtttga atttacaagc 1500atgttctaca gagatggatt
tgtatctaat tttgcaatgg aactcccttc gtttggggtt 1560gctggagtaa atgaatcagc
agatatggca ataggaatga caataataaa gaacaacatg 1620atcaacaatg gaatgggtcc
ggcaacagca caaacagcca tacagttatt catagctgat 1680tatagataca cctacaaatg
ccacagggga gattccaaag tagaaggaaa gagaatgaaa 1740atcataaagg agttatggga
aaacactaaa ggaagagatg gtctattagt agcagatggt 1800gggcccaaca tttacaattt
gagaaacctg catatcccag aaatagtatt aaagtataat 1860ctaatggacc ctgaatacaa
agggcggtta cttcatcctc aaaatccctt tgtgggacat 1920ttgtctattg agggcatcaa
agaggcagac ataaccccag cacatggtcc agtaaagaaa 1980atggactacg atgcggtgtc
tggaactcat agttggagaa ccaaaagaaa cagatctata 2040ctaaacactg atcagaggaa
catgattctt gaggaacaat gctacgctaa atgttgcaac 2100ctatttgagg cctgttttaa
cagtgcatca tacaggaagc cagtgggtca acatagcatg 2160cttgaggcta tggcccacag
attaagaatg gatgcacgat tagattatga atcagggaga 2220atgtcaaagg atgattttga
gaaagcaatg gctcaccttg gtgagattgg gtacatataa 2280gcttcgaaga tgtttatggg
gttattggtc atcattgaat acatgcgata cacaaatgat 2340taaaatgaaa aaaggctcgt
gtttctact 2369732396DNAInfluenza
73agcagaagcg gagcgttttc aagatgacat tggccaaaat tgaattgtta aaacaactgc
60taagggacaa tgaagccaaa acagttttga agcaaacaac ggtagaccaa tataacataa
120taagaaaatt caatacatca aggattgaaa agaatccttc actaaggatg aagtgggcca
180tgtgttctaa ttttcccttg gctctaacca agggcgatat ggcaaacaga atccccttgg
240aatacaaagg gatacaactt aaaacaaatg ctgaagacat aggaaccaaa ggccaaatgt
300gctcaatagc agcagttact tggtggaata catatggacc aataggagat actgaaggtt
360tcgaaagggt ctacgaaagc ttttttctca gaaaaatgag acttgacaac gccacttggg
420gccgaataac ttttggccca gttgaaagag tgagaaaaag ggtactgcta aaccctctca
480ccaaggaaat gcctccggat gaggcgagca atgtgataat ggaaatattg ttccctaaag
540aagcaggaat accaagagaa tccacttgga tacataggga actgataaaa gaaaaaagag
600aaaaattgaa aggaacaatg ataactccaa tcgtactggc atacatgctt gaaagagaac
660tggttgctcg aagaagattc ttgccagtgg caggagcaac atcagctgag ttcatagaaa
720tgctacactg cttacaaggt gaaaattgga gacaaatata tcacccagga gggaataaat
780taactgagtc caggtctcaa tcaatgatag tagcttgtag aaaaataatc agaagatcaa
840tagtcgcttc aaacccactg gagctagctg tagaaattgc aaacaagact gtgatagata
900ctgaaccttt aaagtcatgt ctggcagcca tagacggagg tgatgtagct tgtgacataa
960taagagctgc attaggacta aagatcagac aaagacaaag atttggacgg cttgagctaa
1020aaagaatatc aggaagagga ttcaaaaatg atgaagaaat attaataggg aacggaacaa
1080tacagaagat tggaatatgg gacggggaag aggagttcca tgtaagatgt ggtgaatgca
1140ggggaatatt aaaaaagagt aaaatgaaac tggaaaaact actgataaat tcagccaaaa
1200aggaggatat gagagattta ataatcttat gcatggtatt ttctcaagac actaggatgt
1260tccaaggagt gagaggagaa ataaattttc ttaatcgagc aggccaactt ttatctccaa
1320tgtaccaact ccaacgatat tttttgaata gaagcaacga cctttttgat caatgggggt
1380atgaggaatc acccaaagca agtgaactac atgggataaa tgaatcaatg aatgcatctg
1440actatacatt gaaagggatt gtagtgacaa gaaatgtaat tgacgacttt agctctattg
1500aaacagaaaa agtatccata acaaaaaatc ttagtttaat aaaaaggact ggggaagtca
1560taatgggagc taatgacgtg agtgaattag aatcacaagc acagctgatg ataacatatg
1620atacacctaa aatgtgggaa atgggaacaa ccaaagaact ggtgcaaaac acttatcaat
1680gggtgctaaa aaacttggtg acactgaagg ctcagtttct tctaggaaaa gaggacatgt
1740tccaatggga tgcatttgaa gcatttgaga gcataattcc tcagaagatg gctggtcagt
1800acagtggatt tgcaagagca gtgctcaaac aaatgagaga ccaggaggtt atgaaaactg
1860accagttcat aaagttgttg cctttttgtt tctcaccacc aaaattaagg agcaatgggg
1920agccttatca attcttaaaa cttgtgttga aaggaggagg ggaaaatttc atcgaagtaa
1980ggaaagggtc ccctctattt tcctataatc cacaaacaga agtcctaact atatgcggca
2040gaatgatgtc attaaaaggg aaaattgaag atgaagaaag gaatagatca atgggtaatg
2100cagtattagc aggctttctc gttagtggca agtatgaccc agatcttgga gatttcaaaa
2160ctattgaaga acttgaaaag ctgaaaccgg gggaaaaggc aaacatctta ctttatcaag
2220gaaaaccagt taaagtagtt aaaaggaaaa ggtatagtgc tttgtccaat gacatttcac
2280aaggaattaa gagacaaaga atgacagttg agtctatggg gtgggccttg agctaatata
2340aatttatcca ttaattcaat gaacgcaatt gagtgaaaaa tgctcgtgtt tctact
2396741844DNAInfluenza 74agcagaagca cagcattttc ttgtgaactt caagcaccag
taaaagaact gaaaatcaaa 60atgtccaaca tggatattga cggtataaac actgggacaa
ttgacaaaac accggaagaa 120ataacttctg gaaccagtgg gacaaccaga ccaatcatta
gaccagcaac ccttgcccca 180ccaagcaaca aacgaacccg taacccatcc ccggaaagag
caaccacaag cagtgaagat 240gatgtcggaa ggaaaaccca aaagaaacag accccgacag
agataaagaa gagcgtctac 300aacatggtgg tgaaactggg cgaattctat aaccagatga
tggtcaaagc tggactcaat 360gatgacatgg agagaaatct aatccaaaat gcgcatgccg
tggaaagaat tctattggct 420gccactgatg acaagaaaac cgagttccag aagaaaaaga
atgccagaga tgtcaaagaa 480gggaaagaag aaatagatca caacaaaaca ggaggcacct
tttacaagat ggtaagagat 540gataaaacca tctacttcag ccctataaga attacctttt
taaaagaaga ggtgaaaaca 600atgtacaaaa ccaccatggg gagtgatggc ttcagtggac
taaatcacat aatgattggg 660cattcacaga tgaatgatgt ctgtttccaa agatcaaagg
cactaaaaag agttggactt 720gatccttcat taatcagtac ctttgcggga agcacagtcc
ccagaagatc aggtgcgact 780ggtgttgcaa tcaaaggagg tggaacctta gtggctgaag
ccattcgatt tataggaaga 840gcaatggcag acagagggct attgagagac atcaaagcca
agactgccta tgaaaagatt 900cttctgaatc taaaaaacaa atgctctgcg ccccaacaaa
aggctctagt tgatcaagtg 960atcggaagca gaaatccggg gattgcagac attgaagatc
taaccctgct tgctcgtagt 1020atggtcgttg ttaggccctc tgtggcaagc aaagtggtgc
ttcccataag catttacgcc 1080aaaatacctc aactagggtt caatgttgaa gagtactcta
tggttgggta cgaagccatg 1140gctctttaca atatggcaac acctgtgtcc atattaagaa
tgggagatga tgcaaaagat 1200aaatcgcaat tattcttcat gtcttgcttc ggagctgcct
atgaagacct gagagttttg 1260tctgcattaa caggcacaga attcaagcct agatcagcat
taaaatgcaa gggtttccat 1320gttccagcaa aggaacaggt agaaggaatg ggagcagctc
tgatgtccat caagctccag 1380ttttgggctc cgatgaccag atctgggggg aacgaagtag
gtggagacgg agggtctggc 1440caaataagct gcagcccagt gtttgcagtg gaaagaccta
ttgctctaag caagcaagct 1500gtaagaagaa tgctgtcaat gaatattgag ggacgtgatg
cagatgtcaa aggaaatcta 1560ctcaagatga tgaatgactc aatggctaag aaaaccagtg
gaaatgcttt cattgggaag 1620aaaatgtttc aaatatcaga caaaaacaaa accaatccca
ttgaaattcc aattaagcag 1680accatcccca atttcttctt tgggagggac acagcagagg
attatgatga cctcgattat 1740taaggcaaca aaatagacac tatgactgtg attgtttcaa
tacgtttgga atgtgggtgt 1800ttattcttat taaaataaat ataaaaaatg ctgttgtttc
tact 1844751189DNAInfluenza 75agcagaagca cgcactttct
taaaatgtcg ctgtttggag acacaattgc ctacctgctt 60tcattgacag aagatggaga
aggcaaagca gaactagcag aaaaattaca ctgttggttt 120ggtgggaaag aatttgacct
agactctgcc ttggaatgga taaaaaacaa aagatgctta 180actgatatac aaaaagcact
aattggtgcc tctatatgct ttttaaaacc caaagaccag 240gaaagaaaaa gaagattcat
cacagagccc ttatcaggaa tgggaacaac agcaacaaaa 300aagaaaggcc tgattctggc
tgagagaaaa atgagaagat gtgtgagctt tcatgaagca 360tttgaaatag cagaaggcca
tgaaagctca gcgctactat actgtctcat ggtcatgtac 420ctgaatcctg gaaattattc
aatgcaagta aaactaggaa cgctctgtgc tttatgcgag 480aaacaagcat cacattcaca
cagggctcat agcagagcag cgagatcttc agtgcctgga 540gtgagacgag aaatgcagat
ggtctcagct atgaacacag caaaaacaat gaatggaatg 600ggaaaaggag aagacgtcca
aaagctggca gaagagttgc aaagcaacat tggagtgctg 660agatctcttg gggcaagcca
aaagaatggg gaagggattg caaaggatgt aatggaagtg 720ctaaagcaga gctccatggg
aaattcagct cttgtgaaga aatatctata atgctcgaac 780catttcagat tcttacaatt
tgttctttta tcttatcagc tctccatttc atggcttgga 840caatagggca tttgaatcaa
ataaaaagag gaataaacat gaaaatacga ataaaaggtc 900caaacaaaga gacaataaac
agagaggtat caattttgag acacagttac caaaaagaaa 960tccaggccaa agaaacaatg
aaggaagtac tctctgacaa catggaggta ttgaatgacc 1020acataataat tgaggggctt
tctgccgaag agataataaa aatgggtgaa acagttttgg 1080agatagaaga attgcattaa
attcaatttt actgtatttc ttactatgca tttaagcaaa 1140ttgtaatcaa tgtcagcaaa
taaactggaa aaagtgcgtt gtttctact 1189761101DNAInfluenza
76agcagaagca gaggatttgt ttagtcactg gcaaacaggg aaaaatggcg aacaacaaca
60tgaccacaac acaaattgag gtgggtccgg gagcaaccaa tgccaccata aactttgaag
120caggaattct agagtgctat gaaaggcttt catggcaaag agcccttgac taccctggtc
180aagaccgcct aaacagacta aagagaaaat tagagtcaag aataaagact cacaacaaaa
240gtgagcctga aagtaaaagg atgtcccttg aagagagaaa agcaattgga gtaaaaatga
300tgaaagtact cctatttatg aatccgtctg ctggaattga agggtttgag ccatactgta
360tgaaaagttc ctcaaatagc aactgtacga aatacaattg gactgattac ccttcaacac
420cagagaggtg ccttgatgac atagaggaag aaccagagga tgttgatggc ccaactgaaa
480tagtattaag ggacatgaac aacaaagatg caaggcaaaa gataaaggag gaagtaaaca
540ctcagaaaga agggaagttc cgtttgacaa taaaaaggga tatgcgtaat gtattgtcct
600tgagagtgtt ggtaaacgga acattcctca aacaccccaa tggacacaag tccttatcaa
660ctctgcatag attgaatgca tatgaccaga gtggaaggct tgttgctaaa cttgttgcca
720ctgatgatct tacagtggag gatgaagaag atggccatcg gatcctcaac tcactcttcg
780agcgtcttaa tgaaggacat tcaaagccaa ttcgagcagc tgaaactgcg gtgggagtct
840tatcccaatt tggtcaagag caccgattat caccagaaga gggagacaat tagactggtc
900acggaagaac tttatctttt aagtaaaaga attgatgata acatactatt ccacaaaaca
960gtaatagcta acagctccat aatagctgac atggttgtat cattatcatt attagaaaca
1020ttgtatgaaa tgaaggatgt ggttgaagtg tacagcaggc agtgcttgtg aatttaaaat
1080aaaaatcctc ttgttactac t
1101772305DNAInfluenza 77agcagaagcg gtgcgtttga tttgccataa tggatacttt
tattacaaga aacttccaga 60ctacaataat acaaaaggcc aaaaacacaa tggcagaatt
tagtgaagat cctgaattac 120aaccagcaat gctattcaac atctgcgtcc atctagaggt
ttgctatgta ataagtgaca 180tgaattttct tgacgaagaa ggaaaatcat atacagcatt
agaaggacaa ggaaaagaac 240aaaacttgag accacaatat gaagtaattg agggaatgcc
aagaaccata gcatggatgg 300tccaaagatc cttagctcaa gagcatggaa tagagactcc
aaagtatctg gctgatttgt 360ttgattataa aaccaagaga tttatagaag ttggaataac
aaaaggattg gctgatgatt 420acttttggaa aaagaaagaa aagctgggaa atagcatgga
actgatgata ttcagctaca 480atcaagacta ttcgttaagt aatgaatcct cattggatga
ggaagggaaa gggagagtgc 540taagcagact cacagaactt caggctgaat taagtctgaa
aaacctatgg caagttctca 600taggagaaga agatgttgaa aagggaattg actttaaact
tggacaaaca atatctagac 660taagggatat atctgttcca gctggtttct ccaattttga
aggaatgagg agctacatag 720acaatataga tcctaaagga gcaatagaaa gaaatctagc
aaggatgtct cccttagtat 780cagccacacc taaaaagttg aaatgggagg acctaagacc
aatagggcct cacatttaca 840accatgagtt accagaagtt ccatataatg cctttcttct
aatgtctgat gaattggggc 900tggccaatat gactgaggga aagtccaaaa aaccgaagac
attagccaaa gaatgtctag 960aaaagtactc aacactacgg gatcaaactg acccaatatt
aataatgaaa agcgaaaaag 1020ctaacgaaaa tttcctatgg aagctgtgga gggactgtgt
aaatacaata agtaatgagg 1080aaatgagtaa cgagttacag aaaaccaatt atgccaagtg
ggccacagga gatggattaa 1140cataccagaa aataatgaaa gaagtagcaa tagatgacga
aacaatgtgc caagaagagc 1200ctaaaatccc taacaaatgt agagtggctg cttgggttca
aacagagatg aatttattga 1260gcactctgac aagtaaaaga gctctggacc taccagaaat
agggccagac gtagcacccg 1320tggagcatgt agggagtgaa agaaggaaat actttgttaa
tgaaatcaac tgctgtaagg 1380cctctacagt tatgatgaag tatgtgcttt ttcacacttc
attattgaat gaaagcaatg 1440ccagcatggg aaaatataaa gtaataccaa taaccaatag
agtagtaaat gaaaaaggag 1500aaagtttcga catgctttat ggtctggcgg ttaaaggaca
atctcatctg aggggagata 1560ctgatgttgt aacagttgtg actttcgaat ttagtggtac
agatcccaga gtggactcag 1620gaaagtggcc aaaatatact gtgtttagga ttggctccct
atttgtgagt gggagggaaa 1680aatctgtgta cctatattgc cgagtgaatg gcacaaataa
gatccaaatg aaatggggaa 1740tggaagctag aagatgtctg cttcaatcaa tgcaacaaat
ggaagcaatt gttgaacaag 1800aatcatcgat acaaggatat gacatgacca aagcttgttt
caagggagac agagtaaata 1860gccccaaaac ttttagtatt gggactcaag aaggaaaact
agtaaaagga tcctttggga 1920aagcactaag agtaatattt accaaatgtt tgatgcacta
tgtatttgga aatgcccaat 1980tggaggggtt tagtgccgag tctaggagac ttctactgtt
aattcaagca ctaaaggaca 2040gaaagggccc ttgggtgttc gacttagagg gaatgtattc
tggaatagaa gaatgtatta 2100gtaacaaccc ttgggtaata cagagtgcat actggttcaa
tgaatggttg ggctttgaaa 2160aggaggggag taaagtatta gaatcagtag atgaaataat
gaatgaatga aaaaacatag 2220tactcaattt ggtactattt tgttcattat gtatctaaac
atccaataaa aagaatcgag 2280aatcaaaaat gcacgtgttt ctact
2305782369DNAInfluenza 78agcagaagcg gagcctttaa
gatgaatata aatccttatt ttctcttcat agatgtaccc 60atacaggcag caatttcaac
aacattccca tacaccggtg ttccccctta ctcccatgga 120acgggaacag gccacacaat
agacaccgtg atcagaacac atgagtactc gaacaaggga 180aaacagtatg tttctgacat
cacaggatgt acaatggtag atccaacaaa tgggccatta 240cccgaagaca atgagccgag
tgcctatgca caattagatt gcgttctgga ggctttggat 300agaatggatg aagaacatcc
aggtttgttt caagcagcct cacagaatgc catggaggca 360ctaatggtca caactgtaga
caaattaacc caggggagac agacttttga ttggacagta 420tgcagaaacc agcctgctgc
aacggcacta aacacaacaa taacctcctt taggttgaat 480gatttgaatg gagctgacaa
gggtggattg gtaccctttt gccaagatat cattgattca 540ttggacaaac ctgaaatgac
tttcttctca gtaaagaata taaagaaaaa attgcctgct 600aaaaacagaa agggtttcct
cataaagaga ataccaatga aagtaaaaga caggataacc 660agagtggaat acatcaaaag
agcattatca ttaaacacaa tgacaaaaga tgctgaaagg 720ggcaaactaa aaagaagagc
gattgcaacc gctggaatac aaatcagagg gtttgtatta 780gtagttgaaa acttggctaa
aaatatctgt gaaaatctag aacaaagtgg tttgcccgta 840ggtggaaatg aaaagaaggc
caaactgtca aatgcagtgg ccaaaatgct cagtaactgc 900ccaccaggag ggatcagcat
gacagtaaca ggagacaata ctaaatggaa tgaatgctta 960aatccaagaa tctttttggc
tatgactgaa aggataacaa gagacagccc aatttggttc 1020cgggattttt gtagtatagc
accggtcttg ttctccaata aaatagccag attgggaaaa 1080ggatttatga taacaagcaa
aacaaaaaga ctgaaggctc aaataccttg tccagatctg 1140tttagcatac cattagaaag
atataatgaa gaaacaaggg caaaattaaa aaagctgaaa 1200ccattcttca atgaagaagg
aacggcatct ttgtcgcctg ggatgatgat gggaatgttt 1260aatatgctat ctaccgtgtt
gggagtagcc gcactaggta tcaaaaacat tggaaacaaa 1320gaatatttat gggatggact
gcaatcttct gatgattttg ctctgtttgt taatgcaaaa 1380gatgaagaga catgtatgga
aggaataaac gacttttacc gaacatgtaa attattggga 1440ataaacatga gcaaaaagaa
aagttactgt aatgaaactg gaatgtttga atttacaagc 1500atgttctata gagatggatt
tgtatctaat tttgcaatgg aaattccttc atttggagtt 1560gctggagtaa atgaatcagc
agatatggca ataggaatga caataataaa gaacaatatg 1620atcaacaatg ggatgggtcc
agcaacagca caaacagcca tacaattatt catagctgat 1680tataggtaca cctacaaatg
ccacagggga gattccaaag tggaaggaaa aagaatgaaa 1740attataaagg agctatggga
aaacactaaa ggaagagatg gtctgttagt ggcagatggt 1800gggcccaaca tttacaattt
gagaaactta catatcccag aaatagtatt gaagtacaac 1860ctaatggacc ctgaatacaa
agggcggtta cttcatcctc aaaatccatt tgtaggacat 1920ttatctattg agggcatcaa
agaagcagat ataaccccag cacatggtcc cgtaaagaaa 1980atggattatg atgcagtatc
tggaactcat agttggagaa ccaaaaggaa cagatctata 2040ctaaatactg accagaggaa
catgattctt gaggaacaat gctacgctaa gtgttgcaac 2100ctttttgagg cctgttttaa
tagtgcatca tacaggaaac cagtaggtca gcacagcatg 2160cttgaggcta tggcccacag
attaagagtg gatgcacgac tagattatga atcaggaaga 2220atgtcaaagg atgattttga
gaaagcaatg gctcaccttg gtgagattgg gtacatataa 2280gctccgaaga tgtctatggg
gttattggtc atcattgaat acatgtgata aacaaatgat 2340taaaatgaaa aaaggctcgt
gtttctact 2369792396DNAInfluenza
79agcagaagcg gagcgttttc aagatgacat tggctaaaat tgaattgtta aaacaactgt
60taagggacaa tgaagccaaa acagtattga aacaaacaac ggtagaccaa tataacataa
120taagaaaatt caatacatca agaattgaaa agaacccttc attgaggatg aagtgggcaa
180tgtgttctaa ttttcccttg gctctgacca agggtgatat ggcaaacaga atccccttgg
240aatacaaggg aatacaactt aaaacaaatg ctgaagacat aggaactaaa ggccaaatgt
300gctcaatagc agcagttacc tggtggaata catatggacc aataggagat actgaaggtt
360tcgaaaaggt ctacgaaagc ttttttctca gaaagatgag acttgacaat gccacttggg
420gccgaataac ttttggccca gttgaaagag taagaaaaag ggtactgcta aaccctctca
480ccaaggaaat gcctccagat gaagcaagta atgtgataat ggaaatattg ttccctaagg
540aagcaggaat accaagagaa tctacttgga tacataggga actgataaaa gaaaaaagag
600aaaaattgaa aggaacaatg ataactccca ttgtactggc atacatgctt gagagagaat
660tggttgccag aagaaggttc ctgccggtgg caggagcaac atcagctgag ttcatagaaa
720tgctacactg cttacaaggt gaaaattgga gacaaatata tcacccagga ggaaataaac
780taactgaatc taggtctcaa tcgatgattg tagcttgtag aaagataatc agaagatcaa
840tagtcgcatc aaacccatta gagctagctg tagaaattgc aaacaagact gtgatagata
900ctgaaccttt aaaatcatgt ctgacagcca tagacggagg tgatgtagcc tgtgacataa
960taagagctgc attaggacta aagatcagac aaagacaaag atttggacga cttgaactaa
1020agagaatatc aggaagagga ttcaaaaatg atgaagaaat attaatcggg aacggaacaa
1080tacagaagat tggaatatgg gacggagaag aggagttcca tgtaagatgt ggtgaatgca
1140ggggaatatt aaaaaagagc aaaatgagaa tggaaaaact actaataaat tcagctaaaa
1200aggaagacat gaaagattta ataatcttgt gcatggtatt ttctcaagac actaggatgt
1260tccaaggagt gagaggagaa ataaattttc ttaatagagc aggccaactt ttatctccaa
1320tgtaccaact ccaaagatat tttttgaata gaagcaacga tctctttgat caatgggggt
1380atgaggaatc acccaaagca agtgagctac atggaataaa tgaattaatg aatgcatctg
1440actacacttt gaaaggggtt gtagtaacaa aaaatgtaat tgatgatttt agttctactg
1500aaacagaaaa agtatctata acaaaaaatc ttagtttaat aaaaaggact ggggaagtca
1560taatgggggc taatgacgta agtgaattag aatcacaagc tcagctaatg ataacatatg
1620atacacctaa gatgtgggag atgggaacaa ccaaagaact ggtgcaaaac acctaccaat
1680gggtgctgaa aaatttggta acactgaagg ctcagtttct tctaggaaaa gaagacatgt
1740tccaatggga tgcatttgaa gcatttgaaa gcataatccc ccagaagatg gctggccagt
1800acagtggatt tgcaagagca gtgctcaaac aaatgagaga ccaagaggtt atgaaaactg
1860accagttcat aaagttgttg cccttttgtt tctcaccacc aaaattaagg agaaatgggg
1920agccttatca gttcttgagg cttgtattga agggaggagg agaaaatttc atcgaagtaa
1980ggaaagggtc ccctctattc tcttacaatc cacaaacaga agtcctaact atatgcggca
2040gaatgatgtc attaaaaggg aaaattgaag atgaagaaag gaatagatca atggggaatg
2100cagtattagc gggctttctc gttagtggca agtatgaccc agatcttgga gatttcaaaa
2160ctattgaaga acttgaaaag ctgaaaccgg gggagaaagc aaacatctta ctttatcaag
2220gaaagcccgt taaagtagtt aaaaggaaaa gatatagtgc tttatccaat gacatttcac
2280aaggaattaa gagacaaaga atgacagttg agtccatggg gtgggccttg agctaatata
2340aatttatcca ttaattcaat aaacacaatt gagtgaaaaa tgctcgtgtt tctact
2396801844DNAInfluenza 80agcagaagca cagcattttc ttattaactt caagtaccaa
caaaagaact gaaaatcaaa 60atgtccaaca tggatattga cggtatcaac actgggacaa
ttgacaaaac accggaagaa 120ataacttctg gaaccagtgg gacaaccaga ccaatcatca
gaccagcaac ccttgcccca 180ccaagcaaca aacgaacccg gaacccatcc ccggaaagag
caaccacaag cagtgaagct 240gatgtcggaa ggaaaaccca aaagaaacag accccgacag
agataaagaa gagcgtctac 300aatatggtag tgaaactggg tgaattctat aaccagatga
tggtcaaagc tggactcaac 360gatgacatgg agagaaacct aatccaaaat gcgcatgctg
tggaaagaat tctattggct 420gccactgatg acaagaaaac tgaattccag aggaaaaaga
atgccagaga tgtcaaagaa 480ggaaaagaag aaatagacca caacaaaaca ggaggcacct
tttacaagat ggtaagagat 540gataaaacca tctacttcag ccctataaga attacctttt
taaaagaaga ggtgaaaaca 600atgtacaaaa ccaccatggg gagtgatggc ttcagtggac
taaatcacat aatgattggg 660cattcacaga tgaatgatgt ctgtttccaa agatcaaagg
ccctaaaaag agttggactt 720gacccttcat taatcagtac ctttgcagga agcacactcc
ccagaagatc aggtgcaact 780ggtgttgcaa tcaaaggagg tggaacttta gtggctgaag
ccattcgatt tataggaaga 840gcaatggcag acagagggct attgagagac atcaaagcca
agactgccta tgaaaagatt 900cttctgaatc taaaaaacaa atgctctgcg ccccaacaaa
aggctctagt tgatcaagtg 960atcggaagta gaaatccagg gattgcagac attgaagacc
taaccctgct tgctcgtagt 1020atggtcgttg ttaggccctc tgtggcgagc aaagtagtgc
ttcccataag catttatgct 1080aaaatacctc aactagggtt caatgttgaa gaatactcta
tggttgggta tgaagccatg 1140gctctctaca atatggcaac acctgtttcc atattaagaa
tgggagatga tgcaaaagat 1200aaatcgcaat tattcttcat gtcttgcttc ggagctgcct
atgaagacct gagagttttg 1260tctgcattaa caggcataga attcaagcct agatcagcat
taaaatgcaa gggtttccat 1320gttccagcaa aggaacaggt ggaaggaatg ggggcagctc
tgatgtccat caagctccag 1380ttttgggctc caatgaccag atctggaggg aacgaagtag
gtggagacgg agggtctggc 1440caaataagtt gcagcccagt gtttgcagta gaaagaccta
ttgctctaag caagcaagct 1500gtaagaagaa tgctttcaat gaatattgag ggacgtgatg
cagatgtcaa aggaaatcta 1560ctcaagatga tgaatgactc aatggctaag aaaaccaatg
gaaatgcttt cattgggaag 1620aaaatgtttc aaatatcaga caaaaacaaa accaatcccg
ttgaaattcc aattaagcag 1680accatcccca atttcttctt tgggagggac acagcagagg
attatgatga cctcgattat 1740taaagcaaca aaatagacac tatgactgtg attgtttcaa
tacgtttgga atgtgggtgt 1800ttactcttat tgaaataaat ataaaaaatg ctgttgtttc
tact 1844811190DNAInfluenza 81agcagaagca cgcactttct
taaaatgtcg ctgtttggag acacaattgc ctacctgctt 60tcattgacag aagatggaga
aggcaaagca gaactagcag aaaaattaca ctgttggttc 120ggtgggaaag aatttgacct
agactctgcc ttggaatgga taaaaaacaa aagatgctta 180actgatatac agaaagcact
aattggtgcc tctatctgct ttttaaaacc aaaagaccaa 240gaaagaaaaa gaagattcat
cacagagccc ctatcaggaa tgggaacaac agcaacaaaa 300aagaagggcc tgattctagc
tgagagaaaa atgagaagat gtgtgagttt tcatgaagca 360tttgaaatag cagaaggcca
tgaaagctca gcgctactat attgtctcat ggtcatgtac 420ctgaaccctg gaaattattc
aatgcaagta aaactaggaa cgctctgtgc tttgtgcgag 480aaacaagcat cacattcaca
cagggctcat agcagagcag caagatcttc agtgcctgga 540gtgaggcgag aaatgcagat
ggtctcagct atgaacacag caaaaacaat gaatggaatg 600ggaaagggag aagacgtcca
aaaactggca gaagagctgc aaagcaacat tggagtattg 660agatctcttg gggcaagtca
aaagaatggg gaaggaattg caaaggatgt gatggaagtg 720ctaaagcaga gctctatggg
aaattcagct cttgtgaaga aatacctata atgctcgaac 780catttcagat tctttcaatt
tgttctttca tcttatcagc tctccatttc atggcttgga 840caatagggca tttgaatcaa
ataaaaagag gagtaaacat gaaaatacga ataaaaaatc 900caaataaaga gacaataaac
agagaggtat caattttgag acacagttac caaaaagaaa 960tccaggccaa agaaacaatg
aaggaagtac tctctgacaa catggaggta ttgagtgacc 1020acatagtaat tgaggggctt
tctgctgaag agataataaa aatgggtgaa acagttttgg 1080aggtagaaga attgcattaa
attcaatttt tactgtattt cttgctatgc atttaagcaa 1140attgtaatca atgtcagcaa
ataaactgga aaaagtgcgt tgtttctact 1190821096DNAInfluenza
82agcagaagca gaggatttgt ttagtcactg gcaaacgaaa aaatggcgga caacatgacc
60acaacacaaa ttgaggtggg tccgggagca accaatgcca ccataaactt tgaagcagga
120attttggagt gctatgaaag gctttcatgg caaagagccc ttgactaccc tggtcaagac
180cgcctaaaca aactaaagag aaaattggaa tcaagaataa agactcacaa caaaagtgag
240ccagaaagta aaaggatgtc tcttgaagag agaaaagcta ttggggtaaa aatgatgaaa
300gtgctcctat ttatgaaccc atctgctgga gttgaagggt ttgagccata ttgtatgaaa
360aatccctcca atagcaactg tccagactgc aattgggctg attaccctcc aacaccagga
420aagtaccttg atggcataga agaagaaccg gagaatgttg gtgactcaac tgaaatagta
480ttaagggaca tgaacaacaa agatgcaagg caaaagataa aagaggaagt aaacactcag
540aaagaaggga aattccgttt gacaataaaa agggatatac gtaatgtgtt gtccttgaga
600gtgttggtaa acggaacatt catcaagcac cctaatggat acaagtcctt atcaactctg
660catagattga atgcatatga ccagagtgga agacttgttg ctaaacttgt tgctactgat
720gatcttacag tggaggatga agaagatggc catcggatcc tcaactcact cttcgagcgt
780cttaatgaag gacattcaaa gccaattcga gcagctgaaa ctgcggtggg agtcttatcc
840caatttggtc aagagcaccg attatcacca gaagagagag acaattagac tggttacgga
900agaactttat cttttaagta aaagaattga tgataacata ttgttccaca aaacagtaat
960agccaacagc tccataatag ctgacatgat tgtatcatta tcattattgg aaacattgta
1020tgaaatgaag gatgtggttg aagtgtacag caggcagtgc ttgtgaattt aaaataaaaa
1080tcctcttgtt actact
109683726PRTInfluenza 83Met Asp Thr Phe Ile Thr Arg Asn Phe Gln Thr Thr
Ile Ile Gln Lys 1 5 10
15 Ala Lys Asn Thr Met Ala Glu Phe Ser Glu Asp Pro Glu Leu Gln Pro
20 25 30 Ala Met Leu
Phe Asn Ile Cys Val His Leu Glu Val Cys Tyr Val Ile 35
40 45 Ser Asp Met Asn Phe Leu Asp Glu
Glu Gly Lys Ala Tyr Thr Ala Leu 50 55
60 Glu Gly Gln Gly Lys Glu Gln Asn Leu Arg Pro Gln Tyr
Glu Val Ile 65 70 75
80 Glu Gly Met Pro Arg Thr Ile Ala Trp Met Val Gln Arg Ser Leu Ala
85 90 95 Gln Glu His Gly
Ile Glu Thr Pro Lys Tyr Leu Ala Asp Leu Phe Asp 100
105 110 Tyr Lys Thr Lys Arg Phe Ile Glu Val
Gly Ile Thr Lys Gly Leu Ala 115 120
125 Asp Asp Tyr Phe Trp Lys Lys Lys Glu Lys Leu Gly Asn Ser
Met Glu 130 135 140
Leu Met Ile Phe Ser Tyr Asn Gln Asp Tyr Ser Leu Ser Asn Glu Ser 145
150 155 160 Ser Leu Asp Glu Glu
Gly Lys Gly Arg Val Leu Ser Arg Leu Thr Glu 165
170 175 Leu Gln Ala Glu Leu Ser Leu Lys Asn Leu
Trp Gln Val Leu Ile Gly 180 185
190 Glu Glu Asp Val Glu Lys Gly Ile Asp Phe Lys Leu Gly Gln Thr
Ile 195 200 205 Ser
Arg Leu Arg Asp Ile Ser Val Pro Ala Gly Phe Ser Asn Phe Glu 210
215 220 Gly Met Arg Ser Tyr Ile
Asp Asn Ile Asp Pro Lys Gly Ala Ile Glu 225 230
235 240 Arg Asn Leu Ala Arg Met Ser Pro Leu Val Ser
Val Thr Pro Lys Lys 245 250
255 Leu Thr Trp Glu Asp Leu Arg Pro Ile Gly Pro His Ile Tyr Asp His
260 265 270 Glu Leu
Pro Glu Val Pro Tyr Asn Ala Phe Leu Leu Met Ser Asp Glu 275
280 285 Leu Gly Leu Ala Asn Met Thr
Glu Gly Lys Ser Lys Lys Pro Lys Thr 290 295
300 Leu Ala Lys Glu Cys Leu Glu Lys Tyr Ser Thr Leu
Arg Asp Gln Thr 305 310 315
320 Asp Pro Ile Leu Ile Met Lys Ser Glu Lys Ala Asn Glu Asn Phe Leu
325 330 335 Trp Lys Leu
Trp Arg Asp Cys Val Asn Thr Ile Ser Asn Glu Glu Thr 340
345 350 Ser Asn Glu Leu Gln Lys Thr Asn
Tyr Ala Lys Trp Ala Thr Gly Asp 355 360
365 Gly Leu Thr Tyr Gln Lys Ile Met Lys Glu Val Ala Ile
Asp Asp Glu 370 375 380
Thr Met Cys Gln Glu Glu Pro Lys Ile Pro Asn Lys Cys Arg Val Ala 385
390 395 400 Ala Trp Val Gln
Thr Glu Met Asn Leu Leu Ser Thr Leu Thr Ser Lys 405
410 415 Arg Ala Leu Asp Leu Pro Glu Ile Gly
Pro Asp Ile Ala Pro Val Glu 420 425
430 His Val Gly Ser Glu Arg Arg Lys Tyr Phe Val Asn Glu Ile
Asn Tyr 435 440 445
Cys Lys Ala Ser Thr Val Met Met Lys Tyr Val Leu Phe His Thr Ser 450
455 460 Leu Leu Asn Glu Ser
Asn Ala Ser Met Gly Lys Tyr Lys Val Ile Pro 465 470
475 480 Ile Thr Asn Arg Val Val Asn Glu Lys Gly
Glu Ser Phe Asp Met Leu 485 490
495 Tyr Gly Leu Ala Val Lys Gly Gln Ser His Leu Arg Gly Asp Thr
Asp 500 505 510 Val
Val Thr Val Val Thr Phe Glu Phe Ser Ser Thr Asp Pro Arg Val 515
520 525 Asp Ser Gly Lys Trp Pro
Lys Tyr Thr Val Phe Arg Ile Gly Ser Leu 530 535
540 Phe Val Ser Gly Arg Glu Lys Ser Val Tyr Leu
Tyr Cys Arg Val Asn 545 550 555
560 Gly Thr Asn Lys Ile Gln Met Lys Trp Gly Met Glu Ala Arg Arg Cys
565 570 575 Leu Leu
Gln Ser Met Gln Gln Met Glu Ala Ile Val Glu Gln Glu Ser 580
585 590 Ser Ile Gln Gly Tyr Asp Met
Thr Lys Ala Cys Phe Lys Gly Asp Arg 595 600
605 Val Asn Ser Pro Lys Thr Phe Ser Ile Gly Thr Gln
Glu Gly Lys Leu 610 615 620
Val Lys Gly Ser Phe Gly Lys Ala Leu Arg Val Ile Phe Thr Lys Cys 625
630 635 640 Leu Met His
Tyr Val Phe Gly Asn Ala Gln Leu Glu Gly Phe Ser Ala 645
650 655 Glu Ser Arg Arg Leu Leu Leu Leu
Ile Gln Ala Leu Lys Asp Arg Lys 660 665
670 Gly Pro Trp Val Phe Asp Leu Glu Gly Met Tyr Ser Gly
Ile Glu Glu 675 680 685
Cys Ile Ser Asn Asn Pro Trp Val Ile Gln Ser Val Tyr Trp Phe Asn 690
695 700 Glu Trp Leu Gly
Phe Glu Lys Glu Gly Asn Lys Val Leu Glu Ser Val 705 710
715 720 Asp Glu Ile Met Asp Glu
725 84752PRTInfluenza 84Met Asn Ile Asn Pro Tyr Phe Leu Phe Ile
Asp Val Pro Val Gln Ala 1 5 10
15 Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Val Pro Pro Tyr Ser
His 20 25 30 Gly
Thr Gly Thr Gly Tyr Thr Ile Asp Thr Val Ile Arg Thr His Glu 35
40 45 Tyr Ser Asn Lys Gly Lys
Gln Tyr Ile Ser Asp Val Thr Gly Cys Thr 50 55
60 Met Val Asp Pro Thr Asn Gly Pro Leu Pro Glu
Asp Asn Glu Pro Ser 65 70 75
80 Ala Tyr Ala Gln Leu Asp Cys Val Leu Glu Ala Leu Asp Arg Met Asp
85 90 95 Glu Glu
His Pro Gly Leu Phe Gln Ala Ala Ser Gln Asn Ala Met Glu 100
105 110 Ala Leu Met Val Thr Thr Val
Asp Lys Leu Thr Gln Gly Arg Gln Thr 115 120
125 Phe Asp Trp Thr Val Cys Arg Asn Gln Pro Ala Ala
Thr Ala Leu Asn 130 135 140
Thr Thr Ile Thr Ser Phe Arg Leu Asn Asp Leu Asn Gly Ala Asp Lys 145
150 155 160 Gly Gly Leu
Ile Pro Phe Cys Gln Asp Ile Ile Asp Ser Leu Asp Arg 165
170 175 Pro Glu Met Thr Phe Phe Ser Val
Lys Asn Ile Lys Lys Lys Leu Pro 180 185
190 Ala Lys Asn Arg Lys Gly Phe Leu Ile Lys Arg Ile Pro
Met Lys Val 195 200 205
Lys Asp Lys Ile Thr Lys Val Glu Tyr Ile Lys Arg Ala Leu Ser Leu 210
215 220 Asn Thr Met Thr
Lys Asp Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225 230
235 240 Ile Ala Thr Ala Gly Ile Gln Ile Arg
Gly Phe Val Leu Val Val Glu 245 250
255 Asn Leu Ala Lys Asn Ile Cys Glu Asn Leu Glu Gln Ser Gly
Leu Pro 260 265 270
Val Gly Gly Asn Glu Lys Lys Ala Lys Leu Ser Asn Ala Val Ala Lys
275 280 285 Met Leu Ser Asn
Cys Pro Pro Gly Gly Ile Ser Met Thr Val Thr Gly 290
295 300 Asp Asn Thr Lys Trp Asn Glu Cys
Leu Asn Pro Arg Ile Phe Leu Ala 305 310
315 320 Met Thr Glu Arg Ile Thr Arg Asp Ser Pro Val Trp
Phe Arg Asp Phe 325 330
335 Cys Ser Ile Ala Pro Val Leu Phe Ser Asn Lys Ile Ala Arg Leu Gly
340 345 350 Lys Gly Phe
Met Ile Thr Ser Lys Thr Lys Arg Leu Lys Ala Gln Ile 355
360 365 Pro Cys Pro Asp Leu Phe Ser Ile
Pro Leu Glu Arg Tyr Asn Glu Glu 370 375
380 Thr Arg Ala Lys Leu Lys Lys Leu Lys Pro Phe Phe Asn
Glu Glu Gly 385 390 395
400 Thr Ala Ser Leu Ser Pro Gly Met Met Met Gly Met Phe Asn Met Leu
405 410 415 Ser Thr Val Leu
Gly Val Ala Ala Leu Gly Ile Lys Asn Ile Gly Asn 420
425 430 Lys Glu Tyr Leu Trp Asp Gly Leu Gln
Ser Ser Asp Asp Phe Ala Leu 435 440
445 Phe Val Asn Ala Lys Asp Glu Glu Thr Cys Met Glu Gly Ile
Asn Asp 450 455 460
Phe Tyr Arg Thr Cys Lys Leu Leu Gly Val Asn Met Ser Lys Lys Lys 465
470 475 480 Ser Tyr Cys Asn Glu
Thr Gly Met Phe Glu Phe Thr Ser Met Phe Tyr 485
490 495 Arg Asp Gly Phe Val Ser Asn Phe Ala Met
Glu Leu Pro Ser Phe Gly 500 505
510 Val Ala Gly Val Asn Glu Ser Ala Asp Met Ala Ile Gly Met Thr
Ile 515 520 525 Ile
Lys Asn Asn Met Ile Asn Asn Gly Met Gly Pro Ala Thr Ala Gln 530
535 540 Thr Ala Ile Gln Leu Phe
Ile Ala Asp Tyr Arg Tyr Thr Tyr Lys Cys 545 550
555 560 His Arg Gly Asp Ser Lys Val Glu Gly Lys Arg
Met Lys Ile Ile Lys 565 570
575 Glu Leu Trp Glu Asn Thr Lys Gly Arg Asp Gly Leu Leu Val Ala Asp
580 585 590 Gly Gly
Pro Asn Ile Tyr Asn Leu Arg Asn Leu His Ile Pro Glu Ile 595
600 605 Val Leu Lys Tyr Asn Leu Met
Asp Pro Glu Tyr Lys Gly Arg Leu Leu 610 615
620 His Pro Gln Asn Pro Phe Val Gly His Leu Ser Ile
Glu Gly Ile Lys 625 630 635
640 Glu Ala Asp Ile Thr Pro Ala His Gly Pro Val Lys Lys Met Asp Tyr
645 650 655 Asp Ala Val
Ser Gly Thr His Ser Trp Arg Thr Lys Arg Asn Arg Ser 660
665 670 Ile Leu Asn Thr Asp Gln Arg Asn
Met Ile Leu Glu Glu Gln Cys Tyr 675 680
685 Ala Lys Cys Cys Asn Leu Phe Glu Ala Cys Phe Asn Ser
Ala Ser Tyr 690 695 700
Arg Lys Pro Val Gly Gln His Ser Met Leu Glu Ala Met Ala His Arg 705
710 715 720 Leu Arg Met Asp
Ala Arg Leu Asp Tyr Glu Ser Gly Arg Met Ser Lys 725
730 735 Asp Asp Phe Glu Lys Ala Met Ala His
Leu Gly Glu Ile Gly Tyr Ile 740 745
750 85770PRTInfluenza 85Met Thr Leu Ala Lys Ile Glu Leu Leu
Lys Gln Leu Leu Arg Asp Asn 1 5 10
15 Glu Ala Lys Thr Val Leu Lys Gln Thr Thr Val Asp Gln Tyr
Asn Ile 20 25 30
Ile Arg Lys Phe Asn Thr Ser Arg Ile Glu Lys Asn Pro Ser Leu Arg
35 40 45 Met Lys Trp Ala
Met Cys Ser Asn Phe Pro Leu Ala Leu Thr Lys Gly 50
55 60 Asp Met Ala Asn Arg Ile Pro Leu
Glu Tyr Lys Gly Ile Gln Leu Lys 65 70
75 80 Thr Asn Ala Glu Asp Ile Gly Thr Lys Gly Gln Met
Cys Ser Ile Ala 85 90
95 Ala Val Thr Trp Trp Asn Thr Tyr Gly Pro Ile Gly Asp Thr Glu Gly
100 105 110 Phe Glu Arg
Val Tyr Glu Ser Phe Phe Leu Arg Lys Met Arg Leu Asp 115
120 125 Asn Ala Thr Trp Gly Arg Ile Thr
Phe Gly Pro Val Glu Arg Val Arg 130 135
140 Lys Arg Val Leu Leu Asn Pro Leu Thr Lys Glu Met Pro
Pro Asp Glu 145 150 155
160 Ala Ser Asn Val Ile Met Glu Ile Leu Phe Pro Lys Glu Ala Gly Ile
165 170 175 Pro Arg Glu Ser
Thr Trp Ile His Arg Glu Leu Ile Lys Glu Lys Arg 180
185 190 Glu Lys Leu Lys Gly Thr Met Ile Thr
Pro Ile Val Leu Ala Tyr Met 195 200
205 Leu Glu Arg Glu Leu Val Ala Arg Arg Arg Phe Leu Pro Val
Ala Gly 210 215 220
Ala Thr Ser Ala Glu Phe Ile Glu Met Leu His Cys Leu Gln Gly Glu 225
230 235 240 Asn Trp Arg Gln Ile
Tyr His Pro Gly Gly Asn Lys Leu Thr Glu Ser 245
250 255 Arg Ser Gln Ser Met Ile Val Ala Cys Arg
Lys Ile Ile Arg Arg Ser 260 265
270 Ile Val Ala Ser Asn Pro Leu Glu Leu Ala Val Glu Ile Ala Asn
Lys 275 280 285 Thr
Val Ile Asp Thr Glu Pro Leu Lys Ser Cys Leu Ala Ala Ile Asp 290
295 300 Gly Gly Asp Val Ala Cys
Asp Ile Ile Arg Ala Ala Leu Gly Leu Lys 305 310
315 320 Ile Arg Gln Arg Gln Arg Phe Gly Arg Leu Glu
Leu Lys Arg Ile Ser 325 330
335 Gly Arg Gly Phe Lys Asn Asp Glu Glu Ile Leu Ile Gly Asn Gly Thr
340 345 350 Ile Gln
Lys Ile Gly Ile Trp Asp Gly Glu Glu Glu Phe His Val Arg 355
360 365 Cys Gly Glu Cys Arg Gly Ile
Leu Lys Lys Ser Lys Met Lys Leu Glu 370 375
380 Lys Leu Leu Ile Asn Ser Ala Lys Lys Glu Asp Met
Arg Asp Leu Ile 385 390 395
400 Ile Leu Cys Met Val Phe Ser Gln Asp Thr Arg Met Phe Gln Gly Val
405 410 415 Arg Gly Glu
Ile Asn Phe Leu Asn Arg Ala Gly Gln Leu Leu Ser Pro 420
425 430 Met Tyr Gln Leu Gln Arg Tyr Phe
Leu Asn Arg Ser Asn Asp Leu Phe 435 440
445 Asp Gln Trp Gly Tyr Glu Glu Ser Pro Lys Ala Ser Glu
Leu His Gly 450 455 460
Ile Asn Glu Ser Met Asn Ala Ser Asp Tyr Thr Leu Lys Gly Ile Val 465
470 475 480 Val Thr Arg Asn
Val Ile Asp Asp Phe Ser Ser Ile Glu Thr Glu Lys 485
490 495 Val Ser Ile Thr Lys Asn Leu Ser Leu
Ile Lys Arg Thr Gly Glu Val 500 505
510 Ile Met Gly Ala Asn Asp Val Ser Glu Leu Glu Ser Gln Ala
Gln Leu 515 520 525
Met Ile Thr Tyr Asp Thr Pro Lys Met Trp Glu Met Gly Thr Thr Lys 530
535 540 Glu Leu Val Gln Asn
Thr Tyr Gln Trp Val Leu Lys Asn Leu Val Thr 545 550
555 560 Leu Lys Ala Gln Phe Leu Leu Gly Lys Glu
Asp Met Phe Gln Trp Asp 565 570
575 Ala Phe Glu Ala Phe Glu Ser Ile Ile Pro Gln Lys Met Ala Gly
Gln 580 585 590 Tyr
Ser Gly Phe Ala Arg Ala Val Leu Lys Gln Met Arg Asp Gln Glu 595
600 605 Val Met Lys Thr Asp Gln
Phe Ile Lys Leu Leu Pro Phe Cys Phe Ser 610 615
620 Pro Pro Lys Leu Arg Ser Asn Gly Glu Pro Tyr
Gln Phe Leu Lys Leu 625 630 635
640 Val Leu Lys Gly Gly Gly Glu Asn Phe Ile Glu Val Arg Lys Gly Ser
645 650 655 Pro Leu
Phe Ser Tyr Asn Pro Gln Thr Glu Val Leu Thr Ile Cys Gly 660
665 670 Arg Met Met Ser Leu Lys Gly
Lys Ile Glu Asp Glu Glu Arg Asn Arg 675 680
685 Ser Met Gly Asn Ala Val Leu Ala Gly Phe Leu Val
Ser Gly Lys Tyr 690 695 700
Asp Pro Asp Leu Gly Asp Phe Lys Thr Ile Glu Glu Leu Glu Lys Leu 705
710 715 720 Lys Pro Gly
Glu Lys Ala Asn Ile Leu Leu Tyr Gln Gly Lys Pro Val 725
730 735 Lys Val Val Lys Arg Lys Arg Tyr
Ser Ala Leu Ser Asn Asp Ile Ser 740 745
750 Gln Gly Ile Lys Arg Gln Arg Met Thr Val Glu Ser Met
Gly Trp Ala 755 760 765
Leu Ser 770 86560PRTInfluenza 86Met Ser Asn Met Asp Ile Asp Gly Ile
Asn Thr Gly Thr Ile Asp Lys 1 5 10
15 Thr Pro Glu Glu Ile Thr Ser Gly Thr Ser Gly Thr Thr Arg
Pro Ile 20 25 30
Ile Arg Pro Ala Thr Leu Ala Pro Pro Ser Asn Lys Arg Thr Arg Asn
35 40 45 Pro Ser Pro Glu
Arg Ala Thr Thr Ser Ser Glu Asp Asp Val Gly Arg 50
55 60 Lys Thr Gln Lys Lys Gln Thr Pro
Thr Glu Ile Lys Lys Ser Val Tyr 65 70
75 80 Asn Met Val Val Lys Leu Gly Glu Phe Tyr Asn Gln
Met Met Val Lys 85 90
95 Ala Gly Leu Asn Asp Asp Met Glu Arg Asn Leu Ile Gln Asn Ala His
100 105 110 Ala Val Glu
Arg Ile Leu Leu Ala Ala Thr Asp Asp Lys Lys Thr Glu 115
120 125 Phe Gln Lys Lys Lys Asn Ala Arg
Asp Val Lys Glu Gly Lys Glu Glu 130 135
140 Ile Asp His Asn Lys Thr Gly Gly Thr Phe Tyr Lys Met
Val Arg Asp 145 150 155
160 Asp Lys Thr Ile Tyr Phe Ser Pro Ile Arg Ile Thr Phe Leu Lys Glu
165 170 175 Glu Val Lys Thr
Met Tyr Lys Thr Thr Met Gly Ser Asp Gly Phe Ser 180
185 190 Gly Leu Asn His Ile Met Ile Gly His
Ser Gln Met Asn Asp Val Cys 195 200
205 Phe Gln Arg Ser Lys Ala Leu Lys Arg Val Gly Leu Asp Pro
Ser Leu 210 215 220
Ile Ser Thr Phe Ala Gly Ser Thr Val Pro Arg Arg Ser Gly Ala Thr 225
230 235 240 Gly Val Ala Ile Lys
Gly Gly Gly Thr Leu Val Ala Glu Ala Ile Arg 245
250 255 Phe Ile Gly Arg Ala Met Ala Asp Arg Gly
Leu Leu Arg Asp Ile Lys 260 265
270 Ala Lys Thr Ala Tyr Glu Lys Ile Leu Leu Asn Leu Lys Asn Lys
Cys 275 280 285 Ser
Ala Pro Gln Gln Lys Ala Leu Val Asp Gln Val Ile Gly Ser Arg 290
295 300 Asn Pro Gly Ile Ala Asp
Ile Glu Asp Leu Thr Leu Leu Ala Arg Ser 305 310
315 320 Met Val Val Val Arg Pro Ser Val Ala Ser Lys
Val Val Leu Pro Ile 325 330
335 Ser Ile Tyr Ala Lys Ile Pro Gln Leu Gly Phe Asn Val Glu Glu Tyr
340 345 350 Ser Met
Val Gly Tyr Glu Ala Met Ala Leu Tyr Asn Met Ala Thr Pro 355
360 365 Val Ser Ile Leu Arg Met Gly
Asp Asp Ala Lys Asp Lys Ser Gln Leu 370 375
380 Phe Phe Met Ser Cys Phe Gly Ala Ala Tyr Glu Asp
Leu Arg Val Leu 385 390 395
400 Ser Ala Leu Thr Gly Thr Glu Phe Lys Pro Arg Ser Ala Leu Lys Cys
405 410 415 Lys Gly Phe
His Val Pro Ala Lys Glu Gln Val Glu Gly Met Gly Ala 420
425 430 Ala Leu Met Ser Ile Lys Leu Gln
Phe Trp Ala Pro Met Thr Arg Ser 435 440
445 Gly Gly Asn Glu Val Gly Gly Asp Gly Gly Ser Gly Gln
Ile Ser Cys 450 455 460
Ser Pro Val Phe Ala Val Glu Arg Pro Ile Ala Leu Ser Lys Gln Ala 465
470 475 480 Val Arg Arg Met
Leu Ser Met Asn Ile Glu Gly Arg Asp Ala Asp Val 485
490 495 Lys Gly Asn Leu Leu Lys Met Met Asn
Asp Ser Met Ala Lys Lys Thr 500 505
510 Ser Gly Asn Ala Phe Ile Gly Lys Lys Met Phe Gln Ile Ser
Asp Lys 515 520 525
Asn Lys Thr Asn Pro Ile Glu Ile Pro Ile Lys Gln Thr Ile Pro Asn 530
535 540 Phe Phe Phe Gly Arg
Asp Thr Ala Glu Asp Tyr Asp Asp Leu Asp Tyr 545 550
555 560 87248PRTInfluenza 87Met Ser Leu Phe Gly
Asp Thr Ile Ala Tyr Leu Leu Ser Leu Thr Glu 1 5
10 15 Asp Gly Glu Gly Lys Ala Glu Leu Ala Glu
Lys Leu His Cys Trp Phe 20 25
30 Gly Gly Lys Glu Phe Asp Leu Asp Ser Ala Leu Glu Trp Ile Lys
Asn 35 40 45 Lys
Arg Cys Leu Thr Asp Ile Gln Lys Ala Leu Ile Gly Ala Ser Ile 50
55 60 Cys Phe Leu Lys Pro Lys
Asp Gln Glu Arg Lys Arg Arg Phe Ile Thr 65 70
75 80 Glu Pro Leu Ser Gly Met Gly Thr Thr Ala Thr
Lys Lys Lys Gly Leu 85 90
95 Ile Leu Ala Glu Arg Lys Met Arg Arg Cys Val Ser Phe His Glu Ala
100 105 110 Phe Glu
Ile Ala Glu Gly His Glu Ser Ser Ala Leu Leu Tyr Cys Leu 115
120 125 Met Val Met Tyr Leu Asn Pro
Gly Asn Tyr Ser Met Gln Val Lys Leu 130 135
140 Gly Thr Leu Cys Ala Leu Cys Glu Lys Gln Ala Ser
His Ser His Arg 145 150 155
160 Ala His Ser Arg Ala Ala Arg Ser Ser Val Pro Gly Val Arg Arg Glu
165 170 175 Met Gln Met
Val Ser Ala Met Asn Thr Ala Lys Thr Met Asn Gly Met 180
185 190 Gly Lys Gly Glu Asp Val Gln Lys
Leu Ala Glu Glu Leu Gln Ser Asn 195 200
205 Ile Gly Val Leu Arg Ser Leu Gly Ala Ser Gln Lys Asn
Gly Glu Gly 210 215 220
Ile Ala Lys Asp Val Met Glu Val Leu Lys Gln Ser Ser Met Gly Asn 225
230 235 240 Ser Ala Leu Val
Lys Lys Tyr Leu 245 88109PRTInfluenza 88Met
Leu Glu Pro Phe Gln Ile Leu Thr Ile Cys Ser Phe Ile Leu Ser 1
5 10 15 Ala Leu His Phe Met Ala
Trp Thr Ile Gly His Leu Asn Gln Ile Lys 20
25 30 Arg Gly Ile Asn Met Lys Ile Arg Ile Lys
Gly Pro Asn Lys Glu Thr 35 40
45 Ile Asn Arg Glu Val Ser Ile Leu Arg His Ser Tyr Gln Lys
Glu Ile 50 55 60
Gln Ala Lys Glu Thr Met Lys Glu Val Leu Ser Asp Asn Met Glu Val 65
70 75 80 Leu Asn Asp His Ile
Ile Ile Glu Gly Leu Ser Ala Glu Glu Ile Ile 85
90 95 Lys Met Gly Glu Thr Val Leu Glu Ile Glu
Glu Leu His 100 105
89282PRTInfluenza 89Met Ala Asn Asn Asn Met Thr Thr Thr Gln Ile Glu Val
Gly Pro Gly 1 5 10 15
Ala Thr Asn Ala Thr Ile Asn Phe Glu Ala Gly Ile Leu Glu Cys Tyr
20 25 30 Glu Arg Leu Ser
Trp Gln Arg Ala Leu Asp Tyr Pro Gly Gln Asp Arg 35
40 45 Leu Asn Arg Leu Lys Arg Lys Leu Glu
Ser Arg Ile Lys Thr His Asn 50 55
60 Lys Ser Glu Pro Glu Ser Lys Arg Met Ser Leu Glu Glu
Arg Lys Ala 65 70 75
80 Ile Gly Val Lys Met Met Lys Val Leu Leu Phe Met Asn Pro Ser Ala
85 90 95 Gly Ile Glu Gly
Phe Glu Pro Tyr Cys Met Lys Ser Ser Ser Asn Ser 100
105 110 Asn Cys Thr Lys Tyr Asn Trp Thr Asp
Tyr Pro Ser Thr Pro Glu Arg 115 120
125 Cys Leu Asp Asp Ile Glu Glu Glu Pro Glu Asp Val Asp Gly
Pro Thr 130 135 140
Glu Ile Val Leu Arg Asp Met Asn Asn Lys Asp Ala Arg Gln Lys Ile 145
150 155 160 Lys Glu Glu Val Asn
Thr Gln Lys Glu Gly Lys Phe Arg Leu Thr Ile 165
170 175 Lys Arg Asp Met Arg Asn Val Leu Ser Leu
Arg Val Leu Val Asn Gly 180 185
190 Thr Phe Leu Lys His Pro Asn Gly His Lys Ser Leu Ser Thr Leu
His 195 200 205 Arg
Leu Asn Ala Tyr Asp Gln Ser Gly Arg Leu Val Ala Lys Leu Val 210
215 220 Ala Thr Asp Asp Leu Thr
Val Glu Asp Glu Glu Asp Gly His Arg Ile 225 230
235 240 Leu Asn Ser Leu Phe Glu Arg Leu Asn Glu Gly
His Ser Lys Pro Ile 245 250
255 Arg Ala Ala Glu Thr Ala Val Gly Val Leu Ser Gln Phe Gly Gln Glu
260 265 270 His Arg
Leu Ser Pro Glu Glu Gly Asp Asn 275 280
90123PRTInfluenza 90Met Ala Asn Asn Asn Met Thr Thr Thr Gln Ile Glu Trp
Arg Met Lys 1 5 10 15
Lys Met Ala Ile Gly Ser Ser Thr His Ser Ser Ser Val Leu Met Lys
20 25 30 Asp Ile Gln Ser
Gln Phe Glu Gln Leu Lys Leu Arg Trp Glu Ser Tyr 35
40 45 Pro Asn Leu Val Lys Ser Thr Asp Tyr
His Gln Lys Arg Glu Thr Ile 50 55
60 Arg Leu Val Thr Glu Glu Leu Tyr Leu Leu Ser Lys Arg
Ile Asp Asp 65 70 75
80 Asn Ile Leu Phe His Lys Thr Val Ile Ala Asn Ser Ser Ile Ile Ala
85 90 95 Asp Met Val Val
Ser Leu Ser Leu Leu Glu Thr Leu Tyr Glu Met Lys 100
105 110 Asp Val Val Glu Val Tyr Ser Arg Gln
Cys Leu 115 120 91726PRTInfluenza
91Met Asp Thr Phe Ile Thr Arg Asn Phe Gln Thr Thr Ile Ile Gln Lys 1
5 10 15 Ala Lys Asn Thr
Met Ala Glu Phe Ser Glu Asp Pro Glu Leu Gln Pro 20
25 30 Ala Met Leu Phe Asn Ile Cys Val His
Leu Glu Val Cys Tyr Val Ile 35 40
45 Ser Asp Met Asn Phe Leu Asp Glu Glu Gly Lys Ser Tyr Thr
Ala Leu 50 55 60
Glu Gly Gln Gly Lys Glu Gln Asn Leu Arg Pro Gln Tyr Glu Val Ile 65
70 75 80 Glu Gly Met Pro Arg
Thr Ile Ala Trp Met Val Gln Arg Ser Leu Ala 85
90 95 Gln Glu His Gly Ile Glu Thr Pro Lys Tyr
Leu Ala Asp Leu Phe Asp 100 105
110 Tyr Lys Thr Lys Arg Phe Ile Glu Val Gly Ile Thr Lys Gly Leu
Ala 115 120 125 Asp
Asp Tyr Phe Trp Lys Lys Lys Glu Lys Leu Gly Asn Ser Met Glu 130
135 140 Leu Met Ile Phe Ser Tyr
Asn Gln Asp Tyr Ser Leu Ser Asn Glu Ser 145 150
155 160 Ser Leu Asp Glu Glu Gly Lys Gly Arg Val Leu
Ser Arg Leu Thr Glu 165 170
175 Leu Gln Ala Glu Leu Ser Leu Lys Asn Leu Trp Gln Val Leu Ile Gly
180 185 190 Glu Glu
Asp Val Glu Lys Gly Ile Asp Phe Lys Leu Gly Gln Thr Ile 195
200 205 Ser Arg Leu Arg Asp Ile Ser
Val Pro Ala Gly Phe Ser Asn Phe Glu 210 215
220 Gly Met Arg Ser Tyr Ile Asp Asn Ile Asp Pro Lys
Gly Ala Ile Glu 225 230 235
240 Arg Asn Leu Ala Arg Met Ser Pro Leu Val Ser Ala Thr Pro Lys Lys
245 250 255 Leu Lys Trp
Glu Asp Leu Arg Pro Ile Gly Pro His Ile Tyr Asn His 260
265 270 Glu Leu Pro Glu Val Pro Tyr Asn
Ala Phe Leu Leu Met Ser Asp Glu 275 280
285 Leu Gly Leu Ala Asn Met Thr Glu Gly Lys Ser Lys Lys
Pro Lys Thr 290 295 300
Leu Ala Lys Glu Cys Leu Glu Lys Tyr Ser Thr Leu Arg Asp Gln Thr 305
310 315 320 Asp Pro Ile Leu
Ile Met Lys Ser Glu Lys Ala Asn Glu Asn Phe Leu 325
330 335 Trp Lys Leu Trp Arg Asp Cys Val Asn
Thr Ile Ser Asn Glu Glu Met 340 345
350 Ser Asn Glu Leu Gln Lys Thr Asn Tyr Ala Lys Trp Ala Thr
Gly Asp 355 360 365
Gly Leu Thr Tyr Gln Lys Ile Met Lys Glu Val Ala Ile Asp Asp Glu 370
375 380 Thr Met Cys Gln Glu
Glu Pro Lys Ile Pro Asn Lys Cys Arg Val Ala 385 390
395 400 Ala Trp Val Gln Thr Glu Met Asn Leu Leu
Ser Thr Leu Thr Ser Lys 405 410
415 Arg Ala Leu Asp Leu Pro Glu Ile Gly Pro Asp Val Ala Pro Val
Glu 420 425 430 His
Val Gly Ser Glu Arg Arg Lys Tyr Phe Val Asn Glu Ile Asn Cys 435
440 445 Cys Lys Ala Ser Thr Val
Met Met Lys Tyr Val Leu Phe His Thr Ser 450 455
460 Leu Leu Asn Glu Ser Asn Ala Ser Met Gly Lys
Tyr Lys Val Ile Pro 465 470 475
480 Ile Thr Asn Arg Val Val Asn Glu Lys Gly Glu Ser Phe Asp Met Leu
485 490 495 Tyr Gly
Leu Ala Val Lys Gly Gln Ser His Leu Arg Gly Asp Thr Asp 500
505 510 Val Val Thr Val Val Thr Phe
Glu Phe Ser Gly Thr Asp Pro Arg Val 515 520
525 Asp Ser Gly Lys Trp Pro Lys Tyr Thr Val Phe Arg
Ile Gly Ser Leu 530 535 540
Phe Val Ser Gly Arg Glu Lys Ser Val Tyr Leu Tyr Cys Arg Val Asn 545
550 555 560 Gly Thr Asn
Lys Ile Gln Met Lys Trp Gly Met Glu Ala Arg Arg Cys 565
570 575 Leu Leu Gln Ser Met Gln Gln Met
Glu Ala Ile Val Glu Gln Glu Ser 580 585
590 Ser Ile Gln Gly Tyr Asp Met Thr Lys Ala Cys Phe Lys
Gly Asp Arg 595 600 605
Val Asn Ser Pro Lys Thr Phe Ser Ile Gly Thr Gln Glu Gly Lys Leu 610
615 620 Val Lys Gly Ser
Phe Gly Lys Ala Leu Arg Val Ile Phe Thr Lys Cys 625 630
635 640 Leu Met His Tyr Val Phe Gly Asn Ala
Gln Leu Glu Gly Phe Ser Ala 645 650
655 Glu Ser Arg Arg Leu Leu Leu Leu Ile Gln Ala Leu Lys Asp
Arg Lys 660 665 670
Gly Pro Trp Val Phe Asp Leu Glu Gly Met Tyr Ser Gly Ile Glu Glu
675 680 685 Cys Ile Ser Asn
Asn Pro Trp Val Ile Gln Ser Ala Tyr Trp Phe Asn 690
695 700 Glu Trp Leu Gly Phe Glu Lys Glu
Gly Ser Lys Val Leu Glu Ser Val 705 710
715 720 Asp Glu Ile Met Asn Glu 725
92752PRTInfluenza 92Met Asn Ile Asn Pro Tyr Phe Leu Phe Ile Asp Val Pro
Ile Gln Ala 1 5 10 15
Ala Ile Ser Thr Thr Phe Pro Tyr Thr Gly Val Pro Pro Tyr Ser His
20 25 30 Gly Thr Gly Thr
Gly His Thr Ile Asp Thr Val Ile Arg Thr His Glu 35
40 45 Tyr Ser Asn Lys Gly Lys Gln Tyr Val
Ser Asp Ile Thr Gly Cys Thr 50 55
60 Met Val Asp Pro Thr Asn Gly Pro Leu Pro Glu Asp Asn
Glu Pro Ser 65 70 75
80 Ala Tyr Ala Gln Leu Asp Cys Val Leu Glu Ala Leu Asp Arg Met Asp
85 90 95 Glu Glu His Pro
Gly Leu Phe Gln Ala Ala Ser Gln Asn Ala Met Glu 100
105 110 Ala Leu Met Val Thr Thr Val Asp Lys
Leu Thr Gln Gly Arg Gln Thr 115 120
125 Phe Asp Trp Thr Val Cys Arg Asn Gln Pro Ala Ala Thr Ala
Leu Asn 130 135 140
Thr Thr Ile Thr Ser Phe Arg Leu Asn Asp Leu Asn Gly Ala Asp Lys 145
150 155 160 Gly Gly Leu Val Pro
Phe Cys Gln Asp Ile Ile Asp Ser Leu Asp Lys 165
170 175 Pro Glu Met Thr Phe Phe Ser Val Lys Asn
Ile Lys Lys Lys Leu Pro 180 185
190 Ala Lys Asn Arg Lys Gly Phe Leu Ile Lys Arg Ile Pro Met Lys
Val 195 200 205 Lys
Asp Arg Ile Thr Arg Val Glu Tyr Ile Lys Arg Ala Leu Ser Leu 210
215 220 Asn Thr Met Thr Lys Asp
Ala Glu Arg Gly Lys Leu Lys Arg Arg Ala 225 230
235 240 Ile Ala Thr Ala Gly Ile Gln Ile Arg Gly Phe
Val Leu Val Val Glu 245 250
255 Asn Leu Ala Lys Asn Ile Cys Glu Asn Leu Glu Gln Ser Gly Leu Pro
260 265 270 Val Gly
Gly Asn Glu Lys Lys Ala Lys Leu Ser Asn Ala Val Ala Lys 275
280 285 Met Leu Ser Asn Cys Pro Pro
Gly Gly Ile Ser Met Thr Val Thr Gly 290 295
300 Asp Asn Thr Lys Trp Asn Glu Cys Leu Asn Pro Arg
Ile Phe Leu Ala 305 310 315
320 Met Thr Glu Arg Ile Thr Arg Asp Ser Pro Ile Trp Phe Arg Asp Phe
325 330 335 Cys Ser Ile
Ala Pro Val Leu Phe Ser Asn Lys Ile Ala Arg Leu Gly 340
345 350 Lys Gly Phe Met Ile Thr Ser Lys
Thr Lys Arg Leu Lys Ala Gln Ile 355 360
365 Pro Cys Pro Asp Leu Phe Ser Ile Pro Leu Glu Arg Tyr
Asn Glu Glu 370 375 380
Thr Arg Ala Lys Leu Lys Lys Leu Lys Pro Phe Phe Asn Glu Glu Gly 385
390 395 400 Thr Ala Ser Leu
Ser Pro Gly Met Met Met Gly Met Phe Asn Met Leu 405
410 415 Ser Thr Val Leu Gly Val Ala Ala Leu
Gly Ile Lys Asn Ile Gly Asn 420 425
430 Lys Glu Tyr Leu Trp Asp Gly Leu Gln Ser Ser Asp Asp Phe
Ala Leu 435 440 445
Phe Val Asn Ala Lys Asp Glu Glu Thr Cys Met Glu Gly Ile Asn Asp 450
455 460 Phe Tyr Arg Thr Cys
Lys Leu Leu Gly Ile Asn Met Ser Lys Lys Lys 465 470
475 480 Ser Tyr Cys Asn Glu Thr Gly Met Phe Glu
Phe Thr Ser Met Phe Tyr 485 490
495 Arg Asp Gly Phe Val Ser Asn Phe Ala Met Glu Ile Pro Ser Phe
Gly 500 505 510 Val
Ala Gly Val Asn Glu Ser Ala Asp Met Ala Ile Gly Met Thr Ile 515
520 525 Ile Lys Asn Asn Met Ile
Asn Asn Gly Met Gly Pro Ala Thr Ala Gln 530 535
540 Thr Ala Ile Gln Leu Phe Ile Ala Asp Tyr Arg
Tyr Thr Tyr Lys Cys 545 550 555
560 His Arg Gly Asp Ser Lys Val Glu Gly Lys Arg Met Lys Ile Ile Lys
565 570 575 Glu Leu
Trp Glu Asn Thr Lys Gly Arg Asp Gly Leu Leu Val Ala Asp 580
585 590 Gly Gly Pro Asn Ile Tyr Asn
Leu Arg Asn Leu His Ile Pro Glu Ile 595 600
605 Val Leu Lys Tyr Asn Leu Met Asp Pro Glu Tyr Lys
Gly Arg Leu Leu 610 615 620
His Pro Gln Asn Pro Phe Val Gly His Leu Ser Ile Glu Gly Ile Lys 625
630 635 640 Glu Ala Asp
Ile Thr Pro Ala His Gly Pro Val Lys Lys Met Asp Tyr 645
650 655 Asp Ala Val Ser Gly Thr His Ser
Trp Arg Thr Lys Arg Asn Arg Ser 660 665
670 Ile Leu Asn Thr Asp Gln Arg Asn Met Ile Leu Glu Glu
Gln Cys Tyr 675 680 685
Ala Lys Cys Cys Asn Leu Phe Glu Ala Cys Phe Asn Ser Ala Ser Tyr 690
695 700 Arg Lys Pro Val
Gly Gln His Ser Met Leu Glu Ala Met Ala His Arg 705 710
715 720 Leu Arg Val Asp Ala Arg Leu Asp Tyr
Glu Ser Gly Arg Met Ser Lys 725 730
735 Asp Asp Phe Glu Lys Ala Met Ala His Leu Gly Glu Ile Gly
Tyr Ile 740 745 750
93770PRTInfluenza 93Met Thr Leu Ala Lys Ile Glu Leu Leu Lys Gln Leu Leu
Arg Asp Asn 1 5 10 15
Glu Ala Lys Thr Val Leu Lys Gln Thr Thr Val Asp Gln Tyr Asn Ile
20 25 30 Ile Arg Lys Phe
Asn Thr Ser Arg Ile Glu Lys Asn Pro Ser Leu Arg 35
40 45 Met Lys Trp Ala Met Cys Ser Asn Phe
Pro Leu Ala Leu Thr Lys Gly 50 55
60 Asp Met Ala Asn Arg Ile Pro Leu Glu Tyr Lys Gly Ile
Gln Leu Lys 65 70 75
80 Thr Asn Ala Glu Asp Ile Gly Thr Lys Gly Gln Met Cys Ser Ile Ala
85 90 95 Ala Val Thr Trp
Trp Asn Thr Tyr Gly Pro Ile Gly Asp Thr Glu Gly 100
105 110 Phe Glu Lys Val Tyr Glu Ser Phe Phe
Leu Arg Lys Met Arg Leu Asp 115 120
125 Asn Ala Thr Trp Gly Arg Ile Thr Phe Gly Pro Val Glu Arg
Val Arg 130 135 140
Lys Arg Val Leu Leu Asn Pro Leu Thr Lys Glu Met Pro Pro Asp Glu 145
150 155 160 Ala Ser Asn Val Ile
Met Glu Ile Leu Phe Pro Lys Glu Ala Gly Ile 165
170 175 Pro Arg Glu Ser Thr Trp Ile His Arg Glu
Leu Ile Lys Glu Lys Arg 180 185
190 Glu Lys Leu Lys Gly Thr Met Ile Thr Pro Ile Val Leu Ala Tyr
Met 195 200 205 Leu
Glu Arg Glu Leu Val Ala Arg Arg Arg Phe Leu Pro Val Ala Gly 210
215 220 Ala Thr Ser Ala Glu Phe
Ile Glu Met Leu His Cys Leu Gln Gly Glu 225 230
235 240 Asn Trp Arg Gln Ile Tyr His Pro Gly Gly Asn
Lys Leu Thr Glu Ser 245 250
255 Arg Ser Gln Ser Met Ile Val Ala Cys Arg Lys Ile Ile Arg Arg Ser
260 265 270 Ile Val
Ala Ser Asn Pro Leu Glu Leu Ala Val Glu Ile Ala Asn Lys 275
280 285 Thr Val Ile Asp Thr Glu Pro
Leu Lys Ser Cys Leu Thr Ala Ile Asp 290 295
300 Gly Gly Asp Val Ala Cys Asp Ile Ile Arg Ala Ala
Leu Gly Leu Lys 305 310 315
320 Ile Arg Gln Arg Gln Arg Phe Gly Arg Leu Glu Leu Lys Arg Ile Ser
325 330 335 Gly Arg Gly
Phe Lys Asn Asp Glu Glu Ile Leu Ile Gly Asn Gly Thr 340
345 350 Ile Gln Lys Ile Gly Ile Trp Asp
Gly Glu Glu Glu Phe His Val Arg 355 360
365 Cys Gly Glu Cys Arg Gly Ile Leu Lys Lys Ser Lys Met
Arg Met Glu 370 375 380
Lys Leu Leu Ile Asn Ser Ala Lys Lys Glu Asp Met Lys Asp Leu Ile 385
390 395 400 Ile Leu Cys Met
Val Phe Ser Gln Asp Thr Arg Met Phe Gln Gly Val 405
410 415 Arg Gly Glu Ile Asn Phe Leu Asn Arg
Ala Gly Gln Leu Leu Ser Pro 420 425
430 Met Tyr Gln Leu Gln Arg Tyr Phe Leu Asn Arg Ser Asn Asp
Leu Phe 435 440 445
Asp Gln Trp Gly Tyr Glu Glu Ser Pro Lys Ala Ser Glu Leu His Gly 450
455 460 Ile Asn Glu Leu Met
Asn Ala Ser Asp Tyr Thr Leu Lys Gly Val Val 465 470
475 480 Val Thr Lys Asn Val Ile Asp Asp Phe Ser
Ser Thr Glu Thr Glu Lys 485 490
495 Val Ser Ile Thr Lys Asn Leu Ser Leu Ile Lys Arg Thr Gly Glu
Val 500 505 510 Ile
Met Gly Ala Asn Asp Val Ser Glu Leu Glu Ser Gln Ala Gln Leu 515
520 525 Met Ile Thr Tyr Asp Thr
Pro Lys Met Trp Glu Met Gly Thr Thr Lys 530 535
540 Glu Leu Val Gln Asn Thr Tyr Gln Trp Val Leu
Lys Asn Leu Val Thr 545 550 555
560 Leu Lys Ala Gln Phe Leu Leu Gly Lys Glu Asp Met Phe Gln Trp Asp
565 570 575 Ala Phe
Glu Ala Phe Glu Ser Ile Ile Pro Gln Lys Met Ala Gly Gln 580
585 590 Tyr Ser Gly Phe Ala Arg Ala
Val Leu Lys Gln Met Arg Asp Gln Glu 595 600
605 Val Met Lys Thr Asp Gln Phe Ile Lys Leu Leu Pro
Phe Cys Phe Ser 610 615 620
Pro Pro Lys Leu Arg Arg Asn Gly Glu Pro Tyr Gln Phe Leu Arg Leu 625
630 635 640 Val Leu Lys
Gly Gly Gly Glu Asn Phe Ile Glu Val Arg Lys Gly Ser 645
650 655 Pro Leu Phe Ser Tyr Asn Pro Gln
Thr Glu Val Leu Thr Ile Cys Gly 660 665
670 Arg Met Met Ser Leu Lys Gly Lys Ile Glu Asp Glu Glu
Arg Asn Arg 675 680 685
Ser Met Gly Asn Ala Val Leu Ala Gly Phe Leu Val Ser Gly Lys Tyr 690
695 700 Asp Pro Asp Leu
Gly Asp Phe Lys Thr Ile Glu Glu Leu Glu Lys Leu 705 710
715 720 Lys Pro Gly Glu Lys Ala Asn Ile Leu
Leu Tyr Gln Gly Lys Pro Val 725 730
735 Lys Val Val Lys Arg Lys Arg Tyr Ser Ala Leu Ser Asn Asp
Ile Ser 740 745 750
Gln Gly Ile Lys Arg Gln Arg Met Thr Val Glu Ser Met Gly Trp Ala
755 760 765 Leu Ser 770
94560PRTInfluenza 94Met Ser Asn Met Asp Ile Asp Gly Ile Asn Thr Gly Thr
Ile Asp Lys 1 5 10 15
Thr Pro Glu Glu Ile Thr Ser Gly Thr Ser Gly Thr Thr Arg Pro Ile
20 25 30 Ile Arg Pro Ala
Thr Leu Ala Pro Pro Ser Asn Lys Arg Thr Arg Asn 35
40 45 Pro Ser Pro Glu Arg Ala Thr Thr Ser
Ser Glu Ala Asp Val Gly Arg 50 55
60 Lys Thr Gln Lys Lys Gln Thr Pro Thr Glu Ile Lys Lys
Ser Val Tyr 65 70 75
80 Asn Met Val Val Lys Leu Gly Glu Phe Tyr Asn Gln Met Met Val Lys
85 90 95 Ala Gly Leu Asn
Asp Asp Met Glu Arg Asn Leu Ile Gln Asn Ala His 100
105 110 Ala Val Glu Arg Ile Leu Leu Ala Ala
Thr Asp Asp Lys Lys Thr Glu 115 120
125 Phe Gln Arg Lys Lys Asn Ala Arg Asp Val Lys Glu Gly Lys
Glu Glu 130 135 140
Ile Asp His Asn Lys Thr Gly Gly Thr Phe Tyr Lys Met Val Arg Asp 145
150 155 160 Asp Lys Thr Ile Tyr
Phe Ser Pro Ile Arg Ile Thr Phe Leu Lys Glu 165
170 175 Glu Val Lys Thr Met Tyr Lys Thr Thr Met
Gly Ser Asp Gly Phe Ser 180 185
190 Gly Leu Asn His Ile Met Ile Gly His Ser Gln Met Asn Asp Val
Cys 195 200 205 Phe
Gln Arg Ser Lys Ala Leu Lys Arg Val Gly Leu Asp Pro Ser Leu 210
215 220 Ile Ser Thr Phe Ala Gly
Ser Thr Leu Pro Arg Arg Ser Gly Ala Thr 225 230
235 240 Gly Val Ala Ile Lys Gly Gly Gly Thr Leu Val
Ala Glu Ala Ile Arg 245 250
255 Phe Ile Gly Arg Ala Met Ala Asp Arg Gly Leu Leu Arg Asp Ile Lys
260 265 270 Ala Lys
Thr Ala Tyr Glu Lys Ile Leu Leu Asn Leu Lys Asn Lys Cys 275
280 285 Ser Ala Pro Gln Gln Lys Ala
Leu Val Asp Gln Val Ile Gly Ser Arg 290 295
300 Asn Pro Gly Ile Ala Asp Ile Glu Asp Leu Thr Leu
Leu Ala Arg Ser 305 310 315
320 Met Val Val Val Arg Pro Ser Val Ala Ser Lys Val Val Leu Pro Ile
325 330 335 Ser Ile Tyr
Ala Lys Ile Pro Gln Leu Gly Phe Asn Val Glu Glu Tyr 340
345 350 Ser Met Val Gly Tyr Glu Ala Met
Ala Leu Tyr Asn Met Ala Thr Pro 355 360
365 Val Ser Ile Leu Arg Met Gly Asp Asp Ala Lys Asp Lys
Ser Gln Leu 370 375 380
Phe Phe Met Ser Cys Phe Gly Ala Ala Tyr Glu Asp Leu Arg Val Leu 385
390 395 400 Ser Ala Leu Thr
Gly Ile Glu Phe Lys Pro Arg Ser Ala Leu Lys Cys 405
410 415 Lys Gly Phe His Val Pro Ala Lys Glu
Gln Val Glu Gly Met Gly Ala 420 425
430 Ala Leu Met Ser Ile Lys Leu Gln Phe Trp Ala Pro Met Thr
Arg Ser 435 440 445
Gly Gly Asn Glu Val Gly Gly Asp Gly Gly Ser Gly Gln Ile Ser Cys 450
455 460 Ser Pro Val Phe Ala
Val Glu Arg Pro Ile Ala Leu Ser Lys Gln Ala 465 470
475 480 Val Arg Arg Met Leu Ser Met Asn Ile Glu
Gly Arg Asp Ala Asp Val 485 490
495 Lys Gly Asn Leu Leu Lys Met Met Asn Asp Ser Met Ala Lys Lys
Thr 500 505 510 Asn
Gly Asn Ala Phe Ile Gly Lys Lys Met Phe Gln Ile Ser Asp Lys 515
520 525 Asn Lys Thr Asn Pro Val
Glu Ile Pro Ile Lys Gln Thr Ile Pro Asn 530 535
540 Phe Phe Phe Gly Arg Asp Thr Ala Glu Asp Tyr
Asp Asp Leu Asp Tyr 545 550 555
560 95248PRTInfluenza 95Met Ser Leu Phe Gly Asp Thr Ile Ala Tyr Leu
Leu Ser Leu Thr Glu 1 5 10
15 Asp Gly Glu Gly Lys Ala Glu Leu Ala Glu Lys Leu His Cys Trp Phe
20 25 30 Gly Gly
Lys Glu Phe Asp Leu Asp Ser Ala Leu Glu Trp Ile Lys Asn 35
40 45 Lys Arg Cys Leu Thr Asp Ile
Gln Lys Ala Leu Ile Gly Ala Ser Ile 50 55
60 Cys Phe Leu Lys Pro Lys Asp Gln Glu Arg Lys Arg
Arg Phe Ile Thr 65 70 75
80 Glu Pro Leu Ser Gly Met Gly Thr Thr Ala Thr Lys Lys Lys Gly Leu
85 90 95 Ile Leu Ala
Glu Arg Lys Met Arg Arg Cys Val Ser Phe His Glu Ala 100
105 110 Phe Glu Ile Ala Glu Gly His Glu
Ser Ser Ala Leu Leu Tyr Cys Leu 115 120
125 Met Val Met Tyr Leu Asn Pro Gly Asn Tyr Ser Met Gln
Val Lys Leu 130 135 140
Gly Thr Leu Cys Ala Leu Cys Glu Lys Gln Ala Ser His Ser His Arg 145
150 155 160 Ala His Ser Arg
Ala Ala Arg Ser Ser Val Pro Gly Val Arg Arg Glu 165
170 175 Met Gln Met Val Ser Ala Met Asn Thr
Ala Lys Thr Met Asn Gly Met 180 185
190 Gly Lys Gly Glu Asp Val Gln Lys Leu Ala Glu Glu Leu Gln
Ser Asn 195 200 205
Ile Gly Val Leu Arg Ser Leu Gly Ala Ser Gln Lys Asn Gly Glu Gly 210
215 220 Ile Ala Lys Asp Val
Met Glu Val Leu Lys Gln Ser Ser Met Gly Asn 225 230
235 240 Ser Ala Leu Val Lys Lys Tyr Leu
245 96109PRTInfluenza 96Met Leu Glu Pro Phe Gln Ile
Leu Ser Ile Cys Ser Phe Ile Leu Ser 1 5
10 15 Ala Leu His Phe Met Ala Trp Thr Ile Gly His
Leu Asn Gln Ile Lys 20 25
30 Arg Gly Val Asn Met Lys Ile Arg Ile Lys Asn Pro Asn Lys Glu
Thr 35 40 45 Ile
Asn Arg Glu Val Ser Ile Leu Arg His Ser Tyr Gln Lys Glu Ile 50
55 60 Gln Ala Lys Glu Thr Met
Lys Glu Val Leu Ser Asp Asn Met Glu Val 65 70
75 80 Leu Ser Asp His Ile Val Ile Glu Gly Leu Ser
Ala Glu Glu Ile Ile 85 90
95 Lys Met Gly Glu Thr Val Leu Glu Val Glu Glu Leu His
100 105 97281PRTInfluenza 97Met Ala Asp
Asn Met Thr Thr Thr Gln Ile Glu Val Gly Pro Gly Ala 1 5
10 15 Thr Asn Ala Thr Ile Asn Phe Glu
Ala Gly Ile Leu Glu Cys Tyr Glu 20 25
30 Arg Leu Ser Trp Gln Arg Ala Leu Asp Tyr Pro Gly Gln
Asp Arg Leu 35 40 45
Asn Lys Leu Lys Arg Lys Leu Glu Ser Arg Ile Lys Thr His Asn Lys 50
55 60 Ser Glu Pro Glu
Ser Lys Arg Met Ser Leu Glu Glu Arg Lys Ala Ile 65 70
75 80 Gly Val Lys Met Met Lys Val Leu Leu
Phe Met Asn Pro Ser Ala Gly 85 90
95 Val Glu Gly Phe Glu Pro Tyr Cys Met Lys Asn Pro Ser Asn
Ser Asn 100 105 110
Cys Pro Asp Cys Asn Trp Ala Asp Tyr Pro Pro Thr Pro Gly Lys Tyr
115 120 125 Leu Asp Gly Ile
Glu Glu Glu Pro Glu Asn Val Gly Asp Ser Thr Glu 130
135 140 Ile Val Leu Arg Asp Met Asn Asn
Lys Asp Ala Arg Gln Lys Ile Lys 145 150
155 160 Glu Glu Val Asn Thr Gln Lys Glu Gly Lys Phe Arg
Leu Thr Ile Lys 165 170
175 Arg Asp Ile Arg Asn Val Leu Ser Leu Arg Val Leu Val Asn Gly Thr
180 185 190 Phe Ile Lys
His Pro Asn Gly Tyr Lys Ser Leu Ser Thr Leu His Arg 195
200 205 Leu Asn Ala Tyr Asp Gln Ser Gly
Arg Leu Val Ala Lys Leu Val Ala 210 215
220 Thr Asp Asp Leu Thr Val Glu Asp Glu Glu Asp Gly His
Arg Ile Leu 225 230 235
240 Asn Ser Leu Phe Glu Arg Leu Asn Glu Gly His Ser Lys Pro Ile Arg
245 250 255 Ala Ala Glu Thr
Ala Val Gly Val Leu Ser Gln Phe Gly Gln Glu His 260
265 270 Arg Leu Ser Pro Glu Glu Arg Asp Asn
275 280 98122PRTInfluenza 98Met Ala Asp Asn
Met Thr Thr Thr Gln Ile Glu Trp Arg Met Lys Lys 1 5
10 15 Met Ala Ile Gly Ser Ser Thr His Ser
Ser Ser Val Leu Met Lys Asp 20 25
30 Ile Gln Ser Gln Phe Glu Gln Leu Lys Leu Arg Trp Glu Ser
Tyr Pro 35 40 45
Asn Leu Val Lys Ser Thr Asp Tyr His Gln Lys Arg Glu Thr Ile Arg 50
55 60 Leu Val Thr Glu Glu
Leu Tyr Leu Leu Ser Lys Arg Ile Asp Asp Asn 65 70
75 80 Ile Leu Phe His Lys Thr Val Ile Ala Asn
Ser Ser Ile Ile Ala Asp 85 90
95 Met Ile Val Ser Leu Ser Leu Leu Glu Thr Leu Tyr Glu Met Lys
Asp 100 105 110 Val
Val Glu Val Tyr Ser Arg Gln Cys Leu 115 120
99469PRTInfluenza 99Met Asn Pro Asn Gln Lys Ile Ile Thr Ile Gly Ser Val
Cys Met Thr 1 5 10 15
Ile Gly Met Ala Asn Leu Ile Leu Gln Ile Gly Asn Ile Ile Ser Ile
20 25 30 Trp Ile Ser His
Ser Ile Gln Leu Gly Asn Gln Asn Gln Ile Glu Thr 35
40 45 Cys Asn Gln Ser Val Ile Thr Tyr Glu
Asn Asn Thr Trp Val Asn Gln 50 55
60 Thr Tyr Val Asn Ile Ser Asn Thr Asn Phe Ala Ala Gly
Gln Ser Val 65 70 75
80 Val Ser Val Lys Leu Ala Gly Asn Ser Ser Leu Cys Pro Val Ser Gly
85 90 95 Trp Ala Ile Tyr
Ser Lys Asp Asn Ser Val Arg Ile Gly Ser Lys Gly 100
105 110 Asp Val Phe Val Ile Arg Glu Pro Phe
Ile Ser Cys Ser Pro Leu Glu 115 120
125 Cys Arg Thr Phe Phe Leu Thr Gln Gly Ala Leu Leu Asn Asp
Lys His 130 135 140
Ser Asn Gly Thr Ile Lys Asp Arg Ser Pro Tyr Arg Thr Leu Met Ser 145
150 155 160 Cys Pro Ile Gly Glu
Val Pro Ser Pro Tyr Asn Ser Arg Phe Glu Ser 165
170 175 Val Ala Trp Ser Ala Ser Ala Cys His Asp
Gly Ile Asn Trp Leu Thr 180 185
190 Ile Gly Ile Ser Gly Pro Asp Asn Gly Ala Val Ala Val Leu Lys
Tyr 195 200 205 Asn
Gly Ile Ile Thr Asp Thr Ile Lys Ser Trp Arg Asn Asn Ile Leu 210
215 220 Arg Thr Gln Glu Ser Glu
Cys Ala Cys Val Asn Gly Ser Cys Phe Thr 225 230
235 240 Val Met Thr Asp Gly Pro Ser Asn Gly Gln Ala
Ser Tyr Lys Ile Phe 245 250
255 Arg Ile Glu Lys Gly Lys Ile Val Lys Ser Val Glu Met Asn Ala Pro
260 265 270 Asn Tyr
His Tyr Glu Glu Cys Ser Cys Tyr Pro Asp Ser Ser Glu Ile 275
280 285 Thr Cys Val Cys Arg Asp Asn
Trp His Gly Ser Asn Arg Pro Trp Val 290 295
300 Ser Phe Asn Gln Asn Leu Glu Tyr Gln Ile Gly Tyr
Ile Cys Ser Gly 305 310 315
320 Ile Phe Gly Asp Asn Pro Arg Pro Asn Asp Lys Thr Gly Ser Cys Gly
325 330 335 Pro Val Ser
Ser Asn Gly Ala Asn Gly Val Lys Gly Phe Ser Phe Lys 340
345 350 Tyr Gly Asn Gly Val Trp Ile Gly
Arg Thr Lys Ser Ile Ser Ser Arg 355 360
365 Asn Gly Phe Glu Met Ile Trp Asp Pro Asn Gly Trp Thr
Gly Thr Asp 370 375 380
Asn Asn Phe Ser Ile Lys Gln Asp Ile Val Gly Ile Asn Glu Trp Ser 385
390 395 400 Gly Tyr Ser Gly
Ser Phe Val Gln His Pro Glu Leu Thr Gly Leu Asp 405
410 415 Cys Ile Arg Pro Cys Phe Trp Val Glu
Leu Ile Arg Gly Arg Pro Lys 420 425
430 Glu Asn Thr Ile Trp Thr Ser Gly Ser Ser Ile Ser Phe Cys
Gly Val 435 440 445
Asn Ser Asp Thr Val Gly Trp Ser Trp Pro Asp Gly Ala Glu Leu Pro 450
455 460 Phe Thr Ile Asp Lys
465 1001812DNAInfluenza 100agcattttct tgtgagcttc
gagcactaat aaaactgaaa atcaaaatgt ccaacatgga 60tattgacagt ataaataccg
gaacaatcga taaaaaacca gaagaactga ctcccggaac 120cagtggggca accagaccaa
tcatcaagcc agcaaccctt gctccgccaa gcaacaaacg 180aacccgaaat ccatccccag
aaaggacaac cacaagcagt gaaaccgata tcggaaggaa 240aatccaaaag aaacaaaccc
caacagagat aaagaagagc gtctacaaca tggtggtaaa 300gctgggtgaa ttctacaacc
agatgatggt caaagctgga cttaatgatg acatggaaag 360gaatctaatc caaaatgcac
aagctgtgga gagaatccta ttggctgcaa ctgatgacaa 420gaaaactgaa taccaaaaga
aaaggaatgc cagagatgtc aaagaaggga aggaagaaat 480agaccacaac aagacaggag
gcacctttta taagatggta agagatgata aaaccatcta 540cttcagccct ataaaaatta
cctttttaaa agaagaggtg aaaacaatgt acaagaccac 600catggggagt gatggtttca
gtggactaaa tcacattatg attggacatt cacagatgaa 660cgatgtctgt ttccaaagat
caaaggcact gaaaagggtt ggacttgacc cttcattaat 720cagtactttt gccggaagca
cactacccag aagatcaggt acaactggtg ttgcaatcaa 780aggaggtgga actttagtgg
cagaagccat tcgatttata ggaagagcaa tggcagacag 840agggctactg agagacatca
aggccaagac agcctatgaa aagattcttc tgaatctgaa 900aaacaagtgc tctgcgcccc
aacaaaaggc tctagttgat caagtgatcg gaagtaggaa 960cccagggatt gcagacatag
aagacctaac tctgcttgcc agaagcatga tagttgtcag 1020accctctgta gcgagcaaag
tggtgcttcc cataagcatt tatgctaaaa tacctcaact 1080aggattcaat atcgaagaat
actctatggt tgggtatgaa gccatggctc tttataatat 1140ggcaacacct gtttccatat
taagaatggg agatgacgca aaagataaat ctcaactatt 1200cttcatgtcg tgcttcggag
ctgcctatga agatctaaga gtgttatctg cactaacggg 1260caccgaattt aagcctagat
cagcactaaa atgcaagggt ttccatgtcc cggctaagga 1320gcaagtagaa ggaatggggg
cagctctgat gtccatcaag cttcagttct gggccccaat 1380gaccagatct ggagggaatg
aagtaagtgg agaaggaggg tctggtcaaa taagttgcag 1440ccctgtgttt gcagtagaaa
gacctattgc tctaagcaag caagctgtaa gaagaatgct 1500gtcaatgaac gttgaaggac
gtgatgcaga tgtcaaagga aatctactca aaatgatgaa 1560tgattcgatg gcaaagaaaa
ccagtggaaa tgctttcatt gggaagaaaa tgtttcaaat 1620atcagacaaa aacaaagtca
atcccattga gattccaatt aagcagacca tccccagttt 1680cttctttggg agggacacag
cagaggatta tgatgacctc gattattaaa gcaataaaat 1740agacactatg gctgtgactg
tttcagtacg tttgggatgt gggtgtttac tcttattgaa 1800ataaatgtaa aa
1812101560PRTInfluenza 101Met
Ser Asn Met Asp Ile Asp Gly Ile Asn Thr Gly Thr Ile Asp Lys 1
5 10 15 Thr Pro Glu Glu Ile Thr
Ser Gly Thr Ser Gly Ala Thr Arg Pro Ile 20
25 30 Ile Lys Pro Ala Thr Leu Ala Pro Pro Ser
Asn Lys Arg Thr Arg Asn 35 40
45 Pro Ser Pro Glu Arg Ala Thr Thr Ser Ser Glu Ala Ile Val
Gly Arg 50 55 60
Arg Thr Gln Lys Lys Gln Thr Pro Thr Glu Ile Lys Lys Ser Val Tyr 65
70 75 80 Asn Met Val Val Lys
Leu Gly Glu Phe Tyr Asn Gln Met Met Val Lys 85
90 95 Ala Gly Leu Asn Asp Asp Met Glu Arg Asn
Leu Ile Gln Asn Ala His 100 105
110 Ala Val Glu Arg Ile Leu Leu Ala Ala Thr Asp Asp Lys Lys Thr
Glu 115 120 125 Tyr
Gln Lys Lys Lys Asn Ala Arg Asp Val Lys Glu Gly Lys Glu Glu 130
135 140 Ile Asp His Asn Lys Thr
Gly Gly Thr Phe Tyr Lys Met Val Arg Asp 145 150
155 160 Asp Lys Thr Ile Tyr Phe Ser Pro Ile Arg Ile
Thr Phe Leu Lys Glu 165 170
175 Glu Val Lys Thr Met Tyr Lys Thr Thr Met Gly Ser Asp Gly Phe Ser
180 185 190 Gly Leu
Asn His Ile Met Ile Gly His Ser Gln Met Asn Asp Val Cys 195
200 205 Phe Gln Arg Ser Lys Ala Leu
Lys Arg Val Gly Leu Asp Pro Ser Leu 210 215
220 Ile Ser Thr Phe Ala Gly Ser Thr Leu Pro Arg Arg
Ser Gly Ala Thr 225 230 235
240 Gly Val Ala Ile Lys Gly Gly Gly Thr Leu Val Ala Glu Ala Ile Arg
245 250 255 Phe Ile Gly
Arg Ala Met Ala Asp Arg Gly Leu Leu Arg Asp Ile Arg 260
265 270 Ala Lys Thr Ala Tyr Glu Lys Ile
Leu Leu Asn Leu Lys Asn Lys Cys 275 280
285 Ser Ala Pro Gln Gln Lys Ala Leu Val Asp Gln Val Ile
Gly Ser Arg 290 295 300
Asn Pro Gly Ile Ala Asp Ile Glu Asp Leu Thr Leu Leu Ala Arg Ser 305
310 315 320 Met Val Val Val
Arg Pro Ser Val Ala Ser Lys Val Val Leu Pro Ile 325
330 335 Ser Ile Asn Ala Lys Ile Pro Gln Leu
Gly Phe Asn Val Glu Glu Tyr 340 345
350 Ser Met Val Gly Tyr Glu Ala Met Ala Leu Tyr Asn Met Ala
Thr Pro 355 360 365
Val Ser Ile Leu Arg Met Gly Asp Asp Ala Lys Asp Lys Ser Gln Leu 370
375 380 Phe Phe Met Ser Cys
Phe Gly Ala Ala Tyr Glu Asp Gln Arg Val Leu 385 390
395 400 Ser Ala Leu Thr Gly Thr Glu Phe Lys Pro
Arg Ser Ala Leu Lys Cys 405 410
415 Lys Gly Phe His Val Pro Ala Lys Glu Gln Val Glu Gly Met Gly
Ala 420 425 430 Ala
Leu Met Ser Ile Lys Leu Gln Phe Trp Ala Pro Met Thr Arg Ser 435
440 445 Gly Gly Asn Glu Val Gly
Gly Asp Gly Gly Ser Gly Gln Ile Ser Cys 450 455
460 Ser Pro Val Phe Ala Val Glu Arg Pro Ile Ala
Leu Ser Lys Gln Ala 465 470 475
480 Val Arg Arg Met Leu Ser Met Asn Ile Glu Gly Arg Asp Ala Asp Val
485 490 495 Lys Gly
Asn Leu Leu Lys Met Met Asn Asp Ser Met Ala Lys Lys Thr 500
505 510 Asn Gly Asn Ala Phe Ile Gly
Lys Lys Met Phe Gln Ile Ser Asp Lys 515 520
525 Asn Lys Ile Asn Pro Val Asp Ile Pro Ile Lys Gln
Thr Ile Pro Asn 530 535 540
Phe Phe Phe Gly Arg Asp Thr Ala Glu Asp Tyr Asp Asp Leu Asp Tyr 545
550 555 560
102560PRTInfluenza 102Met Ser Asn Met Asp Ile Asp Gly Ile Asn Thr Gly Thr
Ile Asp Lys 1 5 10 15
Thr Pro Glu Glu Ile Thr Ser Gly Thr Ser Gly Ala Thr Arg Pro Ile
20 25 30 Ile Lys Pro Ala
Thr Leu Ala Pro Pro Ser Asn Lys Arg Thr Arg Asn 35
40 45 Pro Ser Pro Glu Arg Ala Ala Thr Ser
Ser Glu Ala Asp Val Gly Arg 50 55
60 Arg Thr Gln Lys Lys Gln Thr Pro Thr Glu Ile Lys Lys
Ser Val Tyr 65 70 75
80 Asn Met Val Val Lys Leu Gly Glu Phe Tyr Asn Gln Met Met Val Lys
85 90 95 Ala Gly Leu Asn
Asp Asp Met Glu Arg Asn Leu Ile Gln Asn Ala His 100
105 110 Ala Ala Glu Arg Ile Leu Leu Ala Ala
Thr Asp Asp Lys Lys Thr Glu 115 120
125 Phe Gln Lys Lys Lys Asn Ala Arg Asp Val Lys Glu Gly Lys
Glu Glu 130 135 140
Ile Asp His Asn Lys Thr Gly Gly Thr Phe Tyr Lys Met Val Arg Asp 145
150 155 160 Asp Lys Thr Ile Tyr
Phe Ser Pro Ile Arg Ile Thr Phe Leu Lys Glu 165
170 175 Glu Val Lys Thr Met Tyr Lys Thr Thr Met
Gly Ser Asp Gly Phe Ser 180 185
190 Gly Leu Asn His Ile Met Ile Gly His Ser Gln Met Asn Asp Val
Cys 195 200 205 Phe
Gln Arg Ser Lys Ala Leu Lys Arg Val Gly Leu Asp Pro Ser Leu 210
215 220 Ile Ser Thr Phe Ala Gly
Ser Thr Leu Pro Arg Arg Ser Gly Ala Thr 225 230
235 240 Gly Val Ala Ile Lys Gly Gly Gly Thr Leu Val
Ala Glu Ala Ile Arg 245 250
255 Phe Ile Gly Arg Ala Met Ala Asp Arg Gly Leu Leu Arg Asp Ile Arg
260 265 270 Ala Lys
Thr Ala Tyr Glu Lys Ile Leu Leu Asn Leu Lys Asn Lys Cys 275
280 285 Ser Ala Pro Gln Gln Lys Ala
Leu Val Asp Gln Val Ile Gly Ser Arg 290 295
300 Asn Pro Gly Ile Ala Asp Ile Glu Asp Leu Thr Leu
Leu Ala Arg Ser 305 310 315
320 Met Val Val Val Arg Pro Ser Val Ala Ser Lys Val Val Leu Pro Ile
325 330 335 Ser Ile Asn
Ala Lys Ile Pro Gln Leu Gly Phe Asn Val Glu Glu Tyr 340
345 350 Ser Met Val Gly Tyr Glu Ala Met
Ala Leu Tyr Asn Met Ala Thr Pro 355 360
365 Val Ser Ile Leu Arg Met Gly Asp Asp Ala Lys Asp Lys
Ser Gln Leu 370 375 380
Phe Phe Met Ser Cys Phe Gly Ala Ala Tyr Glu Asp Gln Arg Val Leu 385
390 395 400 Ser Ala Leu Thr
Gly Thr Glu Phe Lys His Arg Ser Ala Leu Lys Cys 405
410 415 Lys Gly Phe His Val Pro Ala Lys Glu
Gln Val Glu Gly Met Gly Ala 420 425
430 Ala Leu Met Ser Ile Lys Leu Gln Phe Trp Ala Pro Met Thr
Arg Ser 435 440 445
Gly Gly Asn Glu Val Gly Gly Asp Gly Gly Ser Gly Gln Ile Ser Cys 450
455 460 Ser Pro Val Phe Ala
Val Glu Arg Pro Ile Ala Leu Ser Lys Gln Ala 465 470
475 480 Val Arg Arg Met Leu Ser Met Asn Ile Glu
Gly Arg Asp Ala Asp Val 485 490
495 Lys Gly Asn Leu Leu Lys Met Met Asn Asp Ser Met Thr Lys Lys
Thr 500 505 510 Asn
Gly Asn Ala Phe Ile Gly Lys Lys Met Phe Gln Ile Ser Asp Lys 515
520 525 Asn Lys Thr Asn Pro Ile
Glu Ile Pro Ile Lys Gln Thr Ile Pro Asn 530 535
540 Phe Phe Phe Gly Arg Asp Thr Ala Glu Asp Tyr
Asp Asp Leu Asp Tyr 545 550 555
560 1031842DNAInfluenza 103agcagaagca cagcattttc ttgtgaactt
caagtaccaa caaaaactga aaatcaaaat 60gtccaacatg gatattgacg gcatcaacac
tggaacaatt gacaaaacac cagaagaaat 120aacttccgga accagtgggg caaccagacc
aatcatcaag ccagcaaccc ttgccccacc 180aagcaataaa cgaacccgaa acccatcccc
agaaagggca accacaagca gcgaagcgat 240tgtcggaagg agaacccaaa agaaacaaac
cccgacagag ataaagaaga gcgtctacaa 300tatggtagtg aaactgggtg aattctacaa
ccagatgatg gtcaaagctg gactcaacga 360tgacatggag agaaacctaa tccaaaatgc
acatgctgtg gaaagaattc tattggctgc 420tactgatgac aagaaaactg aataccaaaa
gaaaaagaat gccagagatg tcaaagaagg 480gaaagaagaa atagaccaca acaaaacagg
aggcaccttt tataagatgg taagagatga 540taaaaccatc tacttcagcc ctataagaat
taccttttta aaagaagagg tgaaaacaat 600gtacaagacc accatgggga gtgatggttt
cagtggacta aatcacatca tgattgggca 660ttcacagatg aacgatgtct gtttccaaag
atcaaaggca ctaaaaagag ttggacttga 720cccttcatta atcagtactt ttgcaggaag
cacactcccc agaagatcag gtgcaactgg 780tgttgcgatc aaaggaggtg gaactttagt
ggcagaagcc attcgattta taggaagagc 840aatggcagac agagggctat tgagagacat
cagagccaag acggcctatg aaaagattct 900tctgaatctg aaaaacaagt gctctgcgcc
ccaacaaaag gctctagttg atcaagtgat 960cggaagtaga aacccaggga ttgcagacat
agaagaccta accctgcttg cccgaagcat 1020ggtcgttgtc aggccctctg tagcgagcaa
agtggtgctt cccataagca ttaatgctaa 1080aatacctcaa ctagggttca atgttgaaga
atactctatg gttgggtatg aagccatggc 1140tctttataat atggcaacac ctgtttccat
attaagaatg ggagacgatg caaaagataa 1200atcacaatta ttcttcatgt cttgctttgg
agctgcctat gaagaccaaa gagttttgtc 1260tgcactaacc ggcacagaat tcaagcctag
gtcagcatta aagtgcaagg gtttccacgt 1320tccagcaaag gagcaagtgg aaggaatggg
ggcagctctg atgtccatca agctccagtt 1380ttgggcccca atgaccagat ctggggggaa
cgaagtaggt ggagacggag ggtctggtca 1440aataagttgc agccccgtgt ttgcagtaga
gagacctatt gctctaagca agcaagctgt 1500aagaagaatg ctgtcaatga atattgaggg
acgtgatgca gatgtcaaag gaaatctact 1560caagatgatg aatgattcaa tggctaagaa
aaccaatgga aatgctttca ttgggaagaa 1620aatgtttcaa atatcagaca aaaacaaaat
caatcccgtt gatattccaa ttaagcagac 1680catccccaat ttcttctttg ggagggacac
agcagaggat tatgatgacc tcgattatta 1740aagcaacaaa atagacacta tggctgtgac
tgtttcagta cgtttggaat gtgggtgttt 1800actcttattg aaataaatgt aaaaaatgct
gttgtttcta ct 18421041842DNAInfluenza 104agcagaagca
cagcattttc ttgtgaactt caagtaccaa caaaaactga aaatcaaaat 60gtccaacatg
gatattgacg gcatcaacac tggaacaatt gacaaaacac cagaagaaat 120aacttccgga
accagtgggg caaccagacc aatcatcaaa ccagcaaccc ttgccccacc 180aagcaacaaa
cgaacccgaa acccatcccc ggaaagggca gccacaagca gtgaagctga 240tgtcggaagg
agaacccaaa agaaacaaac cccgacagag ataaagaaga gcgtctacaa 300tatggtagtg
aaactgggtg aattctacaa ccagatgatg gtcaaagctg gactcaacga 360tgacatggag
agaaacctaa tccaaaatgc acatgctgcg gaaagaattc tattggctgc 420tactgatgac
aagaaaactg aattccaaaa gaaaaagaat gccagagatg tcaaagaagg 480gaaagaagaa
atagaccaca acaaaacagg aggcaccttt tacaagatgg taagagatga 540taaaaccatc
tacttcagcc ctataagaat taccttttta aaagaagagg tgaaaacaat 600gtacaaaacc
accatgggga gtgatggttt cagtggacta aatcacatca tgattgggca 660ttcacagatg
aacgatgtct gtttccaaag atcaaaggca ctaaaaagag ttggacttga 720cccttcatta
atcagtactt ttgcaggaag cacactcccc agaagatcag gtgcaactgg 780tgttgcgatc
aaaggaggtg gaactttagt ggcagaagcc attcgattta taggaagagc 840aatggcagac
agagggctat tgagagacat cagagccaag acggcctatg aaaagattct 900tctgaatctg
aaaaacaagt gctctgcgcc ccaacaaaag gctctagttg atcaagtgat 960cggaagtaga
aatccaggga ttgcagacat agaagaccta accctgcttg cccgaagcat 1020ggtcgttgtc
aggccctctg tagcgagcaa agtggtgctt cccataagca ttaatgccaa 1080aatacctcaa
ctagggttca atgttgaaga atactctatg gttgggtatg aagccatggc 1140tctttataat
atggcaacac ctgtttccat attaagaatg ggagacgatg caaaagataa 1200atcacaatta
ttcttcatgt cttgcttcgg agctgcctat gaagaccaaa gagttttgtc 1260tgcactaaca
ggcacagaat tcaagcatag gtcagcatta aagtgcaagg gtttccacgt 1320tccagcaaag
gagcaagtgg aaggaatggg ggcagctctg atgtccatca agctccagtt 1380ttgggctcca
atgaccagat ctggggggaa tgaagtaggt ggagacggag ggtctggtca 1440aataagttgc
agccccgtgt ttgcagtaga aagacctatt gctctaagca agcaagctgt 1500aagaagaatg
ctgtcaatga atattgaggg acgtgatgca gatgtcaaag gaaatctact 1560caagatgatg
aatgattcaa tgactaagaa aaccaatgga aatgctttca ttgggaagaa 1620aatgtttcaa
atatcagaca aaaacaaaac caatcccatt gagattccaa ttaagcagac 1680catccccaat
ttcttctttg ggagggacac agcagaggat tatgatgacc tcgattatta 1740aagcaacaaa
atagacacta tggctgtgac tgtttcagta cgtttggaat gtgggtgttt 1800acttttattg
aaataaatgt aaaaaatgct gttgtttcta ct 1842
User Contributions:
Comment about this patent or add new information about this topic:
People who visited this patent also read: | |
Patent application number | Title |
---|---|
20210302661 | PITCH CONVERSION APPARATUS FOR USE WITH OPTICAL FIBERS |
20210302660 | PAIR ROUTING BETWEEN THREE UNDERSEA FIBER OPTIC CABLES |
20210302659 | TUNABLE OPTICAL FILTER WITH BANDWIDTH TUNING CAPABILITY |
20210302658 | OPTICAL FIBER DEVICE FOR REMOVING CLADDING LIGHT, APPARATUS AND METHOD FOR ETCHING THE SAME |
20210302657 | TERMINATING A CABLE ASSEMBLY WITH CONNECTORIZED PIGTAILS |